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The estrogen receptors (ERs) are typical members of the superfamily of nuclear receptors that
includes the receptors that mediate the effects of steroid hormones, thyroid hormones, retinoid and
vitamin D, as well as numerous orphan receptors. ERs, as other steroid receptors, mainly function
as ligand-inducible transcription factors which bind chromatin, as homodimers, at specific response
elements. It should also be noted that a tight reciprocal coupling between rapid ‘non-genomic’ and
‘genomic’ biological responses to estrogen occurs in many physiological processes. ERs have long been
evaluated for their roles in controlling the expression of genes involved in vital cellular processes such
as proliferation, apoptosis and differentiation. Given the various and pleiotropic functions of ERs,
the dysregulation of their pathways contributes to several diseases such as, the hormone-dependent
breast, endometrial and ovarian cancers as well as neurodegenerative diseases, cardiovascular diseases
and osteoporosis. Several classes of ER ligands with agonist or antagonist activities in different
E2-target tissues have been characterized. Moreover, ER ligands that efficiently block tumor growth
and kill cancer cells have been developed.
In this special issue, “Molecular Pathways of Estrogen Receptor Action”, promising results
in understanding the mechanisms underlying ER-mediated effects in various pathophysiological
processes are represented, covering different roles of ER pathways in the tumorigenesis, the resistance
to endocrine therapy, the dynamics of 3D genome organization and the cross-talk with other
signaling pathways.
A key step in the physiological processes is the regulation of the transcriptional dynamics of
gene networks. The article by Le Dily and Beato [1] summarizes the restructuration and chromatin
folding during steroid hormone exposure, as well as the influence of three-dimensional genome
organization in the response to steroid hormones. Deciphering these events may particularly be
important to understand cell transformation and its progression in cancers where the genome is often
rearranged during tumorigenesis. In addition, Yang et al. [2] update the effect of hypoxia on ER
function in breast cancer. They focus on the link between ERs, the hypoxia inducible factor 1 and
the histone lysine demethylase KDM4B, an important epigenetic modifier in cancer. Additionally,
Saito and Cui [3] describe a possible cross-talk via transcriptional regulation between ERs and the
estrogen-related receptors (ERRs) that partially share common target genes. Moreover, ERs can directly
regulate the expression of genes encoding ERRs through the estrogen-response element within the
promoter region. As ERRα is at the center of the coordination of transcriptional networks for neuronal
and adaptive responses, this can potentially explain estrogenic actions in social behavior. Further,
Hsu et al. [4] provide an overview of the possible role of ERs in lung cancer. Different aspects of
the disease development, clinical studies, effects of tobacco smoking and environmental estrogens as
well as ER activation and interactions with EGFR (epidermal growth factor receptor) are discussed.
A critical review on the natural human anti-ERα antibodies capable of inducing estrogenic responses
in breast cancer cells is given by Guy Leclercq [5]. These observations, not much mentioned previously,
were recently confirmed and have been extended to autoimmune diseases. These data will open new
paths to develop new strategies and to combine immunological and endocrine approaches for the
management of breast cancer. The mechanism of action of these antibodies is also addressed.
Int. J. Mol. Sci. 2018, 19, 2591; doi:10.3390/ijms19092591 www.mdpi.com/journal/ijms1
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In addition to cancerous cells, the non-cancer cells including tumor microenvironment (TME) are
critical mediators of tumor progression. Besides the intracellular signaling, the interactions between
cancer cells, stromal cells, immune cells, and extracellular molecules within the TME greatly impact
antitumor immunity and the immunotherapeutic response. The potential role of estrogen signaling
pathway, as a regulator of tumor immune responses, in the tumor microenvironment is discussed and
reviewed by Rothenberger et al. [6]. Radiation therapy is widely used as one of the most common
and effective therapeutic strategies. Nevertheless, the effect of ionizing radiation on the expression
of ERs and ER signaling pathways in cancerous tissues, as well as on the endocrine therapy is not
well-known. This topic is reviewed and discussed by Rong et al. [7]. They also summarize basic,
pre-clinical and clinical studies that assess the consequences of anti-estrogen treatments in combination
with radiotherapy in cancer.
There is an important link between estrogen signaling pathways and the regulation of the
cardiovascular and immune systems. Trenti et al. [8] review the current understanding of the
protective effects of estrogen on the cardiovascular system, including promoting endothelial healing
and angiogenesis. They also describe the actions of estrogens in the immune function of the
monocyte-macrophage system, through different pathways and in particular with regard to the
production of cytokines. Recent studies have also suggested that estrogens exert their vascular
protective effects, at least in part, through microRNA activity. Pérez-Cremades et al. [9] focus on the
recent progress in determining the roles of estrogen-regulated microRNAs and their contribution
in vascular biology. They summarize the microRNAs involved in estrogen action and the major
role played by miR-23a and miR-22. However, further works focused on characterizing the role of
estradiol-mediated miRNAs involved in vascular function are needed. Wnuk and Kajta [10] highlight
the role of steroid and xenobiotic receptor signaling in apoptosis and autophagy of the central nervous
system, and their potential implications in brain diseases. Finally, Lecomte et al. [11] discuss and
summarize the in vitro and in vivo effects of phytochemicals interacting with ERs and their potential
role in human health. The diversity of the mechanisms of action and the subtle balance between
beneficial and harmful biological outcomes are also given.
In addition to the reviews mentioned above, eight research articles are included in this special
issue. A clinical study reported by Matta et al. [12] describes a substantial variability in DNA repair
capacity among breast cancer subtypes and suggests lowest repairs in triple negative breast cancer.
Cardoso et al. [13] report estrogen metabolism-associated CYP2D6 and IL6-174G/C polymorphisms
in Schistosoma haematobium Infection. From a primary culture approach, Kranc et al. [14] analyze
the expression profile of genes regulating steroid biosynthesis and metabolism in human ovarian
granulosa cells. An in vivo study conducted by d’Adesky et al. [15] indicates that nicotine modifies
ER-β-regulated inflammasome activity and aggravates ischemic brain damage in female rats. The study
conducted by Casanova-Nakayama et al. [16] examines the immune-specific expression and estrogenic
regulation of the four ER isoforms in female rainbow trout. Alexandre-Pires et al. [17] evaluate
functional aspects of sheep inguinal sinus gland and the mRNA and protein expressions of several
hormone receptors including ERs. An in vivo and in vitro study conducted by Hinfray et al. [18]
provides evidence regarding antagonistic effects of estradiol and genistein in combination using
mixture concentration-response modeling in zebrafish. Serra et al. [19] report that triclosan lacks
(anti-)estrogenic effects in zebrafish cells but alters estrogen response in zebrafish embryos.
While much remains to be learned, this special issue provides a background of the molecular
mechanisms of ERs that is needed in clinical studies against estrogen-related diseases. Lastly, I would
like to thank all the authors and referees for their efforts in supporting this special issue.
Conflicts of Interest: The author declares no conflict of interest.
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Jankowski, M.; Jeseta, M.; Pawelczyk, L.; et al. Expression Profile of Genes Regulating Steroid Biosynthesis and
Metabolism in Human Ovarian Granulosa Cells—A Primary Culture Approach. Int. J. Mol. Sci. 2017, 18, 2673.
[CrossRef] [PubMed]
15. D’adesky, N.D.; de Rivero Vaccari, J.P.; Bhattacharya, P.; Schatz, M.; Perez-Pinzon, M.A.; Bramlett, H.M.;
Raval, A.P. Alters Estrogen Receptor-Beta-Regulated Inflammasome Activity and Exacerbates Ischemic Brain
Damage in Female Rats. Int. J. Mol. Sci. 2018, 19, 1330. [CrossRef] [PubMed]
16. Casanova-Nakayama, A.; Wernicke von Siebenthal, E.; Kropf, C.; Oldenberg, E.; Segner, H. Immune-Specific
Expression and Estrogenic Regulation of the Four Estrogen Receptor Isoforms in Female Rainbow Trout
(Oncorhynchus mykiss). Int. J. Mol. Sci. 2018, 19, 932. [CrossRef] [PubMed]
17. Alexandre-Pires, G.; Martins, C.; Galvão, A.M.; Miranda, M.; Silva, O.; Ligeiro, D.; Nunes, T.; Ferreira-Dias, G.
Understanding the Inguinal Sinus in Sheep (Ovis aries)—Morphology, Secretion, and Expression of
Progesterone, Estrogens, and Prolactin Receptors. Int. J. Mol. Sci. 2017, 18, 1516. [CrossRef] [PubMed]
18. Hinfray, N.; Tebby, C.; Piccini, B.; Bourgine, G.; Aït-Aïssa, S.; Porcher, J.M.; Pakdel, F.; Brion, F. Mixture
Concentration-Response Modeling Reveals Antagonistic Effects of Estradiol and Genistein in Combination
on Brain Aromatase Gene (cyp19a1b) in Zebrafish. Int. J. Mol. Sci. 2018, 19, 1047. [CrossRef] [PubMed]
19. Serra, H.; Brion, F.; Porcher, J.M.; Budzinski, H.; Aït-Aïssa, S. Triclosan Lacks (Anti-)Estrogenic Effects in Zebrafish
Cells but Modulates Estrogen Response in Zebrafish Embryos. Int. J. Mol. Sci. 2018, 19, 1175. [CrossRef] [PubMed]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
3
 International Journal of 
Molecular Sciences
Review
Signaling by Steroid Hormones in the 3D
Nuclear Space
François Le Dily 1,2 and Miguel Beato 1,2,*
1 Gene Regulation, Stem Cells and Cancer Program, Centre for Genomic Regulation (CRG),
The Barcelona Institute of Science and Technology (BIST), Doctor Aiguader 88,
08003 Barcelona, Spain; francois.ledily@crg.es
2 Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
* Correspondence: miguel.beato@crg.es; Tel.: +34-93-316-0119; Fax: +34-93-316-0099
Received: 29 December 2017; Accepted: 19 January 2018; Published: 23 January 2018
Abstract: Initial studies showed that ligand-activated hormone receptors act by binding to the
proximal promoters of individual target genes. Genome-wide studies have now revealed that
regulation of transcription by steroid hormones mainly depends on binding of the receptors to distal
regulatory elements. Those distal elements, either enhancers or silencers, act on the regulation of
target genes by chromatin looping to the gene promoters. In the nucleus, this level of chromatin
folding is integrated within dynamic higher orders of genome structures, which are organized in
a non-random fashion. Terminally differentiated cells exhibit a tissue-specific three-dimensional
(3D) organization of the genome that favors or restrains the activity of transcription factors and
modulates the function of steroid hormone receptors, which are transiently activated upon hormone
exposure. Conversely, integration of the hormones signal may require modifications of the 3D
organization to allow appropriate transcriptional outcomes. In this review, we summarize the main
levels of organization of the genome, review how they can modulate the response to steroids in a cell
specific manner and discuss the role of receptors in shaping and rewiring the structure in response to
hormone. Taking into account the dynamics of 3D genome organization will contribute to a better
understanding of the pleiotropic effects of steroid hormones in normal and cancer cells.
Keywords: chromatin conformation; estrogen receptor; steroid receptors; topological domains;
transcription regulation
1. Introduction
Similarly to other steroids, Estrogens (e.g., Estradiol, E2) exert their action by binding to their
cognate nuclear receptors, the Estrogen Receptor (ER), which mainly functions as ligand-activated
transcription factor [1,2]. Upon activation, ER translocates to the nucleus and converges to chromatin
together with effectors of signaling pathways activated at the plasma membrane through non-genomic
pathways [3]. ER binds directly to DNA through Estrogen Responsive Elements (ERE), which correspond
to palindromic repeats [4], as well as indirectly through protein-protein interactions with other
transcription factors [5,6]. It has been initially proposed that the effects E2 exerts on transcription depend
on the binding of the ER to response elements located within the proximal promoters of the target
genes. There, activated receptors orchestrate the recruitment of co-regulators, chromatin remodeling
complexes and general transcription factors [1,2,7]. Although such mechanisms have been described
in details for model estrogen responsive genes [8,9], the emergence of high-throughput technologies
challenged this view: genome-wide analysis of transcripts levels by micro-arrays or RNA-Seq showed
that the hormone modulate the expression of several hundreds of targets genes, many without direct
binding of the ER at the proximal promoter [10–12]. Indeed, ChIP-Seq experiments targeting the ER in
model estrogen-responsive cells showed that the receptors bind to DNA in an unexpected genome-wide
Int. J. Mol. Sci. 2018, 19, 306; doi:10.3390/ijms19020306 www.mdpi.com/journal/ijms4
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fashion. The majority of the binding sites are located in intergenic regions, frequently far away from
genes, and rather correspond to enhancer regions [13–15]. Similar observations have been made for other
steroid receptors, such as the Glucocorticoid (GR) and Progesterone (PR) receptors, suggesting a shared
mode of action [16,17].
Enhancers classically regulate transcription through chromatin looping to bring the regulatory
machinery in close proximity to the promoters they target [18]. This level of chromatin folding and
the formation of regulatory loops is embedded in more complex levels of organization of the genome.
Indeed, it is becoming evident that the genome is organized in a highly compartmentalized and
non-random fashion in the nucleus in interphase [19–21]. Such three-dimensional (3D) structures,
in part cell specific, constrain the treatment of the genetic information in processes such as replication
or transcription [22–25].
In terminally differentiated cells, 3D genome organization may constitute an epigenetic level
controlling signal-induced modifications of transcription, as in the case of the rapid response induced
by steroid hormones [26–29]. In the context of this review, we give an overview of the recent advances
on understanding genome folding in eukaryotic cells and describe how it can interfere with the activity
of transcription factors and the response to external cues. We further discuss observations of steroid
dependent reorganization of the 3D genome architecture at local or more global scales.
2. Genome 3D Organization
Increasing experimental evidences support of a highly compartmentalized organization of the
genome within the nucleus in interphase. Both cytological approaches such as Fluorescent In Situ
Hybridization (FISH), or biochemical methods deriving from the chromosome conformation capture
(3C) technique [30], have demonstrated that chromosomes do not decondense in a random way but
rather organize following hierarchical order of structures [19–21]. The emergence of high-throughput
3C-derivatives, in particular Hi-C [31], allowed analysis of genome organization at various scales:
individual chromosomes are organized in chromosome territories and are segmented in domains
of preferential local contacts known as Topologically Associating Domains (TADs), which belong to
functionally and epigenetically distinct chromatin compartments [24,25,31–33].
2.1. Chromosome Territories
The use of fluorescent whole chromosome paint probes permitted to confirm the hypothesis that
chromosomes do not decompact in an unorganized way after mitosis but rather occupy a discrete area
within the nuclear space [34,35]. These structures, known as chromosome territories, show limited
intermingling between them and appear to distribute at preferential positions within the nucleus.
In human cells, for example, long gene poor chromosomes are preferentially observed at the periphery,
close to the nuclear lamina, while small gene rich chromosomes are frequently located within the central
part of the nucleus. This suggests a functional radial positioning of chromosomes in relation to their
transcriptional activity [35,36]. If the chromosome territories were originally observed by cytological
approaches, this level of structure has also been confirmed by Hi-C experiments, which showed that
most of the contacts detected were occurring in cis (i.e., intra-chromosomal contacts—Figure 1A) and that
the trans, inter-chromosomal, interactions were reflecting the relative positioning of chromosomes [31].
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Figure 1. Hierarchical organization of the genome. Hi-C permits genome-wide detection of pair-wise
contacts between genomic loci. They could be summarized as contact matrices where the color scale
highlights the frequency of ligations events observed between any pairs of loci in the genome (from white
to red, low to high frequencies, respectively). At different scales of resolution (e.g., 1 Mb, 100 or
10 Kb), higher orders of structure emerge: (A) chromosome territories, (B) chromatin compartments,
(C) Topologically Associating Domains (TADs) and loops. (B,C) Bottom panels correspond to possible
interpretations of the contact matrices: (B) active and inactive chromatin segregate spatially in two
distinct chromatin compartments (A and B, respectively). (C) Architectural proteins (blue circles),
such as CTCF (CCCTC-binding Factor), participate in the partitioning of the genome in TADs and
generate sub-megabase structures, which can bring together specific loci or exclude genes from the
activity of distal regulatory regions (orange circle: active enhancer; green arrows: expressed genes;
red arrows: silenced genes).
2.2. Chromatin Compartments
In addition to support the existence of territories, the contact matrices obtained by Hi-C
show a striking “plaid” or “chess” pattern (Figure 1B), which corresponds to the engagement of
preferential long-range associations by non-contiguous genomic domains [31]. Such arrangement
reflects the segregation of two types of genomic domains, which tend to not intermingle between
them. Correlation of this pattern with epigenetic marks and transcription data demonstrated that the
two types of regions corresponded mainly to the active and inactive parts of the genome (Figure 1B),
also referred to as A and B chromatin compartments, respectively [31]. The existence of these two
spatially segregated chromatin compartments has been confirmed by high- resolution microscopy using
specific oligo-paint FISH probes [37]. This approach allowed the distinguishing of the two compartments
spatially polarized in single chromosomes and further suggested that compartmentalization differs
with the transcriptional activity [37]. This bimodal chromatin compartmentalization was initially
observed based on Hi-C contact maps at resolutions between 0.1 to 1Mb. Recent high coverage Hi-C
studies further demonstrated that the segregation of chromatin domains could be defined in a finer
way, with the A and B compartments being subdivided in sub-compartments in correlation with their
activity [33,38]. Importantly, this spatial segregation of chromatin compartments appears largely cell
specific. Through the process of differentiation, chromosomal domains can dynamically switch from
one to the other compartment, in correlation with changes of expression of tissue specific genes [23,39].
Conversely, in the process of dedifferentiation or cell reprogramming, chromosomal domains can change
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dynamically their association to one or the other compartment, in some cases prior to corresponding
transcriptional modifications, supporting an instructive role of the 3D structure on transcription [40].
2.3. Topologically Associating Domains
At a resolution of 100 Kb or below, Hi-C chromosomal contact maps show that chromosomes
are segmented in domains of high local interactions separated from each other by sharp boundaries
(Figure 1C). These megabase-sized domains were referred to as Topological Domains, Topologically
Associating Domains or TADs [24,32]. The boundaries between TADs are characterized by the
presence of highly expressed housekeeping genes as well as by enrichments in epigenetic marks
(e.g., H3K4me3, H3K36me3) linked to gene activation and in binding sites for architectural proteins
such as CCCTC-binding Factor (CTCF) and cohesins [24,25,41,42]. In contrast to what is observed at the
level of chromatin compartments, boundaries between TADs are largely conserved between cell types
and through evolution. This suggests that TADs are important structural levels of organization [23,24].
However, a recent study based on a multi-scale analysis of insulation between genomic domains
suggested that, rather to be a structurally favored level of organization, TADs represent an optimal
functional level of folding for the establishment of specific interactions [43]. Such organization will
notably facilitate the coordinated regulation of genes by facilitating the organization of specific wiring
between genes promoters and regulatory elements [43]. In this view, TADs can be considered as
epigenetic domains characterized by relatively homogeneous epigenetic features, suggesting that the
border between them could limit the spreading of epigenetic marks [24,25,32]. In addition, TADs can
behave as transcription units where genes are co-regulated under the control of specific regulatory
elements during differentiation [32,43,44] or in response to steroid hormones [28].
2.4. Sub-Domains and Chromatin Loops
If the boundaries between TADs are conserved between cell types, their internal organization
appears more dynamic and cell specific. At higher resolutions, the contact maps show cell specific
internal sub-TADs or sub-domains (Figure 1C), which correspond to structures generated by the
interactions between specific elements, either structural and/or related to gene activity [33,38,45,46].
In particular, during differentiation, differential binding of CTCF and cohesins, together with subunits
of the mediator complex lead to the formation of such cell specific sub-domains [45]. This sub-megabase
level of organization leads some authors to propose that chromosome-neighborhoods, which correspond
to the establishment of specific CTCF loops that embed genes together with or without regulatory
elements, might be the functional minimal unit of organization of the genome [33,38,47]. Additionally,
other zinc finger proteins able to form homodimers, such as YY1, can mediate enhancer-promoter loops
and are essential for specific gene regulation [48].
In summary, the genome is organized in a hierarchy of structures that have been correlated with
the processing of the genetic information. Although these preferential structures can be observed
in cell populations, it is important to keep in mind that, in single cells, the underlying spatial
interactions remain highly dynamic and rather stochastic, as exemplified by results obtained in
single cell Hi-C [49] and by the frequent discrepancies observed between 3C derived population
results and direct visualization in single cells by FISH [50]. Globally however, genome-wide contact
datasets suggest a cell type specific organization, which could participate in the integration of the
different signals received by the cell. Degron-mediated knock-down of the levels of CTCF or subunits
of the cohesin complex lead to a loss of the organization in loops and TADs without affecting the
segregation of chromatin compartments [51–53]. These studies confirmed that architectural proteins
are essential for the maintenance of cell specific organization of TADs and suggest that the different
levels of structure are partially uncoupled. However, these proteins probably act in combinations
with other regulatory factors but the precise role of tissue-specific transcription factors in organizing
different levels of organization remains largely unexplored.
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3. 3D Genome Folding Modulates the Response to Steroids
Comparative ChiP-Seq studies demonstrated that the landscape of binding of steroid receptors
varies quantitatively and qualitatively from cell type to cell type, even between cells lines of similar
origins [17,54]. This cell specificity probably participates in the regulation of distinct subsets of
responsive genes, explaining the differences observed in different cell lines in response to the same
stimulus [55,56]. The different levels of structures described above are part of the cell identity and one
can reasonably hypothesize that they act as an epigenetic level to condition the activity of transcription
factors. In particular, in the case of steroid receptors, which activity is regulated by external signals in
terminally differentiated cells, this 3D organization can participate in demarcating the sets of regulatory
elements potentially bound by the receptors as well as in restricting the genes that will be targeted.
3.1. Steroid Receptors Cistrome
Although variables depending on cell types, time of treatment and detection approaches,
results from transcriptomic studies showed that steroid hormones elicit genome-wide changes in
gene expression, with between hundreds to thousands of genes being either up- or down-regulated
upon hours of treatment [10–12,16]. Some of these changes rely on indirect secondary regulations;
nevertheless, the use of Global-Run-On method (GRO-Seq) confirmed these broad effects of E2 on
transcription [12]. In addition, GRO-Seq permitted to highlight rapid changes in transcription not only
of protein coding genes but also of many non-annotated, non-coding transcripts [12]. Rather than giving
a direct explanation to these broad transcriptional changes, analysis of ER binding by ChIP-on-chip or
later on by ChIP-Seq experiments largely modified the classical view of the mechanisms involved in
the cellular response to steroids [13,15,57]. For instance, ChiP-Seq experiments performed in MCF-7
cells after treatment with E2 demonstrated an unexpected genome-wide binding of the ER, with more
than 14,000 binding sites detected; much more than the number of genes actually regulated by the
hormone in these cells [15]. The location of these binding sites throughout the genome was also
unexpected: only a small proportion was located within the proximal regulatory regions of targets
genes; the majority of sites were rather broadly distributed, with particular enrichment in distal
inter-genic regions. This suggests that, in addition to act at the levels of promoters, ER exert their actions
from distal regulatory regions. Similar behaviors were observed in other cell types and for other nuclear
receptors, such as the GR and the PR [16,17]. For instance, upon 30 min exposure to progestins, PR bind
to more than 25,000 sites characterized by enhancer marks and located at more than 30 Kb away from
promoters [16]. This suggests a shared mode of actions of steroid receptors in acting as regulators of the
activity of distal, enhancer or silencer, regions.
3.2. Differential Accessibility of Hormone Response Elements
Despite the large number of steroid receptors binding sites detected by ChIP-Seq, they represent
only a small fraction of the potential Hormone Response Elements (HRE) identified by searching for
consensus sequences in the genome [58], suggesting that a large fraction of HRE is not accessible
for binding. This differential accessibility represents the first level of epigenetic regulation of steroid
receptors function as transcription factors and can consequently dictates the cell specific target genes.
Several mechanisms can explain why the receptors can only bind to part of their consensus element on
DNA. ER, for example, binds preferentially to DNA elements that are not protected by nucleosomes,
and requires the activity of pioneer factors. Pioneer factors are able to bind to nucleosomal DNA
where they orchestrate local arrangements of the chromatin and therefore act cooperatively to facilitate
the binding of activated receptors [59]. For example, Forkhead Box Protein A1 (FOXA1) has been
shown to mark the sites that will be bound by ER after exposure to the hormone [60]. The PR is able
to bind to sites occupied by nucleosomes [16] and other mechanisms, such as methylation of DNA,
potentially prevent its binding to some of its responsive elements [61].
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More generally, the precise mechanisms by which transcription factors find their DNA targets
within the nuclear environment remains mainly unknown [62]. In addition to epigenetic modifications
of DNA and nucleosomes, the way the chromatin is spatially organized in the nucleus can interfere
with, either promote or limit, the accessibility of chromatin to nucleoplasmique factors. Several models
of transcription factor search strategies have been proposed, which notably include facilitated diffusion
through chromatin. In this model, transcription factors binding to specific chromatin sites occurs
through a combination of diffusion, linear tracking and jumps, or hopping, along the chromatin
fiber [63]. The fact that the genome folds readily in a non-random manner may favor such hopping
from regions far away on the linear genome and may direct transcription factors to specific sites
(Figure 2A). In addition, pre-existing chromatin loops can favor the residence time of transcription
factors and lead to the nucleation of transcription factors enriched environments [64]. Finally, active and
inactive (A/B) chromatin compartments are characterized by epigenetic signatures associated with
open or compact chromatin, respectively. Transcription factors may therefore preferentially access
(and bind to) the accessible active chromatin compartment (Figure 2A). The fact that domains belonging
to the same compartment are found preferentially together within the nuclear space can delimit the
space that transcription factors have to visit prior to reach functional sites. In this context, the cell
specific compartmentalization of chromatin can contribute to the establishment of a cell specific
landscape for binding of transcription factors. In line with this hypothesis, differential binding of the
ER in the breast cancer cells MCF-7 and T47D is observed in genomic domains that belong to distinct
chromatin compartments (Figure 2B).
Figure 2. 3D genome folding modulates the binding of steroid receptors. (A) Active and inactive
chromatin compartments can favor or limit, respectively, the diffusion of transcription factors within
the nuclear space. Long-range folding of the chromatin fiber can facilitate the tracking and permit
local enrichment of factors in given nuclear environments. (B) In contrast to the conservation of
borders between TADs (top panel—frequencies of contacts in red), chromosomal domains belong to
the A (green) or B (purple) compartment in a cell specific manner (middle panel). These differences
correlate with the extent of binding of the ER as shown by ChIP-Seq experiments in MCF-7 and T47D
(bottom panel).
3.3. Topological Restraint of Promoter-Enhancer Looping
An important, still opened, question is to determine whether all the sites detected by ChIP-Seq are
functional and participate in transcriptional regulation or whether they are reflecting non-productive
binding or chromatin interactions involved in other processes. The use of ChIA-PET, a method allowing
the analysis of the spatial contacts between loci bound by a specific factor [65], showed that many of
the ER bound loci were interacting together to form complex loops anchoring distal and proximal ER
sites [27]. These observations support the concept that the inter-genic ER binding sites correspond
to enhancer or silencer regions, which could act on distal target genes by chromatin looping. In this
9
Int. J. Mol. Sci. 2018, 19, 306
context, higher levels of organization may constrain the activity of the receptors by delimiting the
targets they can reach. Most of the interactions between enhancers and promoters occur within
TADs [47,66,67]. By limiting the space to be explored, this level of organization favors the activity
of regulatory elements on the genes lying within the same domain, independently of the genomic
distance that separate them (Figure 3). Conversely, the boundaries that separate contiguous domains
can act as barriers and impede ectopic action of regulatory elements on genes located outside of the
domain (Figure 3). The importance of these boundaries in demarcating the targets of a given regulatory
region is supported by experiments where the borders between TADs were specifically deleted [68].
The use of CRISR-Cas9 approach to engineer borders between contiguous TADs induces structural
modifications, with establishment of novel interactions between enhancers and promoters. This rewiring
is accompanied with a misexpression of the genes located outside of the original domain, supporting
a role for TADs in demarcating the range of action of regulatory elements [68]. Within a given TAD,
additional cell specific loops can generate sub-domains, or chromosome neighborhoods [33,38,45,47].
These local structures can serve to isolate given genes from the activity of regulatory elements in order
to maintain them in a silenced state (Figure 3) or conversely to favor the regulation of a given set of
genes [47].
The organization of the genome in chromosomal domains is therefore both limiting the activity of
given regulatory elements to a specific set of target genes and demarcating the 3D space that has to
be explored by a regulatory element to engage specific looping with its targets. This can explain the
frequent genomic clustering of steroid responsive genes as well as their co-regulation within TADs in
response to hormones [28,69–71].
Figure 3. Structural segmentation of the genome restrains the range of action of regulatory elements.
The enrichment in proteins with insulator function at the borders between TADs can prevent contact
with regulatory elements activated by steroid receptors with promoters located outside of the domains.
The natural tendency of contacts within a TAD limits the space to be explored by an activated enhancer
and favor the stability of promoter-enhancer contacts within the domain independently of the genomic
distance. Intra-domain loops established in a cell specific manner can serve to isolate genes from the
activity of distal regulatory elements or conversely, favor contacts between enhancers and specific sets
of genes.
3.4. Influence of Architectural Proteins in Steroid Response
There are evidences that architectural proteins, notably CTCF and cohesins, are directly involved
in the response to E2 [72,73]. Depletion of CTCF affects the transcriptional response to E2 of model
responsive genes [74]. ER binding sites frequently co-localize with CTCF sites in a cell specific manner,
suggesting that CTCF can direct the ER to specific regions, potentially acting upstream of FOXA1
or other pioneer factors [73]. ER is also found at sites occupied by cohesins in a CTCF independent
manner and those sites are associated with responsive genes and more prone to establish chromatin
loops [75]. In this line, depletion of CTCF or RAD21 Cohesin Complex Component by small interfering
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RNA (siRNA) led to destabilization of the loops engaged by ER binding sites [74]. In line with the
models described above, those architectural proteins can participate in licensing ER binding in a cell
specific manner and/or can facilitate the establishment of specific regulatory chromatin loops. In link
with its function as insulator, CTCF also demarcates specific chromosome neighborhoods [47] or
regulatory units, which could restrain the range of interactions of a given ER bound site [76].
4. Steroid Receptors Mediated Genome (re)-Organization
As described above, the conformation of the genome can restrain the response to steroid hormones
by modulating the binding of the receptors to chromatin as well as by demarcating the target genes
that could be regulated in a given cell type. Once bound to their DNA elements, the receptors recruit
a plethora of co-factors, which act as nucleosomes remodeling machinery or histones modifying
enzymes [7,77–79]. Recruitment of these co-regulators leads to either local or long-range modifications
of the chromatin fiber, which can consequently reshape the 3D organization and may be essential to
set the stage for subsequently acting transcription regulators.
4.1. Steroid Receptors Dependent Promoter-Enhancer Loops
The existence of functional chromatin loops between distal steroid receptor binding sites and
promoters during the activation of model genes, such as TFF1 and CTSD, have been demonstrated
by 3C [27,74,80]. In addition to loops between enhancer and promoters, there are also evidences for
steroid induced looping involved in gene repression [81]. These experiments, performed in absence
or presence of ligand, showed increased frequency of contacts of the distal regions with proximal
promoters upon binding of the receptors at the regulatory sites, suggesting that the binding of the
receptors has an instructive role on the looping. However, how receptors actually reorganize the folding
of these loci remains mainly hypothetical. Remodeling of nucleosomes as well as modifications of
histones tails, at or around receptors binding sites, lead to an opening of chromatin. This could provide
more flexibility to the chromatin fiber, increasing the probability for the looping to occur. In addition,
ER and other steroid receptors are known to interact with components of the mediator complex, such as
the Mediator Complex Subunit 1 (MED1), which could help in the stabilization of the contacts between
distal transcription machineries [82–84]. It has also been observed that enhancers bound by ER are sites
of transcription of short RNA products known as enhancer RNA (eRNA)—[12,85,86]. These RNAs
may participate in the stabilization of the contacts between distal elements and/or in the recruitment
of additional co-factors [87]. However, it is still not clear whether their production is necessary and
sufficient to induce the looping between enhancers and target promoters. Inhibition of the production
of the eRNA did not prevent the formation of loops between enhancer and promoter when MCF-7
cells were co-treated with E2 and flavopiridol [86]. In other models, the expression of non-coding RNA
was necessary to the establishment of productive looping [87].
4.2. Dynamic and/or Pre-Settled Organization of Steroid Responsive Hubs
Genome-wide studies of chromosome conformation highlighted that contacts between enhancers
and promoters occur in a complex fashion: enhancers frequently contact multiple targets and
a given gene can be submitted to the activity of several enhancers [67]. The existence of such
chromatin hubs is supported by ChIA-PET data where ER binding sites were observed to be engaged
in multiple interactions, generating a complex network of loops and anchors after exposure to
hormone [27]. Establishment of loops between multiple enhancers and promoters was observed
for other nuclear receptors [26,28,88]. It remains unclear however whether those hubs are relatively
stable structures or whether they are established de novo upon binding of the activated receptors
(Figure 4). ChIA-PET per se does not permit to determine whether the contacts observed depend or not
on the binding of the receptors. However, in the same study, various alternative approaches (3C, 4C and
FISH) were used to confirm that the looping network was dependent on hormone exposure [27].
In response to progestins, changes in transcription are associated with concomitant changes in chromatin
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structure and conformation of TADs [28], arguing for hormone induced rewiring of local spatial contacts
(Figure 4A). On another hand, some contacts between poised enhancers and promoters have also been
observed prior to exposure to the signal (Figure 4B). In this case, activated receptors bind within
a pre-established structure and the binding does not dramatically modify the existing contacts [46].
Steroid receptors themselves could participate in maintaining those pre-existing loops in the absence of
hormones. Indeed, large regulatory regions of clustering of ER and PR after exposure to the hormones
are frequently already occupied by the unliganded receptors in basal conditions. The structure of
TADs exhibiting binding of unliganded ER or PR within these regions largely differ between cells
expressing or not the receptors, suggesting a direct role for the unliganded receptors in maintaining
a structure that could facilitate further binding of the receptors after activation [88]. Active looping
induced by the hormones or binding within pre-existing structures are probably not mutually exclusive
models of action (Figure 4C). For instance, in the case of the response to glucocorticoids, the use of
ChIA-PET targeting p300 showed that a large fraction of enhancers bound by the GR upon exposure
to the hormone were already bound by p300 and engaged in interactions with gene promoters prior
to exposure to the hormone. In parallel, GR also brought de novo the histone acetyl-transferase to
a significant fraction of sites, which interactions with promoters and pre-existing sites were dynamically
modified by the hormone [26].
Figure 4. Different dynamics of promoter-enhancer looping. (A) Binding of the receptors upon
exposure to the hormone induces the formation of loop between promoter and enhancer in an active
process. (B) In other cases, the loop is established prior binding of the receptors, which activate the
enhancer region in an already favorable conformation. (C) A promoter could be regulated by several
enhancers, which require or not de novo chromatin looping. Binding of steroid receptors in the absence
of hormones (unliganded receptors) might serve in maintaining such structures prior exposure to the
hormone. Orange and green arrows correspond to paused or activated promoters, respectively.
4.3. Steroid Induced Changes at Higher Levels of Organization
As mentioned above the loops between regulatory elements and promoters appear to be limited to
loci laying in the same TAD and exposure to steroid hormones can lead to local restructuration of TADs,
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reflecting a rewiring of the contacts [26–28]. Some observations also suggest that steroid responsive
loci located further away are found together within the nuclear space. For instance, clusters of
binding sites of ER and PR located in different TADs can establish long-range interactions between
them [88] and genes responsive to glucocorticoids have been observed to cluster within nuclear
hubs [89]. These observations could suggest the existence of specific hubs or transcription factories
specialized in the response to steroids. In addition, steroids have been shown to induce large-scale
remodeling of chromatin [90,91]. This can occur through spreading of chromatin modifications over
large chromatin domains or even more globally within the nucleus [28,81,92]. Whether these large-scale
modifications are accompanied with more global changes of the 3D genome structure remains unclear.
Despite the important changes of chromatin induced by progestins, dynamic changes of chromosomal
organization were mainly observed at the level of TADs [28]. Similarly, the long-range clustering of
glucocorticoid responsive genes in nuclear hubs was not modified upon exposure to the hormones [89].
In contrast, exposure to E2 have been proposed to induce large-scale reorganization of the structure of
chromosomes [93] and some authors proposed that E2-responsive genes could be actively brought
together within the nuclear space upon exposure to the hormone, facilitating their transcription in
specific hubs [94]. However, such active clustering of E2-responsive genes was not observed by others
in similar models [95].
Although such long-range organizations may be favored, they probably remain highly stochastic
and it will be important to determine to what extent they facilitate the transcriptional response.
Additional studies of their dynamic will be also necessary to determine to what extent they are
reflected by functional modifications of higher levels of structure of the genome.
5. Future Directions
In summary, the way the genome organizes can modulate the activity of steroid receptors and
other transcription factors at several levels: accessibility to their binding sites, topological restraint
of their potential targets as well as facilitation of effective enhancer/promoter looping. Conversely,
the modifications that the receptors exert on chromatin upon exposure to their cognate signal lead to
specific restructuration of the chromatin folding, which are probably important for fine-tuning the
transcriptional response. Together these observations support a role for steroid receptors as genome
organizers, not only at local but also at global scale.
In addition to their direct effects on chromatin, it is also important to consider that steroids exert
important so-called non-genomic actions, which can actively participate in the final transcriptional
output [96,97]. For instance, estrogens and progestins can rapidly activate protein kinases [96–99] and
chromatin effectors such as Poly(ADP-Ribose) Polymerase 1 (PARP1) [100] that are both important
for their transcriptional effects. Activation of PARP1 upon exposure to hormones leads to the
formation of Poly-ADP-ribose (PAR), which directly acts on chromatin structure through histone
H1 displacement [100] as well as on the synthesis of nuclear ATP required for the response to estrogen
and progestins [101]. Interestingly, PAR has been associated with phase transition mechanisms [102]
and ATP acts as an hydrotrope for liquid droplet formation [103]. Such processes have been recently
highlighted for their potential role in the distribution of proteins and chromatin within the nuclear
space. More profound analysis of these non-genomic processes and their consequences on genome
structure will be important to better understand the pleiotropic effects that steroid hormones have on
gene transcription and cell fate.
Finally, if the 3D structure of the genome plays a role in transcription regulation in normal
cells, one could easily hypothesize that its modifications may favor inappropriate responses. Indeed,
chromosomal rearrangements could have dramatic influence on gene expression by modifying the
normal landscape of action of enhancers [68,104]. Juxtaposition of specific chromosomes or genomic
domains in the nucleus in normal cells reflects the preferential breakpoints that lead to oncogenic fusion
proteins in some cancers [105]. Hormone induced double strand breaks upon binding of the Androgen
Receptor (AR) has been involved in such processes in prostate cancers [106]. A better understanding
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of how these events occur is of particular importance in diseases associated with response to steroid
hormones, such as breast or ovarian cancers, where the genome is frequently rearranged during the
process of transformation.
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Abstract: Hormones play an important role in pathophysiology. The hormone receptors, such as
estrogen receptor alpha and androgen receptor in breast cancer and prostate cancer, are critical to
cancer cell proliferation and tumor growth. In this review we focused on the cross-talk between
hormone and hypoxia pathways, particularly in breast cancer. We delineated a novel signaling
pathway from estrogen receptor to hypoxia-inducible factor 1, and discussed the role of this pathway
in endocrine therapy resistance. Further, we discussed the estrogen and hypoxia pathways converging
at histone demethylase KDM4B, an important epigenetic modifier in cancer.
Keywords: estrogen receptor alpha; hypoxia-inducible factor 1; KDM4B; endocrine therapy resistance
1. Introduction
A solid tumor is a heterogeneous mass that is comprised of not only genetically and epigenetically
distinct clones, but also of areas with varying degree of hypoxia that result from rapid cancer cell
proliferation that outgrows its blood supply. To survive in hostile hypoxic environments, cancer cells
decelerate their proliferation rate, alter metabolism and cellular pH, and induce angiogenesis [1].
These responses of cells to hypoxia are largely coordinated by hypoxia-inducible factors HIF-1 and
HIF-2 [2], which drive the expression of a plethora of target genes, such as vascular endothelial
growth factor (VEGF), carbonic anhydrase IX (CA9), and glucose transporter 1 (Glut-1) [2]. HIF is
a heterodimer composed of an alpha subunit (HIF-1α or HIF-2α) and a β subunit (HIF-1β) [3]. HIF-1β
is constitutively expressed, whereas HIF-α is regulated by oxygen availability. Under conditions
of normoxia, HIF-α is hydroxylated at conserved prolyl residues by oxygen-dependent prolyl
hydroxylases (PHDs), resulting in binding of the von Hippel-Lindau protein (VHL), an E3 ubiquitin
ligase, for ubiquitin-mediated degradation [4–6]. Under conditions of hypoxia, however, HIFα is
stabilized through inhibition of hydroxylation, leading to transactivation of its target genes. Preclinical
and clinical studies show that the hypoxia/HIF-1 pathway plays an important role in promoting local
tumor invasion and distal metastasis, as well as negatively influencing the responses to radiotherapy
and chemotherapy [2,7–11]. The hypoxia/HIF-1 pathway is also involved in immunosuppression and
resistance to immunotherapy [12]. In addition to oxygen-mediated degradation of HIFα through VHL,
the hypoxia signaling pathway is regulated by a variety of oncogenes (e.g., ERK [13], HER2 [14],
mTOR [15], Ras [16,17]) tumor suppressors (e.g., LKB1 [18], PML [19], PTEN [20,21], p53 [22],
SDHB [23]), and metabolites (e.g., 2-hydroxyglutarate [24], succinate [25], and fumarate [26]). Here,
we focus on the cross-talk between hypoxia and estrogen-mediated pathways, which converge to
regulate epigenetic modulators in breast cancer, one of the most common cancers with 450,000 deaths
each year worldwide.
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2. The Cross-Talk between Hypoxia and Estrogen
Fifty years ago, Mirand et al. reported that in rodents, estradiol cyclopentylpropionate (ECP)
was able to inhibit erythropoiesis by suppressing the production of erythropoiesis stimulating factor
(ESF), which is now known as erythropoietin (EPO) [27], a direct target of hypoxia inducible factor.
A subsequent study in 1973 by Gordon et al. further confirmed that estrogen inhibits the production of
EPO in female rats exposed to various degrees of hypoxia [28]. Paradoxically, estrogen increases splenic
erythropoiesis that is accompanied with elevated plasma EPO levels [29]. Interestingly, the expression
of EPO mRNA is stimulated by both estradiol and hypoxia in the mouse uterus [30], and the hypoxic
induction of EPO requires the presence of estradiol [30]. In 1999, Ruohola et al. reported that estradiol
caused an increase of the HIF target VEGF mRNA in MCF-7 breast cancer cells, which was blocked
by antiestrogen ICI 182780, suggesting that the effect was mediated by the estrogen receptor [31].
Subsequent studies further demonstrated the dual regulation of VEGF by hypoxia and estrogen [32–34].
These data indicate that estrogen and hypoxia pathways are connected. A later study showed that
17-β estradiol attenuates the hypoxic induction of HIF-1α and EPO in Hep3B cells [35]. However,
in estrogen receptor-positive breast cancer cells, estrogen induces activation of HIF-1α [34] and
co-operates with hypoxia to regulate the expression of a subgroup of genes [36]. Estrogen receptor
antagonists (e.g., tamoxifen, raloxifene, or bazedoxifene) all suppress HIF-1α protein accumulation
in osteoclast precursor cells [37]. Therefore, estrogen-mediated signaling can either negatively or
positively affect the hypoxia pathway in different cellular contexts.
Estrogen receptor alpha (ERα) is an estrogen-dependent nuclear transcription factor that is
not only critical for mammary epithelial cell division, but also breast cancer progression [38,39].
Despite the multiple molecular subtypes that have been classified based on transcriptomic and genetic
features [40], ERα is one of the most important biomarkers directing breast cancer treatment. It is
recommended that all patients with ERα positivity should have adjuvant endocrine therapy. ERα
is expressed in approximately 70% of breast tumors [41], the majority of which depend on estrogen
signaling, thereby providing the rationale for using anti-estrogens as adjuvant therapy to treat breast
cancer [42]. Endocrine therapy drugs for breast cancer include selective ER modulators, such as
tamoxifen, antagonists such as fulvestrant, and aromatase inhibitors such as anastrozole. Tamoxifen is
a first-generation selective ER modulator (SERM) and has been widely used in breast cancer prevention
and treatment [42]. It antagonizes ERα function in breast cancer cells by competing with estrogen for
ERα binding while preserving its activating and estrogen-like functions in the bone [43]. Although now
replaced by aromatase inhibitors (AI) as first-line treatment in post-menopausal women, tamoxifen still
remains important in premenopausal breast cancer and after failure of AIs. The antagonist fulvestrant
leads to ERα protein degradation [44], while aromatase inhibitors block the conversion of androgens to
estrogens thereby reducing overall estrogen levels [45]. The application of endocrine therapies has led
to a significant reduction in breast cancer mortality [46]. However, not all ER-positive patients respond
to endocrine therapies and nearly all women with advanced cancer will eventually die from metastatic
disease [47,48], as resistance often develops [49]. Many mechanisms have been proposed to account
for endocrine therapy resistance [50,51], including loss of ERα expression or expression of truncated
ER isoforms, posttranslational modification of ERα, deregulation of ERα co-activators, and increased
receptor tyrosine kinase signaling. Recent studies further indicate that somatic ERα mutation [52,53],
as well as genomic amplification of distant ER response elements [54] could contribute to hormone
therapy resistance. Hypoxia is also involved in endocrine therapy resistance. Clinical studies have
shown that HIF-1α expression is associated with an aggressive phenotype of breast cancer, i.e., large
tumor size, high grade, high proliferation rate, and lymph node metastasis [55]. Increased HIF-1α
is also associated with ERα positivity [55], whilst HIF-1β, the partner of HIF-1α, has been shown
to function as a potent co-activator of ER-dependent transcription [56]. Importantly, HIF-1α protein
expression was associated with tamoxifen resistance in neoadjuvant, primary therapy of ERα-positive
breast cancers [57], as well as resistance to chemoendocrine therapy [58].
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The exact nature of the relationship between hypoxia and estrogen pathways was a puzzle
until our recent findings showing that the HIF-1α gene is a direct target of ERα [59]. In this study,
we analyzed the global gene expression profile in response to hypoxia and the ERα antagonist
fulvestrant and found a subgroup of genes that were dually responsive to the hormone and to
oxygen. These genes were upregulated by hypoxia but the ERα antagonist fulvestrant significantly
reduced their expression. These data were consistent with previous studies that showed some genes,
such as KDM4B, STC2, and VEGF, bear both a hypoxia response element and estrogen response
element [60–66]. Most interestingly, we found that ERα signaling directly regulates HIF-1α expression.
When MCF7 cells were grown without estrogen and then placed in hypoxia or treated with the
hypoxia mimetic deferoximine, estradiol greatly enhanced HIF-1α expression and this was reversed
by fulvestrant and ERα depletion. By analyzing the HIF-1α genomic sequence that bears 15 exons
and 14 introns, we identified a canonical estrogen response element (ERE) located in the first intron
(Figure 1A). Interestingly, there is also a FOXA1 binding site that is 64 nucleotides downstream of
ERE, further supporting it as a bona fide ERα binding element, because FOXA1 is a pioneer factor
that facilitates ERα recruitment [67]. Actually, one study has shown that overexpression of FOXA1 in
ER-positive breast cancer cell lines promotes resistance to tamoxifen and to estrogen deprivation [68].
We further validated our findings by chromatin immunoprecipitation-PCR and a luciferase reporter
assay, showing that ERα directly binds to this locus, driving HIF-1α gene expression. This finding not
only explains the early findings that estrogen and hypoxia pathways crosstalk, but also indicates that
overactive HIF-1α function may partially compensate for estrogen signaling when ERα function is
compromised, such as in the circumstance of hormone therapy, leading to hormone therapy resistance
(Figure 1B,C).
Figure 1. Estrogen pathway directly drives HIF-1α expression. (A) HIF-1α gene bears a canonical
estrogen receptor binding element (ERE), with a FOXA1 binding site downstream of ERE; (B) When
ERα is bound by its ligand it drives the expression of HIF-1α. However, ERα antagonists block the
expression of HIF-1α; (C) The pathways mediated by hypoxia, estrogen, metabolites, and cancer genes
converge on HIF-1α, which drives a plethora of genes that are involved in multiple biological processes,
cancer progression, and therapeutic resistance.
3. The Hypoxia and Estrogen Signaling Pathways Converge on Histone Demethylases
Genetic abnormalities that drive tumorigenesis are usually coupled with epigenetic alterations
that engage multiple important biological processes such as DNA replication, DNA repair, and gene
expression [69–73]. One such aberrant chromatin modification is histone lysine methylation [69,70],
which was believed to be irreversible until the discovery of lysine-specific demethylase 1 (LSD1) [74].
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Subsequent studies identified another family of histone demethylases, the Jumonji C (JmjC)
domain–containing demethylases [75], which require iron and 2-oxoglutarate (2-OG) for their activities.
The JmjC histone lysine demethylase family (KDMs) is composed of 17 members and is responsible
for reversing most of the histone methyl marks in the human genome. Dysregulated histone lysine
methylation is commonly seen in various cancers [76], which is consistent with observed genetic
alterations and/or dysregulation of histone methyltransferases and KDMs [75,77–81]. Interestingly,
we and others have shown that many JmjC histone demethylases are hypoxia-inducible [61,82], some
of which, including KDM3A [60,61,83], KDM4B [60,61,63], and KDM4C [84], are direct targets of HIFs.
The KDM4 subfamily of histone demethylases consists of four members. KDM4A, KDM4B,
and KDM4C share high sequence homology in their catalytic domains, and they remove methyl
groups from H3K9me2/me3 and H3K36me2/me3 [75]. KDM4A-4C members also bear other similar
functional domains that include two PHD domains and two Tudor domains. However, KDM4D is less
conserved and removes methyl groups only from H3K9me2/me3. KDM4B plays important roles in
the self-renewal of embryonic stem cells and the conversion of induced pluripotent stem cells [85,86],
and is linked to many forms of cancer [87]. KDM4B is amplified in medulloblastoma [88] and
malignant peripheral nerve sheath tumors [89], and is overexpressed in many other cancers [90–92].
KDM4B regulates the expression of key oncogenes, such as C-MYC [93–96] and CDK6 [97], and
is involved in cancer invasiveness, metastasis, and therapeutic resistance [98–100]. Interestingly,
KDM4B is a direct target of p53, exerting its DNA repair function in response DNA damage [101–103].
Recently, we showed that KDM4B is involved in neuroblastoma growth and tumor maintenance [104].
The expression of KDM4B was highly correlated with that of the MYCN oncogene in neuroblastoma,
and it formed a complex with N-Myc protein, thereby facilitating its function by maintaining low levels
of repressive H3K9me2/me3 marks at Myc-binding sites. In breast cancer we have shown that HIF-1α
and ERα can coordinate expression of genes, such as KDM4B, whose expression is driven by both ERα
and HIF-1α and epigenetically regulates the G2/M phase of cell cycle progression in breast cancer
cells [63] and other cancer cell lines (unpublished data), as the expression of several key cell cycle genes
is correlated with changes in the KDM4B substrate, H3K9me3 [63,104]. Similar to other dual responsive
genes such as VEGF and STC2 that are regulated by both estrogens and hypoxia, the genomic locus
of KDM4B bears both HIF-1α and ERα binding elements [60,63] (Figure 2A). The cross-talk between
HIF-1α and ERα converges at KDM4B, which is important for cell cycle progression and tumor growth
in ER positive breast cancer [63,93]. Importantly, in endocrine therapy-resistant breast cancer cells,
the regulation of KDM4B by HIF-1α and ERα is intact and KDM4B is still required for G2/M phase
progression [59] (Figure 2B). In addition, KDM4B is not only required for enhancing androgen receptor
(AR) transcriptional activity through histone modification, but it also enhances AR protein stability
via inhibition of AR ubiquitination [105], demonstrating the functional connection between AR and
KDM4B in prostate cancer. Therefore, HIF-1α plays an important role in modulating anti-androgen
responses via KDM4B in prostate cancer.
Figure 2. Hypoxia and estrogen pathways converge at KDM4B for cancer cell proliferation in ERα
positive breast cancer. (A) KDM4B is one of the genes responsive to both estrogen and hypoxia-mediated
pathways; (B) Regardless of endocrine therapy resistance, ERα drives KDM4B expression, which is
required for G2/M phase progression.
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4. Future Prospects
Many transcriptional factors, such as Myc, ERα, and AR, exert oncogenic functions to drive
cancer cell proliferation. Directly targeting these oncogenic transcription factors is either technically
challenging or leads to therapeutic resistance. Therefore, new approaches need to be developed to
overcome these obstacles. Transcription factors need to complex with other cofactors to drive gene
expression and many of these cofactors are histone modifiers. Thus, development of small molecules
to target the histone modifiers, such as KDM4B, may provide an opportunity to enhance the efficacy of
standard chemotherapeutics or to overcome drug resistance. Recently, efforts have been made by us
and other groups to identify and develop KDM4B inhibitors for cancer treatment [106–109]. By using
a chemoinformatics in combination with high-content imaging approach we identified ciclopirox as
a novel histone demethylase inhibitor. Ciclopirox targeted KDM4B, inhibited Myc signaling, resulting
in suppression of neuroblastoma cell viability and tumor growth associated with an induction of
differentiation [107]. We also found that MCF7 cells (ERα-positive) were much more sensitive to
MDA-MB-231 cells (ERα-negative) (Jun Yang, St Jude Children’s Research Hospital, Memphis, TN,
USA. unpublished data), suggesting ERα-positive breast cancer cells are more addicted to KDM4B.
Chu et al. identified a KDM4B inhibitor that significantly blocked the viability of cultured prostate
cancer cells, which was accompanied by transcriptional silencing of growth-related genes, a substantial
portion of which were AR-responsive [106]. Recently, a more potent and selective KDM4 inhibitor was
developed by Cellgene [108,109], which was efficacious in breast and colon cancer models. Although
whether these KDM4B inhibitors are able to reverse endocrine therapy resistance needs to be tested,
we believe specific and potent KDM4B inhibitors hold a promise for overcoming endocrine therapy
resistance to breast cancer and prostate cancer.
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Abstract: In addition to their well-known role in the female reproductive system, estrogens can act in
the brain to regulate a wide range of behaviors and physiological functions in both sexes. Over the
past few decades, genetically modified animal models have greatly increased our knowledge about
the roles of estrogen receptor (ER) signaling in the brain in behavioral and physiological regulations.
However, less attention has been paid to the estrogen-related receptors (ERRs), the members of
orphan nuclear receptors whose sequences are homologous to ERs but lack estrogen-binding ability.
While endogenous ligands of ERRs remain to be determined, they seemingly share transcriptional
targets with ERs and their expression can be directly regulated by ERs through the estrogen-response
element embedded within the regulatory region of the genes encoding ERRs. Despite the broad
expression of ERRs in the brain, we have just begun to understand the fundamental roles they play at
molecular, cellular, and circuit levels. Here, we review recent research advancement in understanding
the roles of ERs and ERRs in the brain, with particular emphasis on ERRs, and discuss possible
cross-talk between ERs and ERRs in behavioral and physiological regulations.
Keywords: estrogen; estrogen-related receptors; estrogen receptor; brain; central nervous
system; mitochondria
1. Introduction: Estrogen Receptors (ERs) and Estrogen-Related Receptors (ERRs)
Estrogens are steroid hormones known to regulate a wide range of physiological functions,
including but not limited to reproduction, cardiovascular physiology, homeostatic regulation of energy
balance, and a variety of social and learning behaviors. Traditionally, the actions of circulating estrogen
were believed to be mediated mainly by binding to two specific receptors, estrogen receptors α (ERα)
and estrogen receptors β (ERβ), which recognize and activate gene transcription through binding to the
genomic element called the estrogen-response element (ERE), either as a homodimer or heterodimer
with coactivators [1,2]. Notably, apart from their well-known roles in transcriptional regulation,
estrogens were also recently reported to rapidly activate extracellular signal-regulated kinases (ERKs)
according to a new mode of action of ERs as well as the expression of an orphan G-protein-coupled
receptor 30 (GPR30), that functions as a novel type of ER. As such, even after nearly a century since
their discovery, the exact mechanisms by which estrogens regulate different physiological functions
are still incompletely understood and remain an active area of research.
The estrogen-related receptors α and β (ERRα and ERRβ) were the two first orphan nuclear
receptors identified based on their sequence similarity to the ERα [3]. Together with ERRγ, these three
receptors consist of the ERR subfamily of the group III steroid nuclear receptor superfamily. Other
group III nuclear receptors include glucocorticoid, mineralocorticoid, progesterone, and androgen
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receptors as well as ERs. Although ERRs share sequence homologies with ERs, estrogens are not their
natural ligands and ERRs exhibit constitutive activity and can work as transcriptional regulators in
the absence of ligands [4]. The ERRs contain DNA-binding domains (DBDs) constituting two highly
conserved zinc finger motifs that target the receptor to a specific DNA sequence (TCAAGGTCA) called
the estrogen-related response element (ERRE). ERRs bind to ERRE as a monomer or a homodimer
or as a heterodimer with co-activators [5,6]. In addition to ERRE, ERRs can also bind to ERE and,
conversely, ERα, but not ERβ, and can bind to ERRE as well [7], implying shared transcriptional
networks driven by both ERRs and ERα. Not surprisingly, in many tissues both ERα and ERRs are
highly expressed, including metabolically active skeletal muscle, fat and brain [8,9], but whether and
how they are coordinated to control shared and/or distinct transcriptional events remain unclear.
Compared to ERs, our knowledge about the tissue- and cell type-specific roles of ERRs are limited.
Further studies are needed to uncover transcriptional networks driven by ERRs in different cell types
and to investigate how they will affect whole-body physiology either independently or in coordination
with estrogen signaling.
2. ERs and Their Modes of Action
As classical nuclear receptors, upon ligand binding ERs translocate to the nucleus and are
directly recruited to the EREs on the target genes. This mode of action is called the genomic action
of estrogens. However, as mentioned, the estrogen signals can also be mediated through rapid,
cytosolic ER-initiated signaling cascades. Mutant female mice in which ERα’s ability to bind to
the EREs was disrupted, are infertile and display a variety of abnormalities in the reproductive
system [10]. However, this mutation in ERα null background restores the obese phenotype of ERα
knockout mice [11], indicating that ERα’s role in the homeostatic regulation of the energy balance
is independent of its genomic action. One likely signaling pathway downstream of ERα to exert its
rapid, membrane-initiated action is PI3K/Akt pathway. Estradiol activates the PI3K/Akt pathway
in hypothalamic nuclei [11–13]. Genetic inactivation of the PI3K pathway in hypothalamic nuclei
blunts the anti-obese effects of estrogens [14,15]. Although the involvement of classical genomic ERα
signaling cannot be fully ruled out, these studies suggest a critical role of rapid, membrane-initiated
actions of ERα on energy homeostasis. Thus, it is plausible that different modes of action of estrogen
can exert different physiological functions. The latest member of estrogen receptors, GPR30 (also
known as GPER), is a G protein-coupled estrogen receptor that was cloned by several groups in the
1990s [16–19]. Later, this was followed by numerous reports showing GPR30-dependent 17β-estradiol
signaling and actual binding of 17β-estradiol with GPR30 [20–27]. So far, it is unknown whether ERRs
can also activate rapid, membrane-initiated signaling pathways as seen in ERs.
3. ERRs and Their Potential Ligands
Although ERRs were identified based on their sequence similarities to ERs, estrogen is not a
natural ligand of ERRs and to date, endogenous ligand(s) of ERRs remain unclear. Given the established
roles of ERRs in energy metabolism and the development of certain types of cancers [28–32], there have
been active and continuous efforts to identify their endogenous ligands, transcriptional co-activators,
and the synthetic compounds that can be used to modulate the activity of ERRs. Interestingly, a recent
study using affinity chromatography of tissue lipidomes with the ERRα ligand-binding domain
identified cholesterol as an endogenous ERRα agonist [33]. While this study represents a first successful
screening of potential endogenous ligands for ERRs, the specific transcriptional dynamics as well as
physiological functions of cholesterol binding to ERRα remain to be fully determined.
Although endogenous ligands of ERRs remain uncertain, several transcriptional co-activators
interacting with ERRs have been identified, which include peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC1-α) and PGC1-β [4,28,31]. Both PGC1-α and PGC1-β function as
protein ligands for ERRs and the transcriptional activities driven by these interactions have been
shown to be essential for mitochondrial biogenesis and, thus, cellular energy metabolism [4,34,35].
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Therefore, targeting these transcriptional networks may hold promise for treating the metabolic
disorders including diabetes, obesity and cancer [8,34,36–38].
Additionally, multiple inverse agonists or antagonists have been developed. Synthetic estrogen
diethylstilbestrol acts as an inverse agonist for all three ERRs [29]. More selective inverse agonists,
such as XCT 790 and DY 131, have been developed for ERRα, ERRβ/γ, respectively [39]. Most of these
inverse agonists were designed to block the interactions with their protein-binding partners. XCT 790
blocks the interaction between ERRα and PGC1-α and has been shown to inhibit the expression
of ERRα target genes [40] and cancer cell proliferation [41]. Other inverse agonists of ERRα are
compound 29 and 50 developed by Janssen Pharmaceuticals, which show high selectivity for ERRα
and have strong therapeutic potential for treating obesity and diabetes [38]. The estrogenic chemical
Bisphenol A has also been reported to be a potential agonist for ERRγ [42]. Additionally, there is
some evidence showing that dietary products, such as resveratrol, genistein, rutacarpine, piceatanol
and flavone, could function as potential agonists of ERRα [43,44]. More recently, a study screening
the Tox21 compound library has identified multiple potential novel ERR agonists, including a potent
histone deacetylase inhibitor Suberoylanilide hydroxamic acid (SAHA) and a class of lipid-lowering
medication statins, including atorvastatin, fluvastatin, and lovastatin [45]. As such, the use of these
natural and synthesized ligands will facilitate the processes of studying the whole-body effects of
modulating the transcriptional activities of ERRs and help to develop an effective therapeutic strategy
for the diseases associated with ERRs, including cancers and metabolic diseases such as obesity
and diabetes.
4. Transcriptional Regulations by Both ERs and ERRs
ER-signaling is involved in the development of breast cancer. Three quarters of breast tumors
are considered to express ERα [46,47]. The estrogen signaling through ERα regulates the expression
of various genes that play key roles in cell proliferation and cell-cycle progression [48,49]. As a
primary treatment for breast cancer, ER-positive breast cancers are preferentially treated with reagents
that suppress ERα signaling such as tamoxifen and aromatase inhibitors. Unfortunately, after years
of treatment, the recurrence of breast cancer could happen with a resistance to estrogen-signaling
inhibitors. Recently, ERRs have been attracting much attention for the prognosis of ER-positive and
negative breast cancer. ERRα expression is high in breast cancer, especially in cancer cells lacking ERα,
and is considered as a negative prognostic factor for breast-cancer survival [50,51].
While estrogen is not an endogenous ligand of ERRs, there is possible cross-talk between estrogen
signaling and ERRs in different ways (Figure 1). Studies showed that the ERRα promoter has multiple
steroid hormone response-element half-sites, where ERα could bind, and estrogens stimulate ERRα
expression in vivo and in vitro [52,53], suggesting that ERRα is one of the transcriptional targets of
ERα. Chromatin immunoprecipitation for ERα and ERRα coupled with microarray revealed that some
targeted genes are shared by these two receptors [54]. Both ERα and ERRα stimulate the transcription
of Runx2-I, a master regulator of bone development, through a common ERE, and this transcriptional
regulation by ERRα is changed dependent on its binding partner; the binding with PGC1-α acts as a
transcriptional activator, while the binding with PGC1-β acts as a transcriptional repressor [55]. These
studies suggest that ERs and ERRs can cross-talk and mutually regulate the expression of common
target genes. However, chromatin immunoprecipitation (ChIP) study also indicates that the occupancy
of the shared targets by both ERα and ERRα is relatively modest among each of their transcriptional
target genes and, therefore, it is likely that, depending on tissue, both ERα and ERRα maintain a high
degree of independence for their transcriptional regulation [54].
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Figure 1. Schematic drawing showing potential cross-talk between estrogen, estrogen receptors (ERs),
and estrogen-related receptors (ERRs). Dotted lines indicate relatively weak binding ability. MHRE,
multiple-hormone response element; CYP19, aromatase.
Possible interaction between estrogen signaling and ERRs is also supported by a study showing
that ERRα regulates the expression of aromatase, an enzyme responsible for the conversion of
testosterone to estrogen [56,57]. Aromatase expression is also regulated by ERα [58]. Additionally,
it was shown that ERRβ could directly bind to ERα in order to restrain ERα morbidity and suppress
estrogen-dependent cellular function [59]. These reciprocal interactions between estrogen, ERs and
ERRs warrant future research to investigate (1) whether the levels of ERRα expression changes by
ovariectomy or along with different stages of the estrus cycle; (2) whether ERα knockout mice have
altered levels of ERRα expression across the tissues; and (3) conversely, do ERRα knockout mice have
impaired estrogen signaling and/or reproductive dysfunctions?
5. Functions of ERs and ERRs in the Brain
5.1. Actions in the Central Regulation of Energy Homeostasis
Estrogen signaling has been well known to play an essential role in body-weight regulation [60].
Postmenopausal women experience a remarkable decline in circulating 17β-estradiol (E2), which
is often associated with the development or accumulation of body fat, obesity, type II diabetes,
hypertension, and the metabolic syndrome [61]. The involvement of estrogens in energy homeostasis
is more obvious in experimental animal models. The withdrawal of endogenous estrogens by
ovariectomy in female animals leads to hyperadiposity and body-weight gain, and this obese
phenotype can be prevented by E2 supplementation [62,63]. Conversely, microinjections of E2 into
various brain regions suppress feeding behavior and body-weight gain [64,65]. The importance
of central estrogen signaling in energy homeostasis was later confirmed by genetic mouse models.
Among three cloned estrogen receptors, the estrogenic effects on energy homeostasis are believed
to be primarily mediated by ERα. ERα is widely expressed throughout the brain including, but not
limited to, those hypothalamic and brainstem nuclei that are important for the homeostatic regulation
of energy balance, such as the ventromedial nucleus of the hypothalamus (VMH), the arcuate nucleus
of the hypothalamus (ARC), the medial amygdala (MeA), and the nucleus of the solitary tract (NTS).
Humans with a mutation in ERα and mice lacking ERα throughout the body or specifically in the brain
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are obese due to both hyperphagia and/or reduced physical activity and energy expenditure [66–68].
Furthermore, the anti-obesity effects of E2 replacement in ovariectomized mice are blocked in ERα
knockout mice [62].
More specifically, the knockdown of ERα in the VMH by shRNA blunts E2-mediated weight
loss and leads to obesity associated with increased visceral fat [69], likely due to decreased physical
activity and impaired thermogenesis, but not food intake. Consistent with these findings, the mice
with VMH-specific ERα knockout [68] showed modest weight gain due to reduced energy expenditure
but not food intake, and were infertile.
ERα is also abundantly expressed in the ARC [69]. The ARC contains two primarily distinct but
intermingled neuronal populations that express either anorexigenic pro-opiomelanocortin (POMC)
or orexigenic agouti-related peptide (AgRP) and neuropeptide Y (NPY). ERα is expressed in POMC
neurons [68,70,71] and POMC levels change in response to estrogens [72]. Genetic mouse study
revealed that conditional deletion of ERα in POMC neurons leads to hyperphasia and modest weight
gain [68]. AgRP/NPY neurons are also modulated by estrogen signaling. Dhillon and Belsham have
shown that estrogens inhibit NPY release in immortalized hypothalamic cells through a ERα-dependent
mechanism [73]. AgRP and NPY expressions fluctuate along with the estrus stages and the anorexigenic
effect of 17β-estradiol was blunted in mice with the ablation of AgRP neurons [74]. NPY neuronal
excitability is also modulated by estrogen via a change in K+ channel expression [75]. However, which
type of estrogen receptors are responsible for estrogen effects on AgRP/NPY neurons is controversial.
Immunohistochemistry failed to detect ERα in NPY neurons despite clear estrogen effects on this
neuronal population [74]. On the other hand, others reported colocalization of NPY and ERα [76,77].
ERα is also highly expressed in the medial amygdala (MeA). Conditional deletion of ERα in the
MeA led to weight gain in both male and female mice, mainly due to decreased energy expenditure
associated with low physical activity, but not food intake [78]. Interestingly, both male and female
aromatase knockout mice develop obesity due to lowered physical activity, and this body weight gain
is not associated with hyperphasia [79], resembling phenotypes observed in mice lacking ERα in MeA.
As such, ERα expressed by distinct types of neurons in the brain seemingly plays differential
roles in maintaining whole-body energy homeostasis as reviewed elsewhere [60]. By contrast with
the positive energy balance observed in ERα knockout mice, however, it has been reported that
conventional ERRα knockout mice have reduced body weight and fat mass compared to their control
littermates, especially when challenged with high fat diet (HFD) [80]. While food intake seemed
comparable between knockout and control groups in an early report [80], we have recently found
a significant reduction of palatable HFD intake in ERRα knockout mice that is associated with a
significant reduction of body weight [81]. This is not only with general consumption of HFD, and we
also found that hungry ERRα knockout mice display less willingness to obtain HFD pellets in an
operant-responding behavioral paradigm with a progressive ratio schedule compared to their control
littermates, suggesting a reduced motivation to work for palatable food [81]. Interestingly, through
a family-based genetic linkage study combined with whole exome sequencing in a family in which
multiple members are affected by eating disorders, particularly anorexia nervosa, we have identified
a missense mutation in the ERRα gene that co-segregates with illness [82]. A subsequent study in
mice revealed that the level of expression of ERRα in the brain is increased by caloric restriction,
implying that brain ERRα may sense peripheral energy status and convert it into protective behavioral
actions, including motivation to obtain and consume food [81]. It is possible that a genetic deficit of
ERRα disrupts this adaptive (protective?) physiological process upon caloric restriction, leading to
pathological conditions such as eating disorders [81]. Somewhat consistent with the differential role
of ERRα and ERα in body-weight homeostasis, the expression pattern of ERRα in the hypothalamus
is different from ERα. Unlike the high expression of ERα in the mediobasal hypothalamus, which
is critical for the coordinated control of energy balance [68], ERRα expression is nearly absent in the
mediobasal hypothalamus (Figure 2). However, it should also be noted that other than the mediobasal
hypothalamus, in many brain regions, including the cortex and hippocampus, both ERα and ERRα are
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homogeneously expressed (Figure 2). From the viewpoint of brain reward circuits [83,84], however,
some of the extra-hypothalamic regions, such as several frontal cortices and the hippocampus, express
relatively high levels of ERRα, and the ventral striatum, ventral pallidum, and lateral hypothalamus
with moderate levels [81]. Interestingly, the ventral tegmental area (VTA), a key brain region of brain
reward function, had minimal expression of ERRα [81]. We have previously shown that specific
knockdown of ERRα in the medial prefrontal cortex (mPFC) recapitulates reduced motivation for
HFD observed in Esrra-null female mice, indicating that Esrra expression in the mPFC may affects
top-down control of food reward behaviors [81]. Nonetheless, it is possible that ERRα expression in the
periphery, rather than the brain, is responsible for protected weight gain observed in ERRα knockout
mice on HFD feeding. Further studies with conditional a ERRα deletion approach are necessary to
prove this possibility.
Figure 2. Representative immunohistochemistry (IHC) images showing ERRα (A) and ERα (B)
expression in the mouse brain. Digital zooms of individual boxed regions are shown in A1, A2,
B1, and B2. Note that expression pattern of ERRα and ERα is similar in the cortex and the hippocampus
(A1,B1), but strikingly different expression was observed in the mediobasal hypothalamus (A2,B2)
that is critical for the homeostatic regulation of energy balance. Note: the IHC image shown in (A)
was from our previous publication with a zoom-in view [81]. The IHC image shown in (B) was from
the brain sections of an adult female wild-type mouse stained with validated commercially available
ERα antibody (1:1000, Millipore) as reported previously [71]. This ERα antibody was validated in
conditional ERα KO mice previously [68]. Scale bar = 1 mm in A and B, and 500 μm in A1, A2, B1,
and B2.
ERRγ knockout mice die shortly after birth due to cardiac failure [85] and, therefore, the role of
ERRγ in the regulation of body weight homeostasis remains elusive. A recent study with exclusive
overexpression of ERRγ in skeletal muscle of obese db/db mice revealed that gain of function of ERRγ
in skeletal muscle does not ameliorate obesity or diabetic phenotypes in leptin receptor deficiency [34].
ERRγ is also abundantly expressed throughout the brain [86,87], and colocalization of ERRγ and
ERα is confirmed within the same neurons in selected regions [86]. Again, studies with conditional
ERRγ deletion models are necessary to determine the effects of ERRγ in the long-term regulation of
energy homeostasis.
Like ERRγ knockout, global knockout of ERRβ is also lethal for mice [88]. However, a recent
study with conditional deletion of ERRβ using Sox2-Cre revealed that these mice are viable and
exhibit significantly decreased body weight compared to their littermate controls mainly due to
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increased activity and energy expenditure [89]. In fact, food intake was significantly increased,
which is likely a compensatory response for extremely increased energy expenditure. Paradoxically,
however, when ERRβ is deleted from the central nervous system using nestin-Cre, these mice
exhibit significantly increased body weight while maintaining higher activity and energy expenditure.
Consistent with these results, it was found that increased body weight was mainly due to increased
lean mass, but not fat mass, explaining their increased energy expenditure. Interestingly, a loss of
ERRβ caused significant upregulation of ERRγ which, the author concluded, might be responsible
for the decreased NPY expression in these mice affecting the satiety response [89]. Thus, the ERRβ
is clearly involved in long-term regulation of the energy balance, but underlying mechanisms seem
complicated, involving a combination of changes of food intake, meal pattern, activity, and energy
expenditure by different mechanisms.
Compared to peripheral tissues, the study of the cross-talk between ERs and ERRs in the brain is
limited. Further investigation is needed to clarify their cellular colocalization and to better understand
the coordinated actions of these relatives.
5.2. Actions in Learning and Memory
Estrogens are known to affect the hippocampus, a large brain structure critical for learning
and memory. Estrogen can acutely modulate the electrophysiological properties of hippocampal
neurons in ex vivo slice preparations [90–92]. Since this effect is rapid, estrogen is thought to work
through a rapid, membrane-initiated mechanism in this regard. Membrane-initiated estrogen-signaling
activates various protein kinase cascades such as PI3K, protein kinase A, protein kinase C, phospho
lipase C, and mitogen-activated protein kinase, leading to the modulation of signal transduction,
protein phosphorylation, and ion channel activity [76]. Two estrogen receptors, ERα and ERβ,
appear to be located predominantly in synapses, axons, dendrites and dendritic spines [93,94],
and work differentially in the hippocampal inhibitory and excitatory synapses, respectively. Estradiol
acutely enhances excitatory postsynaptic currents, which can be recapitulated by ERβ-specific agonist
diaryl-propionitrile (DPN), but not ERα-specific agonist propyl-pyrazole triol (PPT) [95]. On the other
hand, estradiol works through ERα to suppress inhibitory neurotransmission in the hippocampal CA1
neurons [96]. Estrogen treatment rapidly increases dendritic spine density in CA1 of the hippocampus
associated with improved spatial learning and memory [97]. Rapid estrogen signaling is observed even
with E2-BSA, a membrane-impermeable conjugate of estrogen [98,99]. In addition to these classical ERs,
a number of studies using different technologies indicate that rapid estrogen signaling mediated by
receptors other than ERα/β exists. E2 can potentiate kainate-induced currents, which can be observed
even in the hippocampus of ERα KO mice. In addition, this E2-induced potentiation is unaffected
even in the presence of ERα/β blocker [100]. Selective ligand to G-protein coupled estrogen receptor
STX, that does not bind to ERα and ERβ, and activates G-protein signaling cascade [99].
Despite considerably high expression of ERRs, especially ERRα and ERRγ, in hippocampal
formation, their roles in memory and learning are largely unexplored. Some evidence suggests that
ERRγ-mediated gene transcriptions may affect hippocampal functions. It was shown that bisphenol
A, a potential agonist for ERRγ and ERα/β, modulates spinogenesis in adult hippocampal neurons
through ERRγ, but not ERα/β. Pei et al. showed that ERRγ-deficient hippocampal neurons exhibit
lower metabolic capacity [101]. In addition, ERRγ-deficient hippocampal slices showed a significant
reduction in long-term potentiation (LTP), which could be rescued by pyruvate supplementation,
indicating that the impaired LTP is likely caused by the metabolic deficiency. Consistent with these
observations, ERRγ knockout mice showed impaired spatial learning and memory [101]. Although
ERRα is also widely expressed throughout hippocampal formation (Figure 2), its role in learning
and memory remains to be explored. We have previously shown that the ability of learning and
memory in ERRα knockout mice was comparable to wild-type littermates in a Barnes maze test,
but reversible learning in this behavioral paradigm was significantly impaired in ERRα knockout
mice [81]. However, impaired reversible learning in a Barnes maze test could be interpreted as an
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indication of behavioral rigidity, rather than memory per se. Interestingly, Wrann et al. have recently
shown that exercise-induced increases of brain-derived neurotrophic factor (BDNF), a neurotrophic
factor essential for synaptic plasticity, hippocampal function and learning, is mediated by elevated
expression levels of fibronectin type III domain containing 5 (FNDC5) (precursor of a novel, circulating
myokine irisin) that is driven by a ERRα/PGC1α transcriptional network [40]. These findings indicate
that, while the ERRα may plays a minimal role in learning under normal physiological conditions,
it might be an important molecular mediator of exercise-induced beneficial effects in improving
learning and memory through the ERRα/PGC1α→FNDC5→BDNF pathway. Indeed, it has been
postulated that, rather than in a baseline condition, the roles ERRα plays become more apparent when
animals are subjected to various physiological and environmental challenges requiring them to make
adaptive responses [102]. Therefore, the potential role of ERRα in learning and memory needs to be
further investigated under different physiological conditions or by different behavioral learning and
memory tasks. Additionally, we have previously found that both presynaptic vesicle pool density and
the numbers of dendritic spines are significantly decreased in the striatum of female ERRα knockout
mice [103]. Although it remains unclear whether similar changes also occur in the hippocampus, these
findings are suggestive of impaired synaptic plasticity in ERRα knockout mice by impaired synaptic
vesicle trafficking and/or synaptogenesis. It will be interesting to test whether exercise-induced
beneficial effects on improving learning and memory are lost or impaired in ERRα-deficient mice.
5.3. Actions in Social Behaviors
Estrogens have been shown to impact a wide range of social behaviors, and ERα and ERβ may
play differential roles in this regard in a gender-specific manner [104]. Global ERα knockout male
mice are less aggressive [105], while ERβ knockout mice show enhanced aggressive behavior [106],
indicating that ERα is essential for expressing aggressive behavior whereas ERβ works on it in an
antagonistic manner. Furthermore, ERα in distinct brain nuclei differentially regulates male aggressive
and sexual behaviors. Adeno-associated virus (AAV)-mediated ERα knockdown in the medial preoptic
area reduced sexual but not aggressive behavior while the knockdown in the VMH suppressed both
behaviors. On the other hand, the knockdown in the MeA had no effects on either behavior [107].
MeA also expresses aromatase. Selective ablation of aromatase-expressing cells in the MeA suppresses
male aggressive behavior and female maternal aggressive behavior [108].
The involvement of estrogen-signaling in social behaviors should not ignore its function in the
perceptions of others [109]. Ovariectomized female animals are less attractive to males than intact
female animals, which can be restored by estrogen supplementation [110,111]. Genetic studies suggest
that odors produced from either ERα knockout or ERβ knockout female mice are different from those
from wild-type female mice, and wild-type male mice show less interest in ERα knockout or ERβ
knockout female mice compared to wild-type female mice [112]. The same thing can be said of the
perception of ERα and ERβ knockout male mice by wild-type female mice. Wild-type female mice
can successfully discriminate the odors of wild-type males from those of knockout males and display
significantly higher preference for the WT male odors.
Classic lesion and electrical stimulation studies have identified the brain loci involved in
aggression and other social behaviors, which include the anteroventral periventricular nucleus,
the medial preoptic area, the bed nucleus of stria terminalis, and VMH. Additionally, the recent
development of optogenetic and pharmacogenetic techniques also greatly facilitated the process of
delineating brain circuits that might mediate estrogen actions in these behavioral regulations [99].
The VMH is one of the important nuclei that mediate estrogenic actions in energy homeostasis.
In addition to energy homeostasis, recent studies using optogenetic and pharmacogenetic tools have
begun to unravel the importance of ERα-expressing neurons in the VMH in social behaviors, such
as sexual behavior and aggression. Optogenetic and pharmacogenetic activation of ERα-expressing
neurons in the VMH trigger aggressive behaviors in both males and females [113,114]. This ERα-
expressing subpopulation of VMH neurons seem to not only control aggressive behavior but also
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involve other social behaviors such as investigation and mounting in males, and increasing both the
number of active neurons and the activity level of each neuron can shift the behavioral responses
from mounting to attacking [113]. A separate study targeting ERα-expressing neurons with same Cre
mouse model also showed that VMH ERα-positive neurons are highly active during attacking and are
necessary for female aggressive behavior as well [114]. These studies clearly showed the involvement
of ERα-expressing neurons in aggressive behavior, but it remains unclear whether signaling through
ERs itself is important for the aggressive behaviors.
ERRs, especially ERRα, also regulate social behaviors. Impaired social function was one of the
characteristic behavioral deficits observed in ERRα knockout mice [81]. ERRα knockout mice showed
reduced interaction with a novel mouse tested in a social interaction test. Furthermore, in the tube test
which measures the dominance tendency, ERRα knockout mice were almost always the losers [81].
The recent sophisticated behavioral and optogenetic studies showed that the activity of the dorsomedial
prefrontal cortex (dmPFC), where ERRα is highly expressed, is important for instant winning or losing
in the tube test [115,116]. It will be interesting to test if optogenetic activation of dmPFC ERRα-positive
neurons can rescue social subordination seen in ERRα knockout mice. It is difficult to associate the
VMH-regulated aggressive behavior with dmPFC-regulated social dominance. Social dominance is
important for survival in social animals and aggression could be a means to reach the top of the social
hierarchy. It is noteworthy that the selective knockdown of ERRα in distinct subnuclei of the PFC
can recapitulate some behavioral deficits observed in ERRα knockout mice, such as reduced body
weight and food intake, reduced effort responding for food reward, and increased grooming [81].
Recently, synchronized activity among distant brain nuclei (PFC-lateral septum-lateral hypothalamus)
is suggested to be involved in food-seeking behavior [117]. Whether such a synchronicity exists
between PFC and VMH for the coordinated control of social dominance and/or aggressive behavior
remains to be determined. Cortical parvalbumin (PV)-expressing inhibitory interneurons are a potent
regulator of local network activities [118] and coherent activity of PV neurons orchestrates synchronous
gamma oscillations [119,120]. Widely distributed expression patterns of ERRs (both ERRα [81] and
ERRγ [86,87]) throughout the brain are indicative of their likely expression in both excitatory and
inhibitory neurons. Future studies of conditional deletion models are required to distinguish their
roles in different types of neurons in behavioral regulations. Given an established role of ERRs
in mitochondrial biogenesis [121,122] and, thus, cellular energy supply, it would be interesting to
investigate whether ERRs are enriched in cortical inhibitory interneurons with high energy demand,
particularly fast-spiking PV neurons [123,124], and whether loss of ERRs will cause aberrant firing
of these neurons due to insufficient cellular energy production, leading to behavioral abnormalities
including social behaviors. In line with the involvement of ERRs in mitochondrial biogenesis in
GABAergic interneurons, its protein ligand PGC1-α, a master regulator of mitochondrial biogenesis,
is predominantly expressed in these neuronal populations [125] and bidirectionally regulates PV
expression [126]. PGC1-α in PV neurons transcriptionally regulates genes relevant to synaptic
transmission, as well as metabolism-related genes and conditional deletion of PGC1-α in PV neurons
results in asynchronous GABA release and impaired long-term memory [127]. Notably, a recent
comprehensive gene expression profiling in the hypothalamus, frontal cortex, and amygdala by
RNA-Seq combined with ChIP-Seq revealed that ERRα is in the center of coordinating transcriptional
networks for adaptive responses when animals are challenged to agonistic social encounters [128].
Transcriptional regulatory dynamics that take place under social challenges could be essential for
animals to learn from this type of social challenge and affect future behaviors critical for survival.
The roles of ERRα in adaptive metabolic and behavioral responses to social stressors warrant future
investigation. Additionally, a variety of behavioral deficits caused by ERRα deletion are sexually
dimorphic [81], yet no sexually dimorphic expression patterns of ERRα in the brain were observed.
Further studies are needed to clarify the underlying mechanisms of sexual dimorphic roles of ERRα in
these behavioral regulations.
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6. Concluding Remark
It has been well known that both ERs and ERRs play important roles in physiological regulations
through their abundant expression in peripheral tissues, particularly for metabolic homeostasis and
energy metabolism (Figure 3). Mounting evidence indicates that the brain is also one of the primary
targets of estrogen (via ERs) to regulate a variety of behaviors and physiological functions including
reproduction, energy homeostasis, and learning and memory. ERRs share sequence similarity with
ERs, but estrogen is not their endogenous ligand and little attention has been paid to the cross-talk
between estrogen-signaling and ERRs. Existing evidence supports the idea that estrogen-signaling
and ERRs may cross-talk via transcriptional regulation, or reciprocal binding on each responsive
element, or even intercellularly through the regulation of estrogen synthesis by aromatase. However,
the roles of ERRs in the brain and functional segregation of the isoforms remain largely unknown.
Additionally, the functional overlaps between ERs and ERRs are almost untouched at the behavior
level. Gene-expression profiling studies in peripheral tissues and cell lines indicate that shared target
genes by both receptor families may be modest, with a high degree of independence. While the
expression patterns of ERα and ERRα suggest that these two receptors might colocalize in some brain
regions, to what extent, if any, they share transcriptional targets in the brain is unclear. It is obvious that
both families are involved in the processes important for brain functions such as synaptic transmission,
neuronal firing and mitochondrial biogenesis. A more comprehensive understanding of the target
genes and the transcriptional cross-talk between these receptors may provide more insights into the
estrogen-dependent and -independent regulation of brain functions.
Figure 3. ERs and ERRs regulate a variety of important cellular functions and any disruption in these
processes can lead to different pathological conditions. MitoBio, mitochondrial biogenesis; β-OX,
beta-oxidation; FAO, fatty acid oxidation; Oxphos, oxidative phosphorylation; ETC, electron transport
chain. Red dot indicates estrogens and “?” indicates unknown ligands for ERRs.
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AgRP Agouti-Related Peptide
Akt Protein Kinase B
ARC Arcuate nucleus Of Hypothalamus




DBD DNA Binding Domain




ERE Estrogen Response Element
ERR Estrogen-Related Receptor
ERRE Estrogen-Related Response Element
ERK Extracellular Signal-Regulated Kinase
ETC Electron Transport Chain
FAO Fatty Acid Oxidation
FNDC5 Fibronectin Type III Domain Containing 5
GPER G protein-Coupled Estrogen Receptor




MHRE Multiple-Hormone Response element
MitoBio Mitochondrial Biogenesis
NPY Neuropeptide
NTS Nucleus of Solitary Tract
Oxphos Oxidative Phosphorylation
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PGC Proliferator-Activated Receptor γ Coactivator
PI3K Phosphatidyl Inositide 3-Kinase
POMC Pro-Opiomelanocortin
PPT Propyl-Pyrazole Triol
VMH Ventromedial Nucleus of Hypothalamus
VTA Ventral Tegmental Area
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Abstract: Estrogen has been postulated as a contributor for lung cancer development and progression.
We reviewed the current knowledge about the expression and prognostic implications of the estrogen
receptors (ER) in lung cancer, the effect and signaling pathway of estrogen on lung cancer, the
hormone replacement therapy and lung cancer risk and survival, the mechanistic relationship
between the ER and the epidermal growth factor receptor (EGFR), and the relevant clinical trials
combining the ER antagonist and the EGFR antagonist, to investigate the role of estrogen in lung
cancer. Estrogen and its receptor have the potential to become a prognosticator and a therapeutic
target in lung cancer. On the other hand, tobacco smoking aggravates the effect of estrogen and
endocrine disruptive chemicals from the environment targeting ER may well contribute to the lung
carcinogenesis. They have gradually become important issues in the course of preventive medicine.
Keywords: epidermal growth factor receptor; estrogen; estrogen receptor; hormone; lung cancer;
lung adenocarcinoma
1. Introduction
Estrogens are steroid hormones. 17-β-Estradiol (E2) is the primary reproductive hormone
synthesized in the ovary under the stimulation of the follicular stimulating hormone and the luteinizing
hormone [1–4]. Estrone and estriol are mostly synthesized in the liver from E2. The functions
of estrogen and its receptors in reproductive organs, especially in a female, have been known for
several decades. The importance of the estrogen signaling pathway in various physiologic, pathologic
functions and carcinogenesis has also been extensively investigated, especially in the context of
breast cancer.
There are two types of classical estrogen receptor (ER). ER alpha (ERα, also known as ESR1),
product of genes on chromosome 6, first cloned in 1986 and distributed in breast, ovary, and
endometrium. ER beta (ERβ, also known as ESR2), product of genes on chromosome 14, discovered
in 1996 [5], with a wider distribution including the bone, brain, colon, endothelium, kidney, lung,
ovary, prostate, and testes. They share similar structures and are composed of five domains. The A/B
domain is the site of the transcriptional activation, with the coactivator, AF-1. The C-domain is the
DNA-binding site. The D-domain hinge contains a nuclear localization signal. The E-domain is the
ligand binding domain and the site of the transcriptional activation, with the coactivator, AF-2. The
F-domain may play a complex regulatory role. The 55% homology between the ERα and ERβ in
the ligand binding domain results in the variable affinities. While both exhibit similar affinities to
E2, ERα has a higher affinity to estrone and ERβ has a higher affinity to estriol. In addition to the
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wide-type ERs, several splicing variants or isoforms of the ERs have been described with variable
DNA- or ligand-binding properties.
Upon binding with estrogen, the ERs form either homo- or heterodimers and bind to the estrogen
responsive element, the ERE within the promoter of a target gene, and then regulate its transcription
in the case of the genomic pathway. ERs may also regulate gene expression via the binding to other
transcription factors such as the activator protein 1, AP-1 or the stimulating protein 1, Sp1. On the
other hand, ERs may translocate to the membrane, where they may mediate a non-genomic pathway
that results in more rapid responses, such as the activation of protein kinase, the production of second
messengers, or the regulation of ion channels.
Lung cancer is a leading cause of cancer-related mortality worldwide, including Taiwan. Studies
conducted in Western countries estimated that 85–90% of lung cancer cases were attributed to
smoking [6,7]. Although 80% of female lung cancer patients worldwide have smoked, less than
10% of Taiwanese women are smokers [8]. In our previous lung cancer study, only 6.4% of the female
patients had smoked cigarettes at some time in their lives [9]. There is a lung adenocarcinoma epidemic
with an equal occurrence and prognosis in both genders who have never smoked in Taiwan [10].
Smoking history appeared to be a poor prognostic factor for patients with lung adenocarcinoma,
rather than as a risk factor. The low smoking prevalence and high incidence rate of adenocarcinoma
constituted distinctive characteristics of lung cancer in Asian countries, and leads to the suggested
existence of non-tobacco related risk factors in the pathogenesis of lung adenocarcinoma.
Another study showed a more significant survival advantage for elderly women with lung
adenocarcinoma, as compared with their male counterparts [11]. In addition to the inferior survival of
elderly male patients attributed to the accumulated adverse effect of a higher prevalent smoking habit,
the superior survival of the postmenopausal female patients was possibly due to the less estrogen
cancer promoting effect. The premenopausal women, who comprised one-fifth of the non-smoking
female patients with lung adenocarcinoma, were found to have had the more advanced disease and a
shorter survival rate than the postmenopausal women. The epidemiology results suggest that estrogen
adversely affects the prognosis of patients with lung adenocarcinoma.
Estrogen is speculated as playing an important role in lung carcinogenesis [12,13]. In healthy
lung tissue, ERβ is highly expressed in pneumocytes and in the bronchial epithelial cells, and is
required for the maintenance of the extracellular matrix of the lung [14,15]. The lung tissues of ERβ
null mice were found to have a decreased number of alveoli and a lesser amount of surfactant [16].
Studies of ER deficient mice have shown that ERα mediates the determination of the alveolar number
and the surface area while ERβ affects the lung tissue elastic recoil [17]. Estrogen receptors (ER) are
consistently found in lung cancer tissues and cell lines, especially adenocarcinoma, and mostly in the
form of the ERβ [18–21]. Estrogen has been reported to adversely affect the prognosis of lung cancer
patients [22–30]. However, there are several studies with conflicting results about the effect of estrogen
on the risk and/or survival of lung cancer [31–36].
We demonstrated ERβ was the predominant ER in the A549 and PE089 lung cancer cell lines,
and malignant pleural effusions from the patients with lung adenocarcinoma. Osteopontin (OPN)
is a small integrin-binding ligand N-linked glycoprotein regulating signaling pathways involved in
tumor progression and metastasis [37–39]. Enhanced OPN expression has been noted in the plasma of
advanced lung cancer patients, and OPN has also been speculated to be involved in the formation of
malignant pleural effusion [40,41]. Estrogen up-regulated the OPN expression and promoted lung
cancer cell migration via the ERβ activation of the MEK/ERK signaling pathway. An additive effect of
the ER antagonist and the epidermal growth factor receptor (EGFR) antagonist on the inhibition of
lung cancer cell migration was also observed. Osteopontin supposedly contributes to the cross-talk
between the ER and EGFR signaling pathways [11]. In current clinical practice, breast cancer survivors
offer a unique patient cohort to evaluate the effect of anti-estrogen on the survival of lung cancer
patients [42,43]. We have evaluated the outcome of 26 women who have had second primary lung
cancer among 6361 breast cancer patients diagnosed and treated between January 2000, and December
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2009, at Sun Yat-Sen Cancer Center and found that the patients who were treated with anti-estrogens
for breast cancer had a longer cancer-specific survival rate than those without anti-estrogens [44].
Multivariate analysis confirmed that the anti-estrogen treatment was an independent prognostic
factor. These findings reinforced the evidence that estrogen had, in fact, contributed to the lung
cancer progression.
This review aims to summarize the current knowledge with regard to the expression and
prognostic implications of the ERs in lung cancer, the effect and signaling pathway of estrogen
on lung cancer, the hormone replacement therapy and lung cancer risk and survival, the mechanistic
relationship between the ER and the EGFR, and the relevant clinical trials combining the ER antagonist
and the EGFR antagonist, to investigate the role of estrogen in lung cancer. Interaction between
tobacco smoking and estrogen, and the role of endocrine disruptive chemicals targeting ER from
the environment in the lung carcinogenesis were also discussed from the viewpoint of preventive
medicine. As small cell lung cancer (SCLC) is a distinct neuroendocrine tumor, composed of about
10% to 15% of lung cancer, and the association between estrogen and SCLC was scarcely studied and
mostly obsolete [45,46]. The following issues will focus on the non-small cell lung cancer (NSCLC),
being mostly adenocarcinoma.
2. Estrogen Receptor in Lung Cancer
Baik et al. have systemically reviewed the detection rates of the ERα and ERβ in lung
cancer [47,48]. For the ERα, the detection rate using 1D5 with the epitope in N-terminus is 0% to 55%,
in contrast with 36% to 84% using HC-20 with the epitope in C-terminus, and 0% to 78% using 6F11
for the full length. For the ERβ, the detection rate using H-150 or 14C8 with the epitope in N-terminus
is 49% to 98%, and 16% to 86%, respectively. The detection rate is 9% to 84% using PPG5/10 with
the epitope in the C-terminus. The results were variable. Such an inconsistency may be due to the
differences in the methodology, i.e., which antibody is used, heterogeneous definitions of positivity,
and various patient populations, i.e., pathology, stage, gender, and smoking history [47–49]. The ERα
antibody with epitope in the C-terminus reported a higher detection rate than that with epitope in
the N-terminus in the NSCLC, and was mostly cytoplasm-located. The ERα probably occurs as the
N-terminal deleted mutants in the NSCLC and lacks the nuclear localization [47–49]. Unlike the ERα,
both of the full-length and splicing variants of the ERβ exist in the NSCLC cells. A strong expression
of the ERβ was observed in the cytoplasm as well as the nucleus. Standardized measurement, i.e.,
which antibody was used, or a different approach from immunohistochemistry, e.g., western blot,
mRNA expression by real time quantitative PCR, is necessary to make the ERs as useful biomarkers in
the future.
Estrogen receptor β appears to be the predominant form in lung cancer from the literature [18–21].
Five splicing variants had been identified with ERβ1 being the only full-length receptor able to bind
ligand and form homodimers in human. The rest of the isoforms are inactive, but they can form
heterodimers with ERβ1 to regulate its transcriptional activity [50].
The expressions of ERα and ERβ as a prognosticator for NSCLC have been reported in several
studies [20,21,51–64] (Table 1). Contrary to that in breast cancer, ERα in lung cancer was mainly
observed in the cytoplasm and associated with a poor prognosis. Most reports found that the
nuclear ERβ was predictive of a better prognosis, and the cytoplasmic ERβ was associated with
a poor prognosis [47,48]. Nonetheless, opposing results have also been reported [54,60,62,63,65,66].
Co-expression of the cytoplasmic ERβ and the nuclear ERβ that had been reported correlated with a
poor survival rate when compared to those without co-expression [67]. The nuclear and cytoplasmic
ERs may have a distinct function and affect the prognosis differentially via the genomic or non-genomic
pathway. ERβ has also been shown to localize with the mitochondria in a ligand-dependent or
-independent manner and can affect the bioenergetics and anti-apoptotic signaling. Mitochondrial
ERβ sequesters Bad and inhibit Bad-Bcl-XL, and Bad-Bcl-2 interactions, to protect against apoptosis,
thereby suggesting its value as a new therapeutic target [27,68,69]. Further study is warranted to
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analyze the function of different ERβ isoforms and their cellular localization, which is essential to
completely understand the role of the ERβ in lung cancer. According to the study of Kadota, although
nuclear ERα expression was observed in only 17% of the patients with pT1a lung adenocarcinomas,
it was an independent predictor of recurrence [61]. The nuclear ERα expression positively correlated
with the tumoral FoxP3+ lymphocytes, and poor prognostic immune microenvironments.
Table 1. Estrogen receptor (ER) detected by immune-histochemical stain as prognosticators in NSCLC.
References ER Subtype Location Prognosis
Kawai 2005 [20] α Cytoplasm Worse
β Nucleus Better
Schwartz 2005 [21] β Non-specified Better (male)
Worse (female) *
Wu 2005 [51] β Nucleus Better
Skov 2005 [52] β Nucleus Better (male)
Worse (female)
Nose 2009 [53] α Cytoplasm Worse
β Nucleus Better
Raso 2009 [54] β Nucleus Worse
Stabile 2011 [55] β Cytoplasm Worse
Rouquette 2012 [56] α Nucleus Better
Rades 2012 [57] α Non-specified Worse
Karlsson 2012 [58] β Nucleus Better
Navaratnam 2012 [59] β1 Nucleus Better in earlier stage
Worse in later stage
Liu 2013 [60] β2,5 Cytoplasm Better
Kadota 2015 [61] α Nucleus Worse
Liu 2015 [62] β Cytoplasm Better
Skjefstad 2016 [63] β Nucleus Worse (female)
Tanaka 2016 [64] β Non-specified Worse (male)
* Not significant but with a trend.
The G-protein-coupled estrogen receptor (GPER), discovered in 2005, was proposed to be involved
in the cancer cell proliferation, migration and invasion, and acts as a modulator of the neoplastic
transformation [4,70,71]. It is not only located in the cell membrane, it has also been detected in the
Golgi apparatus and endoplasmic reticulum [72,73]. Increased expression of the GPER was observed
in the lung cancer cell lines as well as the human and mice lung cancer tissue, and more was located in
the cytoplasm [74,75]. Paradoxically, the antagonists/modulators of the classical estrogen receptors
such as tamoxifen, raloxifen and fulvestrant, were found to be the GPER agonists [70].
In contrast with GPER, the classical ERs do not contain a hydrophobic part that may serve as
a transmembrane domain. However, the presence of ERs in the membrane of somatic and cancer
cells have been reported. The membrane translocation of the ERs is mediated by the SRC family
of tyrosine kinase [76]. Specific motifs and modifications are required. The knowledge on how the
classical ERs translocate to the membrane together with the knowledge on the GPER action, and the
interactions between the GPER and the classical ERs is of the greatest importance to understand the
membrane-associated non-genomic pathways of estrogen.
In premenopausal women, estrogens produced by their ovaries play a major role in the
female reproductive organs through the ERα. In postmenopausal women, however, estrogens
produced/activated by peripherally localized estrogen-metabolizing enzymes, such as aromatase,
which converts androgen into estrogens, are thought to play physiologically and pathologically
important roles in various organs through the ERβ, distributing systemically [77]. Estrogen can
be synthesized in situ in lung cancer. Ikeda et al. measured the estrogen concentrations in
the noncancerous peripheral lung tissue using liquid chromatography/electrospray tandem mass
spectrometry in the postmenopausal female patients with synchronous multiple lung adenocarcinomas,
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and found a significantly higher level than the control cases with a single lung adenocarcinoma [78]
(Figure 1). Our study of the malignant pleural effusion of lung adenocarcinoma revealed that some
postmenopausal women had extraordinarily high pleural fluid estradiol concentrations, and there
was no correlation between the pleural fluid concentrations of estradiol and the vascular endothelial
growth factor, a marker of pleural vascular hyperpermeability [79]. In addition, the EGFR wild-type
lung adenocarcinoma is probably an estrogen-dependent carcinoma, as a higher expression and potent
poor prognosticator of aromatase and the ERβ in the group [62].
Thyroid transcription factor 1 (TTF-1) expression, as a lineage marker of the terminal respiratory
unit, is helpful to distinguish the primary (TTF-1 positive) from the metastatic (usually TTF1 negative)
lung adenocarcinoma, the pleural lung carcinoma (TTF-1 positive) from the mesothelioma [80].
The TTF-1-positive adenocarcinomas had a statistically significant prevalence of the female,
non-smoker, and associated with the EGFR mutation [81,82]. The ER and TTF-1 immunoreactivity is
commonly used as a means of distinguishing breast carcinomas from the adenocarcinomas of other
primary sites, including the lung, but mostly using the antibody of the ERα. The TTF-1 positivity
may be associated with the ERβ expression in lung adenocarcinoma with clinical significance, which
therefore deserves further study [83].
 
Figure 1. A 48 year-old non-smoking woman was found to have multiple subcentimetre ground glass
opacities (arrows) in her bilateral lungs on a low-dose CT screening. Video-assisted thoracoscopic
surgery with a right upper lobe wedge resection confirmed the diagnosis of synchronous multiple lung
adenocarcinomas harboring the EGFR wild-type.
3. Hormone Replacement Therapy and Lung Cancer Risk and Survival
There were also controversies in the relationship between the hormone replacement therapy (HRT)
and lung cancer. Although most studies reported estrogen or HRT adversely affected the prognosis
of lung cancer patients [22–30], some reported HRT decreased the risk and favorably affected the
prognosis [31–36]. In the Women’s Health Initiative Trial, HRT using estrogen plus progestin in
postmenopausal women did not increase the incidence of lung cancer, but increased the risk (60%) of
dying from NSCLC [29]. Unlike the use of estrogen plus progestin, the usage of conjugated equine
estrogen alone did not increase the incidence or death from lung cancer [36]. In another Vitamins
and Lifestyle Study, postmenopausal women taking estrogen plus progestin were reported to have a
50% increased risk of incident lung cancer for usage of 10 years or longer and an advanced stage at
diagnosis [30]. Greiser et al. made a systemic review and meta-analysis from 18 studies for the risk of
lung cancer after HRT [84]. Ever use of HRT in non-smoking women may well increase the risk of
lung adenocarcinoma. Data from the randomized controlled trials suggested that estrogen/progestin
therapy increased the lung cancer mortality. The increased risk of death from lung cancer during the
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estrogen plus progestin usage in the Women’s Health Initiative Trial was recently reported attenuated
after the discontinuation of the medication in a 14-year cumulative follow-up [85].
Siegfried and Stabile provided explanations for the discrepancy of the HRT effect [49]. Different
influences of estrogen on the balance of differentiation induction and proliferation in normal lung
epithelium and malignant epithelium have been reported [55]. Compared with the matched normal
lung tissues, ERβ is overexpressed in lung cancer, which could lead to an abnormal response to estrogen.
The ability of the immune system to reject the malignant lung tissues during the early process could be
enhanced by HRT [49] and related to a different level of ER expression [61,86,87]. Exogenous hormone
usage reduces the local estrogen production by inhibiting the pulmonary aromatase expression. The exact
HRT used, i.e., type, duration, timing, and adjusted covariates may modulate the effects of HRT. More
specifically designed studies to address the HRT type, smoking, and histology, are therefore warranted
to arrive at the more definitive conclusions. However, since the HRT is now recommended to be used
for a limited duration, its effects on lung cancer risk or survival may be less pronounced in the future.
4. ER as Targets for Lung Cancer Therapy and Relationship with EGFR
Estradiol is locally produced in the NSCLC mainly by aromatase, which is localized in both the
epithelial cell components of lung tumors as well as in the infiltrating macrophages; even exclusively
confined to the inflammatory cells infiltrated in the pre-neoplastic and neoplastic areas in some of
the animal models [88,89]. Patients whose tumors harbored a higher expression of aromatase and
ERβ have a lower survival rate, especially in postmenopausal women [13,90]. The use of selective ER
modulators and/or aromatase inhibitors have been reported to be clinically effective in the NSCLC
that are positive for both the ER and aromatase [91,92]. Recently, Hamilton et al. utilized a quantitative
high-throughput screening of approved drugs, and identified the ER antagonist, fulvestrant, as being
capable of reducing the mesenchymal features of lung cancer cells and sensitize to the cytotoxic effect
of the chemotherapy [93].
As aforementioned, the activities of the ERβ could be genomic or non-genomic [94] (Figure 2).
The estrogen-ERβ complex binds to the nuclear estrogen response elements directly or through the
transcription factor, to promote the gene expression. Estrogen also combines with membrane-bound
ERβ to activate the cytoplasmic signaling pathway and interacts with the EGFR signaling
pathways [95,96] (Figure 3). EGFR has been reported to directly phosphorylate ER at specific
serine residues (a ligand-independent signaling) in 87.5% of the ER-positive lung tumors [96,97].
In addition to the MEK/ERK signaling pathway, estrogen also activates the PI3K/AKT signaling
pathway, another downstream pathway of the EGFR activation, to promote lung cancer cell metastasis
through epithelial mesenchymal transition [98]. Other non-genomic activities have also been explored.
Fan et al. found a higher ERβ expression in the lymph node as compared to the primary tumor tissues,
and estrogen promotes the lung cancer cell metastasis via the ERβ-mediated up-regulation of the
matrix-metalloproteinase-2 [99]. In the mRNA analyses, when comparing the high versus low ERβ
expressing tumors by the group of Siegfried and Stabile, the top differentially expressed genes in the
high ERβ tumors involved the fibroblast growth factor signaling and the human embryonic stem cell
pluripotency [100].
ER and EGFR, as targets for dual lung cancer therapy, have been studied. A combination of the
ER antagonist and the EGFR tyrosine kinase inhibitor has been shown to decrease cell proliferation and
tumor growth more than one individual treatment in both in vitro and in vivo studies [53,97,101,102].
In the NSCLC cell lines, the EGFR protein expression was down-regulated in response to estrogen
and up-regulated in response to anti-estrogens in vitro. Conversely, the ERβ expression is decreased
in response to the epidermal growth factor and increased in response to gefitinib [101]. A strong
association has been reported between the expression of the ERβ and EGFR mutations in lung
adenocarcinoma [53,54,103,104]. These studies have provided evidence of a functional interaction
between the ER and EGFR pathways in lung cancer and have supported a rationale to use the combined
therapy [95,105].
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Figure 2. The putative role of the estrogen receptor in regulating the lung cancer cells growth.
The estrogen receptor β (ERβ) appears to be the predominant form in lung cancer and is present
in the cytoplasm, nucleus, mitochondria and plasma membrane. The ERβ has been found
to activate the PI3K/IKK/NFκB, PI3K/AKT/Bcl-XL and the RAS/RAF/MEK/ERK signaling
pathways to regulate the cell proliferation, invasion, metastasis, mitochondrial biogenesis and
anti-apoptosis. The G-protein-coupled estrogen receptor (GPER) activates the cAMP/PKA/CREB and
the PI3K/IKK/NFκB signaling pathways and acts as a modulator of the neoplastic transformation.
The available strategies to target the estrogen signaling pathway include the aromatase inhibitors,
the reversible nonsteroidal agents (e.g., letrozole, anastrozole) or the irreversible steroidal inactivator
(e.g., exemestane), the nonsteroidal elective ER modulator (e.g., tamoxifen, raloxifene), and the ER
antagonists (e.g., fulvestrant) [47]. Giovannini et al. reported that the additional effect of letrozole in
a patient with lung adenocarcinoma and scalp metastasis persisted on gefitinib [106]. A pilot study
revealed that treatment combining the gefitinib and fulvestrant for postmenopausal women with
advanced NSCLC was well-tolerated and demonstrated a result [107]. Several phase II clinical trials
are currently ongoing to investigate their effects on advanced NSCLC, mostly in a second-line setting
and combined with the EGFR tyrosine kinase inhibitor [108] (Table 2). Some studies have included
correlative tissue analysis of the ER and the progesterone receptor status to evaluate their role as
a predictor of response. Besides the treatment strategies through inhibiting estrogen synthesis or
blocking its effect, dexamethasone has been demonstrated to induce the estrogen sulfotransferase to
decreases the estradiol levels in tumor tissues and suppress the A549 xenograft tumor growth [109,110].
No significant difference in the clinicopathological characteristic between the ERβ-positive and
ERβ-negative lung adenocarcinoma has been mentioned, except some reported that the ER expression
correlated with the tumor differentiation [111]. Detailed pathologic examination of the ERβ-positive
adenocarcinoma may be necessary to show the genotype-phenotype correlations, similar to those
found in the ALK-rearranged or the EGFR-mutated adenocarcinoma [112,113]. Patients with these
characteristic histologic features might be good candidates for, and could benefit from, therapy
targeting the ER signaling pathways.
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Novel technologies, e.g., next generation DNA sequencing, epigenetics, transcriptomics, proteomics,
and metabolomics, can make an abundant contribution in the understanding of lung cancer [114–116].
The Genetic Epidemiological Study of Lung Adenocarcinoma (GELAC) in Taiwan had found that
the gene polymorphisms related to the estrogen biosynthesis and metabolism was associated with an
increased occurrence of L858R mutation of the EGFR in non-smoking female lung adenocarcinoma
patients [117]. The use of HRT may modify the association of protective EGFR single nucleotide
polymorphisms (SNPs) with lung adenocarcinoma risk [118]. The EGFR SNPs have a cumulative effect
on decreasing the lung adenocarcinoma risk in non-smoking women with HRT. The ER gene SNPs are
associated with a lung adenocarcinoma risk in non-smoking women [119]. The joint effects of the ER
and EGFR gene SNPs and HRT usage on lung adenocarcinoma risk highlight the gene-environment
interaction in lung carcinogenesis.
Figure 3. The schematic diagram illustrating the mechanisms of how the estrogen receptor (ER)
coordinates with the epidermal growth factor receptor (EGFR) to affect the cell growth in the lung
adenocarcinoma. Estrogen stimulates the steroid receptor coactivator (SRC) protein, which in turn,
activates the EGFR signaling pathways. In addition, estrogen upregulates the osteopontin (OPN)
expression and promotes the lung cancer cell migration via the MEK/ERK signaling pathway. The SRC
and OPN contribute to the cross-talk between the ER and the EGFR.
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5. Smoking Aggravates the Effect of Estrogen and Endocrine Disruptive Chemical Targeting ERβ
from the Environment May Contribute to the Lung Carcinogenesis
Tobacco smoking is a common source of complex environmental chemical exposure. More than
3000 chemicals have been identified in tobacco smoke, and many of them are both mutagenic and
carcinogenic. There exists a phenomena associated estrogenic metabolism with tobacco combustion.
Higher levels of polycyclic aromatic hydrocarbon-derived DNA adducts have been reported in female
smokers than in male smokers. Estrogen synergize with the tobacco compounds through the induction
of CYP1B1, an enzyme responsible for estrogenic metabolism, which leads to enhanced reactive oxygen
species formation and carcinogenesis [4,120–122].
On the other hand, there have been constant concerns about the endocrine disruptive chemical
(EDC) in the environment. EDC that have estrogenic properties are known as xenoestrogens. Although
their estrogenic activity is weaker than that of estradiol, newer types of EDC and inadvertent forms
of exposure continue to be discovered. There is increasing concern about their cumulative effects in
carcinogenesis [123]. Endocrine disruptive chemical, e.g., polychlorinated dibenzo-p-dioxins, bisphenol
A, polychlorinated biphenyls, polybrominated flame retardants, and methoxychlor, were supposed to
be a factor in the environment leading to an increased incidence of lung adenocarcinoma [124,125].
They target ERβ with highly variable effects. Their combination with the aryl hydrocarbon receptor
and its nuclear translocator could also modulate the ER activity.
Air pollution containing a mixture of particulate matters (PM) and gas contaminants is generally
considered to play a role in the development of lung cancer. According to the particles’ size, they are
categorized into coarse particles (<10 and >2.5 μm in aerodynamic diameter, PM10), fine particles
(≤2.5 and >0.1 μm in aerodynamic diameter, PM2.5), and ultrafine particles (≤0.1 μm). In addition
to the concern of particle size, the combustion of fossil fuels, road traffic, industries, and waste
dumps, are known to emit a number of different mutagens and carcinogens, many of which possess
xenoestrogenic activity [126,127]. Multifactorial risk assessment incorporating personal exposure
history, genetic polymorphisms related to estrogen biosynthesis and metabolism, ER polymorphisms,
and biomonitoring data collected from the environment may well identify the population at risk.
Collaborations between oncology, system biology, and environmental science will provide an important
step to elucidate the etiology of lung cancer and help to make the relevant legislation in the future.
6. Conclusions
In addition to the well-known drivers of lung cancer, EGFR (55.7%), KRAS (5.2%), BRAF (2.0%),
HER2 (0.7%) mutations, and EML4-ALK translocation (9.8%) [128], a body of epidemiological evidence,
preclinical in vitro and in vivo studies, and recent data from the clinical trials, support estrogen as an
important factor that contributes to lung carcinogenesis, lung cancer growth, metastasis, and affecting
the prognosis. Different pathways of the ER activation and interactions with EGFR were proposed.
Estrogen, with its receptor, has the potential to be a prognosticator and a therapeutic target in lung
cancer. The ER antagonist may well become a new and effective treatment modality for patients with
lung adenocarcinoma and an alternative treatment for patients with acquired resistance to the EGFR
antagonists [101,105,129]. However, there were many conflicting results in the literature that need
to be addressed [31–36,130], of which include the standardized measurements of the ER expression
before adopting them as a useful biomarker, the mechanisms that underlie the controversy in the
effect of hormone replacement therapy, the role of different estrogen and various ER in lung cancer
cell proliferation, migration, and invasion, and the pathways involved in their interactions with other
mediators. The risk of EDC exposure also raises the concern of genetic and environmental interaction
in lung carcinogenesis.
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Abstract: The detection of human anti-estrogen receptor α antibodies (ERαABs) inducing estrogenic
responses in MCF-7 mammary tumor cells suggests their implication in breast cancer emergence
and/or evolution. A recent report revealing a correlation between the titer of such antibodies in sera
from patients suffering from this disease and the percentage of proliferative cells in samples taken
from their tumors supports this concept. Complementary evidence of the ability of ERαABs to interact
with an epitope localized within the estradiol-binding core of ERα also argues in its favor. This epitope
is indeed inserted in a regulatory platform implicated in ERα-initiated signal transduction pathways
and transcriptions. According to some experimental observations, two auto-immune reactions may
already be advocated to explain the emergence of ERαABs: one involving probably the idiotypic
network to produce antibodies acting as estrogenic secretions and the other based on antibodies able
to abrogate the action of a natural ERα inhibitor or to prevent the competitive inhibitory potency of
released receptor degradation products able to entrap circulating estrogens and co-activators. All of
this information, the aspect of which is mainly fundamental, may open new ways in the current
tendency to combine immunological and endocrine approaches for the management of breast cancer.
Keywords: estrogen receptor α; natural antibodies; estrogenic responses; mechanism of action;
auto-immune diseases
1. Introduction
Among modulators of steroid hormone receptors, natural anti-estrogen receptor antibodies
(ERABs) are of peculiar interest in view of their implication in the emergence and/or evolution of
autoimmune diseases and cancers [1]. The present paper focuses on the potential biological relevance
of these antibodies in the context of the hormone-dependence of breast cancer, a topic on which I have
been working for more than four decades.
The recent finding by the group of Pierdominici and Ortona of a correlation between the titer of
ERABs raised against the alpha form of the receptor (ERαABs) in sera from a series of women with
breast cancer and the percentage of Ki67-positive cells (a known marker of proliferation) in samples
taken from their tumors [2] offered to me an opportunity to discuss here the possible implication of
these antibodies in the development of breast cancers. In fact, this concept had already been proposed
in the late 1980s by my colleague Borkowski, who detected a sub-population of IgGs able to interact
with the estradiol (E2) binding site of ERα in sera from healthy women [3,4]. This work, in which
I collaborated, revealed moreover the ability of these IgGs to induce estrogenic (or estrogenic-like)
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responses in ERα-positive MCF-7 breast cancer cells, suggesting that they act on these cells as the
hormone [4]. Further studies revealed that this view was only partly true: the major estrogenic
activity of the IgGs seemed to derive from the neutralization of ERα-related peptides able to inhibit its
activation [5]. Skepticism concerning the biological significance of these various observations, as well
as their potential insertion in therapeutic programs forced us to stop our investigations. We hope
that the recent investigations of Pierdominici and Ortona, which also concern the prominent role
of estrogens in autoimmune diseases [6], may encourage the scientific community to assess again
questions relevant to the suspected role of such natural anti-ERα antibodies in breast cancer.
The present paper devoted to this hope mainly concerns the mechanism(s) by which ERαABs
may operate; processes implicated in their emergence will be also evoked. Available data being quite
tenuous, my proposals are largely speculative. Nevertheless, I anticipate that they may open avenues
for new experimentations not necessarily restricted to ERα, since the existence of natural antibodies
raised against other steroids hormone receptors has been reported, as will be recalled briefly in the
next section.
2. Natural Antibodies against Steroid Hormone Receptors, the Existence of Which Had Been
Reported about Three Decades Ago
To my knowledge, the first evocation of such antibodies must be attributed to the group
of O’Malley that reported in 1981 the existence of “spontaneous” antibodies raised against the
progesterone receptor in two thirds of sheep sera [7]. Surprisingly, these authors limited their
investigation to the assessment of the binding properties of these antibodies for the α and β isoforms
of this receptor without raising any questions relevant to their biological role. This topic was addressed
in the following year by Liao and Witte who reported a high titer of anti-androgen receptors in patients
with prostate disease, when compared with normal subjects [8]. These authors logically proposed
some relevance to this detection in terms of disease management. The discovery of the existence of
anti-ERα may be ascribed to Borkowski [3], as well as to Muddaris and Peck Jr. [9], who detected them
at the same time. While Borkowski focused his studies on the biological function of these antibodies,
Muddaris and Peck reported striking sex and age-related differences in the level of the latter: young
females displayed a higher titer than corresponding males. This level also declined in middle age,
before increasing in old age, in contrast to males in which it continuously decreased. Although these
various observations were quite provocative, they failed to generate a significant interest for about two
decades, as previously mentioned.
3. Major Properties of ERαABs
3.1. Ability to Induce Estrogenic (or Estrogenic-Like) Responses
As reported below, ERαABs act as ERα agonists through both non-genomic and genomic
procedures, which operate sequentially, the non-genomic preceding largely the genomic
procedures [10,11]. This suspected co-operative mechanism [11–14], detected with MCF-7 breast
cancer cells, seems to be initiated at the plasma membrane (Section 3.2).
3.1.1. Signal Transduction Activation and Subsequent Cell Proliferation Enhancement
Highly purified ERαABs almost immediately activate the phosphorylation of ERK (Extracellular
regulated kinase) in MCF-7 cells without producing any similar effect on Akt (Protein kinase B) [2].
The maximal effect of the antibodies occurs after 5 min and subsequently declines, returning to the
original level after 30 min. As expected, a significant increase in proliferation is recorded after one day
of treatment.
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3.1.2. Transcriptions and Related ERα Level Changes
Over-night exposure of MCF-7 cells to highly purified ERαABs (IgGs) enhances their level
of progesterone receptors in a dose-dependent manner, as observed with E2 used as the control;
this increase is progressively inhibited by pure antiestrogens [4,5]. The same behavior is recorded
for cathepsin D secretion. A loss of the capacity of the cells to specifically incorporate [3H]E2 (ERα
whole cell assay) occurs in parallel, which may be ascribed to a decrease of the ERα level, detected
by Western blotting. IgGs also partially abrogate the capacity of the cells to incorporate [3H]E2 in the
presence of an analog of hydroxy-tamoxifen, which stabilizes the receptor within the nucleus [15],
as does E2.
3.2. Selective Ability to Associate with the E2-Binding Site of the Native Form of ERα Localized at the
Plasma Membrane
When submitted to low-salt sucrose gradient sedimentations, ERα from cytosolic extracts is
known to migrate within two distinct oligomeric structures, i.e., of 4 and 8S (note that these velocities
may slightly differ according to the nature of the tissues from which ERα is extracted, the experimental
conditions, as well as the choice of the sedimentation markers used for their assessment) [16,17]. The 4S
entity contains proteolytic products of the receptor, while the latter is maintained within the 8S entity
in its native form (67 kDa) by a protective action of chaperones with which it associates. Interactions
between highly purified ERαABs (IgGs) and ERα occur in the region of its E2-binding site since
an increase of sedimentation velocity of the 8S oligomer is detected when the [3H]E2 labeling of the
receptor is performed after sedimentation on the fractions collected from the gradient. With pre-labeled
cytosols, this sedimentation shift is replaced by a partial displacement of bound [3H]E2 by the IgGs [3].
Complementary experiments including an assessment of the binding parameters of [3H]E2 to ERα,
in the absence and the presence of increasing amounts of these IgGs, respectively, confirmed the
implication of the E2 binding site of the receptor in this complex. Accordingly, these IgGs behaved as
competitive inhibitors (increase of Kd values) [3], a finding in agreement with the recent identification
of an epitope able to recognize ERαABs (Y459TFLSSTLKSLEE471; Figure 1) within the E2-binding core
of ERα (Asn309-Lys529; MW: 26 kDa [18]) [2].
Interestingly, this Tyr459-Glu471 epitope contains a small motif (Thr465-Ser468), which is cleaved
under proteolytic attack without any loss of E2 binding ability [18], a property resulting from a cutting
of the estrogen-binding core of ERα in two distinct entities (7 and 17 kDa) that stick together through
hydrophobic contacts [19]. According to our sedimentation data, such a complex would logically
be sufficient for ERαABs recruitment by the “pseudo” native ERα when it is stabilized in a peculiar
oligomeric quaternary structure. Hence, one may understand that the known dissociation of such
a structure at the time of ERα activation under the action of an appropriate modulator affects the
topology of the ERα-binding core, giving rise therefore to a loss of its recruitment potency for ERαABs,
a property that manifestly does not hold for E2 and most probably other conventional estrogenic
ligands [20–23].
This suspected binding selectivity, as well as the large size of ERαABs may explain their
association in living cells with the plasma membrane-bound receptor form (mERα) [2], principally
localized within caveolae [10,11]. This peculiar localization, which results, at least in part, from the
palmitoylation of the native (newly-synthetized) receptor [13], appears especially appropriate
for this association contributing to rapid, non-genomic, responses (in the present context, ERK
phosphorylation; Section 3.1.1). It does not indeed imply any navigation of ERαABs across the
plasma membrane to reach oligomeric complexes in which they would moreover not easily internalize
to interact with the native and non-markedly altered receptor forms.
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Figure 1. Schematic representation of the regulatory platform of the E2-binding core of ERα
(N309-K529), postulated to mainly contribute to the onset of non-genomic and genomic responses
induced by E2 and ERαABs. The ERαABs’ epitope (Y459-E471) occupies a central, pivotal position
localized between two motifs, each of them being implicated in one of these two types of responses
(non-genomic, E444-S456; genomic, L479-T485). Functions of these three amino-acids sequences, as well
as biological consequences resulting from E2/ERαABs binding and consecutive activation of related
inter-relationships between motifs of the platform are defined below (for details, see Section 3.3).
3.3. Potent Regulatory Functions of the ERαAB-Binding Epitope
The sensitivity to proteolytic attacks of the Thr464-Ser468 amino acid sequence of the ERαAB-binding
epitope of ERα suggests its inclusion within a surface-exposed region, a property usually recorded with
“regulatory platforms” subjected to recruitment and exchange of co-regulators [24]. The identification
within this epitope of two functional motifs localized respectively on the left and right sides of the
ERαAB-binding epitope supports such a view.
The left-side sequence (E444FVCLKSIILLNS456; Figure 1) corresponds indeed to an identified
nuclear exclusion signal that contributes to the return of the activated ERα within the cytoplasm,
where it is subjected to proteasomal degradation [24–27]. This step is key for the pursuit of previously
initiated transcriptional processes. Hence, this motif would play a role in ERα intracellular trafficking
as well as in its resulting turnover rate and related biological activity [11,13,24]. The presence within
this motif of Cys-447, the palmitoylation of which favors the anchorage of the receptor with the plasma
membrane, validates this proposal [28]. In contrast, the right-side motif (L479DKTITDT485) seems
mainly to contribute to (Estrogen response element) ERE-dependent transcription since it corresponds
to one of the three amino-acids sequences of the ERα homo-dimerization interface required for such
transcription [29].
Hence, the pivotal position of the Thr465-Ser468 sequence within the E2-binding core of ERα
(which contains the ERαABs binding epitope) confers to this sequence a primordial role in the onset
of quasi-immediate non-genomic responses, as well as subsequent genomic responses. Such a dual
capacity of action is reminiscent of a model proposed to explain how a ligand of the so-called nuclear
receptor family may activate rapid signal transduction pathways issued from the cellular membrane,
as well as genes’ expression, either individually or sequentially [30,31].
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According to this model, all ligands’ binding sites of the nuclear receptor family are composed of
two adjacent cavities in which potent agonists and antagonists may penetrate [30,31]; for ERα and β,
see [32]. One of these cavities corresponds to a channel conducting to the other cavity in which selected
ligands may be engulfed; the capacity of the ligands to open a protective barrier localized at the
entrance of this second cavity might regulate this selection. Molecular interactions between receptors,
chaperones and co-regulators are also implicated in this access-regulatory process. The entrance
channel, in which access is less restrictive, is directly implicated in quasi-immediate activation of signal
transduction pathways, while the cavity in which ligands are engulfed corresponds to the pocket
contributing to receptor-mediated transcription, the topology of which has been established by X-ray
diffraction crystallography. Cellular localization of the receptor is logically a complementary factor
involved in this dual regulation.
Logically, the rapid ERαAB-induced ERK phosphorylation implicated in the enhancement of
MCF-7 cells’ proliferation (Section 3.1.1) may derive from a relatively low specific interaction of
these antibodies with the entrance cavity, the structure of which may be related to the left-side motif
implicated in non-genomic responses. Such a hypothesis may also hold to some extent for subsequent
indirect induction of ERE-dependent transcription, since this left-side motif seems to play a role in
the intracellular trafficking of the receptor, which regulates such transcription. ERαAB-mediated
enhancement of the progesterone receptor level may obviously not result from an engulfment of these
antibodies within the putative adjacent cavity implicated in gene expression. Access to this adjacent
cavity being under the control of a barrier, one may propose that interactions between ERαABs and
specific residues of the entrance cavity in which they may penetrate would suppress the repressive
function of the barrier, favoring thereby ERα-mediated transcriptions. Receptor-related binding motifs
of the plasma membrane may contribute to this property.
4. ERα-Related Sites Potentially Able to Contribute to the Mechanism of Action of ERαABs
Several sites identified on the plasma membrane may legitimately be proposed as potential
alternative targets for ERαAB-induced responses, some of them acting cooperatively with mERs [33].
Some of these sites are devoid of any E2-binding ability (i.e., HER2, EGFR), while others attract
the hormone as demonstrated with synthetized E2-conjugates unable to penetrate the cells [34].
Among such E2-binding targets, two splice receptor variants (ERα36 and ERα46; see [35,36] and the
references therein), as well as a G protein-coupled receptor (GPR30 [37–39]) have been especially well
studied. The capacity of GPR30 to interact with calmodulin, as well as with the calmodulin-binding
site of ERα, implicating its dimerization for the enhancement of ERE-dependent transcription [40–43],
would confer to this peculiar receptor a potent role in ERαAB-induced genomic functions. In fact,
the capacity of GPR30 to move between the plasma membrane, the endoplasmic reticulum and the
nucleus advocates in favor of its contribution to other ERα-mediated processes under the control of
the antibodies [37,44]: GPR30 appears indeed to be an actor involved in the intracellular trafficking of
the receptor governing its various biological functions.
Of course, the implication of such receptor-related sites in the onset of ERαAB-induced responses
needs to be validated or rejected. Measurement of markers (Ca2+ fluxes or secondary messengers
such as c-AMP or IP3) may be helpful in this regard, especially for the evaluation of complementary
ERα-independent processes [33]. In this context, specific antagonists with a special emphasis on
compounds abrogating the action of HER2, EGFR or GPR30 need also to be tested. This approach
being at the present time quite marginal [2,5], one may consider that any use of such antagonists in the
clinical perspective is out of scope, even if humanized versions of monoclonal antibodies raised against
HER2 (trastuzumab, pertuzumab) seem appropriate for a first-line experimental assessment [45,46].
Induction by such drugs of a decrease of efficiency of signal transductions initiated by the putative
action of ERαABs at the level of HER2 might alter growth of breast cancer cells, which in connection
with the known antibody-dependent cellular cytotoxicity (ADCC) of these compounds related to their
ability to recruit and activate natural killer cells (NK) would generate a major curative effect, even
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in the absence of ERα. Note in this context that pertuzumab abrogates the hetero-dimerization of
HER2 with other members of the HER family, while trastuzumab mainly affects its homo-dimerization.
Since such dimerizations are implicated in the activation of signal transductions enhancing cell growth,
one may consider that pertuzumab might be more efficient for blocking a putative ERαABs association
with membrane ERα-related receptors, promoting proliferation.
Finally, it should be stressed that the estrogen activity of ERαABs should not necessarily be
derived from a direct interaction with the plasma membrane-bound E2-binding site. This assumption
results from experiments conducted with anti-E2~BSA antibodies and highly purified ERαBAs (IgGs),
which displayed an estrogenic activity [5]. Anti-E2~BSA antibodies sharing most likely some structural
similarities with the hormone binding site of ERα, the authors of this observation concluded that
these two classes of antibodies may act as “soluble ERα forms” present in the blood to liberate,
by a competitive process, the receptor from the repressive action exerted by a peptide inhibitor looking
structurally like E2~BSA. Hence, the estrogenic activity of a subpopulation of ERαABs may result,
at least in part, from the ability to abrogate the effect of ERα co-repressors. If confirmed, this concept
would logically also hold for other possible ERαABs targets, as described below.
All hypotheses evoked in Sections 3 and 4 to explain the mechanisms by which ERαABs may
generate estrogenic responses are schematically summarized in Figure 2.
Figure 2. Schematic representation of ERαABs-induced mechanisms initiated at the plasma membrane
to promote enhanced proliferation and ERE-dependent transcription. Reported ERαAB activities
(agonism, antagonism of inhibition) were integrated in a classical model explaining co-operation
between binding sites for growth factors and steroid hormones in the onset of non-genomic and
genomic responses [11,12,14,27,33,37,38]. Note the pivotal role of the Ca2+/calmodulin complex in
the inter-relationships between GPR30 and recruitment sites of the receptor for ERαABs and adjacent
co-activators. AE: antiestrogen; Tam-like: Tamoxifen-like.
5. Mechanisms Implicated in the Emergence of ERαABs
The present section will solely refer to the emergence of ERαABs for which ERα binding properties
have been overviewed. For any topics concerning E2-related changes in immune functions or
auto-immunity, I invite the reader to consult [1,6], which are extensive in this regard.
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For me, insufficient experimental data have been reported to propose mechanisms giving rise to
the production of ERαABs. A priori, two auto-immune reactions involving eventually a contribution of
the idiotypic network may theoretically be advocated, as suggested in the previous sections: one giving
rise to antibodies acting as endogenous estrogenic secretions or any expositions to environmental
estrogens, the other to antibodies abrogating the repressive action of a natural antagonist. In this
context, one may wonder about the participation of recently identified circulating ER (α and β) forms
in human sera in the emergence of ERABs (see Section 5.3). The next sections will analyze the relevance
of these possibilities, schematically presented in Figure 3.
 
Figure 3. Schematic representation of suspected mechanisms able to contribute to ERαABs’ emergence.
Agonists: antibodies able to mimic the action of circulating estrogens (natural, synthetic and
xenoestrogens). Anti-antagonists: antibodies against a natural extra-cellular repressor recognizing
a specific inhibitory site of ERα or preventing the access of activating modulators to the receptor by
a competitive binding process. ERα degradation products including binding sites for estrogens or
LXXLL motifs of co-activators [24], released within the blood, may generate this last class of antibodies.
Es: Estrogens, BF3: Binding function 3, AF2: Activation function 2.
5.1. Anti-Idiotypic Antibodies Acting as Physiological Estrogens
Similarities between E2 and ERαABs, in terms of interactions with the native ERα form, reflect
most probably structural identities between the hormone and the active site of natural anti-idiotypic
antibodies raised against anti-E2 IgGs. Since circulating E2 is mainly conjugated to serum proteins,
one may postulate that such a cross-reaction may also hold for such conjugates, especially anti-E2~BSA
IgGs, the level of which would largely dominate. Since such a concept is not restrictive to this hormone,
it should be extended to all other physiological estrogens, as well as so-called “xenoestrogens” (natural
phytoestrogens and synthetic “endocrine disrupting chemicals” [22,23]) able to interact with the
ligand-binding site of ERα to induce estrogenic (or estrogenic-like) responses. The implication of these
molecules in autoimmune response has been, indeed, evoked [47].
72
Int. J. Mol. Sci. 2018, 19, 411
The production in the early 1990s of a monoclonal antibody (clone 1D5) directed against the
binding site of an anti-E2 monoclonal antibody lends credence to this concept: 1D5 was found to
interact with the hormone-binding domain of the receptor to mimic some estrogenic actions (creatine
kinase induction, rapid Ca2+ flux enhancement), both in vivo and in vitro [48,49]. These experimental
data were proposed to be mainly dependent on an interaction with a membrane-bound form of ERα.
Nevertheless, they were also postulated to result to some extent from an intra-cellular penetration
of 1D5. A lack of knowledge concerning the relationships between the plasma membrane and
intra-cellular ERα forms at the time of such studies may explain this statement, which may appear
now quite obsolete, even if this could not be excluded.
5.2. Antibodies with Anti-Repressive Activities
In theory, all receptor-mediated agonistic activities may result from an ability to abrogate the
antagonism of a modulator acting at the level of the ligand-binding site or an adjacent site implicated
in the recruitment of co-repressors. Such a view has been proposed to explain, at least in part,
the estrogenic activity of ERαABs (Section 4, last paragraph). While a potency to liberate the
E2-binding site of the plasma-bound receptor from the antagonism of a specific inhibitor has been solely
addressed [5], it seems that other sites of the hormone-binding domain involved in the recruitment of
co-activators (LXXLL/AF2, BF3, etc. [24,50]) must also be taken into account. However, the presence of
such sites in the whole family of steroid hormone receptors would largely limit the specificity of action
of antibodies raised against them, giving rise to inappropriate adverse effects. Hence, their importance
seems quite dubious.
In this context, a possible interaction of ERαABs with an identified ERα-binding site implicated
in the recruitment of tamoxifen and other mixed antagonists/agonists [51,52] may also be advocated.
Experiments revealed that that treatment of cytosolic ERα preparations with tamoxifen enhances
the immuno-reactivity of this site for a monoclonal antibody (H222) raised against an epitope of the
receptor ligand-binding domain [53], revealing that this compound may expose an occult antigenic
determinant accessible to a subpopulation of ERαABs. Whatever could be the finality of such
an interaction with a site contributing to the activity of tamoxifen, either agonist or antagonist, one may
consider that it may modulate the SERM character of this compound.
5.3. Implication of ERα or ERα Fragments Released within the Blood in the Onset of ERαABs
Could ERα and β recently detected within human sera [54] be implicated in the emergence of
ERαABs against these two receptors? This important question has some justification in the finding
that the latter display anti-inflammatory properties, the net action of which depends on their relative
proportions (β > α) and localization; ERα is moreover associated with auto-immune processes [55].
These circulating ERα and β forms (detected in patients with Crohn’s disease with a commercial
ELISA) most probably correspond to various receptor fragments issued from their intracellular
proteasomal and lysosomal degradation, released within the blood as small vesicles (exosomes)
implicated in immune responses or processed for MHC (major histocompatibility complex)
presentation after autophagy [56,57]. Hence, one may logically assume that ERα fragments may
be implicated in the emergence of ERαABs with a repressive activity, some of them abrogating the
effect of natural inhibitors present in the blood, others abrogating the potent competitive inhibitory
potency of ERα degradation products able to recruit circulating activators (mainly E2, co-activators),
liberating thereby these agents for the accomplishment of their function.
The detection in media from E2-stimulated cells of a 44-amino-acid peptide including a repressive
motif of ERα (Pro295-Thr311) [58], able to interact with the Pro365-Asp369 type II β turn element of
its BF3 motif that regulates the dimerization of the receptor ([59], and see Section 6), may appear as
a stone in the edification of this concept. A synthetic peptide corresponding to the Pro295-Thr311
motif (ERα17p) induces indeed estrogenic responses, as well as some receptor-independent actions
in various breast cancer cell lines [60], the lack of specificity of these actions resulting most probably
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from distinct interactions with the type II β turn/BF3 motifs of the various steroid hormone receptors
expressed in these cells. Antibodies raised against the P295-T311 sequence (Gentaur: 04-rb-ERα17p)
would logically generate a similar absence of specificity of action in contrast to antibodies raised
against the E2-binding core of the receptor (Section 5.2, first paragraph). Such a lack of specificity
would not be necessarily detrimental for therapeutic purposes, especially in the case of antiestrogen
resistance, as proposed for antagonists aimed to antagonize the recruitment of co-activators [24,61].
6. Conclusions and Perspectives
Structural studies of the estrogenic core of ERα, reported here, reveal that the ERαABs epitope
localizes at a place of prominent importance for the successive onset of non-genomic and genomic
responses. The finding that this epitope is adjacent to regulatory motifs governing these responses
argues in favor of such a statement. Complementary inclusion of these data into a model established
from X-ray crystallographic investigations relevant to the activated intracellular ERα form indicated
that the Leu479-Thr485 motif, which contributes to the dimerization of the receptor, corresponds to
a part of its BF3 motif implicated in ERE-dependent transcription [61] (Figure 4; analysis performed by
my colleague Yves Jacquot, Sorbonne Universités, Université Pierre et Marie Curie, Ecole Normale
Supérieure, Paris, France). This information strongly suggests that ligand-induced conformational
changes relevant to the intracellular receptor may also hold for its plasma membrane-bound form,
justifying the dimerization ability of the latter. Hence, the biochemical assessment of the interactions
between ligands aimed at targeting the “insoluble” ERα entrapped within the plasma membrane and
the conventional “soluble” cytoplasmic and nuclear receptor forms would be a valuable approach to
the decryption of the mechanism by which ERα operates. Hence, interest in ERαABs would not be
restricted to physio/pathological purposes.
Figure 4. Surface structure of the BF3- (in grey) and ERαAB epitope/E2 (in blue)-binding domains of
the human estrogen receptor α (ERα in yellow, Connolly surface). The BF3 domain is composed of
two regions, i.e., the 365–369 type II β-turn region and the 477–488 helix 10 (H10) region, the latter
overlapping the 479–485 sequence implicated in the dimerization of the receptor. The ERαABs epitope
is in close contact with this BF3 domain, as well as the 444–456 nuclear exclusion site (nes, for nuclear
exclusion signal, in pink). Interaction between the 301–311 region with the 365–269 type II β turn seems
to repress the dimerization potency of the 477–488 helix. Transparency allows the visualization of the
helices (in green) that comprise the receptor.
74
Int. J. Mol. Sci. 2018, 19, 411
In this regard, experimental data critically reviewed here leave no doubt about the importance
of ERαABs in breast cancer emergence and/or evolution, even if these biological aspects have only
been marginally addressed at the present time [2,5]. The capacity of ERαABs to stimulate MCF-7 cell
growth suggests some potential implication in the resistance to endocrine treatments. Such a topic
needs to be rapidly assessed with tamoxifen-resistant cell lines. On the other hand, since the mammary
gland is under the control of both ERα and β, which respectively promote or repress its neoplasia [62],
the search for natural antibodies raised against ERβ seems of major interest. Such a task may open
new pathways in the current tendency to combine immunological and endocrine approaches in the
management of cancer. The present review being mainly devoted to fundamental aspects of ERαABs,
I encourage immunologists and endocrinologists to extend my work to reported clinical observations,
especially those that, by ignorance, I failed to refer. Such an issue will be extremely helpful to confirm
or reject a tendency to see a strong autoimmune ER function in breast cancer, which, in the affirmative,
would be taken into account in the design of future therapeutic programs.
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Abstract: Estrogen receptors are broadly expressed in many cell types involved in the innate and
adaptive immune responses, and differentially regulate the production of cytokines. While both
genomic and non-genomic tumor cell promoting mechanisms of estrogen signaling are well
characterized in multiple carcinomas including breast, ovarian, and lung, recent investigations
have identified a potential immune regulatory role of estrogens in the tumor microenvironment.
Tumor immune tolerance is a well-established mediator of oncogenesis, with increasing evidence
indicating the importance of the immune response in tumor progression. Immune-based therapies
such as antibodies that block checkpoint signals have emerged as exciting therapeutic approaches for
cancer treatment, offering durable remissions and prolonged survival. However, only a subset of
patients demonstrate clinical response to these agents, prompting efforts to elucidate additional
immunosuppressive mechanisms within the tumor microenvironment. Evidence drawn from
multiple cancer types, including carcinomas traditionally classified as non-immunogenic, implicate
estrogen as a potential mediator of immunosuppression through modulation of protumor responses
independent of direct activity on tumor cells. Herein, we review the interplay between estrogen and
the tumor microenvironment and the clinical implications of endocrine therapy as a novel treatment
strategy within immuno-oncology.
Keywords: estrogen; cancer; tumor microenvironment; immunotherapy; immunosuppression
1. Introduction
Estrogens are pleiotropic steroids that play a regulatory role in a myriad of physiological processes
from reproduction to lipid metabolism [1]. Biosynthetically converted from precursor androgens by
the enzyme aromatase (CYP19A1), estrogens exert both genomic and non-genomic biological effects
mediated by interactions with one of two cognate receptors, estrogen receptor α (ERα) or estrogen
receptor β (ERβ). Albeit encoded by separate genes, both ER isoforms exhibit similar functional
and structural organization [1]. Displaying high sequence homology within the DNA and ligand
binding domains, both receptors interact similarly with endogenous estrogens, mainly 17β-estradiol
(E2) [2,3]. In addition to mediating biological mechanisms involved in homeostasis, E2 also plays a role
in the development and malignant progression of multiple cancers. The oncogenic role of estrogens is
well characterized in both classical and nonclassical hormone-sensitive carcinomas including breast,
prostate, endometrial, ovarian, colon, and lung [4]. ERs are located in both the nucleus and the
cytoplasm of tumor cells enabling tumor-promoting transcriptional regulation of genes involved
in cell survival and proliferation [5,6], and non-genomic crosstalk with growth factor pathways,
including epidermal growth factor (EGF), insulin growth factor (IGF), and fibroblast growth factor
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(FGF) [7–9]. Due to these tumorigenic mechanisms, therapies that interfere with E2 signaling, such as
selective estrogen receptor modulators or degraders (SERMs or SERDs) and aromatase inhibitors (AIs),
have been developed and clinically implemented for the treatment of ER-positive breast cancer. While
agents that target the estrogen pathway have been seminal in reducing breast cancer mortality over
the past three decades [10], most studies in breast cancer and other cancer types have focused strictly
on tumoral ER expression and signaling.
Along with tumor cells, non-cancerous cells comprising the tumor microenvironment (TME)
are now recognized as critical mediators of tumor progression. Mounting evidence suggests that in
addition to intracellular mechanisms such as mutational load and neoantigen presentation, interplay
between cancer cells, stromal cells, immune cells, and extracellular molecules within the TME
profoundly influence anti-tumor immunity and immunotherapeutic response [11–14]. The notion
that enhancing tumor immunogenicity and inhibiting immunosuppressive mediators can functionally
suppress progression of malignant tumors has led to the development of promising immunotherapeutic
strategies. However, the clinical utility of current immunotherapies remains limited due to marginal
response rates and acquired resistance mechanisms [15–17]. Therefore, greater elucidation of targetable
cellular machinery involved in tumor immune evasion is necessary to improve the clinical benefit
of immunotherapies.
The numerous biological effects of the E2 pathway are facilitated by distinct ER isoform
expression found not only on tumor cells, but also on most immune cell types [18–21]. The impact
of E2 in autoimmune pathogenesis remains heavily investigated, with reports of paradoxical and
disease-dependent effects. The influence of E2 in autoimmunity is potentially concentration-dependent,
and immune cell-specific. Several reviews detail E2-mediated immune responses, including
transcriptional regulation of immune mediating genes possessing ERE sequences and regulation
of lymphopoiesis and immune cell differentiation [22–25]. Given the prevalence of E2 modulation
in both innate and adaptive immune responses, along with its evident role in tumor progression,
there exist several implications for immunomodulatory effects of E2 within the TME. Herein, we will
discuss findings within current literature evaluating the protumoral impact of E2 on the TME and the
implications of targeting the E2 pathway in cancer to promote an anti-tumor immune response.
2. Estrogen Receptor and Aromatase Expression in Tumor Cells: Correlations with
Clinical Outcome
Tumoral ER expression is reported in nearly 30 different types of cancer, predominately in
hormone-sensitive tumors such as breast, ovarian, endometrial, and prostate [26,27]. Studies
comparing clinicopathological characteristics with ER protein expression (typically evaluated by
immunohistochemistry (IHC)) in tumor tissue show differential relation to disease prognosis based on
cellular localization and cancer type. In breast cancer, while predominately expressed in the nucleus,
ERα protein expression in either the nucleus and/or cytoplasm correlates with features of advanced
disease, including larger tumor size and lymph node metastasis [28]. However, ERα-positive breast
cancer patients exhibit improved overall survival (OS) compared to ERα-negative patients, likely owing
to the clinical benefit of adjuvant endocrine therapies for ERα-positive patients [18,29]. The clinical
relevance of ERβ expression in breast cancer remains controversial largely due to challenges associated
with ERβ splice variants and post-translational modifications, as well as the lack of a clinically
standardized ERβ antibody [19,30,31]. As an integral enzyme in estrogen production, intratumoral
aromatase has also been evaluated in breast cancer. While one study reported an association between
aromatase activity and poor prognosis, others have failed to correlate aromatase activity or protein
expression with clinical outcomes, suggesting that paracrine sources of estrogen may be of greater
significance in hormone-dependent breast cancers [32–35]. In contrast to breast cancer, non-small
cell lung cancer (NSCLC) ERα protein expression is more commonly expressed in the cytoplasm and
is a negative prognostic marker [36,37]. Similarly, elevated cytoplasmic ERβ protein expression in
NSCLC is associated with poorer OS [38], potentially indicative of the predominance of non-genomic
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mechanisms in NSCLC. Alternatively, nuclear ERβ expression in NSCLC correlates favorably with OS
in some studies and negatively in others (reviewed in [39]). Tumoral aromatase protein expression
and activity is also reported in NSCLC, with elevated expression identified as a predictor of poorer
survival in women with early stage disease [40]. In advanced ovarian cancer tumors, while aromatase
activity and ERβ mRNA expression do not correlate with any clinical outcomes [41,42], a recent
meta-analysis revealed ERα protein expression was associated with improved OS [43]. Finally,
while clinical correlations with aromatase have yet to be evaluated, both ERα and ERβ expression
are associated with improved OS in endometrial cancer [44]. These clinical correlations, combined
with mounting preclinical studies, indicate an intricate and pervasive protumoral role for hormonal
signaling in multiple cancers, providing rationale for further investigation of ER expression and
oncogenic cellular modulation.
3. Estrogen Receptor and Aromatase Expression and Estrogen-Mediated Effects in the
Tumor Microenvironment
In addition to neoplastic cells, ERs and aromatase are also expressed on stromal and immune cells
within the TME (Table 1). Numerous studies over the past decade have demonstrated that interactions
between tumor cells and surrounding recruited stromal cells are integral in disrupting homeostasis
and potentiating tumorigenesis (reviewed in [14,45]). Albeit highly heterogeneous within and across
tumor types, regularly observed cellular components of the TME include: cancer associated fibroblasts
(CAFs), tumor associated macrophages (TAMs), myeloid derived suppressor cells (MDSCs), immune
T and B cells, natural killer (NK) cells, and endothelial cells [14]. ER and aromatase expression in
TME stromal and immune cells suggest a potential immunomodulatory role of ER signaling in cancer
biology as detailed by cell type below.
Table 1. Estrogen receptor (ER) and aromatase expression in stromal and immune cells in the
tumor microenvironment.









Breast Aromatase ERα PCR, IHC [46,47]
Melanoma ERα IHC [47]
Lung ERα IHC [47]
Endometrial Aromatase IHC [48]
CAF
Breast ERα PCR [49]
Prostate ERα, ERβ IHC [50,51]
Endometrial ERα, ERβ PCR [52]
Ovarian ERα IHC [53]
TAM
Ovarian ERα, ERβ IF, IHC [54]
Breast Aromatase IHC, PCR [55]
Lung Aromatase Aromatase IHC [56,57]
MDSC Ovarian ERα ERα PCR, Western [53]
Studies were identified by PubMed searches using keywords: ERα, ERβ, aromatase, stromal, CAF, TAM, MDSC,
expression, cancer. CAF: cancer associated fibroblast; TAM: tumor associated macrophage; MDSC: myeloid derived
suppressor cell; IHC: immunohistochemistry; PCR: polymerase chain reaction; IF: immunofluorescence; Western:
western blotting analysis.
3.1. Stromal Cells
It has become increasingly evident that tumor progression is reliant not only on tumor cells present
in malignant tissue, but also the distinctive stromal cells recruited to the TME that signal among the
tumor cells and each other. An in vivo murine model evaluating tumor cell-independent mechanisms
of ER signaling within the TME has identified ERα expression and modulation in stromal cell types. In
ovariectomized syngeneic mice transplanted with ER-negative melanoma, breast, or lung cancer cells,
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E2 treatment significantly enhanced tumor growth of each cell type compared to untreated controls via
interactions with stromal ERα [47]. Further, E2-stimulated tumor growth was increased when evaluated
in immunocompromised mice, suggesting this effect may be more reliant on the innate immune
response [47]. In addition to tumor growth, E2 also enhanced angiogenesis by increasing blood vessel
density 2.1-fold in E2-treated mice compared to controls, an effect reliant on host ERα expression [47].
Peritumoral aromatase expression is also reported in endometrial cancer stromal cells, correlating with
advanced disease and poor OS [48,58]. Aromatase is also observed in breast cancer stromal adipocytes
of obese postmenopausal women, and several studies have identified mechanistic associations between
obesity, inflammation, elevated aromatase, and breast cancer development [46,59,60].
3.2. Cancer Associated Fibroblasts
CAFs are among the most prevalent stromal cell type within the TME and act as a paracrine
source of chemokines and soluble growth factors that activate signaling pathways involved in tumor
cell survival, invasion, and metastasis [61]. A study using nuclear receptor arrays to compare
gene expression profiles between normal human breast adipose fibroblasts and primary CAFs from
malignant human breast tissue, observed ERα expression in fibroblasts from primary breast cancer
tissue [49]. Despite similar levels of ERα expression observed in both cancerous and normal fibroblasts,
the E2 responsive gene, liver receptor homolog-1 (LRH-1) was upregulated in CAFs compared to
normal fibroblasts [49]. LRH-1 is also an estrogen response gene and a direct transcriptional regulator
of the aromatase encoding gene CYP19A1 [62–64]. Aromatase is found to be co-expressed in breast
cancers with LRH-1, suggesting a paracrine mechanism of E2 synthesis and ER-mediated oncogenesis
in the breast cancer TME [65]. Endometrial CAFs also express both ERs and can promote tumor cell
proliferation when co-cultured with human endometrial tumor cells [52]. Endometrial CAFs induce
in vitro tumor cell proliferation in part through activation of the phosphatidylinositide 3-kinase (PI3K)
and mitogen-activated protein kinase (MAPK) signaling networks, which are well-known ER-mediated
pathways in breast and lung cancer [52,66–68].
ERα is also expressed in prostate CAFs, however, clinical implications remain unclear with some
reports identifying CAF ERα and ERβ expression as a marker of clinically advanced disease [50],
while other reports suggest ERα expressing CAFs provide a protective effect against tumor cell invasion
and macrophage infiltration [69,70]. In the latter studies, stromal ERα reduced both murine and human
prostate cancer cell invasion using an in vitro co-culture system, and reduced lymph node metastasis
of orthotopically implanted human prostate cancer cells in mice [70]. Mechanistically, ERα-positive
CAFs abated migratory behavior of adjacent prostate tumor cells through reduced expression of C–C
motif chemokine ligand 5 (CCL5) and IL-6 chemokines, both of which have identified roles in tumor
immune recruitment, inflammation, and activation of growth factor signaling [71,72].
3.3. Tumor Associated Macrophages
Macrophages critically regulate innate immune responses under normal physiological conditions;
however, several studies have shown that TAMs can promote tumor cell proliferation, an inflammatory
microenvironment, and metastasis [73,74]. Macrophage immune responses are tissue-specific
and dependent on polarization by different cytokines within the local microenvironment [75].
Fully polarized M1 macrophages produce proinflammatory cytokines including IFNγ, interleukin
12 (IL-12), and TNFα, that contribute to tumor rejection and antigen presentation [75]. Alternatively,
macrophages exhibiting an M2 phenotype produce type-2 cytokines including interleukins 4,5,6,
and 10 [75], all of which are identified promoters of tumor progression through enhanced
tumor cell growth and immune evasion [76]. Infiltrating TAMs observed in malignant tumors
display an M2 phenotype, representing another potential protumoral therapeutic target within
the TME. TAM infiltration is observed in a wide-range of cancer types and correlates with poor
prognosis [77]. For example, TAM infiltration is an independent poor prognostic predictor for ovarian
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cancer, with higher infiltration observed in cancerous specimens compared to benign lesions, and
density-dependent associations with five-year survival rates [78].
Co-localized expression of both ERα and ERβ is reported in human high grade serous ovarian
cancer (HGSOC) TAMs, and premenopausal patients show elevated TAM infiltration compared to
postmenopausal women, with highest overall TAM density observed in ERα-positive tumors [54].
Conversely, while TAM infiltration has been associated with poor prognosis in both hormone receptor
positive and negative breast cancers, TAM enrichment and proliferation is more commonly observed
in hormone receptor negative breast tumors [79,80]. However, M1 versus M2 polarization was not
evaluated in these studies. Furthermore, a separate IHC analysis of breast cancer specimens revealed
aromatase expression in TAMs, enabling local E2 production within the TME and enhanced ER-positive
breast tumor cell proliferation [55]. Aromatase is also expressed in TAMs from NSCLC patient
tumors [56], and both aromatase and ERβ are observed in infiltrating macrophages of preneoplasias in
tobacco carcinogen-induced murine lung tumors [57].
While a paucity of data exists regarding ER expression in TAMs of several cancer types, there
is evidence that E2 can induce M2 polarization and tumor infiltration. Using a polyomavirus
middle T (PyMT) ER-positive breast cancer murine model, E2 increased tumoral M2 TAM infiltration,
while untreated controls alternatively exhibited M1 TAM infiltration [81]. Furthermore, E2 enhanced
M2 macrophage secretion of vascular endothelial growth factor (VEGF), an identified mediator of
M2 macrophage recruitment [81,82]. E2 has been shown to also upregulate VEGF expression and
pulmonary macrophage content in the lungs of mice exposed to a tobacco carcinogen [83]. Evaluation
of E2-mediated tumor growth in a HGSOC murine model showed that E2 not only enhanced the
growth of ER-negative xenografts, but also increased M2 TAM infiltration compared to untreated
ovariectomized mice [54]. In addition to reports of E2-mediated TAM infiltration, a tissue microarray of
patient samples coupled with in vitro analysis revealed endometrial M2 TAMs mediate ER activation
through epigenetic upregulation of ERα by secreted interleukin-17A (IL-17A), increasing E2-driven
malignant endometrial cell proliferation [84]. Taken together, these studies suggest a potential positive
feedback mechanism between the estrogen pathway and M2 TAM infiltration in certain cancers.
Targeting this interaction may therefore provide therapeutic benefit as recently demonstrated in a
lung cancer xenograft model using the phytoestrogen SERM resveratrol [85]. The study showed
resveratrol treatment significantly suppressed tumor growth by inhibiting M2 polarization of TAMs
and decreasing activation of signal transducer and activator of transcription 3 (STAT3) signaling [85].
3.4. Myeloid Derived Supressor Cells
MDSCs are another myeloid cell present in the TME known to disrupt immune surveillance and
promote tumor development [86]. ERα expression was also recently identified by IHC and confirmed
by PCR and immunoblotting in MDSCs isolated from the tumor, bone marrow, and peripheral
blood of human ovarian cancer patients [53]. Using an E2-insensitive syngeneic ovarian cancer
model, ovariectomized mice exhibited improved survival compared to non-ovariectomized mice
following tumor challenge, while E2 supplementation accelerated tumor progression and reversed
the protective effect found in estrogen-depleted mice [53]. Notably, this effect was only observed in
immunocompetent mice with no survival benefit of ovariectomy observed in tumor-bearing T-cell
deficient immunocompromised mice, suggesting the antitumor effects of E2 deficiency is reliant on
functional adaptive immunity [53]. E2-treated mice also exhibited significantly fewer helper and
cytotoxic T cells, but also exhibited significantly elevated recruitment of MDSCs in both the spleen and
tumor beds [53]. Specifically, the immunosuppressive activity of granulocytic MDSCs was increased
in this model. ER-dependence of MDSC expansion was demonstrated using the ERα antagonist
methylpiperidino pyrazole (MPP) to inhibit MDSC proliferation in vitro [53]. In the peritoneal cavity
of ovarian tumor-bearing mice, E2 treatment increased activation of STAT3 signaling, a regulator of
myeloid differentiation and development [87], through transcriptional upregulation of JAK2 and SRC
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activity [53]. Similar findings were also observed in syngeneic lung and breast cancer murine models
and the E2-stimulated tumor growth was abrogated by MDSC depletion using anti-Gr1 antibodies [53].
3.5. Tumor Infiltrating Lymphocytes (TIL)
Lymphocyte composition of the TME vastly differs based on cancer type and immune infiltrates
exhibit opposing properties promoting tumor progression and antitumor immunity depending on the
primary tumor [88]. For example, CD4+ T cell polarization has been identified as a mediator of tumor
immune surveillance. T helper 1 (Th1) T cell responses are associated with tumor suppression and
upregulation of IFNγ and IL-12, while T helper 2 (Th2) responses are reliant of IL-4 production and
exhibit protumor activity [89,90]. Interestingly, several murine and human studies report elevated E2
induces increased Th2 responses and upregulate IL-4 production [22,25]. A recent study utilizing an in
silico machine learning based approach, identified increased immune infiltrate including Th1 T cells,
B cells, and cytotoxic T lymphocytes (CTLs) in ER-negative breast tumors relative to ER-positive breast
tumors [91]. This study observed an inverse correlation between ER activity and immune infiltration of
each of these cells in breast cancer tissues, confirming previous reports that increased TIL, specifically
CD8+ T cells, in ER-negative tumors significantly correlates with improved OS [91,92]. Furthermore,
a post-hoc analysis of gene expression in ER-positive breast cancer patients showed that treatment
with the AI letrozole increased the infiltration of B cell and T helper lymphocyte subsets at early and
late time points following treatment initiation [91].
3.5.1. Cytotoxic T Cells and Natural Killer Cells
Granule-mediated exocytosis is one pathway by which CTLs and NK cells initiate apoptosis to
eliminate pathogenic and tumor cells [93]. Serine proteases such as granzyme B are deposited into the
target cells to initiate caspase-dependent apoptosis [94]. Jiang et.al. cultured ERα expressing human
liver carcinoma cells with E2 and showed E2 treatment upregulated expression of the granzyme B
inhibitor, proteinase inhibitor-9 (PI-9), and protected the cells against NK and CTL-induced apoptosis
in DNA fragmentation assays [95]. E2-induced PI-9 expression was also observed in ERα-positive
MCF7 breast cancer cells, again protecting cells against NK elimination, while PI-9 knockdown blocked
E2’s protective effect against NK granule-mediated apoptosis [96]. These studies suggest that E2
enhances immunosuppression through inhibition of NK and CTL-mediated tumor cell elimination.
3.5.2. Regulatory T Cells
T cell activation and effector differentiation is an essential part of the adaptive immune response.
FoxP3 expressing Tregs are integral in coordinating suppression of anti-tumor immune responses,
secreting immunosuppressive cytokines and inhibiting responder T cell expansion [97]. Physiological
doses of E2 administered to immunocompetent ovariectomized female mice have been shown to
enhance CD4+CD25+ Treg expansion and upregulate Foxp3 expression in multiple tissues [98].
Furthermore, fluorescence-activated cell sorting (FACs) assays revealed ERα expressing CD4+CD25-
cells incubated with E2 acquire CD25 expression [98]. E2 transformed CD4+CD25+ T cells exhibited
an immunosuppressive Treg phenotype, significantly inhibiting T cell proliferation in an in vitro
mixed lymphocyte reaction [98]. Additional studies have reported E2-stimulated Foxp3 expression
in murine Tregs, which is of importance considering that Foxp3 is essential for Treg functionality,
and tumoral aggregation of FoxP3+ Tregs in patients is a predictor of poor prognosis in multiple
cancers [99–101]. For example, in early-stage NSCLC patients, nuclear ERα expression was found
independently associated with increased risk of recurrence and FoxP3+ lymphocyte infiltrate [102].
Further, a recent meta-analysis reported FoxP3+ Treg infiltration significantly correlated with poorer
OS in ER-positive breast cancer patients, but improved survival rates in ER-negative patients [103].
In addition, evaluation of ERα-positive breast tumors from patients treated with letrozole showed a
significant reduction of FoxP3+ Tregs post-treatment [104].
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Moreover, Tregs isolated from mice treated with E2 displayed enhanced suppression and increased
intracellular expression of the immune checkpoint protein programmed death-1 (PD-1), while ERα
and ERβ knockout reduced Treg suppression and PD-1 expression [105]. Of note, E2 treatment
also stimulates in vitro expression of the PD-1 ligand (PD-L1) on ERα-positive endometrial and
breast cancer cells through activation of PI3K signaling [106]. Interactions between PD-L1 expressing
tumor cells and PD-1 positive T cells induces cytotoxic T cell exhaustion, resulting in tumor immune
evasion [107]. Evidence that E2 upregulates both PD-L1 and PD-1, suggests E2 signaling may critically
influence the PD-1/PD-L1 pathway.
3.6. Inflammatory Cytokines and Eicosanoids
Chronic inflammation is widely recognized as an ancillary mechanism promoting tumor
progression. The TME releases cytokines that activate protumoral pathways mediating proliferation,
immune evasion, and metastasis [108]. IL-6, a proinflammatory cytokine, has been shown to enhance
ERα-positive breast cancer cell growth and invasion [109]. Local TAFs in breast cancers act as
a paracrine source of the elevated IL-6, driving STAT3 activation and ERα-positive tumor cell
proliferation both in vitro and in vivo [110]. TNFα, another ubiquitous TME cytokine, regulates
expression of genes associated with metastatic phenotypes in ERα-positive breast cancer cells [111].
TNFα has also been shown to upregulate aromatase expression in cultured human adipose stromal
cells [112]. Transcriptional linear correlations between aromatase and the cytokines TNFα and IL-6
have been reported in patient breast cancer tissue, but not in adjacent non-cancerous tissue [113].
A similar correlation has also been seen between aromatase and the eicosanoid cyclooxygenase-2
(COX-2) [113]. COX-2 is responsible for the synthesis of inflammatory promoting eicosanoids such as
prostaglandin E2 (PGE2) [114]. It is well established that PGE2 promotes upregulated transcription
of aromatase through elevated cyclic adenosine monophosphate (cAMP) in breast tumors [115].
Despite conflicting reports, some epidemiological studies show that regular use of COX-2 inhibiting
nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of developing ERα-positive breast
cancers, but not ERα-negative cancers [116].
Significant correlations between ERα, TNFα, and NF-κB protein expression have also been
reported in breast cancer tissues [117]. NF-κB signaling is well recognized for its role in tumor
initiation and inflammation [118]. Constitutive activation of NF-κB is observed in several cancers,
and is associated with the cytokines IL-6 and TNFα [118]. Increased DNA binding of NF-κB and
activator protein-1 (AP-1) has been observed in SERM-resistant, ERα-positive breast cancer cell line
models and patient specimens [119,120]. Furthermore, E2 exposure in a murine model evaluating
tobacco-induced lung cancer enhanced pulmonary inflammation through increased activation of NF-κB
signaling and expression of VEGF and IL-17A [83]. Alternatively, targeting E2 and inflammatory
pathways with combined AI and NSAID treatment maximally prevented carcinogen-induced lung
tumor development in mice, significantly reducing STAT3 and MAPK signaling, circulating IL-6, and
IL-17A expression [83]. Taken together, these reports indicate potential interactions between the E2
pathway and regulators of tumor-promoting inflammation, representing another beneficial target of
E2 inhibition.
4. Clinical Implications of Targeting the Estrogen Pathway in the Tumor Microenvironment
Immunotherapy is a powerful therapeutic strategy for cancer; however, the immunosuppressive
TME poses major obstacles for this approach. Currently, immune checkpoint inhibitors of cytotoxic
T-lymphocyte-associated antigen 4 (CTLA4) and PD-1/PD-L1 are among the most clinically evaluated
immune therapies [121]. These agentshave remarkably advanced cancer treatment, significantly
improving response rates and survival compared with standard-of-care chemotherapies [122–125].
However, typical response rates to these therapies remain limited to only around 20–35% of patients,
with variable responses depending on stage, tumor type, and PD-L1 staining positivity [126].
Furthermore, while some patients have durable responses, mechanisms of acquired and adaptive
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resistance are becoming apparent, with 25 to 33% of melanoma patients exhibiting delayed relapse on
these therapies [15,16].
Recent efforts to identify molecular events underlying immune evasion and failed therapeutic
response report that damaged DNA repair mechanisms, increased non-synonymous somatic
mutational load, and neoantigen presentation correlate with tumor immunogenicity and improved
clinical outcomes [12,13,127]. Alternatively, mechanisms facilitating immune evasion involve damage
to antigen presenting capacity and recurrence of non-antigenic mutations poorly presented by
MHC class 1 molecules [128,129]. While these findings provide a greater understanding of tumor
immunoediting and potential biomarkers predictive of response, novel therapeutic combinations are
still needed to improve the efficacy of current immunotherapeutic agents. The identification of E2
modulation of the tumor immune phenotype justifies investigation of endocrine agents to reverse
tumor immune tolerance. As depicted in Figure 1, E2 signaling can modulate the immune TME
through enhanced protumoral responses. Therefore, anti-estrogen therapy has the potential to not only
reverse an immunosuppressive TME, but also to augment response in E2-sensitive tumors.
Recently, a high-throughput screening assay in lung cancer cells identified the anti-estrogen
fulvestrant as the top compound that increased tumor sensitivity to immune-mediated lysis [130].
Fulvestrant is an ideal candidate to combine with anti-PD-1/PD-L1 agents, due to its proven safety
profile and non-overlapping toxicities. These new findings of E2 action on immune cells could create a
paradigm shift towards utilizing anti-estrogen therapy to target the immunosuppressive TME, thereby
increasing the efficacy and duration of response of current immunotherapies [131].
Figure 1. The E2 pathway promotes a protumor TME. The E2 pathway contributes to aberrant
regulation of antitumor immunity, enhancing a greater number of protumoral responses within the
TME. Current literature suggests E2 may facilitate an immunosuppressive TME by shifting the balance
in favor of Th2 responses, production of tumor-promoting cytokines (IL-6, IL-4, TNFα, and IL-17A),
and M2 TAM infiltration compared to Th1 responses, associated Th1 cytokines (IL-12 and IFNγ), and
M1 TAM infiltration. E2 may further promote tumor immune evasion through proliferation of Treg and
MDSC populations, increased tumor cell PD-L1 expression, and inhibition of CD8+ T cell and NK cell
induced apoptosis. CAFs may additionally support a protumor environment by supplying paracrine
sources of E2 and IL-6. Therefore, targeted inhibition of the E2 pathway may act as a novel strategy to
enhance the effects of immunotherapies and reverse this immune imbalance within the TME.
5. Conclusions and Perspective
The E2 pathway is an identified promoter of tumorigenesis in several cancers, largely for its direct
genomic and non-genomic effects on tumor cells. However, evidence of ER and aromatase expression
on stromal and immune cells within the TME indicates that additional mechanisms exist by which
estrogens enhance malignant progression. It is becoming increasingly evident that cells comprising
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the TME can impact tumor immunity, either beneficially through enhanced antitumoral immune
responses, or detrimentally through increased protumoral responses. Evidence thus far suggests
that E2 facilitates a primarily tumor-promoting and immunosuppressive TME in multiple tumor
types. While checkpoint blockade immunotherapies have exhibited significant clinical success for the
treatment of certain cancers, partial response rates and acquired resistance to these therapies necessitate
the development of strategies to boost immunotherapeutic responses. The data summarized here
points to the E2 pathway as a regulator of tumor immune responses, suggesting that clinical benefit
may be derived from combining estrogen blocking agents with immune checkpoint inhibitors. Prior to
clinical analysis of this combination, a more comprehensive characterization of E2-related proteins
in the TME of various tumor types is necessary. There is also a need for standardized methods and
CLIA-approved assays for the detection of ERβ and aromatase expression. Future studies evaluating
response to current immunotherapies based on sex-differences, patient demographics including
menopausal status, and obesity are warranted, given the pervasive involvement of the E2 pathway in
tumor immunity.
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ERβ Estrogen receptor β
ERα Estrogen receptor α
ERE Estrogen response element
E2 17β-Estradiol
DC Dendritic cell
Treg Regulatory T cell
SERM Selective estrogen receptor modulator
SERD Selective estrogen receptor degrader
IHC Immunohistochemistry
IF Immunofluorescence
Th2 T helper 2




TNFα Tumor necrosis factor alpha
TME Tumor microenvironment
EGF Epidermal growth factor
IGF Insulin growth factor
FGF Fibroblast growth factor
OS Overall survival
NSCLC Non-small cell lung cancer
CAF Cancer associated fibroblast
TAM Tumor associated macrophage
MDSC Myeloid derived suppressor cell
MPP Methylpiperidino pyrazole
NK Natural killer
LRH-1 Liver receptor homolog-1
PCR Polymerase chain reaction
PI3K Phosphatidylinositide 3-kinase
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MAPK Mitogen-activated protein kinase
CCL5 C–C motif chemokine ligand 5
IL-12 Interleukin-12
VEGF Vascular endothelial growth factor
HGSOC High grade serous ovarian cancer
IL-17A Interleukin-17A
STAT3 Signal transducer and activator of transcription 3
TIL Tumor infiltrating lymphocyte
AI Aromatase inhibitor






NSAID Nonsteroidal anti-inflammatory drug
AP-1 Activator protein-1
CTLA4 Cytotoxic T-lymphocyte–associated antigen 4
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Abstract: Numerous studies have established a proof of concept that abnormal expression
and function of estrogen receptors (ER) are crucial processes in initiation and development of
hormone-related cancers and also affect the efficacy of anti-cancer therapy. Radiotherapy has been
applied as one of the most common and potent therapeutic strategies, which is synergistic with
surgical excision, chemotherapy and targeted therapy for treating malignant tumors. However,
the impact of ionizing radiation on ER expression and ER-related signaling in cancer tissue, as well as
the interaction between endocrine and irradiation therapy remains largely elusive. This review will
discuss recent findings on ER and ER-related signaling, which are relevant for cancer radiotherapy.
In addition, we will summarize pre-clinical and clinical studies that evaluate the consequences
of anti-estrogen and irradiation therapy in cancer, including emerging studies on head and neck
cancer, which might improve the understanding and development of novel therapeutic strategies for
estrogen-related cancers.
Keywords: estrogen; estrogen receptor; radiotherapy; radioresistance; breast cancer; head and
neck cancer
1. Introduction
Estrogens exert many physiological functions in target tissues mainly via two members of the
nuclear receptor superfamily: Estrogen receptor-α (ERα) and ERβ. They are encoded by separate
genes, ESR1 and ESR2, respectively, transcribed from various chromosomal locations, and multiple
mRNA splice variants exist for both receptors in normal and disease states [1,2]. On the structural
level, both receptors possess five distinct structural and functional domains, harboring a DNA-binding
domain (DBD), a ligand-binding domain (LBD), hinge domain and two transcriptional activation
functions (AF-1, AF-2). As members of the hormone nuclear receptor superfamily, they share over
50% similarity in their hormone-binding domains and a predicted 96% similarity within the DBDs.
However, there is a lower degree of sequence similarity within their hormone-independent AF-1
domains (Figure 1A) [3,4].
ERs and their variants mediate distinct effects as transcription factors in the nucleus when
they are bound to their specific ligands through various mechanisms, which could be explained by
genomic or non-genomic signaling pathways [5]. In the genomic mode of ER action, the ligands
(e.g., estrogen hormones) diffuse into the cell and bind to the LBDs of the receptors, which result in
homo- or heterodimer formation and subsequent binding to DNA at estrogen responsive element (ERE)
sequences. Once bound to EREs the ligand-ER complex can modify gene expression by recruitment
of distinct co-regulatory proteins, known as co-activators and co-repressors, or by interaction with
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other transcription factors, such as activator protein 1 (AP1), specificity protein 1 (SP1), and others [6].
In contrast, estrogen can elicit rapid response via non-genomic signaling pathways, which depend on
the presence of a secondary messenger such as cyclic adenosine monophosphate (cAMP) and calcium,
or the activation of protein kinases (Figure 1B) [5].
Figure 1. (A) Structural and functional domains of the ERα and ERβ. Structural domains of
estrogen receptor α (ERα) (595aa) and ERβ (530aa) are labeled A-F. Both receptors have five
distinct structural and functional domains: DNA-binding domain (DBD; C), hinge domain (D),
ligand-binding domain (LBD; E/F), and two transcriptional activation function domains AF-1 (A/B)
and AF-2 (F). The percentage of amino acid homologies between ERα and ERβ domains is also
indicated; (B) Schematic illustration of ER-mediated signaling pathways. In the classical mechanism of
ER action, estrogens (E2) bind to ERs and the E2-ER complex binds directly to estrogen response
elements (EREs). Once bound to EREs the E2-ER complex can modify gene expression by the
recruitment of distinct co-regulatory proteins, known as co-activators and co-repressors. In the
ERE-independent genomic action, nuclear E2-ERs complexes interact with other transcription factors,
such as activator protein 1 (AP1) or specificity protein 1 (SP1). In the ligand-independent genomic
action, growth factors activate protein kinase cascades, such as Ras-ERK or PI3K-Akt, causing activation
of nuclear transcription factors. In the non-genomic action, the E2-ERs complex activates protein-kinase
cascades or cyclin adenosine monophosphate (cAMP) and calcium, leading to altered functions of
proteins in the cytoplasm. ERK: extracellular signal–regulated kinase; PI3K: phosphatidylinositide
3-kinase; CoR: co-repressor; CoA: co-activator.
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Over the last few decades, a growing number of studies have established a proof of concept
that abnormal expression and regulation of ERs are crucial events in initiation and development of
hormone-related cancers and are related to the outcome of cancer therapy. Many lines of evidence
indicate that ERα and ERβ might perform different functions during carcinogenesis and anti-cancer
therapy [2,7]. Currently, radiotherapy is used as one of the most common and potent cancer therapeutic
strategies. It acts synergistically with surgical excision, chemotherapy and targeted therapy for treating
malignant tumors in human. Encouragingly, clinical studies revealed that ER-positive breast cancer
can be targeted by radiotherapy in combination with the modulation of ER activity, namely, endocrine
therapy [8]. Tamoxifen belongs to the most frequently prescribed selective ER modulators (SERMs),
which have been an effective and safe adjuvant endocrine therapy for several decades. However,
the molecular mechanisms through which ionizing radiation (IR) regulates ER activity in cancer
tissue and whether ER signaling has an impact on the efficacy of radiotherapy in various types
of malignancies, remain largely elusive. Furthermore, the variability of ERα and ERβ expression,
diverse response of ER and ER-related signaling to irradiation both contribute to the risk of safety and
efficacy of cancer therapy.
In this review, we will discuss distinct functions of ER and ER-related signaling that are relevant
to cancer radiotherapy. In addition, we will summarize pre-clinical and clinical studies that evaluate
the consequences of anti-estrogen and irradiation therapy in cancer, including emerging studies on
head and neck cancer, which might improve the understanding and development of novel therapeutic
strategies for estrogen-related cancers.
2. Estrogen Receptor Signaling and Ionizing Radiation
2.1. Molecular and Cellular Responses to Ionizing Radiation
Radiotherapy is mainly based on the principle that normal tissue cells exhibit greater DNA
repair capacity than carcinoma cells upon damage due to ionizing radiation [9]. Nowadays, ionizing
radiation has become a widely applied treatment strategy for the majority of solid cancers. A series of
biological effects on genomic DNA, which is considered as the most important target molecule, can
be induced by photons, electrons, or heavy ions, which are generated by linear accelerators [10,11].
The biochemical lesions in genomic DNA of cancer cells can be achieved in a direct and indirect manner.
A therapeutic dose of linear energy transfer (LET), such as particles or neutrons, can directly cause
DNA damage, including single-strand breaks (SSB), modified bases, damage of the sugar backbone,
double strand breaks (DSB) as well as effects on DNA repair [12,13]. Indirect effects are enforced by
the generation of reactive oxygen species (ROS) that target and damage genomic DNA (Figure 2) [14].
It is worth noting that estrogens can also induce ROS in breast cancer cells, resulting in elevated
genomic instability and a higher degree of clonal heterogeneity. The efficacy of radiotherapy might
be modulated by estrogen-reduced ROS. The function of estrogen-induced ROS production in breast
cancer has been reviewed previously by Okoh and coworkers [15]. Most types of human cells dispose
of DNA damage with complicated response mechanisms, collectively named DNA-damage response
(DDR), regardless of whether the damage is induced in a direct or indirect mode of action. Mechanisms
of DDR can be activated and arrest the cell cycle at specific checkpoints, executing either DNA repair
or induce programmed cell death (namely apoptosis) and cellular senescence, which are critical for
maintaining cellular genomic integrity and for preventing neoplastic transformation [16].
DSB damage is the most lethal type of DNA damage induced by ionizing radiation [17].
DNA repair is the frontline response to cellular DNA damage, which also contributes to irradiation
resistance in tumor cells. Efficient DNA repair enables tumor cells to replicate and survive.
Generally, DSB damage repair is carried out by two major pathways: non-homologous end jointing
(NHEJ) and conservative homologous recombination (HR), which have been extensively reviewed
previously [18–20]. NHEJ is considered as the primary DSB repair pathway, which is activated
throughout the cell cycle and relies on rejoining free DNA ends without the requirement for sequence
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homology. During this repair process, DNA strands of DSB sites are cut or modified, and the ligation
of DNA ends are achieved directly and quickly regardless of homology, deletions or insertions.
Although this makes NHEJ possibly error-prone, this mechanism can repair the DNA damage rapidly
to eliminate potential genetic instability [21]. It is worth noting that estrogens have been shown
to induce components of NHEJ in breast cancer cells and that therapeutic targeting of ERs result
in irreparable DSB [22]. HR is widely known as a more precise mode of repair, which uses an
undamaged template to retrieve the chromatid sequence content missing at the DSB sites. During HR,
the damaged chromatid physically contacts with an undamaged sister chromatid with a homologous
sequence for genetic information restoration in the late S/G2 phase of the cell cycle [23]. Compelling
experimental evidence implicates that estrogens mediate both positive and negative regulation
of HR. In melanoma, the tumor suppressor gene MEN1 and ERα stimulate the transcription of
BRCA1, RAD51 and RAD51AP1, which encode key players in HR-directed DNA repair. Fulvestrant
inhibits BRCA1, RAD51 and RAD51AP1 expression, resulting in decreased HR activity [24]. However,
in medulloblastoma, an enhanced ERβ activity has been associated with nuclear translocation of
insulin receptor substrate 1 (IRS-1), which interacts with RAD51 at the sites of damaged DNA and
reduces the HR function [25]. Pharmacological inhibition of ERβ induces medulloblastoma cells
resistance to cisplatin by elevated formation of RAD51 and increased levels of HR [26].
Cell cycle progression can be arrested at distinct cell cycle checkpoints temporarily, which are
the G1 checkpoint during transition from G1 to S phase, and the G2 checkpoint of G2/M phase
boundary. After perception of DNA lesions induced by IR, various biochemical signals are activated
by well-defined cascades of protein kinases. Ataxia telangiectasia mutated (ATM) and ATM- and
Rad3-related (ATR) kinases are upstream activators of IR-induced checkpoint arrest. ATM and
ATR fulfill their physiological functions via phosphorylation of numerous substrates, such as Chk
(checkpoint kinase) 2 and Chk 1, respectively, which are essential for cell cycle arrest at G1/S or G2/M
in response to DNA damage [27,28]. The G1/S checkpoint pathway is mainly operated by two key
effectors, namely the p53 transcription factor and the cell division cycle 25 A (Cdc25A) phosphatase,
which regulate two distinct branches. The key effector for the G2/M checkpoint is the Cyclin B/Cdk1
protein complex, whose activation after IR-induced DNA damage is regulated by ATM/Chk2 and
ATR/Chk1 (see Figure 2 for details) [29].
2.2. Interaction between Estrogen Receptor Signaling and Ionizing Irradiation
It is well established that estrogens regulate cell cycle progression in hormone-related
carcinomas [30]. Therefore, the influence of estrogens or estrogen modulators on cell cycle progression
is a critical factor for the interaction between ER signaling and IR. In MCF-7 cells, a major effect of
estrogen is the activation of cell cycle progression by induction of G1 phase entry and shortening of the
G1/S transition [31]. This effect is at least in part due to induced transcription of c-Myc and Cyclin D1,
two key regulators of cell cycle progression [31]. Genomic approaches were applied to demonstrate
that c-Myc regulates radioresistance through transcriptional activation of Chk1 and Chk2 by direct
binding to their gene promoters in nasopharyngeal carcinoma cells, revealing a potential therapeutic
strategy in reduction of radioresistance through blockade of the c-Myc-Chk1/Chk2 pathway [32].
In breast cancer, several studies provided a functional link between estrogen-related signaling and
c-Myc regulated transcription [33]. Induction of c-Myc by estrogen is achieved via binding of ER to an
atypical estrogen-responsive cis-acting element (ERE) in the promoter sequence [34]. Antisense c-Myc
phosphorothioate oligonucleotides restrained proliferation of estrogen-stimulated cancer cells [35].
Moreover, induction of c-Myc in estrogen deprivation-arrested cells simulated the function of estrogen
by restarting the cell cycle progression [36]. It is also worth noting that Cyclin D1 has been involved
in estrogen/anti-estrogen regulation of cell cycle progression by binding and activating Cdk2 and
Cdk4. Elevated mRNA levels of Cyclin D1 precede modifications at the protein level, suggesting that
the function of estrogen in Cyclin D1 protein expression is mediated at the transcript level [37,38].
Estrogen triggers transcription of Cyclin D1 by a cAMP response element (CRE) in the promoter
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region [39,40]. Induction of Cyclin D1 leads to the formation of Cyclin E-Cdk2 complexes, which results
in increased phosphorylation of pRb and S phase progression [41]. These complexes also contribute to
decreased Cdk inhibitor p21Cip1 and p27Kip1 protein levels [31]. In the same study, estrogen-activated
Cdk2 and DNA synthesis was restrained by antisense Cdc25A oligonucleotides, while inactive Cyclin
E-Cdk2 complexes were reactivated by Cdc25A in vitro and in vivo, identifying Cdc25A as another
grow-promoting effector of estrogen action [31].
Figure 2. Schematic illustration of the signaling pathways in response to DNA damage and key
effectors that interact with ER signaling. After perception of DNA lesions induced by IR directly
or indirectly (by ROS generation), various biochemical signals are activated by cascades of protein
kinases. Ataxia telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) kinases are upstream
activators of IR-induced G1/S and G2/M checkpoint arrest. The G1/S checkpoint pathway is operated
by p53 and Cdc25A in distinct branches. Firstly, ATM or Chk2 directly phosphorylates the p53
transcription factor and targets mouse double minute 2 homolog (Mdm2), achieving the stabilization
and accumulation of the p53 protein. The critical effector of p53-dependent transcription is p21, which is
a Cdk inhibitor and binds the complexes of Cyclin E/Cdk2 and Cyclin D/Cdk4/6. Another branch
of the G1/S checkpoint pathway is activated rapidly via ATM-dependent phosphorylation of Chk2.
Subsequently, Cdc25A, an activator of the Cyclin E/Cdk2 kinase, is degraded, preventing the activation
of Cdk2. The ATM/Chk2-Cdc25A-Cdk2 axis accounts for the activation of the G1/S checkpoint via a
p53-independent mechanism. In the G2/M checkpoint signaling pathway, the key downstream effector
is the Cyclin B/Cdk1 protein complex, whose activation is restrained by ATM/Chk2 and ATR/Chk1
after IR-induced DNA damage. Moreover, Cdc25C phosphatase is also inhibited by Chk1/2 to activate
the G2/M checkpoint. Key effectors that interact with ER signaling are marked in blue.
Interestingly, a ligand-independent induction in ERα was observed in breast cancer cells after
irradiation, which might be a consequence of the cell cycle arrest and related regulatory proteins [42].
Induced cell cycle arrest by low doses of X-ray could be abolished by 17β-estradiol, increasing survival
of tumor cells and restraining cellular senescence by the regulation of p21 and Rb-related pathways,
but independent of p53 [43]. Molinari and coworkers [44] found that estrogen treatment of breast
cancer cell lines modified the intracellular distribution and functional activity of p53, indicating
estradiol-induced inactivation of p53 might contribute to carcinogenesis of estrogen-dependent tumors.
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ERα has been reported to bind directly to p53 at target gene promoters, such as CDKN1A and PCNA,
resulting in abrogation of p53 function. Moreover, 17β-estradiol promotes the interaction of ERα
and p53, consistent with inhibition of p21 transcription [45]. Several studies have also shown that
nuclear factor-κB (NFκB), a transcription factor regulating a variety of cellular processes, is linked to
ER signaling in breast cancer. These studies suggest a critical role of a functional crosstalk between ER
and NFκB in the resistance of cancer cells against endocrine and irradiation therapies [46,47].
Besides transcriptional effects of estrogen, there are also non-genomic signaling pathways to be
considered. Estrogen can induce growth factor signal cascades, including insulin-like growth factor I
receptor (IGF-IR), mitogen-activated protein kinase (MAPK), phosphatidylinositol-3-kinase (PI3K),
and epidermal growth factor receptor (EGFR) signaling, which trigger increased cell proliferation
and enhanced radioresistance (Figure 1B) [48–51]. In ER-positive lung cancer, the EGFR directly
phosphorylates ERα at specific serine residues [52]. Vice versa, estrogen triggers MAPK and
PI3K/AKT signaling pathways to facilitate tumor metastasis through epithelial-to-mesenchymal
transition (EMT) [53,54]. EMT is generally considered to be associated with radioresistance in distinct
tumors [55–58]. Thus, estrogens exert a radioprotective function via genomic signal pathways and
various classical growth factor pathways, indicating a rationale for anti-estrogen treatment to enhance
the radiosensitivity of cancer cells (Figure 3).
Figure 3. Molecular mechanism of estrogen and ER signaling contributions to radioresistance.
The impact of estrogen and ER signaling on cell cycle progression is a critical factor for their
contribution to radioresistance. c-Myc and Cyclin D1, two key regulators of cell cycle progression,
have significant functions in estrogen and ER signaling mediated radioresistance. In addition, ER can
interact with NFκB, a transcription factor, in resistance of cancer cells. Several protein kinase cascades,
such as insulin-like growth factor I receptor (IGF-IR), mitogen-activated protein kinase (MAPK),
phosphatidylinositol-3-kinase (PI3K), and epidermal growth factor receptor (EGFR) signaling, facilitate
EMT, increased cell proliferation and enhanced radioresistance.
3. The Combination of Anti-Estrogen and Irradiation Therapy in Cancer
Anti-estrogen therapy exerts functions by competing with estrogens for binding to ERs,
most widely applied for the treatment of women with ER positive breast cancer. In 1971, a new
anti-estrogen drug tamoxifen was reported firstly in the management of breast cancer [59]. Until now,
tamoxifen reveals a significant clinical benefit and represents the most frequently prescribed
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anti-estrogen drug [59]. However, only a few studies exist that have addressed the potential value of
tamoxifen therapy during or post radiotherapy.
Wazer and colleagues [60] investigated the interaction of tamoxifen and irradiation in the MCF-7
cell line. They observed that growth-inhibitory doses of tamoxifen reduced the radiosensitivity of
breast cancer cells, indicating an enhanced repair of irradiation-related DNA damage. In order to
unravel the effect of tamoxifen on radiosensitivity, Wazer and coworkers [61] extended the study
on the ER-negative cell line MDA-MB-231, in which tamoxifen revealed no alterations in intrinsic
radiosensitivity. They hypothesized that the interaction of estrogen, tamoxifen and irradiation
in ER-positive breast cancer cells would be achieved by the regulation of the G1/S checkpoint.
As introduced above, the G1/S checkpoint can be activated by irradiation to induce cell cycle arrest
and to provide the time for DNA repair. This G1 phase block can be enhanced by tamoxifen and
attenuated by estrogen. These observations have been confirmed by several studies with similar
experimental conditions [62–64]. Interestingly, it has been demonstrated that anti-estrogen therapy can
change radiosensitivity independent of the ER status, indicating that hormonal modulators might exert
their effect via ERs but also in a non-receptor mode of action. Newton and colleagues [65] observed
an enhanced apoptotic cell death in MCF-7 cells which were treated by a combination of irradiation
and ZM182780, a pure anti-estrogen, or tamoxifen. In a more recent study, tamoxifen enhanced the
radiosensitivity of human glioma cells by inducing cell apoptosis and sustaining G2/M arrest [66].
Moreover, fulvestrant, another pure anti-estrogen drug, revealed a positive effect on radiosensitization
of ER-positive breast cancer cells by inducing cell cycle arrest and inhibiting proteins involved in
DSB repair [67]. However, in contrast to these findings, Sarkaria and coworkers [68] reported that
tamoxifen had no impact on radiosenstitivty of MCF-7 cells. The reason for these conflicting findings
might be that MCF-7 cells exhibit an unusual form of apoptosis induction via activation of caspase-7
due to deficient caspase-3 activity [69]. Therefore, the MCF-7 cell line might not be an appropriate
in vitro model to investigate irradiation or tamoxifen-induced apoptosis for breast cancer.
In order to further explore the interaction of anti-estrogen and irradiation therapy, in vivo studies
have been conducted. Kantorowitz and colleagues [70] observed that a combination of tamoxifen
and irradiation leads to a significant reduction of tumor volume and inhibits occurrence of additional
tumors in a rat model of breast cancer induced by 1-methy-1-nitrosourea. Additional animal studies
suggested that tamoxifen inhibits the initiation and promotion of irradiation-induced mammary
tumors [71,72]. In line with these findings, anti-hormonal drugs, such as mifepristone, ICI182780 and
Letrozole showed a sensitizing activity on chemo-radiotherapy in vitro and in vivo by increasing
G2/M arrest in cervical cancer [73,74]. These data support the assumption that the interaction of
anti-estrogen treatment and irradiation might be related to the regulation of cell cycle checkpoints.
Although activation of cell cycle arrest by anti-estrogen drugs can facilitate DNA repair and eliminate
irradiation-induced genomic lesions, its therapeutic activity might be due to the suppression of tumor
cells repopulation after the irradiation interval. It is worth noting that concurrent treatment with
anti-estrogen and irradiation therapy revealed an increased risk of lung fibrosis, cardiac damage
and pneumonitis, which could be caused by the induced levels of transforming growth factor beta
(TGF-β) [75–78].
In contrast to several in vitro studies, in vivo studies indicate a synergistic effect of concurrent
tamoxifen and radiotherapy, which might be due to alterations in the tumor microenvironment.
Several randomized controlled trials have shown that concurrent radiotherapy with tamoxifen
achieved higher local control in breast cancer patients after lumpectomy compared to the treatment
without tamoxifen, indicating that the combination of anti-estrogen and irradiation therapy is effective
in the control of invasive cancer [79,80]. However, the optimal sequencing of endocrine therapy relative
to radiotherapy remains elusive. An increasing number of retrospective clinical studies in breast cancer
suggest that concurrent anti-estrogen and irradiation therapy shows no clear improved local control or
favorable clinical outcome (Table 1) [81–87]. Moreover, the question of sequencing of hormonal and
irradiation therapy for breast cancer has been addressed by several large randomized trials [87,88].
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No significant difference between concurrent or sequential anti-estrogen therapy with irradiation was
observed concerning clinical outcome of patients with breast cancer. Again, breast, lung or cardiac
fibrosis was detected in patients with concurrent hormonal and irradiation therapy [89–93]. Therefore,
it is reasonable for patients to receive hormonal and irradiation therapy sequentially to avoid the
risk of toxicities. However, in view of the uncertainty and complexity of these trials, this conclusion
should be treated with a great deal of caution. Furthermore, the complexity of the human immune
response could explain the discrepancy between preclinical and clinical studies. Preclinical and clinical
studies taking into account the paracrine interaction of tumor and immune cells, including novel
immune-modulating therapies, are urgently needed to further address and to confirm this conclusion.
Although there is some evidence for a benefit of concurrent radiotherapy and anti-hormonal
therapy in breast cancer, it might be more appropriate in other cancer entities. However,
Dahhan and colleagues [94] reported a single case of low grade endometrial stromal sarcoma (ESS),
where radiotherapy and anti-hormonal therapy were administered at the same time. This treatment
resulted in tumor progression and was discontinued. Apart from that single case, no study has been
published for other cancer entities that used concurrent radiotherapy and anti-hormonal therapy.
Recently, a preclinical study conducted in our group provided experimental evidence for a causal link
between ERβ expression and radioresistance in head and neck cancer [95].
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4. ER Signaling in Head and Neck Cancer
In contrast to breast cancer, the role of estrogen and ER-related signaling is less well established
in head and neck cancer (HNC). HNC is one of the most common human malignancies with around
600,000 new cases per year worldwide [96]. More than 90% of cases are diagnosed as head and
neck squamous cell carcinoma (HNSCC), which develop from the mucosal epithelium of the upper
aerodigestive tract. This includes oral cavity, nasopharynx, oropharynx, larynx and hypopharynx.
Main risk factors are tobacco and alcohol consumption, human papilloma virus (HPV) and to a lesser
extent Epstein–Barr virus (EBV) infection [97,98]. Current treatment options mainly consist of surgery,
radiotherapy and chemotherapy, mostly platinum based [99].
Healthy tissues of human oral epithelium and salivary glands express mainly ERβ [100]. However,
one study focusing on parotid gland pleomorphic adenoma found ERα and ERβ expression in normal
tissue of the parotid gland especially in ductal cells. ERβ expression was enhanced in pleomorphic
adenoma compared to normal tissue suggesting a possible role in tumor development [101].
There is also a possible role of ER signaling during HNSCC carcinogenesis. In a cell culture model,
premalignant cells showed prominent ERβ but not ERα expression. Estradiol (E2) treatment induced
Cytochrome P450 1B1 (CYP1B1), an enzyme that causes formation of carcinogenic metabolites from E2.
E2 inhibited apoptosis but did not alter proliferation. In human tissue sections, ERβ showed distinct
expression in normal tissue, dysplasia and squamous cell carcinoma (SCC) with most prominent
staining in SCC [102]. In contrast, ERα expression was almost absent, suggesting a more prominent
role of ERβ-related signaling. On the contrary, when using an artificial overexpression system for ERα
combining with E2-treatment, Sumida et al reported an increase in proliferation and expression of
EMT-markers [103].
First in vivo evidence for a causal role of ER-related signaling in the pathogenesis of HNSCC
emerged in the late 1980s. In a mouse xenograft model for laryngeal cancer estradiol treatment
enhanced the kinetic of tumor formation and tumor size [104]. Although there are some studies
suggesting that HNSCCs express mostly ERα rather than ERβ [105], most research points in the
opposite direction, claiming ERβ outweighing ERα. Two studies reported a more favorable outcome
of ERβ positive tumors as compared to ERβ negative tumors [95,106]. Tumors positive for ERα,
the effects of which are reported to be counteracted by ERβ, have been associated with slightly poorer
survival [102,107]. However, it is worth noting that those results were produced investigating HNSCC
from different primary sites and were based on different detection methods for ER expression.
It has also been shown that estrogen signaling exerts different biological effects in HNSCC tumor cells.
E2-stimulation activates MAPK signaling in an additive fashion with EGF and induce invasion of HNSCC
tumor cells [48]. This activity could be mediated by ERs or GPER1 (G protein-coupled estrogen receptor
1), which was shown to trigger proliferation and migration in laryngeal squamous cell carcinoma (LaSCC)
via Interleukin-6(IL-6) and signal transducer and activator of transcription 3 (STAT3) [108]. There are
also experimental data indicating that ERβ causes an increase of NOTCH1 expression and thereby favors
differentiation in SCCs, including HNSCC. In line with this assumption, ERβ overexpression or treatment
with specific agonists inhibited proliferation of SCC cell lines, including HNSCC [109].
More recently, our laboratory demonstrated an accumulation of ERβ-positive HNSCC cells after
fractionated irradiation in vitro, suggesting a critical role of ERβ-related functions in radioresistance.
Indeed, tamoxifen or Fulvestrant treatment revealed a sensitization of these cells to irradiation,
which was accompanied by augmented apoptosis. Radioresistant tumor cells were also positive
for submaxillary gland androgen-regulated protein 3A (SMR3A), which is a putative ERβ downstream
target and was shown to serve as a prognostic biomarker for HNSCC patients. Accordingly,
HNSCC with a high ERβ and SMR3A expression pattern were significantly associated with an
unfavorable progression-free survival and disease specific survival [95].
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5. Conclusions and Perspectives
The controversial findings of in vitro and in vivo preclinical studies in breast cancer indicate an
enormous complexity and context-dependency with a strong impact on the efficacy of anti-estrogen
treatment in combination with radiotherapy. Many questions are waiting to be resolved including
better understandings of estrogen and estrogen modulators action on normal and cancer cells,
precise mechanisms of interaction of estrogen signaling and irradiation, the development of novel
estrogen modulators, as well as effective therapeutic strategies of combination of endocrine therapy and
radiotherapy. Moreover, the distinct expression of ER subtypes in various cancer tissues, components
of the ER-related signaling cascade, and regulation of many transcription factors, all contribute to
a complex situation that impedes the therapeutic efficiency of endocrine therapy and radiotherapy.
Therefore, not only breakthroughs from basic and preclinical studies but also translational clinical trials
are urgently required to further explore and develop the combination therapies in distinct malignancies.
Finally, the oncology research community including academic, hospital, industry and government will
need to overcome challenges and achieve an encouraging therapeutic outcome for cancer patients.
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Abstract: Estrogen plays an important role in the regulation of cardiovascular physiology and the
immune system by inducing direct effects on multiple cell types including immune and vascular
cells. Sex steroid hormones are implicated in cardiovascular protection, including endothelial healing
in case of arterial injury and collateral vessel formation in ischemic tissue. Estrogen can exert potent
modulation effects at all levels of the innate and adaptive immune systems. Their action is mediated
by interaction with classical estrogen receptors (ERs), ERα and ERβ, as well as the more recently
identified G-protein coupled receptor 30/G-protein estrogen receptor 1 (GPER1), via both genomic
and non-genomic mechanisms. Emerging data from the literature suggest that estrogen deficiency in
menopause is associated with an increased potential for an unresolved inflammatory status. In this
review, we provide an overview through the puzzle pieces of how 17β-estradiol can influence the
cardiovascular and immune systems.
Keywords: estrogen; 17β-estradiol; angiogenesis; metabolism; endothelium; macrophages;
immune response
1. Setting the Stage: Estrogen, the Cardiovascular System and the Immune Response
In addition to its essential role in sexual development and reproduction in females, estrogen
is involved in a wide range of physiological processes in different tissues [1], even in male subjects.
Evidence accumulated over the years demonstrated that estrogen has protective effects on the
cardiovascular system [2–4], mainly related to interaction with multiple cell types including immune
cells, such as B lymphocytes and macrophages [5] and vessel wall cells, including smooth muscle [6,7]
and endothelial cells [8–11].
In women, estrogen circulating levels fluctuate during the menstrual cycle and its concentration
changes in relation to age [12]. The most important estrogen circulating from menarche to menopause
is 17β-estradiol (E2). Close to menopause, estrogen plasma levels decrease compared to those present
in fertile women [13] and become equivalent to those present in men. However, E2 continues to be
synthesized, starting from androgens, in extragonadal sites such as breast, brain, muscle, bone and
adipose tissue where it acts locally as a paracrine or autocrine factor [14]. Declining estrogen levels are
associated with a variety of metabolic changes and cardiovascular diseases [15]. The metabolic effects
mediated by estrogen take place in multiple tissues including skeletal muscle and liver [16].
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E2 prevents endothelial dysfunction, vascular inflammation and atherosclerosis [15]. In addition,
available evidence points to E2 as a key factor in promoting endothelial healing and angiogenesis [8–10,17]
through endothelial progenitor cells, immune inflammatory cells and platelet mobilization, which
contribute synergistically to endothelial repair [18–20]. The important role of E2 in the angiogenic process is
also noticed in ischemia-reperfusion tissue injury, where E2 induces the formation of collateral vessels [21].
Angiogenesis stimulation by E2 accelerates functional endothelial recovery after arterial injury, which
could be beneficial in coronary artery disease, peripheral arterial disease, cerebral ischemia and congestive
heart failure [21]. The direct actions of E2 on endothelial cells contribute to accelerate re-endothelialization
in vivo [22]. This process following endothelial damage [20,22] is accompanied by reduced neointima
formation as a result of inhibition of smooth muscle cell proliferation and migration [23]. Furthermore,
E2 promotes the natural resolution of inflammation in wound healing [24].
The immune system demonstrates remarkable sex differences: females tend to have a more
responsive immune system compared to their male counterparts. The outcome and survival rates
from e.g., infections or sepsis are sometimes better in females than in males [25]. Females, however,
respond more aggressively to self-antigens and are more susceptible to autoimmune diseases [26].
The body of human data on gender differences in immune response is rapidly growing. Amadori and
colleagues [27] were the first to demonstrate that circulating T lymphocytes in fertile women are more
abundant than those in men; this also occurs in other female mammals, suggesting a common trait in
different species that endows females with a more rapid and efficient immune response [28,29]. It has
long been recognized that steroid hormones play a role in the regulation of the immune response to
infection or tissue damage and modulate all levels of the innate (neutrophils, macrophages/monocytes,
natural killer cells, dendritic cells) and adaptive immune systems (T and B cells) (reviewed in [30]).
Estrogen has been shown to regulate neutrophil number and function, and the production of
chemokines such as monocyte chemoattractant protein (MCP)-1 and cytokines including tumor
necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β. On the other hand, since ovarian activity
decreases and eventually stops with aging, several disease conditions may show up, which are
characterized by a strong inflammatory component associated with the post-menopausal state [26,31].
The aim of this review is to discuss the multifaceted role of estrogen in vascular biology and in the
immune response, particularly in the monocyte/macrophage system, and to further integrate available
evidence (i.e., solve the puzzle) regarding the estrogenic control of double-edged processes such as
angiogenesis and metabolism.
2. Estrogen Receptors
The effects induced by estrogen in different tissues are the result of the activation of transcriptional
and non-transcriptional signal pathways. Estrogen exerts both rapid and long-term actions through
their binding with ERs [1]. Several ER subtypes have been identified: the nuclear isoforms, ERα and
ERβ, and the transmembrane G-protein-coupled receptor 30/G-protein estrogen receptor 1 (GPER1).
ERα and ERβ act as transcription factors responsible for many genomic effects, modulating gene
expression by direct binding to DNA at specific estrogen response elements (EREs) [32]. In contrast,
GPER1 is mainly involved in mediating rapid intracellular responses induced by estrogen [33,34].
The genes encoding ERα, ERβ and GPER1 are ESR1, ESR2 and GPER1, respectively. The two
intracellular receptors have different molecular weights; in particular, ERα consists of 595 and ERβ of
530 amino acids, respectively [35]. Their structure consists of two main domains: the carboxy-terminal
domain for interaction with the ligand (ligand-binding domain, LBD), which contains the activator
factor-2 (AF-2), mediating a wide range of functional responses, and the central DNA-binding domain,
responsible for binding to EREs [36]. Other regions are involved in transcriptional activation: the
transcriptional regulatory domain (constitutively active amino-terminal domain, AF-1) and a hinge
domain between the DNA-binding domain and LBD, which gives flexibility to the protein [1,37].
ERα is a ligand-dependent transcription factor that exerts its genomic, also called nuclear actions
through binding to chromatin and mobilization of cofactors to influence the transcription of its target
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genes. A fraction of ERα can elicit membrane signaling (non-genomic effects) by association with
the plasma membrane [38,39]. Rapid changes in adenylate cyclase, mitogen-activated protein kinases
(MAPK) and phosphatidylinositol 3 kinase (PI3K) activities or in cytoplasmic calcium concentration
and endothelial nitric oxide synthase (eNOS) activation constitute established non-genomic effects.
By using mice expressing ERα proteins with inactivated genomic or nongenomic signaling, it has
been shown that the preserved arterial actions of E2 were membrane-dependent [40], whilst the
estrogenic responses of uteri were highly dependent upon the genomic actions of ERα [41]. These
studies thus demonstrated for the first time that the respective contributions of nuclear/genomic and
membrane effects towards the estrogenic response are tissue-specific. Accordingly, we showed that
administration of a selective ERα agonist confers cardiovascular protection dissected from unwanted
uterotrophic effects [3], suggesting that ERα-selective agonists represent a potential safer alternative to
natural hormones.
The estrogenic membrane receptor GPER1 belongs to the family of G protein-coupled receptors
and is characterized by the presence of seven transmembrane helices. The organization of the seven
helices involves the amino-terminal portion located outside the cell and the carboxy-terminal portion
in the cytoplasm. Cytoplasmic loops are involved in the selective binding and activation of various
heterotrimeric proteins [1]. This receptor is expressed at the endoplasmic reticulum and in the plasma
membrane [33,42]. E2 binds to GPER1 with nanomolar affinity, in the range of 3–6 nM [33], while
its affinity for nuclear receptors is ten times higher, in the range of 0.1–0.4 nM [1]. However, in
cells expressing both ERα and GPER1, coordinated signaling is likely to occur, with some evidence
supporting this in monocytes [43], ovarian cancer cells [44], uterine stromal cells [45] and coronary
vessels [46]. Accordingly, the emerging notion that GPER acts as an autonomous ER in vivo and also
interacts with intracellular ERs has been recently reviewed by Romano and Gorelik [47].
3. Estrogen Receptors and Endothelial Function
ERα is expressed in the vascular tissue [48,49]; although ERβ distribution in vascular tissues is
less characterized, human endothelial cells do express ERβ [50]. ERα has been long recognized to
mediate most beneficial cardiovascular effects of E2 [2–4], but it is also involved in pathologic cell
proliferation in the setting of cancer [51].
Several of estrogen cardiovascular actions are actually mediated by direct effects on the vessel wall
resulting in the control of endothelial function and plasma lipid profile. In particular, estrogen increases
the synthesis and release of nitric oxide (NO) and prostacyclin, well-known endothelial-derived
vasodilators and anti-platelet agents, and negatively regulates production of several pro-inflammatory
mediators in situations of vascular injury [52]. More specifically, estrogen upregulates the expression of
enzymes involved in prostacyclin biosynthesis, i.e., cyclooxygenase (COX)-1 and prostacyclin synthase,
thereby increasing systemic prostacyclin levels in rodents [53]. Moreover, estrogen increases both
COX2 expression and prostacyclin generation in ovariectomized low-density lipoprotein receptor
null (LDLR−/−) mice and substantially reduces atherosclerotic lesion size [54]. Accordingly, the
protective effects of estrogen were abrogated by disruption of the prostacyclin receptor (IP) gene in
the double LDLR−/−/IP−/− null mouse, suggesting that the protective actions of estrogen within
the cardiovascular system are, at least in part, mediated by endothelial prostacyclin and its receptor,
the IP. Notably, a physiological concentration of E2 induces transcription but not translation of COX-2
in human endothelial cells exposed to laminar shear stress [4]. E2 increases NO levels in cerebral
and peripheral endothelial cells in vitro via eNOS activation and ER-mediated mechanisms [55].
NO is essential for vascular endothelial growth factor (VEGF)-induced angiogenesis in vitro [56] and
in vivo [57]. Recent studies have shown that changes in the relative expression of ERβ/ERα may
influence some E2 effects, such as the modulation of vascular NO bioavailability in aging rodents [58].
Endothelial cells also express GPER1 [59], which mediates nongenomic rapid effects including
calcium influx, cAMP synthesis or kinase (such as PI3K) activation. These events are involved in the
regulation of vascular tone [33,34,60]. Interestingly, a novel role for GPER has emerged in regulating
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the expression of NADPH oxidase 1 (NOX1), which is essential for reactive oxygen species generation
in the cardiovascular system [61].
In conclusion, estrogen mediates both rapid and longer-term effects on the vessel wall.
Novel vascular target genes regulated by ER subtypes are being identified, thereby providing potential
opportunities for pharmacological intervention.
4. Estrogen, Angiogenesis and Metabolism
Additional puzzle pieces that need to fit together include estrogen, angiogenesis and metabolism.
Migration and proliferation of endothelial cells are closely involved in re-endothelialization and
angiogenesis. Angiogenesis consists of a number of subsequent biological events and is a tightly
regulated process. In adult organisms, angiogenesis is virtually absent under normal conditions,
except in the female reproductive tract, where it is routinely observed in the uterus in association
with E2 fluctuations [62]. E2 stimulates endothelial cell proliferation in vitro [8] and in vivo [8,9,17],
and inhibits spontaneous, as well as TNF-α-induced, apoptosis [63,64]. Furthermore, E2 enhances
adhesion of HUVECs to various matrix proteins and increases cell migration, thus promoting
angiogenesis [8,10]. The mechanisms responsible for the proangiogenic effect of E2 have been widely
investigated and appear to be largely mediated by ERα activation [65]; accordingly, angiogenesis is
impaired in ERα knockout mice [66]. In HUVECs, E2 has been shown to enhance cyclins A and B1
gene expression through involvement of the classical ER pathway [67]. E2 treatment also promotes
proliferation and increases RhoA gene expression and activity in an ERα-dependent manner [10,68].
Through a rapid, non-genomic pathway ligand activated by ERα, E2 promotes rearrangements of actin
cytoskeleton that allow the formation of specialized cell membrane structures, such as focal adhesion
complexes, pseudopodia and membrane ruffles [50]. Estrogen also stimulates VEGF production in
uterine and vascular tissue [69,70]. The rapid re-endothelialization induced by estrogen after vascular
injury may be due, in part, to increased local expression of VEGF [9,17]. E2-induced increases in VEGF
receptor-2 expression on human myometrial microvascular endothelial cells appears to be mediated
primarily by ERα [71]. In addition, E2 promotes increased β1, α5 and α6 integrin expression on
endothelial cell surface [72] and induces phosphorylation of focal adhesion kinase (FAK) followed by
its translocation toward membrane sites, where focal adhesion complexes are assembled [65].
In pathological circumstances, such as breast cancer, a clear association has been made between
estrogen, ER expression by endothelial cells, angiogenic activity and/or tumor invasiveness [73]. In this
context, transient E2 induction of VEGF results from E2-induced upregulation of the oncogenic nuclear
transcription factor c-Myc via ERα activation, whereas estrogen withdrawal in tumors induces hypoxic
conditions responsible for VEGF upregulation [74]. Because the expression of glucose transporter
1 (GLUT1) is regulated by c-myc [75], it is conceivable that estrogen interaction with ERα activates
c-myc, which in turn up-regulates GLUT-1 expression, thereby affecting tumor perfusion and glucose
transport and metabolism through glycolysis. However, recent in vitro and in vivo observations
indicate that membrane ERα signaling effects could mediate, or at least potentiate, the beneficial
actions of estrogen on energy balance, insulin sensitivity, and glucose metabolism. Indeed, selective
activation of the extranuclear ERα pool appears to induce endothelial actions and limit adipose tissue
and fatty liver accumulation [76]. Moreover, preliminary data obtained from a mouse model with
membrane-specific loss of function of ERα support a significant role of membrane ERα pool and
membrane-derived signaling effects in the metabolic protective effects of estrogen [77].
During angiogenesis, endothelial cells must increase their metabolic activity to generate energy
quickly and to facilitate the incorporation of nutrients into biomass. De Bock and colleagues [78]
demonstrated that phosphofructokinase-2/fructose-2,6-bisphosphatase-3 (PFKFB3)-driven glycolysis
regulates vessel branching. PFKFB3 is a direct target of E2 action; in ER-responsive breast cancer
cells (MCF-7), E2 promotes PFKFB3 mRNA transcription and up-regulates PFKFB3 protein expression
through ERα via direct binding to PFKFB3 promoter [79]. Recently, we demonstrated that the increased
angiogenic response in E2-stimulated HUVEC is mediated by enhanced PFKFB3 expression peaking
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after 3 h, consistent with the activation of a membrane receptor considering that a nuclear/genomic
effect would require a longer time. Treatment with the selective GPER1 agonist G-1 mimics the
chemotactic and proangiogenic effect of E2 and also increases PFKFB3 expression, suggesting that
E2-induced angiogenesis is mediated, at least in part, by the membrane receptor GPER1 [11]. Hence,
even if steroid hormones have been classically described to mediate biological effects via intracellular
receptors, non-genomic mechanisms of activation through membrane receptors responsible for
endothelial cell motility, proliferation, and angiogenesis have also been demonstrated. Additional
mechanisms for GPER1-mediated angiogenic stimulation may include the up-regulation of acid
ceramidase expression, the increase of X-linked inhibitor of apoptosis protein (XIAP) and the regulation
of Na+/H+ exchanger-1 (NHE-1) activity as reviewed recently by De Francesco et al. [80].
Experimental evidence accumulated over the past decade indicates that the direct effect of E2 on
endothelial cells explains some cardiovascular benefits of the ovarian sex steroid hormone (Figure 1),
but the specific pathways they influence remain to be elucidated. We have unraveled a previously
unrecognized mechanism of estrogen-dependent endocrine-metabolic crosstalk in HUVECs which may
have implications in angiogenesis occurring in ischemic or hypoxic tissues [11]. However, fitting these
puzzle pieces together would require dissecting the molecular mechanisms of estrogen’s proangiogenic
effect in different disease contexts such as cancer. Thus, tissue-specific pharmacological control of
endocrine-metabolic crosstalk appears to be a rewarding therapeutic strategy.
 
Figure 1. Multiple effects of 17β-estradiol (E2) in endothelial cells and macrophages. E2 induces
protective effects on the cardiovascular system by promoting endothelial healing and angiogenesis
through various pathways including the acceleration of re-endothelialization in vivo, the induction
of proliferation and rearrangements of the actin cytoskeleton. E2 regulates the induction of
chemokines and cytokines, and modulates macrophage immune phenotypes. These events are
mediated by intracellular and membrane ER subtypes that are operatively linked in several cell
types. The interaction between endothelial cells and macrophages is relevant in multiple disease
settings such as atherosclerosis and cancer.
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5. Estrogen and Macrophage Function
New data are redefining macrophages as diverse, polyfunctional and plastic cells that respond
to the needs of the tissue at steady state and during disturbed homeostasis. Inflammation plays
a critical role in the onset and progression of degenerative diseases, and is characterized by activation
of tissue-resident macrophages as well as monocyte-derived macrophages that originate and renew
from adult bone marrow. Under normal conditions, these cells provide immune surveillance and host
defense in tissues to maintain homeostasis. However, upon sensing changes in the microenvironment,
macrophages become activated, undergoing a morphological and functional switch [81]. Activation of
these cells is not an “all-or-none” process, but rather a continuum characterized by a wide spectrum
of molecular and functional phenotypes ranging from the “classical” M1 activated phenotype,
with a highly pro-inflammatory profile, to the “alternative” M2 phenotype, associated with a beneficial,
less inflammatory, protective profile [82,83]. Accordingly, these new models of activation and
classification account for the functional diversity of macrophages that is relevant in vivo both in health
and disease conditions including obesity, autoimmunity and neurodegeneration [84]. For instance,
since a prominent feature of tissue remodeling is neoangiogenesis, macrophage polarization could
affect the angiogenic process [85,86], which in turn is a determinant of adipose tissue expansion during
obesity [87].
Estrogen has been shown to act as regulator of the immune function of the monocyte-macrophage
system, especially regarding the production of cytokines. For instance, estrogen treatment in
ovariectomized animals reduces expression of vascular MCP-1 and leukocyte infiltration into
injured tissues, such as arteries and lung [88,89]. Estrogen affects the activation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) in monocytes derived from umbilical cord
blood, suggesting that high E2 concentrations during gestation affect the immune response in
newborns [90]. Later in life, the production of cytokines by monocyte/macrophages is heavily
influenced by the ovarian cycle, oral contraceptive use and estrogen replacement [91,92]. In vitro
pre-treatment with E2 of human macrophages inhibits the NF-κB signaling pathway and the
production of TNF-α induced by lipopolysaccharide (LPS) [93]. Estrogen has been also shown to
enhance production [94] and prevent degradation of the endogenous NF-κB inhibitor IκB-α [95].
Other authors have reported the inhibitory effect of E2 on the production of pro-inflammatory
cytokines [96]. By contrast, chronic exposure of murine macrophages to E2 in vivo increases production
of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α) [97,98].
Macrophages have long been recognized as crucial regulators of vascularization and
healing [99,100]; in particular, the macrophage switch from the inflammatory to resolving phenotype
is an essential step. In fact, in patients with non-healing and diabetic venous ulcers, failure in the
M1-to-M2 switch results in local chronic inflammation with impaired healing progression [101].
Interestingly, gene regulation by estrogen is a key mediator of age-related delayed human wound
healing [24]. The beneficial effects of estrogen on cutaneous healing are, in part, mediated through
macrophage ERα, and estrogen fails to promote alternative macrophage activation in the absence of
ERα in vitro [102]. Thus, we propose that estrogen acts as a reprogramming stimulus that accelerates
macrophage transition towards a resolving, reparative phenotype [93,103].
Local and systemic metabolism is integrated at the cellular level to regulate immune cell function.
By interacting with ER subtypes as discussed in Section 6 below, estrogen also affects metabolic
reprogramming in macrophages, which accompanies different activation pathways in response to
microenvironmental cues [15,32,81]. It is worth noting that similarities in metabolic reprogramming of
macrophages, other immune cells and endothelial cells are emerging [104]. Hence, new insights in
immunometabolism can be translated to the clinic to improve current treatments and develop novel
therapies for metabolic diseases, inflammation, autoimmunity, and cancer.
These findings point to a complex and partially unresolved role of estrogen in immune
and inflammatory responses [98]. Here we suggest that the duality in the action of estrogen on
monocyte/macrophages cytokine production depends on many factors including the stimulus
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triggering the inflammatory response (endogenous or exogenous antigens), the target organ,
the different estrogen concentration and ER expression patterns in tissues.
6. Estrogen Receptors in the Monocyte/Macrophage System
Recently, ER expression in human monocytes and macrophages has been investigated, increasing
the number of pieces of this already complex puzzle. Both cell types express all ERs (Figure 1).
Human primary monocytes express the ERα 36-kDa splice variant and GPER1 in a sex-independent
manner [43], and these are physically associated. Macrophages have a higher ERα expression and lower
ERβ expression than monocytes, and treatment with E2 in monocytes and in human macrophages
in vitro induces an increase in ERα expression in macrophages, but not in monocytes [5]. Deficiency
of ERα, but not of ERβ, increased TNF-α production by mouse peritoneal macrophages in response
to bacterial stimuli, suggesting a prominent role of ERα in mediating the anti-inflammatory effects
of estrogen [32,93,96]. Moreover, treatment with the selective GPER1 agonist G-1 is able to inhibit
LPS-induced TNF-α production in human macrophages [105]. GPER1 also affects macrophage function
via decreasing the expression of TLR4 [106]. In another recent study, it has been demonstrated that
E2 confers protection against LPS/NF-κB–induced inflammation, with a role for ERα and GPER1 in
mediating these anti-inflammatory properties [43]. In this study, treatment with both ICI 182,780, an ER
antagonist/GPER agonist, and G15, a GPER antagonist, blocked the effects of E2. Studies about ERβ
and macrophage function are limited; Kramer and colleagues [107] showed that ERβ suppresses CD16
expression with no effect on the activation of MAPKs and NF-κB, while Xing et al. [94] demonstrated
an opposite effect showing the ability of selective ERβ activation to inhibit expression of inflammatory
mediators. A recent study in human macrophages demonstrated that LPS is able to increase ERα
phosphorylation but has no effect on ERβ activation [108]. This study also showed that macrophages
isolated from males are more sensitive to the LPS effects than those from females.
As noted above, E2 is able to modulate the activation of different macrophage immune
phenotypes [103,109]. The deletion of ERα in hematopoietic cells in mice causes an inability to induce
the alternative phenotype in IL-4-stimulated macrophages, and induces high levels of inflammation
and insulin resistance, suggesting that ERα is involved in the control of inflammation [110]. Defects in
macrophage function due to myeloid-specific ERα deletion also lead to a variety of metabolic disorders
including obesity and increased atherosclerosis [110]. Toniolo and colleagues demonstrated that
in vitro isolated macrophages stimulated for 48 h with LPS and interferon (IFN)-γ show decreased
ERα expression (with unchanged ERβ and GPER-1), and that pre-treatment with E2 counteract the
LPS/IFNγ-mediated down-regulation of M2 markers, suggesting that female hormones modulate
macrophage immune phenotypes [93]. The observation of a transient up-regulation of ERα mRNA
in human macrophages following treatment with IL-4/IL-13 [93] as well as in mouse macrophages
treated with IL-4 [103] suggests that this IL-4 effect is well conserved in mammals and may be
functionally relevant to the inhibition of the pro-inflammatory response. By using a transcriptomic
approach in peritoneal mouse macrophages, Pepe and colleagues recently reported that E2 promotes
an anti-inflammatory and pro-resolving macrophage phenotype, which converges on the induction of
genes related to macrophage alternative activation and on IL-10 expression in vivo [109].
The regulation of the immune response to infection or tissue damage is a complex interplay of
multiple factors, but it has long been recognized that estrogen steers the innate and adaptive immune
systems at various levels. Thus, we believe that pharmacological targeting of macrophage estrogen
pathways may restore the impaired resolution of inflammation associated with aging and chronic
inflammatory disease.
7. Estrogen in Women’s Health
It has been reported that young women generally have much lower rates of cardiometabolic
disease than men. However, midlife women lose this apparent protection during the menopausal
transition, so that cardiometabolic disease is most common in post-menopause than any other stage of
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a woman’s lifespan. In fact, fundamental aspects of metabolic homeostasis are regulated differently
in males and females [16,31,111], and influence both the development of disease and the response to
pharmacological intervention. Estrogen effects on the cardiovascular system include the modulation
of inflammatory response and immune cell function. Aging is characterized by systemic inflammatory
changes and organ dysfunction. In females, loss of estrogen makes these changes more intense [112].
Menopause is associated with an increased risk of cardiovascular and metabolic disease largely due to
post-menopausal estrogen reduction. For instance, changes in the metabolism of sex hormones lead
to accumulation of excess fat in intra-abdominal adipose tissue [15,113]. Post-menopausal women
have an abrupt acceleration of atherosclerosis. Although restoration of estrogen would seem to be
protective, double-blind clinical studies on the use of estrogen replacement have not shown a benefit
in terms of e.g., reduced mortality (reviewed in [114]).
Sex steroid hormones alter the biology of vessel wall cells and the inflammatory cells that accrue
as atherosclerosis progresses differently in the early versus later stages of the disease [52]. Hence,
the beneficial effects of menopausal hormone therapy in preventing atherosclerotic cardiovascular
disease occur only if therapy is initiated before the development of advanced atherosclerosis. Proof of
this concept has come from a randomized trial showing that initiation of menopausal hormone
therapy in women early after menopause significantly reduces the risk of the combined endpoint of
mortality, myocardial infarction or heart failure without resulting in an increased risk of breast cancer
or stroke [115]. This suggests that inflammatory pathways should remain an important therapeutic
target of estrogen for treating women close to the onset of menopause.
An age relationship of estrogen–monocyte/macrophage number and function has long been
identified, which may have several implications for postmenopausal health [112,116]. Studies in human
macrophages derived from men and post-menopausal women treated in vitro with E2 highlight that E2
has no influence on the expression of TNF-α, IL-6 and IL-1β, regardless of gender [117,118]. However,
the work of Toniolo and colleagues on macrophages derived from women in fertile or menopausal state
showed that the response to M2-associated stimuli (IL-4/IL-13) is markedly impaired in macrophages
from post- vs. pre-menopausal women, while the response to M1-associated stimuli (LPS/IFNγ) is
similar. This results in an increased M1/M2 response ratio in menopausal state, associated with the
loss of circulating estrogen [93].
The role of E2 in regulating macrophage function is still an evolving topic. In particular, there is
interest in understanding how E2 levels in vivo influence the activation of macrophage phenotypes in
physiological conditions at different stages of the menstrual cycle as well as in pathological conditions
associated with changes in circulating estrogen levels. This piece fits into the broader puzzle of
how estrogen pathways impact on macrophage function and, consequently, on immune response,
angiogenesis, wound healing and metabolism (Figure 1). Further research on gender differences
in the immune response and the onset and progression of autoimmune disease will allow the
identification of new preventive strategies and personalized therapeutic approaches for treatment of
these immuno-mediated disorders.
8. Conclusions
The role of estrogen and its multiple receptors in health and disease is heterogeneous. This makes
trying and putting the numerous puzzle pieces together a rather complex task. The protection
against cardiovascular disease in women during reproductive age is related, at least in part,
to estrogen since endogenous E2 levels and ER expression differ considerably between sexes.
Estrogen prevents endothelial dysfunction and atherosclerosis by promoting endothelial healing
and increasing angiogenesis. The number of puzzle pieces and with them our knowledge of the
mechanisms of estrogen action is growing (Figure 1). Today, it is clear that the combined rapid and
genomic effects of estrogen are critical to its overall function; however, these interactions are complex
and involve multiple receptor subtypes, both intracellular and membrane-associated. Pharmacological
research is poised to design ER ligands that can drive specific transcriptional outcomes, including
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pathway- and tissue-selective signaling. Targeting specific ERs in the cardiovascular system and
fitting together the entire puzzle may result in novel and possibly safer therapeutic options for
cardiovascular protection.
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Abstract: The beneficial effects of estrogen on the cardiovascular system have been reported
extensively. In fact, the incidence of cardiovascular diseases in women is lower than in age-matched
men during their fertile stage of life, a benefit that disappears after menopause. These sex-related
differences point to sexual hormones, mainly estrogen, as possible cardiovascular protective factors.
The regulation of vascular function by estrogen is mainly related to the maintenance of normal
endothelial function and is mediated by both direct and indirect gene transcription through the
activity of specific estrogen receptors. Some of these mechanisms are known, but many remain to be
elucidated. In recent years, microRNAs have been established as non-coding RNAs that regulate the
expression of a high percentage of protein-coding genes in mammals and are related to the correct
function of human physiology. Moreover, within the cardiovascular system, miRNAs have been
related to physiological and pathological conditions. In this review, we address what is known about
the role of estrogen-regulated miRNAs and their emerging involvement in vascular biology.
Keywords: miRNA; estradiol; estrogen receptors; epigenetic regulation; endothelial cells
1. Introduction
Estrogen is involved in many physiological processes, including sexual development and
reproduction, regulation of skeletal homeostasis, lipid and carbohydrate metabolism, electrolyte
balance, central nervous system function (including cognition and behavior), and cardiovascular
system regulation [1,2]. In addition to its physiological relevance, the effects of estrogen (or its absence)
on target tissues are related to the development of numerous diseases, which include various types
of well-known hormone-dependent cancers including breast, ovarian, endometrial, and prostate
cancer, among others. However, estrogen is also implicated in the progression of osteoporosis,
neurodegenerative diseases, metabolic disorders (insulin resistance and obesity), autoimmune diseases
(lupus erythematosus, multiple sclerosis, and rheumatoid arthritis), endometriosis, and cardiovascular
diseases [3].
Sex differences in cardiovascular diseases have been extensively reported [4], suggesting that
sex hormones have an important influence on the cardiovascular system. Indeed, statistical data
have shown that women develop cardiovascular disease 7–10 years later than men [5]. In addition,
epidemiological studies have provided evidence that cardi ovascular diseases are more frequent in men
than in premenopausal women of the same age. However, during the fifth decade of a woman’s life, the
decrease in estrogen levels that occurs in menopause is accompanied by an increase in the incidence of
cardiovascular diseases [6,7], suggesting that estrogen plays a beneficial role in cardiovascular system.
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Based on the beneficial role of estrogen, hormonal replacement therapies (HRT) have been used
in postmenopausal women with controversial findings [8,9]. The current consensus on HRT indicates
that the vascular protective effects of estrogen depend on the onset of treatment after menopause,
which has been recently reviewed in depth elsewhere [10]. The phenomenon, referred to as the
“timing hypothesis”, postulates that the beneficial effects of hormonal replacement in the prevention
of cardiovascular disease may occur only when hormonal supplementation is initiated before the
detrimental effects that aging has on the cardiovascular system have become established [11]. In this
regard, it has been reported that age moderates the vasodilatory [12] and anti-inflammatory [13] effects
that estrogen have on vascular tissue in postmenopausal women.
Estrogen can modulate the cardiovascular system by acting directly on vascular cells or indirectly
by systemic effects. Endothelial cells, vascular smooth muscle cells (VSMCs), and cardiomyocytes
are estrogen targets because they express estrogen receptors (ER) [14]. In addition, ER expression
described in monocytes, macrophages, and dendritic cells suggests that modulation of inflammatory
processes, a key event in the initiation and development of cardiovascular diseases, may also be
estrogen-dependent [15,16].
ERs function through two predominant mechanisms. In the “classical” mechanism, estrogen
diffuses into the cell and binds the ERs, creating a complex that then binds to specific DNA motifs
called estrogen response elements (EREs) in the promoter region of estrogen-responsive genes [17].
Classical mechanisms are mediated by two main ER isoforms, ERα and ERβ, which form homo- or
heterodimers before binding to EREs, and which induce changes in gene expression. Several studies
have provided evidence that ERα and ERβ have different physiological functions [18]. Indeed, these
subtypes can have opposing gene-expression regulatory effects [19,20] and also have redundant
mediatory roles [21,22]. In addition, estrogen signaling is selectively regulated by the relative balance
between ERα and ERβ expression in target organs [23], although studies using ERα and ERβ knockout
mice revealed that the beneficial effects estrogen has on the vascular system are mainly mediated by
ERα [24,25].
Besides their classic genomic action, ERs can also trigger faster responses (in minutes) through
plasma membrane receptors. Indeed, ERα and ERβ are present in plasma membranes and other
cytoplasmic organelles such as mitochondria and endoplasmic reticulum membranes [26]. In addition,
the recently described G protein-coupled ER (GPER) is also expressed in vascular tissues [27]. Indeed,
many of the beneficial effects of estrogen seen in human and animal models, such as reduced
myocardial pro-inflammatory cytokine expression, inhibition of VSMC proliferation, and nitric oxide
(NO)-dependent vasodilation [28], have been recently attributed to the presence of GPER in the
cardiovascular system.
2. Role of Estrogen in Vascular Physiology
As described above, vascular tissues are targets for sex hormones because specific receptors
are expressed in both endothelial cells and VSMCs [14] and clinical and experimental data have
demonstrated that estrogen has beneficial effects at the cardiovascular level [29,30]. In general, these
protective effects have been attributed to their role in increasing arterial vasodilation and inhibiting
inflammatory processes, which, in turn, prevent the development of atherosclerosis [6]. Moreover,
estrogen can also indirectly influence plaque progression by modulating systemic lipid metabolism [31]
and oxidative status [32].
The regulation of vascular reactivity by estrogen is mainly related to the maintenance of normal
endothelial function [33]. Indeed, enhanced acetylcholine-induced vasodilation mediated by NO
release in arteries isolated from estrogen-treated ovariectomized rabbits was one of the first evidence
indicating the role of estrogen in vascular tone [34]. In endothelial cells, the modulation of NO
bioavailability by estrogen has been extensively studied and is attributed to both genomic and
non-genomic effects [35–37]. In addition to NO, the action of estrogen has also been implicated
in the release of other endothelial-derived molecules such as prostacyclin [38] and angiotensin (Ang)
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1–7 [39] and a decrease in endothelin-1 bioavailability [40] and Ang II receptor type 1 expression [41],
thus reducing vasoconstriction and promoting vasodilation.
Besides their effect on vasomotor regulation, the anti-inflammatory responses induced by
estrogen have been described in in vitro assays as well as in different vascular-injury models [42–45].
In this regard, estrogen reduces cell adhesion molecule expression in endothelial cells exposed
to pro-inflammatory stimuli [46,47], and significantly decreases the cytokine-induced adhesion of
monocytes to endothelium [48,49]. Moreover, the modulation of neutrophil chemotaxis [44] and
leukocyte infiltration [45] by estradiol has been described in rat carotid arteries after acute injury.
Estrogen treatment after rat carotid artery damage [50] also attenuates neointima formation by
increasing endothelial cell growth and decreasing VSMC proliferation.
Estrogen also participates in the regulation of lipid accumulation in the vascular wall by
modulating the plasma lipid profile and inhibiting the direct action of lipids on the vascular system.
On the one hand, estrogen reduces the level of circulating cholesterol [51] and the rate of conversion of
hepatic low-density lipoprotein (LDL) into bile acids [52] while on the other, it increases high-density
lipoprotein (HDL) levels [53]. In addition, estrogen is associated with reduced lipid loading in human
monocyte-derived macrophages [54] and VSMCs [55], preventing foam cell formation. Furthermore,
estradiol exposure inhibits cellular permeability [56] and apoptosis [57] in LDL-exposed endothelial
cells. Finally, estrogen attenuates the oxidative stress-mediated increase in LDL modifications, which
accelerates lipid accumulation in arterial walls [58].
Although the antioxidant properties of steroids were first attributed to their phenolic structure [59],
estrogen can also modulate antioxidant enzyme expression [60,61]. For instance, estradiol attenuates
Ang II-induced superoxide production by increasing superoxide dismutase activity and protein
expression in VSMCs [60] and endothelial cells [61]. Estradiol also reduces superoxide production by
inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression, thus reducing
adhesion molecule and cytokine expression in VSMCs [62] and, in an experimental murine model
of menopause, by reverting cyclooxygenase (COX) 2-dependent superoxide production in aortic
tissue [63].
3. miRNA as Epigenetic Regulatory Mechanism
As previously described, classical regulation of physiological processes by estradiol includes
estrogen signaling induced by direct and indirect target gene transcription. However, epigenetic
mechanisms have recently emerged as another important source of gene expression regulation and are
being widely studied. At the molecular level, epigenetics is based on three main pathways: (1) DNA
methylation; (2) histone density, variants, and post-translational modifications; and (3) RNA-based
mechanisms [64]. Together, these pathways are characterized by their ability to influence gene
expression without changing the DNA sequence and many have been established as fundamental
determinants of cardiovascular health and disease [65,66].
There is some evidence that epigenetic estrogen-regulation mechanisms are implicated in the
regulation of cardiovascular function. For example, genes encoding ERs are more methylated
(denoting the suppression of estrogenic activity) in atherosclerotic plaques compared to non-plaque
regions in vascular tissues [67,68], thus suggesting that epigenetic ER inhibition plays an important
role in atherosclerosis formation. On the other hand, histone modifications and chromatin
remodeling also likely have estrogen-dependent effects on the vasculature [69,70]. Indeed, divergent
estrogen-dependent gene expression in endothelial cells and VSMCs is linked to differential target-gene
promoter histone acetylation [69]. Moreover, the vascular dysfunction prevented by estradiol
is associated with histone 3 acetylation in a post-menopausal metabolic syndrome experimental
model [70]. Finally, RNA-based epigenetic gene-expression regulatory mechanisms mediated by
sequence-specific interactions have more recently been described and are our main focus in this review.
Regulatory non-coding RNA can be classified depending on the RNA length. Long non-coding
RNA (lncRNA) is a heterogenic class of RNA that includes intergenic lncRNA, antisense transcripts,
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and enhancer RNA. All of them are described as non-protein-coding transcripts larger than
200 nucleotides (nt) so as to differentiate them from small non-coding RNAs [71]. These include
microRNA (miRNA), small interfering RNA (siRNA), and Piwi-interacting RNA (piRNA), and are
defined as small (20–30 nt) RNAs, which are associated with Argonaute (AGO) family proteins [72].
Moreover, a new class of non-coding RNAs derived from sequences located adjacent to miRNAs,
termed miRNA offset RNA (moR), has been described [73]. Although moRs were first considered a
by-product of miRNA biogenesis, recent studies have provided evidence that are biologically active
and can alter gene expression to regulate cell proliferation in VSMCs [74].
miRNAs about 20–22 nt long are the dominant class of small non-coding RNA in most tissues and
are derived from nuclear transcripts with characteristic stem–loop structures (pri-miRNAs). The first
step in miRNA biosynthesis is pri-miRNA cleavage, mediated by a processing complex comprising the
RNase III Drosha and DiGeorge syndrome critical region 8 (DGCR8), also known as the microprocessor
complex. Nuclear processing involves cropping the stem–loop to release a small hairpin-shaped RNA
(pre-miRNA), which is then transported into the cytoplasm through exportin 5 where maturation can
be completed. The second processing step is mediated by the RNase III, DICER1, which cleaves the
pre-miRNA into 22-nt miRNA duplexes. Usually, one strand from the cleavage products remains as
a mature miRNA due to a selective process that depends on thermodynamic stability. Finally, RNA
generated is loaded into an AGO protein to form the effector RNA-induced silencing complex (RISC)
along with other component such as TAR RNA-binding protein (TRBP) or protein kinase R-activating
protein (PACT). miRNAs function as a guide by base pairing with their target messenger RNAs
(mRNAs), while AGO proteins recruit factors that induce this translational repression; miRNA-binding
sites are usually located at the 3′-untranslated region (UTR) of the target mRNA [75]. Figure 1 shows a
schematic of the miRNA biosynthesis pathway along with most of the relevant implicated molecules.
Although no specific research has so far focused on the influence estrogen might exert on
miRNA biosynthesis in vascular tissues, our group’s work on human endothelial cells treated
with estradiol produced mRNA microarray data revealing the deregulation of key miRNA
biosynthesis pathway genes [76]. Our data shows DGCR8 upregulation and DICER1 and AGO-2
downregulation in estradiol-treated cells (Table 1), suggesting that estrogen regulates endothelial
miRNA production machinery.
Table 1. Microarray expression data for key miRNA biosynthesis pathway molecules. mRNA
expression data were obtained from previously published mRNA microarray data obtained for human
umbilical vein endothelial cells (HUVECs) treated with 1 nmol/L estradiol for 24 h. The probe set ID,
gene symbol, official full name, p-value, and fold change are shown. These mRNA microarray data
are deposited in NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo), accessible
through GEO series accession number GSE16683.
Probe Set ID Symbol Official Full Name Fold Change p Value
218269_at DROSHA drosha, ribonuclease type III −1.117 0.586
64474_g_at DGCR8 DiGeorge syndrome criticalregion gene 8 2.376 0.016
223056_s_at XPO5 exportin 5 1.514 0.259
213229_at DICER1 dicer 1, ribonuclease type III −1.979 0.012
225569_at AGO-2 argonaute-2 −1.290 0.002
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Figure 1. MicroRNA biosynthesis pathway. MicroRNAs (miRNAs) are transcribed by RNA
polymerase II (Pol II) activity to generate the primary transcripts (pri-miRNAs). miRNA production is a
two-step process involving nuclear cropping and cytosolic dicing processes. First, pri-miRNA cleavage
is mediated by a processing complex comprising the RNase III, Drosha, and DiGeorge syndrome critical
region 8 (DGCR8), which is also known as the microprocessor complex. This generates a hairpin-shaped
pre-miRNA, which is recognized by nuclear exportin 5 and is exported to the cytoplasm where the
RNase III, Dicer, cleaves pre-miRNA into 22-nucleotide miRNA duplexes. One strand from the cleavage
products remains as a mature miRNA on the Argonaute (AGO) 1–4 proteins, whereas the other strand
is degraded. Dicer, TAR RNA-binding protein (TRBP), protein kinase R-activating protein (PACT),
and AGO 1–4 proteins mediate the assembly of the RISC (RNA-induced silencing complex). Finally,
miRNAs guide translational repression by base-pairing with their target mRNAs, while AGO proteins
recruit factors that induce this translational repression.
In addition to data obtained in estradiol-treated endothelial cells, the relationship between
estrogen action and miRNA biosynthesis has been extensively described in breast cancer samples,
where differences in key miRNA-processing genes have been observed between ER+ and ER− breast
cancer cells [77,78]. Specifically, the expression of DICER1, DGCR8, and DROSHA was higher, and
that of AGO-2 lower, in ER+ breast tumors. In addition, of the miRNA processing genes this group
studied, only DICER1 contains an ERα binding site in its regulatory region [79]. Indeed, miRNAs that
are differentially expressed between ERα− and ERα+ breast cancer cells negatively control DICER1
expression [80], suggesting that a regulatory loop exists between ERs and miRNAs. In addition, other
studies suggest that ERs interact with DROSHA to modulate its activity in breast cancer cells [81]
and that a significant increase in Exportin-5 mRNA is induced in the mouse uterus by the action of
estrogen [82].
Specific miRNAs target ERs and could therefore act as important ER-dependent gene expression
modulators. Indeed, some estrogen-induced miRNAs such as miR-18a, miR-19b, and miR-20b target
and regulate ERα expression, thus forming a negative feedback loop [83]. Other miRNAs, including
miR-18a, miR-22, miR-206, and miR-221/222 have also been implicated in ERα targeting [84]. Finally,
the only miRNAs identified as targeting ERβ [85] and GPER [86], respectively, are miR-92 and miR-424.
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4. Vascular miRNA and Estrogen Action
The importance of miRNAs in vascular biology was first observed in 2005 by Yang et al., who
described impaired vascular formation in DICER1 knockout mice [87]. In endothelial cells, DICER1
knockdown resulted in impaired proliferation and vessel formation, as well as altered expression of
key proteins implicated in vascular tone regulation and angiogenesis, such as vascular endothelial
growth factor receptor 2 (VEGFR), interleukin 8 (IL-8), and endothelial NO synthases (eNOS) [88,89],
thus suggesting a role of miRNAs production in endothelial and vascular function.
Sex differences in miRNA expression have also been described in different physiological and
pathological conditions [90,91], providing evidence for a role for sex hormones in miRNA regulation.
Nevertheless, the relationship between sex-dependent miRNA expression and cardiovascular diseases
has so far been little explored [90], although regulation of miRNA expression by estrogen was observed
in different cell types and tissues [92]. In addition, the role of estrogen in the circulating miRNA
profile has been described in both ovariectomized rats and postmenopausal women receiving hormone
replacement treatments [93,94]; based on these results, different authors have proposed using these
miRNA profiles as possible biomarkers for pathologies involving estrogen.
4.1. Estrogen-Dependent miRNA and Cardiovascular Function
Different studies have proposed that estrogen exerts its vascular protective effects, at least in
part, via miRNA activity. For instance, the role of estrogen-induced miRNAs in heart tissue, VSMCs,
and endothelial cells has been described; Table 2 summarizes the main miRNAs involved in the
action of estrogen at cardiovascular level. Additionally, sex-dimorphic miRNA expression in heart
tissue from males versus females has been noted, including for miR-222. As previously mentioned,
this miRNA is involved in ERα regulation [84] and is implicated in modulating eNOS expression in
cardiomyocytes by directly inhibiting the transcription factor ets-1 [95]. These results suggest that
estrogen plays a role in regulating both the miRNA expression profile in cardiac tissues as well as the
key molecules involved in cardiac function. In addition, miR-21, miR-24, miR-27a/b, and miR-106a/b
were among the sex-specific miRNAs expressed via ERβ modulation in a murine model of pressure
overload-induced cardiac fibrosis [96] and could help explain the differences in adaptation to pressure
overload and vascular remodeling observed between women and men [97].
Important roles for miR-23a and miR-22 have also been described in cardiac function involving
the action of estrogen. Specifically, miR-23a has regulatory regions containing ERα binding sites
and plays a protective role in estrogen deficiency-induced cardiac gap-junction damage in rats [98].
The authors showed that estradiol inhibits miR-23-dependent downregulation of connexin 43 in a
menopausal rat model, and provide new mechanisms of post-menopause-related arrhythmia [99].
In addition to its role in cardiac function, miR-23a levels also differ in males and females after cerebral
ischemia and are related to accelerating apoptosis by regulating X-linked inhibitor of apoptosis (XIAP)
expression and XIAP-caspase complex formation [100]. Thus, this evidence provides new insights into
the molecular mechanisms underlying the sex-dependent responses observed following stroke [101].
Moreover, miR-22 provides estrogenic cardioprotection in female rats by controlling myocardial
oxidative stress [102]. This same study also described a reciprocal feedback loop between ERα and
miR-22, suggesting that estrogen action is closely regulated via post-transcriptional control of ERα
expression. Similarly, the sex-specific regulation of miR-22 processing in muscle lipid metabolism has
also recently been described and may contribute to understanding the well-described differences in
muscle metabolism and body weight between males and females [103].
Considering vascular tissue, some studies show that VSMC proliferation is affected by miRNAs
and highlight their potential as therapeutic agents in the treatment of proliferative cardiovascular
diseases. In the case of mouse aorta, miR-203 contributes to the inhibition of VSMC proliferation
because its upregulation is ER-dependent [104]. Estradiol induces miR-143 and miR-145 expression
in pulmonary artery VSMCs via specific ER binding sites located in their promoter regions [105].
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Moreover, estradiol-treated VSMCs secrete exosomes enriched with miR-143 and miR-145 which
regulate VSMC-endothelium crosstalk in pulmonary arterial hypertension [105].
Focusing on the endothelium, microarrays were recently used to reveal that physiological
(1 nmol/L) estradiol concentrations induce changes in the miRNA expression profile of endothelial
cells [106]; among these, the miRNAs with the strongest differential expression were miR-30b-5p,
miR-487a-5p, miR-4710, miR-501-3p, miR-378h, and miR-1244. Functional analysis using bioinformatic
tools revealed that estradiol-modulated miRNAs were associated with key molecular pathways such as
extracellular signaling from signal-regulated kinase/mitogen activated protein kinase (ERK/MAPK),
integrins, and actin cytoskeleton signaling, which are important pathways in the regulation of vascular
physiology in health and disease [106]. Additionally, most validated estradiol-regulated miRNAs were
modulated by ERα, and to a lesser extent, by ERβ and GPER [106], thus lending weight to the idea that
ERα plays a crucial role in estradiol-dependent effects on vascular tissues. On the other hand, estradiol
is also implicated in the increased miR-126-3p expression observed in endothelial cells, resulting in
increased cell migration, proliferation, and tube formation and decreased monocyte adhesion [107].
As previously described, estrogen plays a key role in modulating the immune system and this
is probably the underlying cause of the sex differences observed in the inflammatory processes
of atherosclerosis [108]. For instance, estradiol is involved in nuclear factor-kB (NF-kB) activity
inhibition by regulating let-7a and miR-125b expression in stimulated macrophages [109]. Moreover,
specific estradiol-regulated miRNAs—miR-146a and miR-223—have been described as key regulators
of lipopolysaccharide-induced interferon-gamma (IFNγ) in lymphocytes [110]. Therefore, selective
miRNA expression regulated by estrogen in immune cells could also be involved in the sex dimorphism
observed in vascular diseases.
Table 2. miRNA-dependent estrogen actions. Focusing on the role of estrogen in cardiovascular system
and in HRT, estrogen-dependent effect and its associated estrogen-related miRNA are shown.
Estrogen Action miRNA References
Sex differences in heart miR-1 miR-106b miR-720 miR-29b miR-144miR-34b-5p miR-205 miR-222 [95]
Sex differences in cardiac fibrosis miR-21 miR-24miR-27a/b miR-106a/b [96]
Cardiac gap junction regulation miR-23a [98]
Regulation of oxidative stress in the
myocardium miR-22 [102]
Inhibition of VSMC proliferation miR-203 [104]
VSMC and endothelial cell communication miR-143 miR-145 [105]
Endothelial cell proliferation miR-126-3p [107]
miRNA expression profile in
estradiol-treated endothelial cells
miR-30b-5p miR487a-5p miR-4710
miR-501-3p miR-378h miR-1244 [106]
Regulation of NF-kB pathway in
macrophages let-7a and miR-125b [109]
Regulation of IFNγ released in lymphocytes miR-146a miR-223 [110]
Regulation of Insulin/IGF-1 pathway in
skeletal muscle miR-182 and miR-223 [111]
Circulating
Inflammation markers miR-21 miR-146a [105]
Negative regulation of bone mass. miR-127 and miR-136 [112]
Serum biomarker in osteoporosis miR-30b-5p [93]
Circulating miRNA miR-106-5p miR-148a-3p miR-27-3pmiR-126-5p miR-28-3p miR-30a-5p [94]
4.2. miRNA and Hormone Replacement Therapy
The use of HRT has recently been associated with the miRNA content of circulating exosomes
in women [94]. In addition, the miRNA-mediated effects of this type of estrogenic therapy appear to
improve the parameters of some disorders such as osteoporosis and sarcopenia and help to reduce the
inflammation markers associated with these phenomena in postmenopausal women using HRT.
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Although the relationship between estrogen levels and osteoporosis has been established for
decades [113], changes in the miRNA expression profile in bone tissue from ovariectomy-induced
osteoporotic mice and in postmenopausal women have recently been described [93,112]. Specifically,
from among the miRNAs that are differentially expressed in estrogen-depleted mice, miR-127 and
miR-136 negatively regulate bone mass [112], whereas miR-30b-5p may be a suitable serum biomarker
for osteoporosis and osteopenia in postmenopausal women [93]. Moreover, suppressing the expression
of miR-182 and miR-223, both implicated in regulating the insulin/insulin-like growth factor (IGF-1)
pathway, in the skeletal muscle of postmenopausal women using HRT plays a central role in
muscle mass regulation [111]. Therefore, the identification of estrogen-regulated miRNAs could
be used as possible therapeutic targets to provide new insights into aging-related disorders such as
sarcopenia. In addition, a study in monozygotic twin pairs revealed a relationship between changes in
serum inflammatory markers and inflammatory-related miRNAs such as miR-21 and miR-146a, in
postmenopausal women using HRT [114]. Thus, estrogen-sensitive miRNAs could be used as potential
biomarkers for specific physiological deteriorations associated with female aging.
In another study, in premenopausal women and their monozygotic postmenopausal twins using
estrogenic HRT, other circulating miRNAs included in exosomes, such as miR-148a-3p, miR-27-3p,
miR-28-3p, miR-30a-5p, miR-106b-5p, and miR-126-5p were associated with serum estradiol levels [94].
miR-148a is related to regulation of plasma LDL/HDL ratio by directly regulating hepatic LDL
receptor (LDLR) [115]. This effect could be related to the previously demonstrated effects of estrogen
on circulating cholesterol levels as estrogen is implicated in the reduction of circulating cholesterol
by increasing LDLR expression [116]. Another estrogen-related miRNA, miR-27, is also implicated in
LDLR expression without producing changes in plasma cholesterol levels [117]; this miRNA is also
related to angiogenic processes [89] and was recently suggested as a biomarker for stenotic progression
in asymptomatic carotid stenosis [118]. In this regard, there are sex-related differences in patients with
this pathology [119] that may be partly related to the role of estrogen-regulated miRNAs. Therefore,
a better understanding of the mechanisms underlying these processes could improve new sex-specific
therapeutic approaches.
MiR-106b-5p decreases tumor necrosis factor (TNF) α-induced apoptosis by repressing
phosphatase and tensin homolog (PTEN)-caspase activity in vascular endothelial cells [120]. Moreover,
these effects correlate with the repressive effects that estrogen have on PTEN and apoptosis [121,122].
miR-126-5p is required to produce correct vascular integrity and is key in angiogenic processes [123,124]
and also decreases leukocyte-endothelium interactions by suppressing vascular cell adhesion molecule
(VCAM)-1 [125]. In line with the aforementioned studies, miR-126-5p is among the estradiol-regulated
miRNAs present in endothelial cells [107]. Therefore, the estradiol-sensitive miRNAs described could
provide insight into the mechanisms by which estrogen modulates important endothelial processes
such as apoptosis or angiogenesis to provide correct vascular physiology.
5. Conclusions
The differences observed in cardiovascular diseases between the sexes attribute a protective
role to estrogen, which is mediated through the regulation of transcription processes and, in turn,
cellular physiology. Indeed, sex-biased gene expression in the cardiovascular system and mediated
by estrogen has already been reported. It is estimated that miRNAs regulate the expression of
approximately 30% of all protein-coding genes in mammals, implying their importance in correctly
functioning human physiology, including that of the cardiovascular system. However, although there
is increasing evidence to establish epigenetic mechanisms, including miRNAs, as crucial regulators of
vascular function, the role of miRNAs in estrogen-mediated vascular functions must still be elucidated.
Therefore, future research focused on characterizing the role of specific estradiol-mediated miRNAs
involved in vascular function will be required to provide new knowledge about how the levels of sex
hormones can contribute to sex-related differences in cardiovascular diseases.
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Abstract: Apoptosis and autophagy are involved in neural development and in the response
of the nervous system to a variety of insults. Apoptosis is responsible for cell elimination,
whereas autophagy can eliminate the cells or keep them alive, even in conditions lacking
trophic factors. Therefore, both processes may function synergistically or antagonistically. Steroid and
xenobiotic receptors are regulators of apoptosis and autophagy; however, their actions in various
pathologies are complex. In general, the estrogen (ER), progesterone (PR), and mineralocorticoid
(MR) receptors mediate anti-apoptotic signalling, whereas the androgen (AR) and glucocorticoid
(GR) receptors participate in pro-apoptotic pathways. ER-mediated neuroprotection is attributed
to estrogen and selective ER modulators in apoptosis- and autophagy-related neurodegenerative
diseases, such as Alzheimer’s and Parkinson’s diseases, stroke, multiple sclerosis, and retinopathies.
PR activation appeared particularly effective in treating traumatic brain and spinal cord injuries and
ischemic stroke. Except for in the retina, activated GR is engaged in neuronal cell death, whereas MR
signalling appeared to be associated with neuroprotection. In addition to steroid receptors, the aryl
hydrocarbon receptor (AHR) mediates the induction and propagation of apoptosis, whereas the
peroxisome proliferator-activated receptors (PPARs) inhibit this programmed cell death. Most of
the retinoid X receptor-related xenobiotic receptors stimulate apoptotic processes that accompany
neural pathologies. Among the possible therapeutic strategies based on targeting apoptosis via
steroid and xenobiotic receptors, the most promising are the selective modulators of the ER, AR,
AHR, PPARγ agonists, flavonoids, and miRNAs. The prospective therapies to overcome neuronal
cell death by targeting autophagy via steroid and xenobiotic receptors are much less recognized.
Keywords: apoptosis; autophagy; steroid receptors; xenobiotic receptors; nervous system;
estrogen receptors
1. Introduction
It is generally accepted that mechanisms of neuronal demise involve apoptosis and autophagy.
Apoptosis (“self-killing”) and autophagy (“self-eating”) are involved in neural development, as well
as in the response of the nervous system to a variety of insults. Apoptosis is mainly responsible for cell
elimination, whereas autophagy can either eliminate the cells or keep them alive, even in conditions
lacking trophic factors. Therefore, both processes may act in the same direction or oppositely [1].
An excess of apoptosis or a defect in autophagy have been implicated in neurodegeneration.
Autophagy is a basic cellular process that is crucial for postmitotic neurons, whereas apoptosis occurs
at each stage of neural development and affects mitotically active and differentiated cells. Last year’s
Nobel Laureate in Physiology or Medicine, Yoshinori Ohsumi, discovered and elucidated mechanisms
underlying autophagy, a fundamental process for degrading and recycling cellular components,
using baker’s yeast (The Nobel Prize in Medicine, 2016).
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Apoptosis is considered to be the form of programmed cell death that is mediated via specific
DNA fragmentation and apoptotic body formation. After initially being cut into pieces of 300–50,000
base pairs, DNA is cleaved by endonucleases (e.g., CAD - caspase-activated DNase) and Nuc-18 -
endonuclease II) into pieces of 180–200 base pairs. In addition to apoptosis, this ladder-type DNA
fragmentation is also found in some cells dying of necrosis [2]. Recent revelations suggest that
apoptosis shares characteristics with necrosis, and these phenomena are interlinked in necroptosis.
Apart from specific DNA fragmentation and apoptotic body formation, apoptosis is characterized by
cell rounding, membrane blebbing, cytoskeletal collapse, cytoplasmic condensation and fragmentation,
nuclear pyknosis, and individual cell death without inflammatory response to damage. Apoptosis has
been documented to be involved in etiology of various types of neural degenerations, particularly these
related to mitochondrial dysfunctions.
Autophagy is another form of programmed cell death that regulates lysosomal turnover of
organelles and proteins via sequential events including double-membrane formation, elongation,
vesicle maturation, and delivery of the targeted materials to the lysosome. This process is deleterious in
acute neural disorders, such as stroke and hypoxic/ischemic injury [3]. However, autophagy appears
protective in chronic neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and encephalopathy,
where it is responsible for degrading not only damaged organelles, but also misfolded proteins [4].
Neural degeneration has been postulated to be associated with acceleration of apoptosis and
impairment of autophagy, except for in cases of acute neural injury where both processes are stimulated.
The development of the nervous system is a highly complex process in which progenitor and stem
cells differentiate into neurons, astrocytes and oligodendrocytes. During this process, not only does
differentiation occur, but also the decisions of cell survival or cell death. The appropriate interplay
between apoptosis and autophagy is believed to be essential for the normal development of the nervous
system in mammals; therefore, neural development requires the degradation or subsistence of different
organelles and proteins. Both major types of programmed cell death play roles in regulating neural
cell numbers, tissue remodelling processes, and homeostasis. Apoptosis that occurs physiologically
during the period of the growth spurt eliminates excessive neurons during the developmental process
termed pruning [5]. Studies revealed an essential role of autophagy in the development and maturation
of axons, dendrites and synapses [6].
Steroid and so-called xenobiotic receptors are involved in neural development; however, their actions
as regulators of apoptosis and autophagy are complex. In general, estrogen, progesterone,
and mineralocorticoid receptors mediate anti-apoptotic signalling, whereas androgen and glucocorticoid
receptors participate in pro-apoptotic pathways. Estrogen receptors (ERs) play crucial roles
in neurogenesis, astroglial proliferation and synaptogenesis. Neural progenitor cells (NPCs) express
robust levels of aryl hydrocarbon receptor (AHR) that participate in NPC expansion and their
differentiation into neurons. Retinoid X receptor (RXR) exerts its action by binding to gene sequences
as either a homodimer or heterodimer and by regulating the transcription of specific genes. It forms
RXR homodimers, such as RXRα, RXRβ, and RXRγ, and heterodimers, including the pregnane X
receptor (PXR), constitutive androstane receptor (CAR), liver X receptor (LXR), and peroxisome
proliferator-activated receptors (PPARs). All these receptors act as transcription factors, including the
RXR-related xenobiotic receptors, which regulate neuronal differentiation both during development
and adult neurogenesis. The RXR/nuclear receptor related 1 protein (NURR1) heterodimer has been
postulated to be essential for the differentiation of the midbrain dopamine neurons [7].
Although steroid and xenobiotic receptors are essential for proper brain development, this review
focused on the roles of steroid and xenobiotic receptors in apoptosis- and autophagy-related
pathologies of the nervous system.
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2. Molecular Mechanisms of Apoptosis and Autophagy
2.1. Mechanisms of Apoptosis
To identify potential drug targets, a major focus of neuroscience research is to examine the
mechanisms involved in neuronal loss. Neurotrophins, such as nerve growth factors (NGFs),
brain-derived neurotrophic factors (BDNFs), and neurotrophin-3 (NT-3), has been found to promote
neuronal survival via RAS and PI-3K (3-phosphatydylinosytol kinase) pathways. Deficiency of
neurotrophic factors inhibits PI-3K and promotes reactive oxygen species (ROS) production,
which activates JNK (c-Jun N-terminal kinase)/SAPK (stress-activated protein kinase)-dependent
apoptosis [2,8]. Genetic studies have demonstrated that the removal of specific JNK genes can reduce
the neuronal death associated with cerebral ischemia [9]. A controversy has emerged regarding
the question of whether limited neurotrophic factors are associated with the absence of inhibitors
of cell death or if they are active signals of apoptosis. In general, apoptotic processes have been
classified as extrinsic or intrinsic apoptotic pathways. The extrinsic pathway is induced by specific
cell damage and is mediated through so-called “death receptors”, e.g., FAS, TNF-R1 (tumour necrosis
factor receptor-1), TRAMP (death receptor 3/APO-3/LARD/wsl-1), TRAILR2 (death receptor 5/DR5),
and DR6 (death receptor 6). The intrinsic pathway is initiated by non-specific cell damage that leads
to the loss of the mitochondrial membrane potential, cytochrome c release from mitochondria and
activation of the evolutionarily conserved cysteine-aspartic acid proteases-caspases. Mitochondrial
membrane permeability to cytochrome c is primarily regulated by proteins from the BCL2 family,
including anti-apoptotic (BCL2, BCLw, and BCLxL) and pro-apoptotic (BAX, BID, BAK, BAD, BOX,
and BCLxS) proteins [10,11].
Apoptosis is usually a caspase-dependent process that depends on either the interaction
of a death receptor with its ligand and subsequent activation of procaspase-8 or on the
participation of mitochondria and the activation of procaspase-9. The main executioner protease
of the apoptotic cascade is caspase-3, which activates CAD after cleavage of ICAD (inhibitor
of caspase-activated DNase), thereby inducing apoptotic DNA fragmentation and apoptotic cell
death [12,13]. In addition to their roles in apoptosis, executioner caspases (e.g., caspases-3, -6, and -7)
have been recognized as important regulators of an array of cellular activities in the nervous system,
including axonal pathfinding and branching, axonal degeneration, dendritic pruning, and microglial
activation in the absence of death. Caspase activation has been postulated to be coordinated at multiple
levels, which might underlie apoptotic and non-apoptotic roles of caspases in the nervous system.
It has been shown that apoptosis may also be mediated by other cysteine-dependent proteases such
as calpains, which are calcium-activated neutral proteases [14].
The intrinsic and extrinsic apoptotic pathways are regulated by p53, which is a cellular sensor for
cell cycle and genomic stability. The most commonly inactivated tumour suppressor gene p53 causes
loss of p53 function, inhibits apoptosis, and promotes tumour progression and chemoresistance.
Several proteins have been shown to interact with the p53 to regulate its functions. One of
these regulatory proteins is glycogen synthase kinase 3 beta (GSK-3β), which binds to p53 and
promotes p53-induced apoptosis [15]. GSK-3β is involved in modulating a variety of functions,
including cell signalling, growth metabolism, DNA damage, hypoxia, and endoplasmic reticulum
stress [16]. GSK-3β has been recognized as a primary kinase involved in tau hyperphosphorylation,
and thus, it is responsible for neurodegenerative tauopathies, such as AD [17]. RNA interference
silencing of GSK-3β has been found to inhibit the phosphorylation of tau protein, which may have a
therapeutic effect on the pathological progression of AD [18]. Moreover, GSK-3β is involved in the
accumulation of α-synuclein aggregates, oxidative stress and mitochondrial dysfunction, which make
this kinase an attractive therapeutic target for neurodegenerative disorders, such as AD or PD [19].
Apart from the intrinsic and extrinsic apoptotic pathways, there are also other pathways
such as the caspase-12-mediated pathway, which is activated by calcium ions stored in the
endoplasmic reticulum. Chronic or unresolved endoplasmic reticulum stress can induce neuronal
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apoptosis by activating JNK, GSK-3β, and the caspase-12 pathway [20]. The activated caspase cleaves
procaspase-3 to induce classical apoptosis. Endoplasmic reticulum stress can be induced by a
variety of physiological conditions, including perturbations in calcium homeostasis, glucose/energy
deprivation, redox changes, ischemia, hyperhomocysteinemia, viral infections and mutations that
impair protein folding. The endoplasmic reticulum stress response, also called the unfolded
protein response, activates autophagy to remove aggregates of misfolded proteins that cannot
be degraded. A previous study suggested that autophagy can provide neuroprotection by enhancing
the clearance of these aggregates [21]. Recently, it has been shown that the tumour suppressor p53 can
regulate cell death and autophagic activity, particularly mitophagy [22]. The p53 protein was found to
be a cellular sensor of various stresses, including apoptotic stimuli. The induction of p53-dependent
apoptosis leads to the activation of the intrinsic and extrinsic pathways to trigger cell death through
transcription-dependent and transcription-independent mechanisms, among which is mitochondrial
ROS production. In neurons, the extracellular signal-regulated kinases (ERKs) have been observed
to mediate apoptosis; however, the majority of studies have demonstrated an anti-apoptotic role of
ERK signalling. These processes have been visualized in Figure 1.
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Figure 1. Mechanisms of apoptosis. Apoptosis has been classified as external, internal,
and caspase-12-dependent processes. Additional details have been provided in part 2.1. CAD:
caspase-activated DNase; GSK-3β: glycogen synthase kinase 3 beta; ROS: reactive oxygen species; JNK:
c-Jun N-terminal kinase; SAPK: stress-activated protein kinase.
2.2. Mechanisms of Autophagy
Autophagy is a system of cellular degradation that ensures adequate digestion of cell debris
and toxic material. The cytoplasmic debris is first enclosed in an autophagosome, which then
fuses with the lysosome and forms an autophagolysosome for full digestion of the sequestered
material. The formation of autophagosomes depends on several core Atg proteins, such as
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the following: ULK1 complex, Beclin1: Vps34/Atg14 L complex, and WIPIs, Atg12 and LC3
conjugation systems, and Atg9. In addition to the degrading function, autophagy promotes the
recycling of cellular components, cellular renovation and homeostasis. Due to its important role,
it is not surprising that autophagy dysregulation is found in many human diseases, such as
cancer and neurodevelopmental and neurodegenerative diseases [23]. Recognition of the molecular
mechanisms of autophagy processes was achieved through broad genetic research using mutagenesis
in yeast cells, Saccharomyces cerevisiae, which allowed for the understanding of this complicated process
in mammalian cells [24]. Autophagy can be divided into 3 stages: (1) formation of the autophagosome;
(2) formation of the autophagolysosome; and (3) digestion the contents of follicles.
Formation of the autophagosome involves induction, nucleation and elongation. Induction of
autophagosome formation has its origins in co-assemblies of ULK1/2, FIP200, and Atg13
and Atg101 creating a so-called ULK1/2 complex. The initiation phase mainly depends on
mammalian target of rapamycin (mTOR) kinase, which is a kind of sensor watching over the
cell’s condition; however, it can also be induced by diverse input signals such as nutrients,
growth factors, Ca2+, ATP, cAMP, hormones, and protein accumulation. Under nutrient-rich conditions,
phosphoinositide 3-kinase (PIK3C1) activates mTORC1, which then phosphorylates ULK1 and Atg13
and inhibits autophagy. Under autophagy-inducing cases, such as starvation or hypoxia, mTORC1
is inactivated, and this results in activation of ULK1/2, which phosphorylates Atg13 and FIP200
and regulates proper localization of Atg9 and PIK3C3, both of which are essential in further steps
of autophagy. For nucleation, at this stage, the most important factor is the complex of PIK3C3:
Beclin1: p150-serine kinase. This complex is located at the phagophore and recruits other Atg proteins.
PIK3C3 induces phosphatidyl-inositol-3-phosphate (PI3P) and the activity of this kinase is regulated by
Beclin1, which interacts with multiple modulators. Elongation is a step of autophagosome formation
that is based on two ubiquitin-like conjugation systems: Atg12-Atg5-Atg16 L (consisting of Atg5,
Atg7, Atg10, Atg12, Atg16) and LC3-PE (composed of LC3, 3-phosphatidyl ethanolamine, Atg4,
Atg7, Atg3). After formation of the autophagosome, it undergoes a process of maturation, i.e., a fusion
with lysosome, thus forming the autophagolysosome [25]. It is a complicated and unclear action which
requires several proteins such as LAMP-2, RAB proteins, SNAREs, ESCRT, and HOPS [26]. The fusion
with lysosomes leads to the start of degradation of vesicle content by hydrolases and lipases. The final
stage of autophagy is the efflux of autophagolysosome content into the cytoplasm. Scheme of these
processes is presented in Figure 2.
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Figure 2. Mechanisms of autophagy. Autophagy can be divided into 3 stages: (1) formation of the
autophagosome; (2) formation of the autophagolysosome; and (3) digestion the contents of follicles.
Phagophore/autophagosome content: unneeded/misfolded proteins, carbohydrates, lipids, nucleic acids,
whole organelles. More information has been provided in part 2.2.
2.3. Crosstalk between Apoptosis and Autophagy
The crosstalk between autophagy and apoptosis has only been partially uncovered.
These processes interfere with themselves, mainly with regard to the BCL2 protein family, p53,
and Atg5. Autophagy-related Beclin-1 inhibits or stimulates apoptosis, depending on the pro-
or anti-apoptotic nature of the members of the BCL2 protein family with which it interacts [27].
Pro-apoptotic p53 initiates or inhibits autophagy depending on the cellular localization of the
protein [22]. Atg5 participates in the formation of autophagosomes, translocates to the mitochondria
and becomes a pro-apoptotic factor after catalytic incision by calpains [28]. In addition, mTOR,
which is an inhibitor of autophagy, also acts on apoptosis-related p53, BAD and BCL2 [29].
Furthermore, caspases mediate cleavage of autophagy-related proteins, including Beclin-1, Atg4D,
Atg8, and Atg5 [30]. The latest studies have demonstrated that the anti-apoptotic protein
FLIP prevents elongation of autophagosomes by competing with LC3 for binding to Atg3 [31].
However, many questions regarding the interconnecting regulators of apoptosis and autophagy
remain unanswered [1]. Crosstalk between apoptosis and autophagy has been outlined in Figure 3.
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Figure 3. Crosstalk between apoptosis and autophagy. These processes interfere with themselves,
mainly with regard to the BCL2 protein family, p53, and Atg5. The crosstalk has been described in
detail in part 2.3.
3. Interactions of Apoptosis and Autophagy with Steroid and Xenobiotic Signalling
3.1. Interactions with Estrogen Receptors
ER-dependent pathways stimulate neurotrophin expression, e.g., BDNF and glial cell-derived
neurotrophic factor (GDNF), concomitantly with dendritic growth and spinogenesis [10]. In addition to
beneficial effects of estrogens on cognitive dysfunction, estrogens were found to protect the functioning
of GABAergic neurons [32]. A decline in ERα has been reported in the brains (hippocampus and
frontal cortex) of individuals with schizophrenia and AD [33,34]. There was a greater accumulation
of amyloid-beta (Aβ) in the brain of ERα knockout mice, and this accumulation greatly worsened
memory when compared to control mice [35]. In rapidly autopsied human brain tissue, the frontal
cortices of female AD patients exhibited significantly reduced mitochondrial ERβ compared to
that in normal controls [36]. In the embryonic brain, ERβ appeared to be necessary for the
development of calretinin-immunoreactive GABAergic interneurons and for neuronal migration
in the cortex [37]. It became evident that a membrane-bound ER, GPR30, modulates synaptic plasticity
in the hippocampus, and its deficiency in male mice results in insulin resistance, dyslipidemia, and a
pro-inflammatory state [38].
Most of the biological effects of estrogens are mediated by the classical ERs: ERα and ERβ.
The best recognized effects are the interactions between the ERs and the intrinsic mitochondrial
apoptotic pathway [39]. There is a line of evidence that suggests that ERs directly interfere with
BCL2-dependent apoptotic processes, namely, those observed in AD and PD. Neuroprotection against
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- (MPTP-) or Aβ-induced toxicity was found to be
mediated via ERα and ERβ, as well as by an increase in BCL2/BAD ratio [40,41]. The involvement
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of ERs in the inhibition of caspase- and GSK-3β-mediated neuronal cell death has also been shown,
including in our studies [42–44]. Furthermore, ERs were found to suppress the extrinsic death
receptor-mediated apoptotic pathway by decreasing the cell-surface expression of the Fas/Apo-1
receptor in neuroblasts [45]. Studies have shown that GPR30, also known as G-protein-coupled
ER1 (GPER1), mediates non-genomic estradiol signalling in a variety of tissues, including the brain,
with particularly high expression in the hypothalamus, hippocampus, cortex, and striatum [46,47].
Recently, GPR30 has been noticed to mediate the neuroprotective effects of estradiol in murine
hippocampal and cortical cells [48,49]. It has also been found that GPR30 stabilized blood-brain
barrier permeability after ischemic stroke, improved cognitive function that was impaired by traumatic
brain injury, and inhibited PD-related neuroinflammation [50–52].
Our data demonstrated a key involvement of GPR30 and/or ERβ in the neuroprotective
and anti-apoptotic actions of the phytoestrogens daidzein and genistein [53,54]. Similarly, ERβ
signalling has been linked to flavonoid troxerutin-induced mitigation of apoptosis in a
6-hydroxydopamine-induced lesion rat model for PD [55]. In addition, we provided evidence for a
crucial role of ERα in the neuroprotective function of raloxifene during hypoxia [56]. According to our
in vitro data, the protective action of the selective estrogen receptor modulator (SERM) is mediated by
ERα, but not by ERβ or GPR30 and involves the inhibition of apoptosis. This is in line with results from
Guo et al., 2016 that showed the enhancement of the ERα-mediated transactivation of the BCL2 gene
upon ischemic insult and that provided in vitro evidence that metastasis-associated protein 1 (MTA1)
enhances the binding of ERα with the BCL2 promoter via recruitment of HDAC2, together with other
unidentified coregulators [57]. In male Wistar rats subjected to transient right middle cerebral artery
occlusion (tMCAO), Jover-Mengual et al., 2017 detected the increased expression of ERα or ERα and
ERβ in response to estradiol and the SERM bazedoxifene, respectively [58]. In the most recent study,
Guo et al., 2017 linked estradiol neuroprotection against ischemic brain injury and apoptosis to the
SIRT1-dependent adenosine monophosphate (AMP)-activated kinase (AMPK) pathway [59].
The protective action of notoginsenoside R1 against cerebral hypoxic-ischemic injury was found to be
the result of the estrogen receptor-dependent inhibition of endoplasmic reticulum stress pathways,
involving a caspase-12-mediated apoptosis, and the activation of Akt/Nrf2 pathways [60,61].
The ginsenoside Rg1 protection against Aβ peptide-induced neuronal apoptosis was shown to
involve ERα, as well as the up-regulation of ERK1/2 phosphorylation and the reduction of NF-κB
nuclear translocation [62]. Additionally, the pharmacological administration of the isoflavone daidzein
was shown to stimulate cell proliferation and inhibit high fat diet-induced apoptosis and gliosis in the
rat hippocampus [63]. Furthermore, it became evident that the impairments of ERα and/or GPR30
participate in mechanisms of apoptotic actions of DDT and a chemical UV-filter benzophenone-3
(BP-3) [43,64]. Autosomal dominant optic atrophy, a progressive blinding disease featured by retinal
ganglion cell degeneration, has recently been linked to the inhibition of the estrogen receptor expression,
which promoted apoptosis in mouse females carrying the human recurrent OPA1 mutation [65].
Estrogen receptors are important regulators of neuronal apoptosis; however, little is known
about their impact on autophagy. Knockdown of ERα or antagonizing GPR30 has been found
to induce autophagy and apoptosis in cancer cells [66,67]. The phytoestrogen gypenoside XVII
(GP-17) attenuated the Aβ25-35-induced parallel autophagic and apoptotic death of NGF-differentiated
PC12 cells through the ER-dependent activation of the Nrf2/ARE pathways [68]. In SH-SY5Y cells,
ERs mediated Aβ degradation via the up-regulation of neprilysin and promoted autophagy as
a protective mechanism against chronic minimal peroxide treatment [69]. Moreover, ER agonists
activated PI3K/Akt/mTOR signalling in oligodendrocytes to promote remyelination in a mouse model
of multiple sclerosis (MS) [70,71], and the up-regulation of the membrane ERα was associated with
functional signals that were compatible with autophagic cytoprotection of neuronal cell line SH-SY5Y.
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3.2. Interactions with Androgen Receptors
Dehydroepiandrosterone (DHEA), also known as androstenolone, binds with high affinity
to androgen receptors; however, it may also activate the ER, PXR, CAR, and PPARα. There is
a body of evidence showing that DHEA activates Akt in neural precursors, in association with
inhibition of apoptosis [72]. However, its sulfated derivative, DHEA, has the opposite effect of
DHEA during neurogenesis. An anabolic-androgen 17β-trenbolone was found to induce apoptosis
in primary hippocampal neurons that was accompanied by the up-regulation of β-amyloid peptide
42 (Aβ42) and the activation of caspase-3 [73]. Androgen-induced neurotoxicity has been detected in
the dopaminergic cell line N27 [74]. Following treatment with testosterone or dihydrotestosterone,
the cells exhibited mitochondrial dysfunction and died due to apoptosis. Androgens appeared to have
both neuroprotective and neurotoxic effects depending on age and sex, as evidenced by examining
the effect of androgens on cell survival after an excitatory stimulus in the developing hippocampus in
both males and females [75]. Pike et al., 2008 discussed the involvement of androgen cell signalling
pathways in neuroprotection, showing, as an example, the age-related testosterone loss in men with
increased risk for AD [76].
3.3. Interactions with Progesterone Receptors
Many studies have shown that progesterone promotes the viability of neurons in the brain
and spinal cord. Progesterone appeared particularly effective in treating traumatic brain and spinal
cord injuries, as well as ischemic stroke [77]. Moreover, progesterone has been shown to attenuate Aβ
(25–35)-induced neuronal toxicity via JNK inactivation and the inhibition of mitochondrial apoptotic
pathway by progesterone receptor membrane component 1 [78]. Studies using yeast as a model system
extended the protective actions of progesterone to the reduction of cytosolic calcium and the reduction
in ROS production and ATP levels; however, these effects did not depend on the yeast orthologue of
the progesterone receptor, Dap1 [79]. Progesterone receptor membrane component 1 (PGRMC1) is a
key regulator of apoptosis, and its up-regulation was found in retinal degeneration 10 (rd10) mice,
which are a model system for autosomal recessive retinitis pigmentosa [80].
3.4. Interactions with Glucocorticoid and Mineralocorticoid Receptors
Previous studies have shown that dexamethasone-induced apoptosis of primary hippocampal
neurons involved GR and was counteracted by an MR agonist aldosterone [81]. In general, GR activation
has been implicated in the induction of an endangered neural phenotype, whereas MR expression
appeared to be associated with a neuroprotective phenotype [82]. When used therapeutically to
treat respiratory dysfunction associated with premature birth, the endogenous rodent glucocorticoid
corticosterone has been shown to activate GR and cause progenitor cell apoptosis, as well as
neurodevelopmental deficits, particularly in the cerebellum [83]. In contrast, MR overexpression
inhibited apoptosis and promoted survival of embryonic stem cell-derived neurons [84]. Unlike in other
brain regions, glucocorticoids play a critical role in retinal photoreceptor survival, whereas mifepristone,
which has the capacity to block glucocorticoid receptors, promotes photoreceptor death [85].
Furthermore, an MR agonist aldosterone appeared to be a critical mediator of retinal ganglion cell loss
that was independent of elevated intraocular pressure [86].
3.5. Interactions with Aryl Hydrocarbon Receptor
There are data, including ours, that have revealed that the aryl hydrocarbon receptor (AHR)
regulates apoptosis in the mammalian brain [42,43,87–90]. Previously, we demonstrated that the
selective AHR agonist, β-naphthoflavone, induced caspase-3-dependent apoptosis in primary
cultures of mouse neurons. This effect was accompanied by the increased expression of AHR that
co-localized with ERβ, thus supporting the direct interaction between AHR-mediated apoptosis and
ERs signalling [42]. We also showed the involvement of AHR in apoptotic and neurotoxic actions
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of the pesticide dichlorodiphenyltrichloroethane (DDT) and the antimicrobial agent triclosan [43,90].
In addition, we detected the enhanced mRNA and protein expression levels of AHR in one-month-old
mice that were prenatally exposed to DDT [91]. Since enhanced AHR expression was accompanied by
DNA hypomethylation, both global DNA and the DNA of the specific AHR gene, we hypothesized
that AHR signalling leads to apoptosis that underlies the fetal basis of the adult onset of disease.
In our study, we showed that by targeting AHR/AHR nuclear translocator (ARNT) signalling,
3,3’-diindolylmethane (DIM) inhibited caspase-3-dependent apoptosis and rescued neurons from
hypoxia [89]. This effect was followed by a decrease in the expression levels of AHR, AHR-regulated
cytochrome P450 1A1 (CYP1A1), and ARNT.
3.6. Interactions with RXR-Related Xenobiotic Receptors
Recently, we showed that CAR, PXR, and RXRs were involved in nonylphenol-initiated apoptosis
in mouse hippocampal neurons in primary cultures [44,92]. We also found that RXRs participated in
the propagation of DDE- and BP-3-induced neuronal apoptosis [93,94], whereas PPARγ was impaired
in response to apoptotic actions of BP-3, dibutyl-phthalate, and tetrabromobisphenol A [64,95,96].
Interestingly, the activation of CAR by the CITCO agonist increased ABC-transporter expression
(Abcb1 and Abcg2) in blood-brain barrier and inhibited growth and expansion of brain tumour
stem cells via inducing cell cycle arrest and apoptosis [97,98]. Similarly, a PPARα-selective activator
4-chloro-6-(2,3-xylidino)2-pyrimidinylthioacetic acid (Wy-14,643) enhanced cell death in cultured
cerebellar granule cells [99]. On the other hand, RXR activation was essential for docosahexaenoic acid
to protect retina photoreceptors against oxidative stress (paraquat, H2O2)-induced apoptosis [100,101],
and the addition of 9-cis-retinoic acid prevented dimerization of RXR and a nerve growth
factor-induced clone B (NGFI-B) that rescued cerebellar granule neurons from calcium-induced
apoptosis [102]. An RXR agonist bexarotene was found to up-regulate the lncRNA Neat1 and to
inhibit apoptosis in mice after traumatic brain injury [103]. Moreover, activated LXR inhibited a
7-ketocholesterol-induced apoptosis in human neuroblastoma SH-SY5Y cells [104]. Mutation of
NR4A2 (also called NURR1), a RXR-partner for heterodimerization, is involved in familiar form of PD.
In patients with PD, NR4A2 expression is downregulated, whereas in patients with AD reduced NR4A1
level is observed [105]. Additionally, NR4A has been identified as a key regulator of catecholamine
production by macrophages and the mediator of CREB-induced neuronal survival [106,107].
4. The Roles of Apoptosis and Autophagy in Pathologies of the Nervous System
4.1. Apoptosis in Pathologies of the Nervous System
Apoptosis is involved in the pathogenesis of neurodegenerative diseases, such as stroke, HD, AD,
and PD. The accumulation of misfolded Aβ and α-synuclein, two major toxic proteins in AD and PD,
leads to neuronal apoptosis. There is increasing evidence that caspase-6 is highly involved in axon
degeneration in HD and AD. Active caspase-6 has been found in the early stages of AD [108], and cleavage
at the caspase-6-cleavage site in mutated huntingtin protein is a prerequisite for the development of
the features of HD [109]. The PTEN-induced kinase 1 (PINK1) that is linked to the autosomal recessive
familial form of PD has been found to protect cells from mitochondrial dysfunction and is a key player in
many signalling pathways in response to oxidative stress, including apoptosis [110]. A previous study
supports an important role of ceramides in neuronal apoptosis, particularly their role in the stabilization
of β-secretase, amyloidogenic processing of Aβ precursor protein (APP), and generation of Aβ, which is
the major component of the senile plaques [111].
Currently, there has been considerable effort directed towards GSK-3β as a potential target for
the treatment of many diseases, including Type-II diabetes and neurodegenerative diseases [112].
Activated GSK-3β has been reported to induce apoptosis in neurons [113,114] and to regulate
tau phosphorylation and Aβ peptide production. Extracellular deposits of Aβ and intracellular
deposits of hyperphosphorylated tau protein are major histopathological hallmarks of AD. Because
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GSK-3β phosphorylates tau proteins, it is thought that disruption of GSK-3β signalling may
contribute to the onset of the disease. Targeting this enzyme has been found to inhibit the
symptoms of PD, such as enhanced expression of α-synuclein and the loss of dopaminergic
neurons in the substantia nigra pars compacta [115]. We previously showed that the neuroprotective
action of genistein is mediated by the inhibition of GSK-3β signalling [53]. Our recent study
demonstrated that the pesticide DDT-induced apoptosis of mouse neurons is a caspase-9-, caspase-3-,
and GSK-3β-dependent process [43]. By activating GSK-3β and JNK, the endoplasmic reticulum
stress can induce caspase-12-dependent apoptosis, which has been implicated in a broad range of
human diseases, including neurodegenerative diseases, cancer, diabetes, and vascular disorders.
Preclinical data showed that, apart from the inhibition of excitatory activity of neurons
via modulation of two major neurotransmitter receptor groups, i.e., N-methyl-D-aspartate
(NMDA) receptors, and γ-aminobutyric acid (GABA) receptors, anasthetics caused apoptosis and
neurodegeneration in the developing brains of neonates [116]. These effects could lead to learning and
memory deficits, as well as abnormalities in social memory and social activity. Similarly, glucocorticoid
therapy, which was invented to accelerate lung maturation and reduce inflammation in newborns,
was also found to induce apoptosis in the cerebellar external granule layer. The therapy caused a
disruption of cerebellar development that was followed by neuromotor and cognitive deficits [117].
4.2. Autophagy in Pathologies of the Nervous System
Dysregulation of autophagy is involved in the etiology of neurodevelopmental diseases, such as
autism and fragile X syndrome [23]. Global knockout of Beclin 1, Ambra, Atg5, or Atg7 is lethal and
causes death within a few days after birth [118]. The impairment of autophagy has been postulated to
be involved in the onset of neural degeneration in PD, AD, and HD, as well as the degeneration
accompanying ALS and MS [4]. An age-related decrease in the expression of the indispensable
autophagy protein, Beclin1, has been suggested to have consequences for mHtt accumulation in
HD [119]. Selective inhibition of autophagy with 3-MA and chloroquine has been shown to cause a delay
in tau clearance, and Atg7 knockout mice were shown to exhibit excessive amount of phosphorylated
tau that is typical for AD [120]. Moreover, the failure of autophagy or mutations in Parkin and PINK1
have been found to result in abnormal autophagic degradation of α-synuclein aggregates [121].
The dysfunction of mitochondria that intensively influences the autophagy pathway is one of
the important factors in the pathogenesis of MS [122]. Administration of rapamycin, an inhibitor
of mTOR, ameliorates relapsing-remitting experimental autoimmune encephalomyelitis (EAE).
However, ALS-associated autophagy remains controversial, and it is still not known whether
activating autophagy is beneficial or harmful for motor neuron degradation. Studies reported that
toxic accumulation of mutant superoxide dismutase (SOD1) protein contributes to autophagy by its
retardation [123]. In addition, it has been found that autophagy may be pro- or anti-inflammatory.
The interplay between the microglial inflammatory response and microglial autophagy is inherent to
acute central nervous system (CNS) injury as well as the recovery stage of chronic CNS injury [124].
Studies have suggested that autophagy can provide neuroprotection by enhancing the clearance
of misfolded protein aggregates [21]. There are, however, data that indicated that autophagy
acts in parallel with neurodegenerative processes initiated by kainic acid and hypoxia [125,126].
Recent advances in neurodegenerative models associated with the formation of protein aggregates,
such as PD, HD, and AD, target autophagy by treatment with the mTOR inhibitor rapamycin or
analogues to force the degradation of potentially toxic aggregates. Surprisingly, the inhibition of
mTOR has been found to cause neural degeneration, whereas excessive activity of the kinase was
found to impair neural development and lead to neuroectodermal dysplasia [127]. Recent studies
have demonstrated that cellular autophagy markers are up-regulated in humans upon treatment with
antidepressants [128]. One may assume that autophagy might be a double-edged sword in major
depressive disorder (MDD), which suggests why some MDD patients remain resistant to certain
antidepressant medications.
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5. Perspectives Related to Targeting Apoptosis and Autophagy via Steroid and Xenobiotic
Receptor Signalling
5.1. Targeting Apoptosis
5.1.1. Via Estrogen Receptors
There is a wealth of information indicating that estrogens exert actions involved
in neuroprotection. They protect neurons against different insults, such as anoxia, oxidative stress,
glutamic acid, hydrogen peroxide, iron, and the Aβ peptide. However, the application of estrogens as
neuroprotectants in humans presents numerous limitations mainly due to the endocrine actions of
the molecules on peripheral tissues and the increased frequency of hormone-dependent tumours as
well as cerebrovascular disease and stroke risk. In addition, the highly oxidative cellular environment
present during neurodegeneration stimulates the hydroxylation of estradiol to the catechol-estrogen
metabolites, which can undergo reactive oxygen species-producing redox cycling, setting up a
self-generating toxic cascade [129].
The conflict between basic scientific evidence for estrogen neuroprotection and the lack of
effectiveness in clinical trials is only now being resolved. From birth to menopause, the ovaries produce
high circulating levels of estradiol, which correlates with a low incidence of neurodegenerative disease.
Once the menopausal transition occurs, the risk for neurodegenerative diseases, including ischemic
stroke and AD, increases. Although the Women’s Health Initiative Memory Study (WHIMS) pointed to
some cognitive adverse effects of postmenopausal hormone therapy, these results were not relevant to
peri- and early menopause, since WHIMS recruited women above the age of 65 years [130]. Emerging
evidence from basic science and clinical studies suggests that there is a “critical period” for the
beneficial effect of estradiol on the brain. The critical window hypothesis suggests that initiating
hormone therapy at a younger age in closer temporal proximity to menopause may reduce the risk of
AD [131]. This is in accordance with a transcriptome meta-analysis that revealed a central role for sex
steroids in the degeneration of hippocampal neurons in AD [132]. Currently, there is a need for a new,
safe, and effective ER-dependent therapy.
The possibility of using SERMs to induce estrogen-like protective actions in the brain has emerged
as an alternative to estrogen treatment. SERMs have been found to trigger neuroprotective mechanisms
that reduce neural damage in different experimental models of neural trauma, brain inflammation,
and neural degeneration. Most studies have focused on tamoxifen and raloxifene, which have
been used in human clinics for years. Their neuroprotective actions have been assessed in different
experimental models of neural dysfunction. These include models of traumatic injury to the central
nervous system and peripheral nerves, stroke, MS, and PD and AD [133]. The best documented
neuroprotective actions are antioxidant effects and the prevention of excitotoxicity, which is a common
cause of neuronal death in neurodegeneration [134]. Some key molecules have been identified, such as
mitogen-activated protein kinases (MAPK), PI3K/Akt, cAMP response element binding protein
(CREB), and NF-κB [135–137], but the precise molecular targets and mechanisms involved in the
neuroprotective actions of SERMs need to be determined. Our recent study demonstrated protective,
including anti-apoptotic, effects of raloxifene on brain neurons subjected to hypoxia [56]. We showed
that raloxifene-induced neuroprotection almost exclusively depended on ERα but not ERβ and GPR30.
Currently, a major focus of neuroscience research is to examine the mechanisms involved in
neuronal loss that will be necessary to identify potential drug targets. These include microRNA,
such as miR-7-1, which enhanced the neuroprotective effects of estrogen receptor agonists, i.e.,
1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), Way 200070, and estrogen, in preventing
apoptosis in A23187 calcium ionophore-exposed VSC4.1 motoneurons [138]. Targeting ERβ, with a
combination of natural estrogen-like compounds that bind the receptor with high selectivity, has been
proposed as a therapeutic strategy for Leber’s hereditary optic neuropathy [139]. ERβ ligand AC186
is a new candidate for neuroprotection in MS [140]. Following HIV-1 Tat (1–86) exposure, soy
isoflavones induced anti-apoptotic actions in neurons by targeting ERs [141]. Purple sweet potato
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colour significantly suppressed endoplasmic reticulum stress-induced apoptosis and promoted
ERα-mediated mitochondrial biogenesis in mice challenged with domoic acid [142]. An inverted
correlation between the levels of ERα and parkin in the striatum of adult mice suggests a possible role
of the receptor in preventing the parkin-related PD in humans [143]. The discovery of a binding site
of ERβ in the Tnfaip1 (Tumour necrosis factor-induced protein 1) promoter region points to a novel
regulatory site that could be targeted by estrogen or other selective ligands to protect the brain against
AD and apoptosis [144]. A new strategy for neuroprotection against ischemic insults could involve
targeting a novel 36-kDa variant of ERα, i.e., ERα36, which is associated with the phosphorylation of
Akt in the cells exposed to glucose deprivation [145]. Targeting ERβ by Cicer microphyllum seed extract
could rescue neurons from global hypoxia [146].
Up-regulation of neuroglobin upon 17β-estradiol (E2) stimulation has recently been linked to
neuroprotection. After relocalization to the mitochondria, neuroglobin associates with cytochrome c,
which reduces cytochrome c release into the cytosol, and subsequently inhibits caspase-3 activation
and apoptotic cell death. Neuroprotection could also be directed to seladin-1 (selective AD indicator-1),
which is down-regulated in the brain regions affected by AD and confers protection against
β-amyloid-induced toxicity via the inhibition of caspase-3 activity. A seladin-1 gene has been found to
be identical to the gene encoding the enzyme, 3-β-hydroxysterol Δ24-reductase, which is up-regulated
by estrogen and involved in the cholesterol biosynthetic pathway [147].
5.1.2. Via Androgen, Progesterone, and Corticoid Receptors
It recently became evident that the selective androgen receptor modulator (SARM), RAD140,
has the capacity to protect cultured neurons and brain tissue against kainate-induced apoptosis [148].
This action depended on MAPK signalling, including ERK phosphorylation, and showed the relevance
of androgen signalling to neural health and resilience to neurodegeneration. Progesterone was found
to play a neuroprotective role in various models of neurodegeneration, including AD, through the
inhibition of the mitochondrial apoptotic pathway, and by blocking Aβ-induced JNK activation [78].
A synthetic form of the female hormone progesterone, Norgestrel, which acts via progesterone
receptor membrane component 1, has been proposed as therapeutic for the treatment of retinitis
pigmentosa [80]. In patients with AD, increased expression of the translocator protein (TSPO;
the former peripheral benzodiazepine receptor or PBR) shows another possibility for neuroprotection
that could be executed via TSPO-mediated stimulation of steroid synthesis; as such, its neuroprotective
and neuroregenerative properties resulted in the inhibition of apoptotic cell death. A novel TSPO
(18 kDa) ligand, ZBD-2, which is involved in the synthesis of endogenous neurosteroids (e.g.,
pregnenolone, DHEA, and progesterone), effectively prevented NMDA-induced excitotoxicity and
apoptosis and protected mouse brains against focal cerebral ischemia [149]. Recent studies provided
evidence that corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells can be
attenuated by HBOB, an HDAC6 inhibitor, by inhibiting mitochondrial GR translocation and the
intrinsic apoptosis pathway [150]. Furthermore, agonizing the MR with fludrocortisone promoted
cell survival and proliferation of adult hippocampal progenitors, but inhibited apoptotic signalling,
including GSK-3β [151].
5.1.3. Via AHR
Flavonoids have been shown to inhibit the development of AD-like pathology, and red wine
consumption appeared to reduce age-related macular degeneration, stroke, and cognitive deficits.
In addition to well documented free radical scavenging and anti-inflammatory properties, resveratrol,
which is one of the key ingredients responsible for the neuropreventive action of red wine, has been
shown to act as AHR antagonist and an inhibitor of apoptosis. The recent study of our group has shown
the strong neuroprotective capacity of a selective aryl hydrocarbon receptor modulator (SAHRM) DIM
against the hypoxia-induced damage in mouse hippocampal cells in primary cultures [89]. DIM-evoked
neuroprotection was mediated by the impairment of AHR/ARNT signalling, as evidenced by the
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use of specific siRNAs, as well as quantitative (qPCR, ELISA) and qualitative (western blot analysis
and confocal microscopy) assessments. Neuroprotective properties of DIM have also been shown in
the cellular and animal models of PD [152]. Exciting prospects to overcome the cellular mechanisms
that lead to neuronal injury involving apoptosis and autophagy have recently been related to Wnt
(wingless-type) signalling, which is known to interact with AHR during neural development [153].
5.1.4. Via Xenobiotic Receptors
In addition to the steroid receptor- and AHR-mediated signalling, xenobiotic receptors have
become attractive mediators that can cause neuroprotection through interaction with the apoptotic
pathways. PPARγ agonists (derivatives of thiazolidinediones, e.g., troglitazone, rosiglitazone
and pioglitazone) have been associated with neuroprotection in different neurological pathologies,
including AD and PD, cerebral ischemia, MDD and stroke [154–157]. However, the mechanisms
involved in PPARγ effects in the nervous system are still unknown. PPARs and many other
nuclear receptors form heterodimers with RXRs, and these heterodimers regulate the transcription
of various genes. The activation of RXR/PPARγ by bexarotene was found to have neuroprotective
potential in mice subjected to focal cerebral ischemia [158]. UAB30, a novel RXR agonist that induces
apoptosis in human neuroblastoma, has also been shown to have a potential therapeutic role [159].
Recently, treatments with RXR agonists (bexarotene and fluorobexarotene) were found to promote Aβ
degradation and rapidly reversed Aβ-induced behavioural deficits in AD [160–162]. Bexarotene was
also found to protect dopaminergic neurons in animal models of PD [163].
5.2. Targeting Autophagy
In comparison to apoptosis, there is very little known about the interactions between the steroid
and xenobiotic receptor signalling pathways and the process of autophagy. Therefore, targeting
autophagy via steroid and xenobiotic receptors needs to be further elucidated. Estradiol has been
shown to inhibit autophagy in the hippocampus CA1 region and to alleviate neurological deficits
following cerebral ischemia [164]. The estrogen receptor and the estrogen-related receptor antagonists,
tamoxifen, and 4-hydroxytamoxifen, were shown to induce cytotoxic autophagy in glioblastoma.
However, the effect of 4-hydroxytamoxifen in malignant peripheral nerve sheath tumour cells did
not depend on ER signalling, but on the degradation of the pro-survival protein Kirsten rat sarcoma
viral oncogene homologue [165]. According to Felzen et al.2015, ERα-expressing neuroblastoma cells
have a higher autophagic activity than cells expressing ERβ or lacking ER expression [166]. This new
non-canonical autophagy is mediated by ERα, but it is estrogen response element (ERE)-independent
and involves the function of the co-chaperone BCL2-associated athanogene 3 (BAG3). In studies using
the SH-SY5Y cell line, mERα has been postulated to promote the maturation of autophagosomes into
functional autolysosomes by regulating ERK [167].
6. Perspectives Related to Targeting Specific miRNAs which Interact with Steroid and Xenobiotic
Receptor Signalling
MicroRNAs (miRNAs) are small non-coding RNA molecules that are almost exclusively negative
regulators of gene expression in the nervous system. It has been shown that miR-218-affected tau
phosphorylation is oppositely-regulated by classical estrogen receptors. ERα was found to increase the
expression of miR-218 that was followed by diminished protein expression of tyrosine phosphatase
alpha (PTPα), as well as by activation of GSK-3β and inactivation of protein phosphatase 2A,
the major tau enzymes involved in AD pathology. In contrast, ERβ reduced miR-218 levels that
resulted in inhibition of tau phosphorylation [168]. Recently, Micheli et al., 2016 demonstrated
that 17β-estradiol-evoked neuroprotection from the Aβ-induced neurotoxicity was mediated by
an increase in miR-125b expression and subsequent decrease in mRNA and protein expression of
pro-apoptotic factors BAK1 and p53 [169]. Furthermore, an involvement of estrogen receptors in
regulation of specific miRNAs in response to cerebral ischemia has been demonstrated. 17β-estradiol
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alone or in combination with progesterone was found to upregulate miR-375 expression and its
target BCL2 in rat model of cerebral ischemia [170]. MiR-375 was also positively regulated by
ERα in response to a phytoestrogen-calycosin that caused protection against cerebral ischemia [171].
Recently, the roles of estrogen and glucocorticoid receptors in regulation of cerebral miRNAs have
been supported by contribution of miR-23a and miR-210 in response to cerebral ischemia [172,173].
Glucocorticoid-mediated attenuation of BDNF-dependent neuronal function has been linked to
reduced expression of miR-132 [174]. The most relevant reports on AHR- and CAR-regulated miRNA
showed the inversely co-related expression of AIP (AHR-interacting protein) and miR-107 in pituitary
adenomas, as well as CAR and miR-137 in neuroblastoma cells [175,176].
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Abbreviations
AD Alzheimer’s disease
AHR aryl hydrocarbon receptor
AIP AHR-interacting protein
ALS amyotrophic lateral sclerosis
AMP adenosine monophosphate
AMPK adenosine monophosphate activated kinase
APP Aβ precursor protein
AR androgen receptor
ARNT AHR nuclear translocator
Aβ amyloid-beta
Aβ42 β-amyloid peptide 42
BAG3 BCL2-associated athanogene 3
BDNF brain-derived neurotrophic factors
BP-3 benzophenone-3
CAD caspase-activated DNase
CAR constitutive androstane receptor
CNS central nervous system
CREB cAMP response element binding protein




DR6 death receptor 6
E2 17β-estradiol
EAE experimental autoimmune encephalomyelitis
ER estrogen receptor
ERE estrogen response element
ERK extracellular signal-regulated kinase
GABA g-Aminobutyric acid
GDNF glial cell-derived neurotrophic factor
GP-17 gypenoside XVII
GPER1 G-protein-coupled ER1, membrane-bound estrogen receptor
GPR30 membrane-bound estrogen receptor, also known as GPER1
GR glucocorticoid receptor
GSK-3β glycogen synthase kinase 3 beta
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HD Huntington’s disease
HDAC histone deacetylases
ICAD inhibitor of caspase-activated DNase
JNK c-Jun N-terminal kinase
LXR liver X receptor
MAPK mitogen-activated protein kinases





MTA1 metastasis-associated protein 1
mTOR mammalian target of rapamycin kinase
NGF nerve growth factors
NGFI-B nerve growth factor-induced clone B
NMDA N-methyl-D-aspartate
NPC neural progenitor cells
NT-3 neurotrophin-3
NURR1 nuclear receptor related 1 protein
PD Parkinson’s disease




PINK1 PTEN-induced kinase 1
PTPα tyrosine phosphatase alpha
PPAR peroxisome proliferator-activated receptor
PR progesterone receptor
PXR pregnane X receptor
rd10 retinal degeneration 10
ROS reactive oxygen species
RXR retinoid X receptor
SAHRM selective aryl hydrocarbon receptor modulator
SAPK stress-activated protein kinase
SARM selective androgen receptor modulator
seladin-1 selective AD indicator-1
SERM selective estrogen receptor modulator
SOD1 superoxide dismutase
tMCAO transient right middle cerebral artery occlusion
Tnfaip1 tumour necrosis factor-induced protein 1
TNF-R1 tumour necrosis factor receptor-1
TRAILR2 death receptor 5/DR5
TRAMP death receptor 3/APO-3/LARD/wsl-1
TSPO translocator protein
WHIMS women’s health initiative memory study
Wnt wingless-type
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64. Wnuk, A.; Rzemieniec, J.; Lasoń, W.; Krzeptowski, W.; Kajta, M. Apoptosis Induced by the UV Filter
Benzophenone-3 in Mouse Neuronal Cells Is Mediated via Attenuation of Erα/Pparγ and Stimulation of
Erβ/Gpr30 Signaling. Mol. Neurobiol. 2017. [CrossRef] [PubMed]
65. Sarzi, E.; Seveno, M.; Angebault, C.; Milea, D.; Rönnbäck, C.; Quilès, M.; Adrian, M.; Grenier, J.; Caignard, A.;
Lacroux, A.; et al. Increased steroidogenesis promotes early-onset and severe vision loss in females with
OPA1 dominant optic atrophy. Hum. Mol. Genet. 2016, 25, 2539–2551. [CrossRef] [PubMed]
66. Bai, L.Y.; Weng, J.R.; Hu, J.L.; Wang, D.; Sargeant, A.M.; Chiu, C.F. G15, a GPR30 antagonist, induces
apoptosis and autophagy in human oral squamous carcinoma cells. Chem. Biol. Interact. 2013, 206, 375–384.
[CrossRef] [PubMed]
67. Cook, K.L.; Clarke, P.A.; Parmar, J.; Hu, R.; Schwartz-Roberts, J.L.; Abu-Asab, M.; Wärri, A.; Baumann, W.T.;
Clarke, R. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated
unfolded protein response activation, promoting ROS-induced breast cancer cell death. FASEB J. 2014,
28, 3891–3905. [CrossRef] [PubMed]
68. Meng, X.; Wang, M.; Sun, G.; Ye, J.; Zhou, Y.; Dong, X.; Wang, T.; Lu, S.; Sun, X. Attenuation of
Aβ25-35-induced parallel autophagic and apoptotic cell death by gypenoside XVII through the estrogen
receptor-dependent activation of Nrf2/ARE pathways. Toxicol. Appl. Pharmacol. 2014, 279, 63–75. [CrossRef]
[PubMed]
69. Liang, K.; Yang, L.; Yin, C.; Xiao, Z.; Zhang, J.; Liu, Y.; Huang, J. Estrogen stimulates degradation of β-amyloid
peptide by up-regulating neprilysin. J. Biol. Chem. 2010, 285, 935–942. [CrossRef] [PubMed]
70. Barbati, C.; Pierdominici, M.; Gambardella, L.; Malchiodi Albedi, F.; Karas, R.H.; Rosano, G.; Malorni, W.;
Ortona, E. Cell surface estrogen receptor α is upregulated during subchronic metabolic stress and inhibits
neuronal cell degeneration. PLoS ONE 2012, 7, e42339. [CrossRef] [PubMed]
71. Kumar, S.; Patel, R.; Moore, S.; Crawford, D.K.; Suwanna, N.; Mangiardi, M.; Tiwari-Woodruff, S.K.
Estrogen receptor β ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes
remyelination in a mouse model of multiple sclerosis. Neurobiol. Dis. 2013, 56, 131–144. [CrossRef] [PubMed]
72. Zhang, L.; Li, B.; Ma, W.; Barker, J.L.; Chang, Y.H.; Zhao, W.; Rubinow, D.R. Dehydroepiandrosterone (DHEA)
and its sulfated derivative (DHEAS) regulate apoptosis during neurogenesis by triggering the Akt signaling
pathway in opposing ways. Brain Res. Mol. Brain Res. 2002, 98, 58–66. [CrossRef]
73. Ma, F.; Liu, D. 17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone,
contributes to neurodegeneration. Toxicol. Appl. Pharmacol. 2015, 282, 68–76. [CrossRef] [PubMed]
74. Cunningham, R.L.; Giuffrida, A.; Roberts, J.L. Androgens induce dopaminergic neurotoxicity via
caspase-3-dependent activation of protein kinase Cdelta. Endocrinology 2009, 150, 5539–5548. [CrossRef]
[PubMed]
75. Zup, S.L.; Edwards, N.S.; McCarthy, M.M. Sex- and age-dependent effects of androgens on
glutamate-induced cell death and intracellular calcium regulation in the developing hippocampus.
Neuroscience 2014, 281, 77–87. [CrossRef] [PubMed]
76. Pike, C.J.; Nguyen, T.V.; Ramsden, M.; Yao, M.; Murphy, M.P.; Rosario, E.R. Androgen cell signaling pathways
involved in neuroprotective actions. Horm. Behav. 2008, 53, 693–705. [CrossRef] [PubMed]
77. Schumacher, M.; Guennoun, R.; Stein, D.G.; De Nicola, A.F. Progesterone: Therapeutic opportunities for
neuroprotection and myelin repair. Pharmacol. Ther. 2007, 116, 77–106. [CrossRef] [PubMed]
78. Qin, Y.; Chen, Z.; Han, X.; Wu, H.; Yu, Y.; Wu, J.; Liu, S.; Hou, Y. Progesterone attenuates Aβ(25–35)-induced
neuronal toxicity via JNK inactivation and progesterone receptor membrane component 1-dependent
inhibition of mitochondrial apoptotic pathway. J. Steroid Biochem. Mol. Biol. 2015, 154, 302–311. [CrossRef]
[PubMed]
161
Int. J. Mol. Sci. 2017, 18, 2394
79. Stekovic, S.; Ruckenstuhl, C.; Royer, P.; Winkler-Hermaden, C.; Carmona-Gutierrez, D.; Fröhlich, K.U.;
Kroemer, G.; Madeo, F. The neuroprotective steroid progesterone promotes mitochondrial uncoupling,
reduces cytosolic calcium and augments stress resistance in yeast cells. Microb. Cell 2017, 4, 191–199.
[CrossRef] [PubMed]
80. Jackson, A.C.; Roche, S.L.; Byrne, A.M.; Ruiz-Lopez, A.M.; Cotter, T.G. Progesterone receptor signalling in
retinal photoreceptor neuroprotection. J. Neurochem. 2016, 136, 63–77. [CrossRef] [PubMed]
81. Crochemore, C.; Lu, J.; Wu, Y.; Liposits, Z.; Sousa, N.; Holsboer, F.; Almeida, O.F. Direct targeting of
hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation.
Mol. Psychiatry 2005, 10, 790–798. [CrossRef] [PubMed]
82. Rogalska, J. Mineralocorticoid and glucocorticoid receptors in hippocampus: Their impact on neurons
survival and behavioral impairment after neonatal brain injury. Vitam. Horm. 2010, 82, 391–419. [CrossRef]
[PubMed]
83. Noguchi, K.K.; Lau, K.; Smith, D.J.; Swiney, B.S.; Farber, N.B. Glucocorticoid receptor stimulation and
the regulation of neonatal cerebellar neural progenitor cell apoptosis. Neurobiol. Dis. 2011, 43, 356–363.
[CrossRef] [PubMed]
84. Munier, M.; Law, F.; Meduri, G.; Le Menuet, D.; Lombès, M. Mineralocorticoid receptor overexpression
facilitates differentiation and promotes survival of embryonic stem cell-derived neurons. Endocrinology 2012,
153, 1330–1340. [CrossRef] [PubMed]
85. Cubilla, M.A.; Bermúdez, V.; Marquioni Ramella, M.D.; Bachor, T.P.; Suburo, A.M. Mifepristone, a blocker of
glucocorticoid receptors, promotes photoreceptor death. Investig. Ophthalmol. Vis. Sci. 2013, 54, 313–322.
[CrossRef] [PubMed]
86. Nitta, E.; Hirooka, K.; Tenkumo, K.; Fujita, T.; Nishiyama, A.; Nakamura, T.; Itano, T.; Shiraga, F. Aldosterone:
A mediator of retinal ganglion cell death and the potential role in the pathogenesis in normal-tension glaucoma.
Cell Death Dis. 2013, 4, e711. [CrossRef] [PubMed]
87. Collins, L.L.; Williamson, M.A.; Thompson, B.D.; Dever, D.P.; Gasiewicz, T.A.; Opanashuk, L.A.
2,3,7,8-Tetracholorodibenzo-p-dioxin exposure disrupts granule neuron precursor maturation in the
developing mouse cerebellum. Toxicol. Sci. 2008, 103, 125–136. [CrossRef] [PubMed]
88. Sánchez-Martín, F.J.; Fernández-Salguero, P.M.; Merino, J.M. Aryl hydrocarbon receptor-dependent induction
of apoptosis by 2,3,7,8-tetrachlorodibenzo-p-dioxin in cerebellar granule cells from mouse. J. Neurochem.
2011, 118, 153–162. [CrossRef] [PubMed]
89. Rzemieniec, J.; Litwa, E.; Wnuk, A.; Lason, W.; Krzeptowski, W.; Kajta, M. Selective Aryl Hydrocarbon
Receptor Modulator 3,3′-Diindolylmethane Impairs AhR and ARNT Signaling and Protects Mouse Neuronal
Cells Against Hypoxia. Mol. Neurobiol. 2016, 53, 5591–5606. [CrossRef] [PubMed]
90. Szychowski, K.A.; Wnuk, A.; Kajta, M.; Wójtowicz, A.K. Triclosan activates aryl hydrocarbon receptor
(AhR)-dependent apoptosis and affects Cyp1a1 and Cyp1b1 expression in mouse neocortical neurons.
Environ. Res. 2016, 151, 106–114. [CrossRef] [PubMed]
91. Kajta, M.; Wnuk, A.; Rzemieniec, J.; Litwa, E.; Lason, W.; Zelek-Molik, A.; Nalepa, I.; Rogóż, Z.;
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Abstract: In mammals, the effects of estrogen are mainly mediated by two different estrogen receptors,
ERα and ERβ. These proteins are members of the nuclear receptor family, characterized by distinct
structural and functional domains, and participate in the regulation of different biological processes,
including cell growth, survival and differentiation. The two estrogen receptor (ER) subtypes are
generated from two distinct genes and have partially distinct expression patterns. Their activities
are modulated differently by a range of natural and synthetic ligands. Some of these ligands
show agonistic or antagonistic effects depending on ER subtype and are described as selective
ER modulators (SERMs). Accordingly, a few phytochemicals, called phytoestrogens, which are
synthesized from plants and vegetables, show low estrogenic activity or anti-estrogenic activity
with potentially anti-proliferative effects that offer nutraceutical or pharmacological advantages.
These compounds may be used as hormonal substitutes or as complements in breast cancer treatments.
In this review, we discuss and summarize the in vitro and in vivo effects of certain phytoestrogens
and their potential roles in the interaction with estrogen receptors.
Keywords: estrogen receptor; ligand; xenoestrogens; selective estrogen receptor modulators;
transcription; epigenetic regulation; cell signaling; cancer
1. Introduction
Estrogens, such as 17 β-estradiol (E2), are steroid hormones derived from cholesterol by the
successive action of steroidogenic enzymes. They are involved in multiple physiological processes
by acting on various tissues. In particular, they participate in the establishment and regulation of
the reproductive organs in both males and females, including the gonads or the mammary gland [1].
Furthermore, estrogens participate in many physiological processes in non-reproductive tissues, such
as growth and remodeling of bone, differentiation and protection of the central nervous system,
vasodilation of cardiovascular systems and lipid metabolism in the liver [1,2]. At the cellular level, E2
has multiple effects, including proliferation, differentiation and survival. E2 is a small, liposoluble
molecule that passively enters the cell through the plasma membrane. E2 actions are mainly mediated
by their binding to two estrogen receptors, ERα and ERβ, which are localized in the cytoplasm and
in the nucleus (Figure 1B). These receptors are members of the nuclear receptor superfamily, which
also includes receptors for androgens, progesterone, glucocorticoids, thyroids, retinoid acids, and
vitamin D, as well as more than twenty orphan receptors (Figure 1A) [3]. Many nuclear receptors
are activated by specific ligands and generally act as transcription factors by binding to specific
DNA sequences in the genome. Similar to the other nuclear receptors, ERs are modular proteins
that consist of distinct structural and functional domains. The N-terminal domain contains the
ligand-independent transactivation function (AF1). The central domain contains the conserved
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zinc finger DNA-binding-domain, and the C-terminal domain contains the ligand-dependent
transactivation function (AF2), as well as the ligand binding and dimerization sequences (Figure 1).
ER-mediated E2 actions at the transcriptional level of the estrogen-sensitive genes are called
“genomic” E2 actions. Direct binding of ERs to the chromatin occurs at the estrogen-responsive-element
(ERE) at target gene promoters. This induces the mobilization of the transcription coregulators needed
to modify chromatin structure and thereby transcriptional regulation of specific gene (Figure 1B).
This represents the classical pathway, but many E2-target genes do not contain the ERE. In this case,
ERs modulate transcription through DNA-binding sites for Sp1 (stimulating protein 1) or AP1 (activator
protein 1) transcription factors [4]. Furthermore, genome-wide studies performed by ChIP (chromatin
immunoprecipitation) experiments in breast cancer cell lines specified that ER preferentially regulates
its target genes by binding distal regulatory elements [5]. These distal regulatory sites can interact
with the promoters of E2 target genes due to chromatin looping. This mechanism of transcriptional
regulation represents more than 90% of E2-target genes [5]. Interestingly, these regulatory elements are
capable of interacting with several promoters and other enhancers at the same time and are mainly
contained in genomic areas called TADs (topologically associating domains) [6,7].
In contrast to the genomic action, the non-genomic actions of estrogens involve cytoplasmic
signaling pathways (Figure 1B) and occur rapidly, on the order of seconds or minutes. This leads to
the activation of several intracellular signaling pathways such as MAPK (mitogen activated protein
kinase) or PI3K (phosphatidylinositide 3-kinase) [8]. Recent studies reported convergence or cross-talk
between the genomic and non-genomic actions of ER, enabling a fine regulation of target genes and
increasing the complexity of the estrogenic pathways [9–12].
ERs are generated from two different genes that are localized on chromosome 6, for ERα, and
chromosome 14, for ERβ, in humans. The utilization of different promoters and splicing processes
results in multiple ER variants that can interfere with the transcriptional activity of wild type ERs in
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(B) 
Figure 1. Structure and mechanisms of action of the estrogen receptor (ER). (A) The evolutionarily
conserved domains of several nuclear receptors, including ER, AR (androgen receptor), PR
(progesterone receptor), GR (glucocorticoid receptor), VDR (vitamin D receptor), RAR (retinoid acid
receptor) and TR (thyroid receptor). Domains involved in DNA and ligand binding, as well as in
dimerization, ligand-independent transactivation function (AF1) and ligand-dependent transactivation
function (AF2) are shown. The number of amino acids for each domain is presented. The approximate
molecular weight of each nuclear receptor is also indicated on the right side; (B) estradiol (E2) mediates
multiple phenotypic changes in cells by binding to its receptor. E2 enter the cell through the lipid
membranes and binds ER in the cytoplasm or the nucleus. ER mediates E2 effects through diverse
transcriptional mechanisms. In the nucleus, the activated ER forms a dimer to tightly fix DNA directly
at the ERE sites or indirectly at Sp1 or Ap1 sites. The activated ER is then able to recruit cofactors
and RNA polymerase II (pol. II), which allows the transcription of target genes (ER genomic action).
Furthermore, ERs can use rapid non-genomic action through the activation of intracellular kinases
related or not to the growth factor signaling.
Many tissues express both ER subtypes, but with variable expression profiles. For instance, ERα
is highly expressed in female reproductive tissues (ovary, womb, mammary gland). ERβ is greatly
expressed in ovaries but poorly expressed in the mammary gland. In men, ERα is strongly expressed
in the testicle (Leydig cells and gubernaculum), whereas ERβ is found in the prostate, germinal cells
and epididymis. On the other hand, both receptors with variable expression levels are found in male
and female, lung, hepatic, fat, osseous, and nervous tissues and endothelial cells [1,17–19]. Knockout in
mice demonstrated crucial roles for both ERα and ERβ during the development of reproductive tissues,
gametogenesis, and neuronal growth and differentiation [1,20,21]. The appearance of ER seems to be
under spatio-temporal control during development [1,19,20]. For instance, ERα expression has been
found in the developing uterus as soon as the 15th day of fetal in mesenchymal cells, while it appears
later in the epithelial cells and it rises during the neonatal period. In the cerebral cortex of rodents,
ERα expression is greater in postnatal life and decreases substantially during puberty [20]. In the testis
under development, ERα is expressed in the gubernaculum, a ligament which differentiates into the
cremaster muscle involved in the final positioning of the testis within the scrotum. Its expression is
strong between 17 to 20 dpc and barely detectable between 4 and 12 dpp, indicating a role of estrogens
and ERα in the right positioning of the testis [19]. However, during mouse brain development, ERβ
distribution varies in different areas. ERβ is found mostly in the midbrain and hypothalamus at E12.5,
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and its expression increases at E15.5 and E16.5. Interestingly, ERβ expression appears intensely and
extensively throughout the brain, including in the cerebellum and striatum, at E18.5, whereas very few
positive cells may be distinguished in the ventricular region [21].
Many natural and synthetic chemicals in the environment and in food have been reported
with hormonal activity, particularly showing estrogenic potency [22]. These compounds are called
endocrine disrupting chemicals (EDCs). A lot of EDCs are generated from human activities.
For example, polycyclic aromatic hydrocarbons (PAH), such as polychlorinated dibenzo-p-dioxins and
dibenzofurans, or polychlorinated biphenyls (PCBs), which are the most persistent and widespread in
the environment. Bisphenol A, nonylphenol and ethinyl estradiol were also reported to be among the
major environmental estrogens. A series of experimental and epidemiological studies over the past
decades have suggested that these environmental contaminants can interfere with normal hormonal
processes and induce deterioration of the reproduction function in males and females [22–27].
Furthermore, numerous natural molecules present in vegetables and plants possess estrogen- and
antiestrogen-mimetic activities. These natural molecules are mainly phytoestrogen isoflavones, the
most widely consumed. The most abundant isoflavones are genistein and daidzein, which are present
in soybean, in particular, and also found in certain fruits, legumes and nuts [28]. Flavones, such as
coumestans and lignans are other classes of phytoestrogens, which are also found in certain fruits and
legumes [28]. Moreover, some mushrooms, mosses and fungi produce compounds with estrogenic
activity. These compounds are called mycoestrogens, such as zearalenone [28]. In this review, we focus
on these phytochemicals interacting with ERs and discuss their molecular actions and their potential
effects on human health.
2. Structure and Sources of the Major Dietary Phytoestrogens
Against environmental stresses and aggressions, plants produce secondary metabolites belonging
to the large family of polyphenols, which have many biological activities, such as antioxidant,
antifungal and antibiotic properties. All of these compounds contain one or several aromatic rings
with at least one hydroxyl group. Hydroxyl groups can be free, but most of the time they are engaged
in another function with an ester, ether or a glycoside. Among these compounds, phytoestrogens have
a structural similarity with 17β-estradiol and could bind both ERs. Phytoestrogens are classified into
six groups based on their chemical structures (Figure 2). In this review, we have chosen to present only
the aglycone structure of a few phytoestrogens.
2.1. Flavonoids
Flavonoids, from flavus (yellow in Latin), are pigments of flowers and fruit, and represent the
major group. They are formed by 2 aromatic rings bearing at least one hydroxyl group. The aromatic
rings, called A and B, are connected by a carbon bridge consisting of three carbons combined with an
oxygen to carbons of the A ring. Together, they formed a new 6-ring structure, called C [29] (Figure 2).
Flavonoids could be divided into sub-classes depending on the position of the B ring at position 2 for
flavones and derivatives and at position 3 for isoflavones and derivatives. Moreover, depending on
hydroxylation degree and/or the position of the hydroxyl group, one can distinguish the flavan-3-ols,
the flavanones and the flavonols [29].
Here, we have focused on flavones and isoflavones. Flavones are represented by compounds,
such as apigenin, found in parsley or chamomile. Apigenin has a beneficial effect on human health [30].
The daily intake of flavones is very low and estimated between 0.3 and 1.6 mg/day [31]. Isoflavones
such as genistein or daidzein are found in large quantities in soybean. The daily intake of isoflavones
is low in Western countries (0.1–1.2 mg/day) and higher in Asian countries, where they consume more
soy product (up to 47 mg/day) [29,32]. Approximately 30% of the population in Western countries
and 60% of the population in Asian countries possess gut microbiota able to metabolize daidzein into
the isoflavan equol, which shows a greater affinity for ERs than daidzein. Equol exists through two
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enantiomers, the R-(+) equol and the S-(−) equol. This latter enantiomer is the natural compound
produced by microbiota in human and rat [33].
Class Subclass Compounds 
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Figure 2. Illustration of the chemical structures of different groups of phytoestrogens. Ex: Example.
2.2. Pterocarpans
Pterocarpans derive from isoflavones. Their structure is described as a benzo-pyrano-furano-
benzene, where the B-rings are coupled to position 4-one [34]. Glyceollins, which correspond to
prenylated 6a-hydroxy pterocarpans, are the main delegates of this family [35]. They belong to
phytoalexin and are produced from daidzein via an enzymatic pathway, mainly in soybean, by the
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action of a diversity of elicitors such as UV stress, bacterial or fungi infection [36]. These compounds
have been known since the 1970s for their involvement in plant defense [37], but the ability of these
compounds to act as phytoestrogens was only established in 2000 [38].
2.3. Coumestans
Coumestans are produced by oxidation of pterocarpan [39]. The structure of coumestans consists
of a benzoxazole fused to a chromen-2-one [40]. The first, discovered in 1957 by Bickoff et al., and the
best documented is coumestrol, which is abundant in alfalfa, soybean and clover [41]. This compound
was shown to have a high affinity for both ERs and to induce a response of the same magnitude as that
observed with E2 [42].
2.4. Stilbenes
Like glyceollins, stilbene belongs to the phytoalexins and participates in plant defense against
injury, stress or infection [29]. Resveratrol, the main representative of the stilbene family, is abundant
in grape and red wine, with a concentration up to 12 mg/L [43]. Although resveratrol was reported to
interact with ERs, its agonist or antagonistic effects remain controversial [44,45].
2.5. Lignans
The two best-documented lignans are secoisolariciresinol and matairesinol [46]. Lignans are
particularly abundant in flaxseed and sesame seed, and at minor concentrations in cereals, vegetables
and fruits. The two major metabolites of lignans in human are also produced by gut microbiota.
They present a weak estrogenic action and are called enterolactone and enterodiol [47].
2.6. Mycoestrogens
Another family of dietary estrogen, called mycoestrogens, is produced by fungi. In this family,
the most documented is zearalenone and its derivatives. Zearalenone is produced by Fusarium
and is found in poorly stored cereals. Zearalenone structure consists of resorcinol moiety fused
with a 14-member macrocyclic lactone [48]. According to the European Safety Authority (EFSA),
zearalenone is found in 15% of cereals consumed in Europe [49]. Zearalenone has adverse effects on
human health, including reprotoxicity [50,51], genotoxicity, and oxidative stress [49]. This chemical
and its metabolites, particularly α-zearalenol, which is used as growth promoter in cattle, are able to
bind ERs with high affinity and act as strong ERα agonists [51].
3. In Vitro Effects of Phytoestrogens
The proliferation of ERα-positive breast cancer cells is enhanced by estrogens, which induce
multiple growth factors, cyclins and cytokines involved in cell survival and cell cycle progression.
Although ERα has a proliferative effect, ERβ acts as a negative regulator of ERα in breast cancer cells,
counteracting the mitogenic effect of estrogens [15,52–54]. Interestingly, in many reported ER-selective
bioassays, such as the proliferation of breast cancer cell lines, gene reporter assays in mammalian or
non-mammalian cells, and ER binding assays, it was found that most phytoestrogens preferentially
interact with ERβ and display high specificity toward ERβ transactivation [55–57]. Recently, using
a fluorescence resonance energy transfer (FRET) assay, Jiang et al. [57] showed that some phytoestrogens,
such as genistein, daidzein, equol and liquiritigenin, recruit the coactivator SRC3 much more efficiently
to ERβ than to ERα. These data strengthen the ERβ-selectivity of many phytoestrogens. Hence,
a relationship between the ERα/ERβ ratio and phytoestrogen effects exists [58,59]. It is suggested that
the presence of ERβ is associated with the “good” effect of phytoestrogen whereas a high concentration
of phytoestrogen in cells expressing ERα was associated to the “bad” effect of phytoestrogen [60].
Several in vitro studies showed that genistein, the most abundant isoflavone present in
soybean, has antiproliferative effects on various cancer cells, including prostate, ovarian, and breast
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cancer [61–63]. While genistein effects can be mediated at least in part by ERβ, other molecular
mechanisms, for exemple caspase-3 activation, have been reported to explain growth inhibition
or proapoptotic effects of genistein. Additionally, by direct inhibition of tyrosine kinase activities,
genistein is also able to prevent cancer cell growth. For example, genistein pretreatment could
significantly reduce the activation of Akt kinase by epidermal growth factor (EGF). The inhibition
of nuclear factor κB (NF-κB) activity by genistein was also reported in prostate, breast, lung, and
pancreatic cancer cells [64–68]. An explanation of this effect is that genistein significantly inhibits Akt
kinase activity by decreasing its phosphorylation at serine 473, which can inhibit NF-κB activity [65,69].
Another study reported that the inhibition of prostate cancer cell growth exerted by genistein is
linked to a reduction of telomerase activity that is pivotal for cellular proliferation capacity and
immortality. [70]. Together, these actions of the isoflavone genistein could contribute to its apoptotic
effects in different human cancer cells. It is also interesting to note that in ER-positive MCF-7 cells,
the biphasic actions of genistein can be observed with growth stimulation at low concentrations and
inhibition at high concentrations. These observations indicate the complexity of the actions of genistein
and phytoestrogens globally for their anti-cancer properties.
One of the key mechanisms underlying the maintenance of genome stability and gene expression is
DNA methylation. This process occurs on the cytosine of cytosine-guanine dinucleotides (CpG regions).
In the human genome, the majority of CpG regions are methylated, except for those located within
CpG-rich regions, called CpG islands, which are usually found within gene promoters. Methylation
of CpG islands could lead to the inactivation of gene expression by inhibiting the recruitment of
transcription factors necessary to induce transcription. Indeed, DNA methylation/demethylation is
a dynamic process that allows certain genes to switch ON and OFF at different periods of time.
This process appears to be particularly crucial during embryonic development, tumorigenesis,
cell division and cell differentiation. For instance, the OCT4 gene, which is essential to maintain
pluripotency in embryonic stem cells, becomes methylated in differentiated tissues to avoid unsuitable
pluripotency [71]. On the other hand, the loss of expression of tumor suppressor genes by DNA
methylation is often observed in cancerous cells. Re-expression of these genes by the inhibition of
DNA methyltransferases has provided many successes in the treatment of cancers.
Interestingly, a recent study showed that genistein can reduce DNA methylation in the promoter
regions of the Wingless-int (Wnt) genes, which induces the expression of Wnt proteins in colon cancer
cells [72]. The Wnt signaling pathway includes a large number of proteins involved in organogenesis
and cell-cell adhesion, cell proliferation and differentiation. In addition to its importance in normal
cellular physiology, Wnt signaling is also closely involved with carcinogenesis. Notably, the loss of the
expression of Wnt proteins by promoter hypermethylation or abnormal activation of Wnt signaling
have been detected in the majority of colon tumors and colon cell lines [73–75]. It is, therefore, possible
that genistein, acting as an inhibitor of the DNA methyltransferase, could be able to induce significant
Wnt signaling pathways to protect the development of colon cancer. Another study conducted on the
human colon cancer cell lines SW480 and HCT15 showed that genistein blocks cell proliferation in
the G2 phase of the cell cycle [76]. The authors showed that the action of genistein-inhibition on cell
growth is mediated by overexpression of Dickkopf 1 (DKK1) in SW480 and HCT15 cells treated with
genistein. DKK1 is a key regulator of the Wnt signaling pathway that promotes cell differentiation and
apoptosis. The repression of the tumor suppressor DKK1 by the hypermethylation of its promoter is
reported in various diseases, including colorectal cancer [77–80]. However, DNA methylation of the
DKK1 promoter is not affected by genistein treatment in either cell line. However, genistein induces
acetylation of histone H3 within the promoter region of the DKK1 gene in SW480 and HCT15 cells.
This indicates that genistein induction of the expression of the DKK1 gene is linked to the increase in
histone acetylation [76]. Another recent study showed that genistein is able to epigenetically reactivate
ERα in ERα-negative breast cancer models, both in vitro and in vivo [66]. Similarly, in the prostate
cancer cell lines LNCaP and LAPC-4, genistein was able to increase the expression of ERβ through
decreasing the methylation of the ERβ promoter at physiological ranges (0.5–10 μmol/L) [81]. Hence,
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genistein could increase the sensitivity of these cancers to endocrine therapies, such as the antiestrogen
tamoxifen. In this study, the authors showed that genistein significantly increased histone acetylation
patterns in the ERα promoter by inhibiting the enzymatic activities of histone deacetylase (HDAC).
It is of interest to note that this effect was enhanced in a synergistic manner when ERα-negative
MDA-MB-231 breast cancer cells were co-treated with genistein and TSA, an inhibitor of HDACs.
Importantly, the anticancer properties of tamoxifen to inhibit cell growth become much more efficient
both in vitro and in vivo, in xenograft nude mice as well as in spontaneous breast tumor mouse
models, in the presence of genistein [66]. Together, these studies suggest that in addition to DNA
methylation, genistein may also modify histone marks of critical genes to prevent cancer development
and progression. These epigenetic actions of genistein mediate the activation of tumor suppressor genes
in cancer cell lines but also in animal models. The consequences of endocrine disruptors to different
cell types have been widely studied. However, in industrial countries, detectable levels of EDCs were
found in human, indicating that people are constantly exposed. Hence, studies on acute effects do not
reflect the consequences of constant exposure. Chronic exposure of MCF7 cells with genistein induces
a down-regulation of the PI3K/Akt signaling pathway, inhibits the growth-promoting activity of E2 or
EGF, and reduces histone H3 acetylation without affecting ER expression. This indicates that chronic
treatment leads to epigenetic changes in the cells [82,83].
4. In Vivo Effects of Phytoestrogens
The concentration of phytoestrogens in the plasma is considerably different in the human
population. For example, in Finnish men the average plasma concentration of genistein is about 0.5 nM
whereas it is about 276 nM in Japanese males. However, after absorption of dietary phytoestrogen,
a plasmatic peak was detected between 0.2 and 6.5 μM with bioavailability between 5% and 66% [84].
Moreover a pharmacokinetic study performed on postmenopausal women found that the concentration
of free genistein could reach 40 nM [85]. Epidemiological studies reveal that a lower risk of breast and
prostate cancers is observed in Asians, who consume 20–50 times more soy products than Americans [86].
In vivo experimental studies have also reported that some dietary components, including isoflavones
and enterolignans, could inhibit the development of cancers [69,87,88]. This suggests that active
molecules in the soybean, such as genistein, daidzein, equol and glycitein, may act as natural
chemopreventive agents and could be used against tumor progression in humans. Moreover, clinical
studies carried out to assess the effectiveness of isoflavones in patients with prostate cancer found
that isoflavone supplementation significantly reduced the expression of the poor prognostic tumoral
marker, prostate specific antigen (PSA), and the expression of androgen receptor (AR), but without
effecting the expression of ERβ or circulating hormones. These studies have suggested that isoflavones,
including genistein and daidzein, may be beneficial in the prevention of prostate cancer by inhibiting
the expression of AR and PSA [89,90]. Furthermore, in vivo xenografts in mice model and in vitro
studies conducted on androgen-dependent (LNCaP) and androgen-independent (DU145 or PC3)
prostate cancer cell lines showed that some phytoestrogens, such as coumestrol, are able to elicit
caspase-dependent apoptosis, supporting the hypothesis that phytoestrogens may have anticancer
effects in prostate cancer. Conversely, some clinical trials seeking to establish that consumption of
phytoestrogens is beneficial in prostate cancer have been inconclusive [91]. For instance, a double-blind
trial conducted by Adams and collaborators [92] showed no significant difference in PSA among men
who did or did not consume a diet rich in isoflavones for 12 months. Although this study is limited by
the relatively small number of patients, it could indicate that the period and duration of treatment may
be essential for the anticancer effects of isoflavones. While the exact mechanisms by which isoflavones
can prevent the development or progression of prostate cancer remain unclear, many mechanisms have
been proposed, including the regulation of genes involved in the cell cycle, such as an upregulation
of p21 resulting in cell cycle arrest at the G1/S phase, apoptosis, antioxidant effects, DNA repair,
inhibition of angiogenesis and metastasis, and also the antagonism of estrogen and androgen signaling
pathways (for review see [93]). It should be noted, therefore, that changes in some signaling pathways
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or in the expression of key enzymes involved in steroid metabolism during different stages of prostate
cancer could play an essential role in the effects of phytoestrogens.
In vivo studies carried out in a true physiological context in humans and animals have indicated
that the food content of isoflavones poses no safety issue, as generally consumed in diets based on soy
products [94]. Moreover, the concentration of isoflavones varies considerably depending on the place
of soybean cultivation (from 85 mg/100 g in Taiwan to 178 mg/100 g in Korea) or according to the
culinary process (6 mg/100 g 195 mg/100 g in Foojook soup) [95]. A similar observation was made
in lyophilized cabbage compared to fermented cabbage [96]. As the structure of the major isoflavone
compounds is close to that of E2 and because these compounds are known to have weak estrogenic
activities, the possible effects of some isoflavones on estrogen-target tissues and on reproductive function
have been extensively explored [97–100]. However, there are conflicting results regarding the effects of
isoflavones on reproductive function because the long-term studies on the impact of these compounds
on the development and function of reproductive tissues are not sufficient. In addition, comparisons
between different studies are complicated because there are differences in the experimental design,
such as the physiological state of the animal, the presence of circulating hormone, and the duration,
doses and methods of exposure (injection or gavage). More importantly, differences in the metabolism
of isoflavones between animal models and humans can also give inconclusive results. Thus, all these
parameters must be considered when assessing the impact of isoflavones on reproductive function.
All major soybean isoflavones, genistein, daidzein, equol and glycitein, were reported to be estrogenic
in the mouse or rat uterine growth assay [97,98]. For instance, 100 mg/kg body weight of genistein or
equol, administered by gavage for 4 successive days (post-natal at day 17–20), was found to significantly
increase uterine weights and the expression of ERα in the uterus [97]. Another study compared
the estrogenic potential of several phytoestrogens, including genistein, daidzein and coumestrol in
immature mice using different morphological and biochemical tests on the uterus. Interestingly, while
certain compounds, such as genistein and coumestrol, showed estrogenic activity in all tests, others
showed estrogenicity in only a single test or did not show estrogenicity in any test [101].
The estrogenic potency of isoflavones was also assessed, in vivo, in several non-mammalian
model organisms. For example, goldfish or medaka fed for several weeks with a diet containing
coumestrol or genistein showed an increased production of the vitellogenin, an egg yolk protein
precursor, which is normally produced in the liver under estrogenic stimulation. However, no adverse
effects on reproduction function (fecundity and fertility) have been reported [102,103], indicating that
the production of vitellogenin may serve as an indicator of estrogen exposure but not as an indicator
of reproductive dysfunction by estrogen exposure. In contrast, a recent study from Bennetau-Pellisero
and collaborators reported [104] that goldfish fed soybean meal for 20 weeks after hatching show
a reduction in fertility success and larvae production. Particularly, both male and female fish groups
displayed changes in the plasma testosterone and E2 levels, as well as in their spermatogenesis process
and oocyte maturation.
Concerning male reproductive function, a study has been conducted on marmosets fed with
soy-based milk during the first six weeks of life and compared to animals fed with a standard cow’s
milk-based diet [105]. This study reported that soy-fed marmosets had body weights, organ weights
(prostate, seminal vesicles, pituitary, thymus and spleen) and penis lengths comparable to the other
animals. Although lower blood testosterone and higher Sertoli and Leydig cell numbers per testis were
observed in soy-fed marmosets, no adverse reproductive consequences were detected in adulthood,
including the timing of puberty and overall fertility [105]. On the other hand, Adachi et al. have carried
out a toxicogenomic analysis in mice to investigate long-term effects of neonatal exposure to genistein
on testicular gene expression. In addition, the authors used diethylstilbestrol (DES), known as a potent
estrogen, as a positive control because exposure to DES has been reported to induce morphological
changes and alteration of gene expression in reproductive organs. Male mice fed with genistein
(1000 μg/mouse/day) from days 1–6 after birth did not show any morphological changes in testes at
12 weeks of age, despite decreased ER and AR gene expression. As expected, DES (50 μg/mouse/day)
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did show gene expression and morphological changes in testes at 12 weeks of age [106]. This suggests
that neonatal exposure to genistein has no long-term effects, according to this analysis.
Following menopause in women, there is more brain-related pathology, incidence of stroke and
loss of bone mass observed than in men [107]. Because estrogens are neuroprotective agents that are
involved in bone remolding, one possible explanation may be the decline in estrogen levels. Isoflavones
are generally considered to have beneficial effects on bone and brain, although controversial results
have been published [108]. In ovariectomized rats, genistein showed a weak osteoprotective effect
by promoting bone mineral density [109,110]. Similarly, coumestrol showed a neuroprotection effect
in ovariectomized rats subjected to global ischemia [111]. Interestingly, using an ER antagonist, the
authors showed that the neuroprotective actions of coumestrol are only partially abolished, suggesting
that in addition to classical ER signaling, coumestrol may act via other cellular pathways. Thus, the
beneficial effects of isoflavones may depend on the quantity and ratio of the expression of ER subtypes,
the endogenous steroid hormones and period of life [111]. Moreover, it would be interesting to find
out the cellular targets of coumestrol mediating its neuroprotective action. These cellular pathways
could be used in the therapeutic potential of coumestrol in the treatment of pathologies related to the
central nervous system.
There is growing evidence suggesting that during critical windows of prenatal and postnatal
development, environmental chemicals can induce epigenetic modifications, affecting gene expression
and consequently impacting developmental pathways. Importantly, it has been suggested that the
effects of some environmental chemicals could act across generations, leading to phenotypic and
physiological variation in the development and behavior of offspring. The transmission can be
a consequence of changes in the transcriptome and epigenome programming within germ cells.
While these effects have been recently reported for a number of environmental compounds, such
as vinclozolin, atrazine, bisphenol A (BPA), DES, and dioxine [112–118], studies on the potential
transgenerational effects of phytoestrogens are very rare, if any, and need additional work [69,115].
Although the situation is different for phytoestrogens produced by plants, it is worth
noting that some fungi also produce compounds, called mycotoxins, with estrogenic properties.
For example, zearalenone and fusarin C act as estrogen agonists and are classified as mycoestrogens.
These compounds, which could contaminate improperly stored grains, have been linked to increased
cancer rates. In vitro, fusarin C, as well as zearalenone and its metabolites, can stimulate the growth
and proliferation of human breast tumor cells [119–121]. Moreover, in vivo exposure of rats to
environmental doses of zearalenone in the last two to three weeks of fetal development and the first
days after birth resulted in long-term changes in the development of the mammary gland associated
with increased risk for the development of mammary tumors [122].
5. Conclusions
Although more research is needed, it is clear that some natural compounds from plants, such as
phytoestrogens, could have beneficial effects on certain diseases, such as cancer or neurodegenerative
diseases. However, in vitro or in vivo studies to analyze the final effects of phytoestrogens may be
quite different at low (<1 μM) or high concentrations (>10 μM). For instance, at low doses (from
10 nM to 1 μM), genistein showed mitogenic effects on breast cancer cell growth, whereas at higher
concentrations (>10 μM), it showed antiproliferative effects [123,124]. Some of these effects are
explained by their interactions with ER subtypes. The ratios and the expressions of ERα and ERβ are
different in various tissues depending on the period of life. ERα is mostly expressed in tissues such as
the mammary gland, uterus, liver and pituitary, while ERβ is expressed in tissues such as the brain,
bone and bladder. Moreover, the abilities of ER subtypes to recruit cofactors, regulate gene expression
and stimulate or inhibit cell growth are slightly different. Therefore, in vivo, phytoestrogens may have
a complex role, acting as weak estrogens and antiestrogens depending on the tissue. Furthermore, it is
believed that the signaling pathways induced by phytoestrogens are not completely identical to those
induced by estrogens. As illustrated in Figure 3, phytoestrogens may have different mechanisms of
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action; therefore, some of these compounds could be considered therapeutic agents and used alone
or in combination with usual hormone therapies. For example, the protective effect of isoflavones
on prostate cancer may be related to their effects on metabolic pathways involved in androgen and
estrogen synthesis [125] or to their epigenetic modifications of DNA, such as the demethylation of
CpG islands within the promoters of tumor suppressor genes [81,126,127]. On the other hand, the
phytoestrogen coumestrol, which exhibits an important cancer-preventive effect in estrogen-responsive
carcinomas, was recently reported to inhibit epithelial ovarian cancer proliferation and invasion by
modifying AKT, p70S6K and ERK1/2 phosphorylation [128]. Moreover, previous studies showed
an antagonistic effect of genistein and apigenin against the association of ERα with the ubiquitous
calcium-dependent protein, calmodulin (CaM). By interacting with ERα, CaM plays a key role in the
stabilization and transcriptional activity of ERα dimers at the ERE. The agonistic effect of genistein
and apigenin in this interaction may also account for the anti-tumor origin of these compounds against
ER-positive breast cancers [129,130]. It is, therefore, essential to continue advances in the understanding
diverse signaling pathways activated by phytoestrogens, to fully exploit their anticancer properties
and/or their potential roles in estrogen-related diseases. Accordingly, it should also be remembered
that changes in the expression or activity of nuclear and membrane receptors for steroids and growth
factors, as well as key steroid synthesis enzymes, during cancer progression could play crucial roles
in the effects of phytoestrogens (Figure 3). Indeed, flavonoids, especially flavones (ex: luteolin) and
flavanones (ex: naringenin), are described as potent inhibitors of aromatase activity [131]. Aromatase
is the main enzyme that participates in the transformation of testosterone into estradiol and is hence
involved in breast cancer pathology. Moreover, luteolin was also shown to downregulate aromatase
gene expression [131]. Phytoestrogens are also able to inhibit proteasome [132], which appears to
be essential for breast cancer cell survival [133]. For example, apigenin is capable of inhibiting the
catalytic activity of proteasomes, leading to stabilization of ERβ and apoptosis of prostate cancer
cells [134].
An important application of phytoestrogens is that they could be used as an alternative to
the synthetic selective estrogen receptor modulators (SERMs), which exhibit estrogen agonist or
antagonist activity in a tissue-specific manner. Indeed, SERMs are used in the treatment of some
estrogen-associated pathologies, such as breast cancer, brain diseases, osteoporosis and menopausal
symptoms. In other words, the challenge is to minimize the adverse effects of ER (mitogenic effect)
without reducing the beneficial effects (protective effects), such as the control of cell differentiation,
neuroprotection, anti-osteoporosis effects, and anti-oxidant activity. Our recent study screening the
SERM activity of these compounds revealed a beneficial effect of apigenin and resveratrol, whereas
zearalenone has been characterized as having a strong ER-agonist property in breast cancer cell lines
and having adverse effects in neuritogenesis [135].
Although recent studies have reported that certain environmental agents caused epigenetic effects
that could act across generations, leading to physiological changes of the offspring, there are no
examples of perinatal exposure to phytoestrogens at environmentally relevant doses. There is still a
need to understand the molecular mechanisms and to investigate how these compounds can influence
epigenetic patterns during development.
In this review, we have discussed the effects of phytoestrogens used alone. However, populations
are exposed to several compounds at the same time. Thus, it might be important to perform studies
of the effect of mixtures of botanical estrogen on human health to improve recommendations for
public health.
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Figure 3. Different targets of phytoestrogens in cells. Cell signaling pathways for estrogens through the
nuclear receptors ERα, ERβ and the transmembrane receptor G-protein-coupled ER (GPER; formerly
known as GPR30) [136] are shown. Phytoestrogens are able to inhibit mitogenic pathways via ERα or
PI3K/MAPK, which in turn inhibit cancer cell proliferation and invasion by modifying AKT, p70S6K
and ERK1/2 phosphorylation as well as interaction between ERα with various coregulatory proteins
such as calmodulin (CaM). Activation of ERβ inhibits dedifferentiation pathways and induces apoptosis
and cell cycle arrest. GPER activation is anti-tumorigenic, as it upregulates p21 and induces cell cycle
arrest in prostate cancer [137]. Epigenetic modifications by phytoestrogens, such as demethylation of
CpG islands within the promoters of tumor suppressor genes, could contribute to cell growth arrest.
Inhibition of proteasomes by phytoestrogens also appears to be another mechanism of phytoestrogen
activity in decreasing cancer cell survival.
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Abstract: Breast cancer (BC) is a heterogeneous disease which many studies have classified in at
least four molecular subtypes: Luminal A, Luminal B, HER2-Enriched, and Basal-like (including
triple-negative breast cancer, TNBC). These subtypes provide information to stratify patients for
better prognostic predictions and treatment selection. Individuals vary in their sensitivities to
carcinogens due to differences in their DNA repair capacity (DRC) levels. Although our previous
case-control study established low DRC (in terms of NER pathway) as a BC risk factor, we aim
to study this effect among the molecular subtypes. Therefore, the objectives of this study include
investigating whether DRC varies among molecular subtypes and testing any association regarding
DRC. This study comprised 267 recently diagnosed women with BC (cases) and 682 without BC
(controls). Our results show a substantial variability in DRC among the molecular subtypes, with
TNBC cases (n = 47) having the lowest DRC (p-value < 0.05). Almost 80 percent of BC cases had a
DRC below the median (4.3%). Low DRC was strongly associated with the TNBC subtype (OR 7.2;
95% CI 3.3, 15.7). In conclusion, our study provides the first report on the variability among the
molecular subtypes and provides a hypothesis based on DRC levels for the poor prognosis of TNBC.
Keywords: breast cancer; molecular subtypes; phenotypic variability; DNA repair capacity;
multinomial regression analysis; precision medicine
1. Introduction
Worldwide, breast cancer (BC) is the most common cancer affecting women [1]. In the U.S. and
Puerto Rico, BC now accounts for 30% of all new cancers in women [2,3]. Molecular studies of BC
have revealed distinct disease subtypes, each associated with different risk factors, etiology, incidence,
prognosis, survival rates, treatment approaches, and responses [4–7]. While high-throughput gene
expression analysis continues to reveal more distinctions between BC subtypes, their classification is
still in flux. For example, what collectively has been known as triple-negative breast cancer (TNBC)
is now yielding distinct genetic profiles for basal-like and claudin-low BC (the latter seeming to be
an intermediate between basal-like and luminal BC) [8,9]. Despite gene expression profiling’s ability
to supply vital genetic information for stratifying patients [10], it is costly, not uniformly available,
and the subset of genes analyzed vary by manufacturer. Therefore, immunohistochemistry (IHC) for
receptor status and gene expression is a frequently used surrogate tool to classify BC subtypes. Under
IHC auspices, Luminal A is ER+, PR+/−, HER2−; Luminal B is also positive for ER and PR+/− but is
HER2+. HER2-enriched BC is ER−, PR−, HER2+. Triple-negative BC is negative for all three receptors
and has the worst prognosis and treatment response [11,12].
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For over a decade, our laboratory has focused, using lymphocytes as surrogate markers, on
the role of DNA repair capacity (DRC) as risk factor for BC in women. We have previously shown
in our large BC cohort (n = 824) that women with BC (n = 285) had a mean DRC of 2.40% (range:
0.14–15.00%); whereas the women without BC had a mean DRC level of 6.13% (range: 0.14–19.00%) [13].
In addition, we showed that the likelihood of developing BC increases by 64% for every 1% decrease
in DRC measurement [13]. Therefore, our findings support what have been previously published,
that low DRC is a marker that correlates with higher cancer risk [14–16]. In BC, the nucleotide
excision repair (NER) pathway is particularly affected. NER deficiency is now well established as
a DNA repair phenotype in BC, which suggests that it contributes to the etiology of both familial
and sporadic BCs [13,16,17]. We also recently showed that ER status is associated with that defective
repair phenotype [18]. This current study investigates whether DRC levels vary among BC subtypes
and whether that variability is associated with an accompanying variance in risk of developing
sporadic BCs.
2. Results
In the analysis of results, first an initial description of the study group was performed. Afterwards,
a bivariate analysis was performed for assessing the association between different BC risk factors and
molecular subtype of BC, in order to identify the potential confounders for this association. Finally, the
magnitude of the association between BC molecular subtype and DRC was estimated, controlling for
different confounding variables using a multinomial logistic regression model.
2.1. Description of Study Group
This study comprised 682 controls (women without BC) and 267 treatment-naïve women
with recently diagnosed BC: 157 had Luminal A, 41 Luminal B, 22 HER2-positive, and 47 had
triple-negative BC (TNBC). At the time of initial diagnosis, the age (years) distribution varied
significantly (p-value < 0.05) by subtype; TNBC were the oldest (median 60 years), followed by Luminal
A (median 58 years) and Luminal B (median 55 years) (Table 1). This distribution of BC molecular
subtypes is consistent with national U.S. statistics [6,7,19–21].














n = 949 682 (71.9) 157 (16.5) 41 (4.3) 22 (2.3) 47 (4.9)
DRC <0.001
<4.3 271 (39.7) 122 (77.7) 26 (63.4) 17 (77.3) 39 (83.0)
≥4.3 411 (60.3) 35 (22.3) 15 (36.6) 5 (22.7) 8 (17.0)
Family History of BC 0.082
No 457 (67.0) 118 (75.2) 33 (80.5) 18 (81.8) 32 (68.1)
Yes 225 (33.0) 39 (24.8) 8 (19.5) 4 (18.2) 15 (31.9)
Age at Diagnosis 0.040
<45 193 (28.3) 26 (16.6) 6 (14.6) 3 (13.6) 9 (19.1)
45–55 228 (33.4) 46 (29.3) 15 (36.6) 6 (27.3) 16 (34.0)
56–65 142 (20.8) 43 (27.4) 15 (36.6) 7 (31.8) 10 (21.3)
66–75 95 (13.9) 33 (21.0) 4 (9.8) 5 (22.7) 9 (19.1)
>75 24 (3.5) 9 (5.7) 1 (2.4) 1 (4.6) 3 (6.4)
Median age b 51 (43, 61) 58 (47, 66) 55 (50, 62) 54 (46, 66) 60 (52, 69)
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No 258 (37.8) 39 (25.0) 8 (19.5) 6 (27.3) 13 (27.7)
Yes 424 (62.2) 117 (75.0) 33 (80.5) 16 (72.7) 34 (72.3)
Not specified 0 1 0 0 0
Age at Menarche >0.1
<13 292 (42.9) 74 (48.1) 19 (46.3) 13 (59.1) 22 (46.8)
≥13 389 (57.1) 80 (51.9) 22 (53.7) 9 (40.9) 25 (53.2)
Not specified 1 3 0 0 0
BMI >0.1
<25 236 (34.6) 43 (27.4) 14 (34.2) 10 (45.5) 13 (27.7)
25–30 258 (37.8) 52 (33.1) 18 (43.9) 5 (22.7) 20 (42.6)
>30 188 (27.6) 62 (39.5) 9 (21.9) 7 (31.8) 14 (29.8)
Alcohol Intake 0.033
Never 555 (82.6) 138 (89.0) 39 (95.1) 17 (77.3) 43 (91.5)
Ever 117 (17.4) 17 (11.0) 2 (4.9) 5 (22.7) 4 (8.5)
Not specified 10 2 0 0 0
Smoking Habit >0.1
Never 614 (91.1) 137 (87.8) 39 (95.1) 20 (90.9) 43 (91.5)
Ever 60 (8.9) 19 (12.2) 2 (4.9) 2 (9.1) 4 (8.5)
Not specified 8 1 0 0 0
Oral Contraceptives (Pre-Menopausal Women Only) 0.054
Never 303 (45.2) 89 (58.2) 22 (53.7) 12 (54.5) 23 (48.9)
Ever 367 (54.8) 64 (41.8) 19 (46.3) 10 (45.5) 24 (51.1)
Not specified 12 4 0 0 0
Vitamin Intake (Multivitamin or Calcium) <0.001
No 333 (48.8) 96 (61.1) 28 (68.3) 14 (63.6) 37 (78.7)
Yes 349 (51.2) 61 (38.9) 13 (31.7) 8 (36.4) 10 (21.3 )
HRT (Post-Menopausal Women Only) 0.009
Never 205 (48.3) 68 (58.1) 22 (66.7) 12 (75.0) 23 (67.6)
Ever 219 (51.7) 49 (41.9) 11 (33.3) 4 (25.0) 11 (32.4)
TN: triple negative; DRC: DNA repair capacity; HRT: hormone replacement therapy; SEM: standard error of the
mean; a p-values were computed without missing values (“not specified” information); b between parentheses
percentile 25, and percentile 75.
2.2. Differential Distribution of DRC
The DNA repair capacity (DRC in %) distribution by molecular subtype of BC showed a positive
skew (were highly concentrated at low values) for Luminal A (median 2.0%; p25 = 1.3, p75 = 7.3)
and TNBC (median 1.6%; p25 = 1.0, p75 = 2.9). After sorting the DRC (%), the value of the DRC
(%) that reached 25% of the women (percentile 25) is different for each subtype: 3.4% for controls,
1.3% for Luminal A, 1.3% for Luminal B, 1.9% for HER2+ and 1.0% for TNBC. These differences were
statistically significant (p-value < 0.05) (Table 1). In contrast, the DRC % distribution among controls
was quite symmetrical (median 5.1%; p25 = 3.4, p75 = 7.3); however, this group showed the largest
interquartile range (3.9) (Figure 1).
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Figure 1. Distribution of DNA repair capacity (DRC) in controls and breast cancer cases stratified using
the four principal molecular subtypes of breast cancer. The numbers included on each panel for each
group include the median.
2.3. Molecular Subtypes of Breast Cancer by Different Characteristics
The bivariate analysis showed that the following factors had a significant association
(p-value < 0.05) with molecular subtype: DRC, age, menopausal status, alcohol intake, vitamin intake,
and HRT. Approximately 60% of the controls had DRC values above 4.3%, while only 17% of the
women with TNBC women had DRC values above this median value. Among women with Luminal B
tumors, only 19.5% reported having a family history of BC, while this distribution in controls was 33%.
Around 72% of the women with tumors classified as TNBC were menopausal. Alcohol intake was
more frequent in HER2+ (22.7%) followed by women in the control group (17.4%). Approximately 51%
of women in the control group had multivitamin consumption (including calcium) and only 21.3%
of the TNBC women reported this consumption. Among the post-menopausal women, 51.7% of the
controls reported having taken HRT, while only 32.4% of the women with TNBC reported having
undergone HRT therapy (Table 1).
2.4. Pathological Characteristics of Breast Tumors
Among women with BC, the results did not show significant differences (p-value > 0.05) regarding
the type of BC (in situ, invasive, and mixed invasive) and the molecular subtypes. On the contrary,
the grade of the tumor showed different patterns (p-value < 0.001) according to the molecular subtype
of BC. Grade II cancer was the most prevalent among Luminal A and B subtypes; however, Grade III
was the most prevalent in HER2+ and TN BCs (p-value < 0.001). Consistent with other findings [22,23],
the highest prevalence of Grade III (most aggressive) BC occurred in the TNBC patients (30 of 44; 68%)
(Table 2).
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Type of Breast Cancer >0.1
Carcinoma in situ 7 (4.6) 3 (7.3) 4 (18.2) 1 (2.2)
Invasive 130 (85.0) 34 (82.9) 17 (77.3) 42 (93.3)
Mixed invasive 16 (10.4) 4 (9.8) 1 (4.5) 2 (4.4)
Not specified 2 0 0 2
Grade <0.001
I 28 (20.3) 2 (5.0) 0 (0.0) 0 (0.0)
II 81 (58.7) 22 (55.0) 9 (42.9) 14 (31.8)
III 29 (21.0) 16 (40.0) 12 (57.1) 30 (68.2)
Not specified 19 1 1 3
a p-values were computed without missing values. Ductal and lobular tumors were included into each category of
carcinoma in situ and invasive BC. Mixed invasive refers to ductal and lobular components within the same tumor.
2.5. Magnitude of the Association
When ranked proportionally, more women with TNBC had a low DRC than any other BC
subtype. The proportions of cases with low DRC were: 83% TNBC (39/47), 78% Luminal A (122/157),
77% HER2+ (17/22), 63% Luminal B (26/41). Low DRC was most strongly associated with women
who had TNBC (adjusted OR: 7.2; 95% CI 3.3, 15.7). Women with HER2+ and Luminal A BC had
virtually the same high association with low DRC (point estimates of the adjusted OR were 5.2 and 5.4,
respectively). Women with Luminal B breast cancer had the weakest association between BC subtype
and DRC levels (adjusted OR: 2.5; 95% CI 1.3, 4.9) and the least number of cases with a low DRC
(Table 3).










(reference) 271 411 1.0 1.0
Luminal A 122 35 5.3 (3.5, 7.9) 5.4 (3.5, 2.8)
Luminal B 26 15 2.6 (1.4, 5.1) 2.5 (1.3, 4.9)
HER2+ 17 5 5.2 (1.9, 14.4) 5.2 (1.9, 14.3)
Triple-negative 39 8 7.4 (3.4, 16.1) 7.2 (3.3, 15.7)
TOTALS 475 474
a Fully adjusted OR: model adjusted for age, menopause status and multivitamin and/or calcium consumption.
No significant interaction terms were found in this model using the likelihood ratio test (p > 0.05). (n = 949).
3. Discussion
This study represents the first report that a low DRC (in relation to controls) is present in the four
principal molecular BC subtypes and that is more pronounced in TNBC. Since our study is based on a
large sample size, it suggests that significant phenotypic variability in terms of DRC exists amongst
the four molecular subtypes studied. Our previous studies [13,16,18] and the study of Latimer et al.
(2010) [17] had clearly established the critical importance of low DRC (measured in terms of NER
pathway) as a risk factor for BC. Although the focus of our previous work was to study the relationship
between DRC and BC, considering the disease as a single entity, we now aim to study this effect in
terms of molecular subtypes.
The lowest DRC was associated with TNBC, the molecular subtype associated with the worst
prognosis [22,24]. Among the molecular subtypes included, the highest adjusted OR (7.2) was found for
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TNBC. Our findings show that recently diagnosed, untreated women with TNBC, had a significantly
lower DRC when compared to controls and women with Luminal A, Luminal B, and HER2+ BC.
This may provide a hypothesis to at least partially explain why TNBC have a poorer prognosis when
compared with other molecular subtypes. Our phenotypic measurement of DRC levels obtained from
untreated women with BC confirms what is known about the prognosis of TNBC.
Our results obtained using a phenotypic assay to assess DRC are consonant with the findings
reported by Ribeiro et al. (2013) at the gene expression level. This group found significant
downregulation of 13 DNA repair genes, including five genes from the NER pathway (ERCC1, XPA,
XPD, XPG, XPF) in TNBC [25]. Gene expression patterns were obtained following an RNA extraction
from formalin-fixed paraffin embedded samples from 70 Luminal A, BC tumors and 80 TNBC tumors
obtained from 150 women with BC in Italy. In addition to this group, Alexander et al. (2010) were
able to establish prognostic markers for time to recurrence in TNBC through immunohistochemical
assessment of key proteins in multiple DNA repair pathways. Among the four markers, a low
expression of the NER protein XPF was associated with shorter time to recurrence. Moreover, this
group developed a four-antibody model that was able to successfully identify high- and low-risk
groups in terms of time to recurrence in TNBC [26]. These two studies, along with our findings,
highlight the important role of NER in the biology of TNBC.
Given the research impetus in recent years for a more advanced precision medicine approach, the
inclusion of phenotypic variability in DRC levels provides a tool for implementing that goal in BC
diagnostic and treatment. Although the main therapeutic focus of DNA repair appears to be in the
area of PARP inhibitors, DRC levels might allow us to distinguish subtle differences in BC molecular
subtypes and prognosis. Since TNBC patients usually have the worst prognosis and acquire drug
resistance more frequently than any other molecular subtype [27], our approach of using lymphocytes
as surrogate markers of overall DRC could aid in the prediction of overall therapy response of women
with TNBC. A new focus area in our studies is applying phenotypic measurement of DRC levels
to study recurrence and metastasis in the large cohort of women with BC that we have studied for
the last decade. Our findings may also prove useful in predicting (in terms of DRC levels) which
molecular subtypes have a higher risk of recurrence and/or metastasis of BC, an important area in
precision medicine.
4. Materials and Methods
4.1. Patient Recruitment
Patients were selected from our larger BC study (1183 patients and controls recruited 2006–2013).
This study’s cohort comprised 949 Puerto Rican women age 21 or older: 267 with newly diagnosed BC
(cases) and 682 without BC (controls). From a previous study [13] in which we recruited 824 Puerto
Rican women, age 21 or older (285 newly diagnosed cases and 539 controls) power and sample size
calculations were made. Sample size calculations performed initially revealed that a sample size of
824 participants (312 women with BC, 515 women without BC) would allow us to have a statistically
significant odds ratio as low as 1.7 when the percent exposed to a low DRC among controls is 15%
or higher (e.g., 15% controls are 21 to 30 years of age) with 5% significant level and 80% of statistical
power. Selection bias was minimized by recruiting women who were getting routine gynecological
screenings in the same clinics and hospitals where they would be treated if they were to develop BC.
Those facilities represented 83% of the municipalities (65/78 counties) on the island.
To reduce the likelihood of including undiagnosed BC cases in our controls, only women who had
normal results from a clinical breast exam and mammogram within the past six months were included.
BC cases were limited to only recently diagnosed, histopathologically confirmed, treatment-naïve BC
patients with primary tumors and pathology reports that included hormone receptor information.
Because blood transfusions, radio- and chemotherapy can significantly affect DRC [28–30], patients
who had received any of those treatments in the past five years were excluded from the study. Also
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excluded from this analysis were those with metastatic BC, secondary BC, breast metastases from
another type of cancer, or any acquired or genetic immunodeficiency.
4.2. Use of Human Subjects
The Ponce Health Sciences University Institutional Review Board approved this study (IRB
#130207-JM; Date: 13 February 2013). Each participant signed an informed consent form, giving us
permission to draw their blood and review their pathology reports. All participants also completed an
epidemiological questionnaire.
4.3. Blood Collection and Isolation of Lymphocytes
With the participants’ permission, we drew approximately 30 mL of peripheral blood into
heparinized tubes and isolated the lymphocytes using the Ficoll gradient technique. Blood collection
was performed during morning hours. Lymphocytes were suspended in 2 mL of freezing media
(10% dimethyl sulfoxide, 39% RPMI 1640 medium, 50% fetal bovine serum, 1% antibiotic/antimycotic).
Aliquots were stored in a −80 ◦C freezer for 1–3 weeks until thawed in batches for host-cell reactivation
(HCR) assays.
4.4. DNA Repair Capacity Measurements
The isolated lymphocytes were used as surrogate markers of the patients’ overall DRC [31,32].
The cells were purified and grown, then the HCR assay was performed on them to measure in vivo
DRC, as described in previous studies [13,16,33–35]. Briefly, the lymphocytes were transfected with
a plasmid containing the luciferase reporter gene. Plasmids had been damaged with UVC prior to
transfection. The cells’ ability to repair the foreign DNA was measured via HCR [35] within a specific
time frame (40 h) that mirrored the true cellular process [32]. Results reflected the cells’ inherent DRC,
measured primarily in terms of their NER pathway activity. Details about HCR’s sensitivity, specificity,
and plasmid transfection efficiency have been published previously [13].
To calculate DRC, the luciferase activity after repair of the UVC-damaged plasmid DNA was
compared with the undamaged plasmid DNA. The amount of residual luciferase remaining after the
allotted repair time (activity in luminescence units) was a percentage that represented the amount of
the individuals’ DRC. Because DRC is traditionally low in BC cases, results were analyzed in tertiles,
as described in our previous study [13]. However, to perform the proposed statistical analyses, the
obtained experimental values of DRC of were dichotomized using the median DRC levels. With a
median DRC of 4.3%, this study categorized DRC a dichotomous variable: “low” was <4.3%; “high”
was ≥4.3%.
4.5. Hormone Receptor Status
Pathology reports from all cases were reviewed to confirm the diagnosis, tumor grade and size,
presence/absence of axillary lymph node metastasis, and ER, PR, and HER2 status, as previously
described [13,18]. Receptor status results were provided by 10 private Puerto Rican laboratories,
following ASCO (American Society of Clinical Oncology, Alexandria, VA, USA) and CAP (College
of American Pathologists, Northfield, IL, USA) guidelines for those immunohistochemistry (IHC)
methods. [36,37] ER and PR results included the percentage of positive-staining cells, the intensity of
staining (weak, moderate, or strong), and an interpretation. “Receptor positive” meant ≥1% of tumor
cells stained positive for ER/PR [37]. HER2 results were reported as 0, 1+, 2+, or 3+. For this study,
any 1+ or 2+ result was considered equivocal and was followed up with FISH (Fluorescence In Situ
Hybridization) to so we could categorize HER2 as a dichotomous variable (HER2+ = all 3+ results;
HER2− = 2+ to 0 results).
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4.6. Classification of Tumors Based on IHC Receptor Status Information
Breast cancer subtypes have been defined by others [9,38,39]. Briefly, we used the data collected
from the pathology reports on three IHC markers (ER, PR, and HER2) to classify tumors into four
groups. Luminal A tumors were ER+, PR+/−, and HER2−. Luminal B tumors differed only by
being HER2+. HER2-positive tumors were ER−, PR−, HER2+. Triple-negative tumors were ER−,
PR−, HER2.
4.7. Statistical Analysis
Descriptive statistics were used to evaluate categorical data as percentages and continuous
variables in terms of mean/standard deviation. Chi-square probability distribution was used to assess
the statistical relationship between BC subtypes and the following characteristics: DRC, age, onset
of menarche, parity and menopause status, BMI, lactation history, alcohol intake, smoking habits,
contraceptive use, vitamin intake (multivitamin/calcium), and hormone replacement therapy (HRT)
use. To assess the magnitude of the association between DRC and BC subtype, controlling for potential




= β0k + β
k
DRC + ∑ β jXj
where Pk indicates the prevalence of the kth-category of BC subtype, P0 indicates the prevalence of the
control group under the DRC comparison (<4.3 vs. ≥4.3), βkDRC is the coefficient associated to DRC, Xj
indicates the potential confounders, and βj is the coefficient associated with Xj. Crude and adjusted
odds ratios (OR) were estimated with 95% confidence levels from this model. Statistical analyses were
performed using Stata v14 (Stata Corp, College Station, TX, USA).
5. Conclusions
In general, our findings support what is known about the biology of molecular subtypes of BC.
However, the ORs in terms of DRC values do not always match with the basic biology of BC. For
example, the lowest OR (2.5) corresponded to Luminal B which is a more aggressive BC than Luminal
A (OR = 5.4). This suggests that in terms of DNA repair, it might be important (future direction) to
look at other pathways in addition to NER. It is possible that double-strand DNA breaks repaired
by homologous and non-homologous end joining might also us to distinguish differences in repair
between Luminal A and Luminal B.
This study has some limitations. Our study was based only on the NER pathway and we were
not able to measure other pathways. We are now standardizing technology in order to be able to
obtain a more comprehensive view of the dysregulation of DNA repair in BC. The HCR assay used
is very costly and not easily amenable to large scale population studies such as this one. This assay
depends on having viable living cells (lymphocytes) from participants (requires a blood sample) versus
genetic tests that can be done with DNA isolated from paraffin embedded tumor samples (no need
for live cells or draw blood). However, our study provides the first report evidence of the significant
phenotypic variability among the four principal molecular subtypes of BC and provides a hypothesis
based on DRC levels for the poor prognosis of TNBC. It suggests that significant phenotypic variability
in terms of DRC exists amongst the four molecular subtypes studied.
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Abstract: Schistosoma haematobium is a human blood fluke causing a chronic infection called urogenital
schistosomiasis. Squamous cell carcinoma of the urinary bladder (SCC) constitutes chronic sequelae
of this infection, and S. haematobium infection is accounted as a risk factor for this type of cancer. This
infection is considered a neglected tropical disease and is endemic in numerous countries in Africa
and the Middle East. Schistosome eggs produce catechol-estrogens. These estrogenic molecules
are metabolized to active quinones that induce modifications in DNA. The cytochrome P450 (CYP)
enzymes are a superfamily of mono-oxygenases involved in estrogen biosynthesis and metabolism,
the generation of DNA damaging procarcinogens, and the response to anti-estrogen therapies.
IL6 Interleukin-6 (IL-6) is a pleiotropic cytokine expressed in various tissues. This cytokine is largely
expressed in the female urogenital tract as well as reproductive organs. Very high or very low levels
of IL-6 are associated with estrogen metabolism imbalance. In the present study, we investigated the
polymorphic variants in the CYP2D6 gene and the C-174G promoter polymorphism of the IL-6 gene
on S. haematobium-infected children patients from Guine Bissau. CYP2D6 inactivated alleles (28.5%)
and IL6G-174C (13.3%) variants were frequent in S. haematobium-infected patients when compared
to previously studied healthy populations (4.5% and 0.05%, respectively). Here we discuss our
recent findings on these polymorphisms and whether they can be predictive markers of schistosome
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infection and/or represent potential biomarkers for urogenital schistosomiasis associated bladder
cancer and infertility.
Keywords: estrogen biosynthesis; estrogen metabolism; BMI; S. haematobium-associated
bladder cancer
1. Introduction
Schistosoma haematobium is a human blood fluke causing a chronic infection called urogenital
schistosomiasis. Squamous cell carcinoma of the urinary bladder (SCC) constitutes chronic sequelae
of this infection, and S. haematobium infection is accounted as a risk factor for this type of cancer.
This infection is considered a neglected tropical disease and is endemic in many countries of Africa
and the Middle East [1].
S. haematobium is endemic in 53 countries in the Middle East and in most of the African continent,
including the islands of Madagascar and Mauritius. Following successful eradication programs,
the infection is no longer of public health importance in Egypt, Lebanon, Oman, Syria, Tunisia and
Turkey since transmission is low or nonexistent. A borderline and indefinable focus is still in existence
in India and requires additional evidence [2].
Infection with Schistosoma spp. affects more than 258 million people worldwide. Praziquantel is
the main antihelminthic drug currently used to treat this infection. This drug is effective in eliminating
adult worms, but is unsuccessful in the prevention of re-infection and does not treat severe liver
damage nor bladder cancer [3].
Schistosome eggs produce catechol-estrogens. These estrogenic molecules are metabolized by
cytochrome P450 oxygenases to active quinones that cause alterations in DNA, known to promote
breast or thyroid cancer [4–6]. Our group has shown that schistosome egg-associated catechol
estrogens induce tumor-like phenotypes in urothelial cells, possibly due to the formation of parasite
estrogen-host cell chromosomal DNA adducts [5]. These estrogen metabolites also contribute to
schistosomiasis-associated infertility [6].
The cytochrome P450 (CYP) supergene family encompasses a cluster of oxygenases that play
a key role in the metabolism of a miscellaneous group of endogenous substrates such as fatty acids,
steroids, and vitamin D as well as exogenous compounds including phytochemicals, environmental
pollutants, and pharmaceuticals [7]. Given the vital function of CYP genes in the biosynthesis of
steroids, especially estrogen, altered expression of CYPs might contribute to the development and
proliferation of tumor cells and increase tumor growth through the activation of procarcinogens.
Specifically CYP2D6 encodes a critical enzyme on estrogen biosynthesis and metabolism, and the
outcome of this CYP gene variant can have a downstream cost on patient response [8].
Interleukin-6 (IL-6) is a pleiotropic proinflammatory cytokine, vastly expressed in the female
urogenital tract and reproductive organs. It has been given a role in estrogen metabolism imbalance.
The promoter region of the IL-6 gene is dynamically regulated at multiple sites, as well as the
23 base-pair “multiple response element” site, which is activated by interleukin-1, tumor necrosis factor
alpha, and other factors [9]. The C-174G promoter polymorphism of the IL-6 gene has been established
to control transcriptional regulation [10] and has been associated with plasma IL-6 levels in patients
with systemic-onset juvenile chronic arthritis and in patients with primary Sjögren’s syndrome [11].
To the best of our knowledge, despite the established role of CYP2D6 and IL6 in estrogen
metabolism, there are no studies addressing these gene variants in S. haematobium-infected
patients. In the present study, we investigated polymorphic variants in CYP2D6 and the -174 G/C
(rs1800795) promoter polymorphism of the IL-6 gene on a cohort of S. haematobium-infected children
from Guinea-Bissau.
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2. Results
2.1. CYP 2D6 Alleles *3, *4 and *5/*5 in S. haematobium-Infected Patients
From the 18 patients studied, we obtained frequencies of CYP2D6 for 14 patients. Mutant samples were
analyzed in Channel 705 of Light Cycler 2.0 Instrument showing melting peaks for hCR5 (amplification
control) at 47.5 ◦C. The CYP 2D6 Alleles *3 and *4 were not found in any of the samples studied.
In contrast, we found that 4 of 14 (28.5%) schistosomiasis-haematobia-infected patients are carriers
of the inactivated allele CYP2D6*5, which is characterized by a deletion of the entire CYP2D6 gene
(Table 1 and Figure 1). Microhaematuria was found in all of the CYP2D6 inactivated allele carriers and
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Figure 1. Genotyping of CYP2D6 *3*4*5/5. (A) Derivative melting curve plots—dF/dT vs. temperature.
Red = Wildtype. Black = Heterozygote. Green = Mutant. (B) Genotyping in a mutant patient. In the
case where no melting signals are visible, but the control gene has been amplified as shown by the
melting point at 48.0 ◦C, the CYP 2D6 gene is deleted (*5/*5).
Table 1. Population characteristics of CYP2D6*5/*5 carriers vs. wild type in children infected with
S. haematobium.
Population Characteristics
CYP; n = 4
(28.5%)
WT; n = 10
(71.4%)
p Value OR 95% CI
Age (years, median ± SD) 10.75 10.8 n.s.
Female 1 4 n.s. 0.5242 0.01537, 7.015
Male 3 6 n.s. 1.908 0.1426, 65.05
Microhaematuria (%) 4 8 n.s. 1.599 0.07674, 72.45
BMI (median ± SD) 15.2 15.5 n.s.
CYP—genotype CYP2D6*5/*5; CI—confidence interval; SD—standard deviation; BMI—body mass index;
OR—odds ratio; n.s.—not significant; WT—wild type.
2.2. IL6-174C Variant in S. haematobium Infected Patients
Fifteen out of the 18 patients studied presented the IL6-174C variant. Mutant samples were
analyzed in Channel 640 of the LightCycler 2.0 Instrument showing melting peaks at 57 ◦C.
The IL6-174C variant was found in 2 of 15 (13.3%) schistosomiasis-haematobia-infected patients
(Table 2 and Figure 2). The two patients carrying the mutant genotype were younger than the ones
with the wild type (WT) (6.5 ± 0.7 vs. 10.1 ± 3.1; p = 0.005) and presented a lower BMI (10.6 ± 5.9 vs.
14.8 ± 1.8; p = 0.04). Microhaematuria was present in one of the mutant carriers (50%) and in 9 of the
13 (69%) WT carrier patients.
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Table 2. Population characteristics of IL6-174C/C carriers vs. wild type in children infected with
S. haematobium.
Population Characteristics
IL6; n = 4
(28.5%)
WT; n = 10
(71.4%)
p Value OR 95% CI
Age (years, median ± SD) 6.5 ± 0.7 10.1 ± 3.1 0.005
Female 1 5 n.s. 1.549 0.03441, 69.74
Male 1 8 n.s 0.6455 0.01434, 29.06
Microhaematuria (%) 1 9 n.s 0.4714 0.01033, 21.51
BMI (median ± SD) 10.6 ± 5.9 14.8 ± 1.8 0.04
IL6—genotype IL6-174C/C; CI—confidence interval; SD—standard deviation; BMI—body mass index; OR—odds
ratio; n.s.—not significant; WT—wild type.
Figure 2. Genotyping of the promoter IL6 G-174C region. (A) Derivative melting curve plots—dF/dT
vs. temperature. Red = Wildtype. Black = Heterozygote. Green = Mutant. (B) Genotyping in
a mutant patient. The presence of a melting peak at 57 ◦C indicate a mutant patient corresponding
with IL6-174C7C genotype.
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3. Discussion
This preliminary study with a limited number of patients suggested that CYP2D6 *5/*5 and
IL6-174C polymorphisms has an effect on severity and morbidity of schistosomiasis. In the present
study, we found that 28.5% of schistosomiasis-infected patients were carriers of CYP2D6 *5/*5. To our
knowledge, this is the first study of this polymorphism conducted on an African population. According
to [12], the frequency of this allele in a healthy population is 4.5%. The cytochrome P450 enzyme
debrisoquine 4-hydroxylase (CYP2D6) metabolizes countless diverse classes of universally used drugs
and toxins. Due to autosomal recessive inheritance of two mutant CYP2D6 null alleles, individuals
are classified as carriers of the inactivated allele CYP2D6*5, which is characterized by a deletion of
the entire CYP2D6 gene and confers the phenotype of poor metabolizers (PM) [13]. Poor metabolizer
subjects might acquire toxic plasma concentrations and adverse drug reactions. Additionally, mutant
CYP2D6 alleles have been implicated as a predictor of susceptibility for diseases such as cancer and
for neurological disorders [13]. In our study, 28.5% are classified as poor metabolizers. Given the fact
that in the present study 4 of 5 (80%) of the poor metabolizers are underweight (BMI < 15), a feature
associated in our previous study with S. haematobium infection [14], it is likely that this genotype might
increase the susceptibility to infection and morbidity of this parasite [13].
Our group has been involved in the identification of parasite-derived substances that might be
implicated in the host–parasite interactions of schistosomes [15]. The bulk of these substances are
catechol estrogens. The genotoxic effects of these estrogen metabolites are ascribed to oxidation of
catechol estrogens to quinones, followed by redox cycling and the formation of reactive oxygen species
that sequentially react with DNA [16]. These electrophilic compounds are able to react with DNA to
form depurinating adducts [17]. It is conceivable that apurinic sites in chromosomal DNA that result
from this reaction generate mutations that might underlie the carcinogenic effect of schistosomes [1,18].
Given the context of the unarguable link between imbalance in the metabolism of estrogens and the
production of depurinating estrogen–DNA adducts, the presence of schistosomiasis-derived estrogen
metabolites may have practical consequences in the growth development of infected children carriers
of the CYP2D6 *5/*5 allele.
We observed that 174 G/C (rs1800795) promoter polymorphism of the IL-6 gene was found in
2 of 15 (13.3%) of S. haematobium-infected individuals. The frequency of this variant in a healthy
African population is 0.05% [10]. These authors also studied Caucasians and Gujarati Indians
and found a frequency of 0.4% and 0.1%, respectively, for the mutant IL6-174 C/C genotype [10].
The presence of the mutant genotype results in a lower IL-6 expression after a given inflammatory
stimulus compared with the wild-type genotype [10]. Therefore, the presence of the mutant genotype in
S. haematobium-infected patients therefore suggests that this genotype confers a susceptibility influence
for the development of the disease. We also found it to be significantly associated with lower BMI
(10.6 ± 5.9 vs. 14.8 ± 1.8; p = 0.04), indicating that infected carriers of this variant might have an
increased risk of developing schistosomiasis-associated chronic sequelae at a much younger age.
Concerning the role of IL6 in estrogen metabolism, there is emerging evidence linking IL6 deficiency
with reproductive impairment, leading to in how this cytokine contributes to infertility [19]. This is
in accordance with our recent new findings that schistosomiasis is associated with infertility and
suboptimal fecundity [6].
Altogether, the current survey provides primary data on the frequency of inactivating alleles
of CYP2D6 and IL6 G-174C polymorphisms in S. haematobium-infected patients. Despite a limited
number of patients, we found an appalling increase in the frequencies of CYP2D6 *5/*5 and
IL6-174C/C genotypes in comparison to previously studied healthy populations, including populations
of healthy African subjects previously studied. The presence of these genotypes could explain
schistosomiasis-associated cancer and infertility and may represent potential predictors for growth
development and metabolism disorders in these patients. On the other hand, they may have prognostic
significance, namely, regarding the development of cancer and infertility, something that will need to
be addressed in further studies.
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4. Material and Methods
4.1. Study Area, Population and Design
This research (PTDC/AAC-CLI/103539/2008) was carried out in compliance with the Helsinki
Declaration and with the approval of the Executive Board of the Institute of Biomedical Sciences Abel
Salazar of Porto University.
The study was conducted in a children population from Guinea-Bissau (West Africa) in early
September 2011 during the peak of the wet season.
Eighteen schoolchildren aged 6–13 infected with S. haematobium were targeted in this study.
The purpose of the study was explained to all childrens’ parents, and individual informed consent
was obtained.
4.2. Urine Collection
Following the anthropometric measurements, each child was asked to urinate in a plastic cup.
Urine (50–200 mL) was immediately transferred to 15 mL sterile non-heparinized vacuum tubes,
and kept refrigerated in cool boxes.
4.3. Urine Analysis
Upon collection, urine was checked for microhaematuria by means of appropriate reagent strips
(Combur®. Roche Diagnostics Division, Basel, Switzerland). In the laboratory, in Portugal, the presence
of eggs of S. haematobium was detected and quantified by microfiltration of 10 mL of urine through
nucleopore filters [20].
4.4. Anthropometric Measurements
Body weight and height were measured using a standardized method of anthropometric
techniques (WHO, 1995). Height was measured to the nearest 0.1 cm, and weight was measured to
the nearest 0.1 kg using portable digital scales. Body mass index (BMI) of each child was calculated.
BMI < 15 kg/m2 was considered underweight [21].
4.5. DNA Collection and Extraction
Genomic DNA was extracted from urine sediments using High Pure PCR Template Preparation
kits (Roche Diagnostics, GmbH, Mannheim, Germany) [22].
4.6. Genetic Analysis
4.6.1. Detection of CYP 2d6 Alleles *3, *4 and *5/*5
We used Lightmix Kit for the detection of CYP 2D6 Alleles *3, *4, and *5/*5. This kit provides
a fast, easy, and accurate system to identify CYP 2D6 Alleles *3 and *4 as well as a homozygous
deletion of the gene (*5/*5) in a nucleic acid extract according to the manufacturer (TIBMolBiol
GmbH, Berlin, Germany) [23]. After amplification with specific primers, the genotypes were identified
through specific melting points (Tm) recorded during the melting curve analysis. For identification of
Allele *3, a 317 bp fragment from Exon 5 was amplified and analyzed with a SimpleProbe oligomer
(Channel 530) depicting a Tm of 60.2 ◦C for the wild-type allele and 55.0 ◦C for the deletion 2637delA
allele. For analysis of Allele *4, a 336 bp fragment spanning the Intron 3–Exon 4 junction was generated
and analyzed with LightCycler Red 640 labeled hybridization probes, exhibiting a Tm of 56.3 ◦C
for the wild-type allele and 64.5 ◦C for the variant 1934A. The deletion of the entire CYP2D6 gene
(CYP 2D6*5/*5) did not produce any signal in Channels 530 or 640. In this case, to demonstrate the
presence of amplifiable DNA in these biological samples, a 234 bp fragment of the human chemokine
receptor type 5 (hCR5) was co-amplified with specific primers. The hCR5 amplification was detected
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using hybridization probes labeled with LightCycler Red 690 (Channel 705), exhibiting a specific
melting peak at a Tm of 48 ◦C.
4.6.2. Detection of IL6 G-174C
We used Lightmix Kit for the detection of IL6 G-174C. This kit provides a fast, easy, and accurate
system for identifying the genotype of IL6 G-174C in a nucleic acid extract according to the
manufacturer (TIBMolBiol, GmbH, Berlin, Germany) [24]. A 175 bp fragment of the human IL6 gene
spanning the promoter IL6 G-174C region was amplified with specific primers. The resulting PCR
fragments were analyzed with hybridization probes labeled with LightCycler Red 640. The genotype
was identified by running a melting curve with specific melting points (Tm). The wild-type allele IL6
G-174C exhibited a Tm of 64.0 ◦C in Channel 640. The allele variant IL6-174C exhibited a Tm of 57.0 ◦C
in Channel 640.
4.6.3. PCR Experiment Protocol
A total of 20 μL of PCR mixture containing 2–5 μL of sample DNA according to Roche’s datasheet
of LightCycler FastStart DNA Master Plus HybProbe (Roche Diagnostics, Mannheim, Germany) was
used [25]. The LC PCR assay was performed on the LightCycler 2.0 Instrument (Roche Diagnostics,
Mannheim, Germany) with an initial denaturation at 95 ◦C for 10 min, followed by 45 cycles with
denaturation at 95 ◦C for 5 s, 60 ◦C for 10 s, and 72 ◦C for 15 s. After amplification cycles, the reaction
mixture was denatured at 95 ◦C for 20 s, held at 40 ◦C for 20 s followed by one step at 40 ◦C for 30 s,
and gradually heated to 85 ◦C at a rate of 0.2 ◦C/s. The melting curves were converted to melting peaks
by plotting the negative derivative of the fluorescent signal with respect to temperature [d(F2)/dT].
In this way, the presence of a mutant heteroduplex (containing the wild-type sequences and the mutant
allele) is easily detectable because of its low melting temperatures.
4.7. Statistical Analysis
For the group comparison, chi-square tests with Yate’s correction were used or with Fisher’s exact
test (two-sided) when expected values were below 5. For independent samples, a Student’s t-test was
used for the comparison of means (OpenEpi software, version 3.03, Atlanta, GA, USA).
5. Conclusions
Altogether, the current survey provides primary data on the frequency of inactivating alleles
of CYP2D6 and IL6 G-174C polymorphisms in S. haematobium-infected patients. Despite a limited
number of patients, we found an appalling increase in the frequencies of CYP2D6 *5/*5 and IL6-174C/C
genotypes in comparison to previously studied healthy populations, including those of African subjects.
The presence of these genotypes could explain schistosomiasis-associated cancer and infertility and
may represent potential predictors for growth development and metabolism disorders in these patients.
On the other hand, they may have prognostic significance, namely regarding the development of
cancer and infertility, something that will need to be addressed in further studies.
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Abstract: Because of the deep involvement of granulosa cells in the processes surrounding the cycles
of menstruation and reproduction, there is a great need for a deeper understanding of the ways in
which they function during the various stages of those cycles. One of the main ways in which the
granulosa cells influence the numerous sex associated processes is hormonal interaction. Expression of
steroid sex hormones influences a range of both primary and secondary sexual characteristics, as well
as regulate the processes of oogenesis, folliculogenesis, ovulation, and pregnancy. Understanding
of the exact molecular mechanisms underlying those processes could not only provide us with
deep insight into the regulation of the reproductive cycle, but also create new clinical advantages in
detection and treatment of various diseases associated with sex hormone abnormalities. We have
used the microarray approach validated by RT-qPCR, to analyze the patterns of gene expression in
primary cultures of human granulosa cells at days 1, 7, 15, and 30 of said cultures. We have especially
focused on genes belonging to ontology groups associated with steroid biosynthesis and metabolism,
namely “Regulation of steroid biosynthesis process” and “Regulation of steroid metabolic process”.
Eleven genes have been chosen, as they exhibited major change under a culture condition. Out of
those, ten genes, namely STAR, SCAP, POR, SREBF1, GFI1, SEC14L2, STARD4, INSIG1, DHCR7, and
IL1B, belong to both groups. Patterns of expression of those genes were analyzed, along with brief
description of their functions. That analysis helped us achieve a better understanding of the exact
molecular processes underlying steroid biosynthesis and metabolism in human granulosa cells.
Keywords: human; granulosa cells; in vitro culture (IVC); steroid biosynthesis
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1. Introduction
The increase of knowledge about the processes underlining the development of human gametes
have brought into light the unique interactions between the tissues involved in that process. Granulosa
cells, being a part of almost every stage of folliculo and oogenesis, are deeply involved in storage and
maturation of the oocytes, expressing a range of reciprocal interactions with the female gamete [1–3].
Additionally, they play a major role in synthesis, expression, and metabolism of a range of hormones,
that not only function in maintenance of gamete maturation, regulation of ovulation, and sustenance
of pregnancy, but also perform a wide range of secondary functions defining almost every aspect
of physiology associated with reproduction [4]. Because of the fact that the mammalian female
reproduction cycle is a highly dynamic process, all the processes involved in its regulation and
maintenance are extremely complex. Understanding of the exact molecular mechanisms underlining
the processes that granulosa cells are a part of directly or indirectly, through endocrinal regulation,
not only broadens the knowledge about one of the most essential processes in the mammalian life cycle,
but also opens the way for a search for potential clinical possibilities [2,5]. From advances in assisted
reproduction, to uncovering the exact mechanism that underline various diseases associated with both
the reproduction and hormonal abnormalities, the basis of knowledge that would describe the exact
cellular processes that underline those phenomena lies in the patterns of genetic expression associated
with all the tissues involved [6–8]. In addition, while the functional analyses of those processes have
been long performed and provided us with wide understanding of the ways in which granulosa cells
function both by themselves and in relation to the developing oocytes, the knowledge about their exact
molecular basis is relatively small [9].
By employing the in vitro cultures of human granulosa cells, we aim to analyze and describe
changes in the transcriptome during the long term culture. As regulation of steroid sex hormone
synthesis, expression, and metabolism is one of the major functions of the granulosa, we have used
microarray assays, together with RT-qPCR validation, to analyze the expression patterns of genes
involved in the “Regulation of steroid biosynthesis process” and “Regulation of steroid metabolic
process”. The genes we aim to identify might later serve for markers for the processes, both normal
and pathophysiological, occurring through the whole reproductive cycle, while the expression patterns
that they exhibit, together with their mutual relations, might serve as factors to better understand the
ways in which granulosa cells behave in vitro and possibly in vivo.
2. Results
Whole transcriptome profiling by Affymetrix microarray allowed us to analyze the expression
profile of genes regulating steroid biosynthesis and metabolism in human ovarian granulosa cells
in primary culture. By Affymetrix® Human HgU 219 Array (Affymetrix, Santa Clara, CA, USA),
we examined the expression of 22,480 transcripts. Genes with fold change higher than |2| and with
a corrected p value lower than 0.05 were considered as differentially expressed. This set of genes
consisted of 2278 different transcripts. The first detailed analysis based on the gene ontology biological
process (GO BP) allowed for the identification of differentially expressed genes belonging to the
significantly enriched GO BP terms.
DAVID (Database for Annotation, Visualization and Integrated Discovery) software (Leidos
Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA) was used for extraction of
the genes belonging to the analyzed GO BP terms. Up and down regulated gene sets were subjected
separately to a DAVID search, and only gene sets where adjusted p values were lower than 0.05 were
selected. The DAVID software analysis showed that differently expressed genes belong to 582 gene
ontology groups and 45 KEGG pathways. In this paper, we focused on the “regulation of steroid
biosynthetic process” (GO:0050810) and “regulation of steroid metabolic process” (GO:0019218) GO
BP terms. These sets of genes were subjected to a hierarchical clusterization procedure and presented
as heat maps (Figure 1). The gene symbols, fold changes in expression, Entrez gene identifications
(IDs), and corrected p values of these genes are shown in Table 1.
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Figure 1. Heat map representation of differentially expressed genes belonging to the “regulation of
steroid biosynthetic process” and “regulation of steroid metabolic process” gene ontology biological
process (GO BP) terms. Arbitrary signal intensity acquired from microarray analysis is represented
by colors (green, higher; red, lower expression). Log2 signal intensity values for any single gene were
resized to Row Z-Score scale (from −2, the lowest expression to +2, the highest expression, for a single
gene). D: Day of Culture.
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Table 1. Gene symbols, fold changes in expression, Entrez gene identifications (IDs), and corrected

















DHCR7 0.174701154 0.135435372 0.287884941 0.039383847 0.023551624 0.084599974 1717
GFI1 0.310857826 0.318291331 0.286701236 0.001572194 0.001472925 0.000931728 2672
IL1B 0.068991209 0.095213232 0.183379317 0.027149434 0.035799475 0.083315453 3553
INSIG1 0.112401766 0.111379044 0.231549573 0.040421878 0.035709593 0.102319923 3638
POR 0.297205384 0.246609697 0.226675727 0.02007617 0.011465695 0.008491922 5447
SCAP 0.428465981 0.37245418 0.350801297 0.00234869 0.001405483 0.000934051 22937
SEC14L2 0.393655866 0.47190842 0.474492018 0.049169113 0.080230709 0.075670468 23541
SREBF1 0.342373023 0.40104925 0.351769946 0.004735431 0.007059315 0.004002643 6720
STAR 0.020791115 0.015709262 0.021002203 0.000945846 0.000687578 0.000705428 6770
STARD4 0.192889636 0.155104665 0.215393387 0.037708661 0.023368014 0.037965777 134429
STAT5B 0.343238914 0.381840346 0.358794257 0.008451029 0.010289799 0.007445427 6777
Additionally, using an RT-qPCR assay, we analyzed the relative abundance of IL1B, STAR, and
POR in order to quantitatively validate the results obtained through the qualitative microarray analysis.
The results were presented in Figure 2. STAR and IL1B were selected for validation as they presented the
most extreme fold changes. POR was selected as a mean of control as it presented fold changes on the
most intermediate levels. Additionally, STAR is a gene that is very important for the described steroid
associated processes, while the presence of IL1B is especially interesting as it is usually associated with
the inflammatory response and not steroid synthesis and metabolism. We have identified the presence
of transcripts of the aforementioned genes in human granulosa cells.
Figure 2. Results from RT-qPCR validation, presented in the form of a bar chart with comparisons
to the results obtained with microarray. All the values presented are the relative changes of gene
expression, as compared to Day 1 of primary culture. D: Day of Culture.
For both IL1B and STAR, we found that the levels of transcripts at day 15 were nearly identical
as at day 1. In the case of IL1B, this does not correspond with the microarray finding. For day 7
there was a slight change in mRNA levels observed, as compared to the entry readings. The most
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substantial change was observed at day 30 for both of those genes. Moreover, for both STAR and
IL1B, the fold change of expression was relatively the same as in the results shown by microarray
analysis, which can be considered as validation of those results. For the POR gene, the smallest fold
change was observed at day 15, with major changes at both day 7 and 30, as compared to those at the
entry point. Again, on day 15, the results of microarray and RT-qPCR analysis varied significantly in
scale. Overall, the direction of changes in expression is confirmed by RT-qPCR analysis, while the
scale of change often varies, which can be explained by the much higher accuracy of RT-qPCR. It does
not interfere with the results of research focused on expression patterns, but indicates the need for
extensive validation of microarray results during the studies involving the analysis of the extent of
expression changes.
Moreover, in the gene ontology database, genes that formed one particular GO group can also
belong to other different GO term categories. For this reason, we explored the gene intersections between
selected GO BP terms. The relation between those GO BP terms are presented in a chart (Figure 3).
Figure 3. The representation of the mutual relationship between the “regulation of steroid biosynthetic
process” and “regulation of steroid metabolic process” GO BP terms. The ribbons indicate which gene
belongs to which categories. The genes were sorted by logFC from most to least changed gene, with
the most changed gene marked with the most intense color on the side and presented topmost, and the
least changed gene marked with the least intense color on the side and presented on the bottom.
We used a STRING (Search Tool for the Retrieval of Interacting Genes/Proteins)-generated
network to evaluate the interactions between differentially expressed genes belonging to each of the
selected GO BP terms. Using this prediction method provided us with the molecular interaction
network which is formed between the protein products of the studied genes (Figure 4).
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Figure 4. STRING (Search Tool for the Retrieval of Interacting Genes/Proteins)-generated interaction
network among differentially expressed genes belonging to the “regulation of steroid biosynthetic
process” and “regulation of steroid metabolic process” GO BP terms. The intensity of the edges reflects
the strength of the interaction score.
3. Discussion
Granulosa cells are the primary cell type found in the mammalian ovary. They perform multiple
functions associated with oocyte storage, maturation, as well as maintaining pregnancy and embryonic
development. Because of that, it can be said that they are a somatic cell type that carries the strongest
and closest association with the processes underlying development of female gametes and their
progression through the process of reproduction. They surround the oocyte all the way from the
primary follicle to the moment of ovulation, performing a major role in synthesis and expression
of sex hormones [1,10]. The interactions between oocyte and granulosa cells are reciprocal, with
both structures expressing signals that influence the development and functioning of the other.
After the follicular rupture, granulosa cells that remain in the newly formed corpus luteum undergo
transition into granulosa lutein cells, which produce progesterone, taking further part in maintenance
of pregnancy. While the function of granulosa cells is fairly well understood, the exact mechanisms and
genes expressed through the significant amount of change undergone by these cell types is still full of
unknowns [1]. Because of their major significance for the process of follicle development and oogenesis,
the complete understanding of gene expression underlining the functioning of granulosa cells and
their interactions with oocytes is essential for developing possible clinical applications associated with
gene therapy, tissue and cell engineering, as well as prevention, early detection, and treatment of
cancers originating in the ovarian region that associated with granulosa cells [11].
By using the microarray approach, we have identified and measured the changes in expression of
genes that are part of ontological groups of interest. The RNA analyzed was isolated from primary
cell cultures of granulosa cells after 1, 7, 15, and 30 days of maturation in vitro. Two gene ontology
groups were inspected: (1) “Regulation of steroid biosynthesis process” and (2) “Regulation of steroid
metabolic process”. Eleven genes were identified, out of which ten, namely STAR, SCAP, POR, SREBF1,
GFI1, SEC14L2, STARD4, INSIG1, DHCR7 and IL1B, belonged to both groups. One of the genes,
STAT5B, only belonged to the “Regulation of Steroid Metabolic Process” ontological group. Most of
the genes presented a uniform pattern of expression. Large upregulation of expression was observed
at day 1 of cell culture, with significant downregulation at days 7, 15, and 30. Three genes showed
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a different pattern at day 30: INSIG1 and DHCR7 had very little downregulation and IL1B had no
change in expression. Despite that, we can assume that the pattern of expression was fairly unified for
all the genes, with upregulation at day 1 and general downregulation through the other days. There
are several readings that could indicate a slight upregulation in expression in several genes in different
days of cell cultures apart from day 1, however, all of the readings do not appear consistently in both
reads performed and are contradicted by strong downregulation recorded in the other read, which
indicates that they are probably no more than an error in measurement.
Two of the genes identified are very closely associated with processes underlying steroid
intracellular transport. They are both hosts to the STAR-related transfer domain (START), with
the main function of binding lipids, including sterols [12]. STAR steroid acute regulatory protein,
otherwise called STARD1, encodes a protein that is a key factor in regulation of steroid hormone
synthesis. By mediating the transport of cholesterol between mitochondrial membranes, the protein
allows cholesterol to be converted into pregnenolone, completing the first major step in the process
of steroidogenesis [13,14]. Disruption of the STAR gene has been proven to cause congenital lipoid
adrenal hyperplasia (CLAH) [15], an endocrine disorder, causing mineralocorticoid deficiency which
impairs the synthesis of all categories of adrenal steroids [16]. The other gene that hosts the START
domain is the STAR-related lipid transfer protein 4 (STARD4). It is a gene encoding a soluble protein
involved in cholesterol transport. It is a cholesterol regulated gene with two known homologues
belonging in its family: STARD5 and STARD6. While being expressed in most tissues, the highest
levels of STARD4 are observed in the liver and kidneys [17]. There are strong suggestions of STARD4’s
particular involvement in movement of cholesterol to the endoplasmic reticulum [18].
Three of the genes identified work closely for maintenance of intracellular cholesterol homeostasis.
The sterol regulatory element binding transcription factor 1 (SREBF1) gene encodes a basic
helix-loop-helix leucine zipper transcription factor (SREBP1) binding the sterol regulatory element
(SRE1) [19]. SREBP1 is stored as a membrane bound precursor and is released by proteolytic cleavage
in sterol depleted cells. The loose fragment generated through the cleavage translocates to the nucleus,
activating transcription [20]. It has been proven to play a major role in the induction of lipogenesis,
as well as an auxiliary factor in synthesis of fatty-acids [21]. SCAP is closely associated with SREBP1,
the protein encoded by SREBF1. It is an escort protein that regulates the effects of SREBP1 expression,
detecting the changes of cholesterol concentration. It is the effector of SREBP1 cleavage, allowing
that transcription factor to abandon its membrane-bound state, transduce to the nucleus, and allow
transcription of the genes activated by the SREBP1 [22]. The cleavage occurs in the Golgi apparatus,
which requires SCAP to escort SREBP1 to the Golgi apparatus from the endoplasmic reticulum, where
SREBP1 is synthesized [23]. SREBP1 transcriptional regulation effects also cause negative feedback by
causing degradation of SCAP to prevent sterol overexpression [24]. Large concentrations of sterols
prevent the exit of the SREBP1/SCAP complex from the endoplasmic reticulum in order to prevent
accumulation of cholesterol inside of the cell [22]. This regulative step is achieved with involvement of
another gene, insulin induced gene 1 (INSIG1). This gene encodes a membrane protein found in the
endoplasmic reticulum. In the presence of high sterol concentrations, INSIG1 binds the sterol-sensing
domain of SCAP. This causes retention of the SREBP1/SCAP complex in the endoplasmic reticulum
and prevents its translocation to the Golgi apparatus, therefore, prevents cleavage of SREBP1 and
cholesterol synthesis upregulation [25].
The genes described above are closely associated in the process involved in lipid synthesis
and metabolism. However, there are several more genes that were identified in our study that
possess individual involvement with lipid metabolic and synthetic processes. POR is a gene encoding
cytochrome P450 oxidoreductase. This enzyme plays a critical role in the synthesis of cholesterol and
steroid hormones as an obligatory intermediate which transfers electrons from NADPH (nicotinamide
adenine dinucleotide phosphate carrying electrons and bonded with a hydrogen) to all cytochrome
P450 enzymes [26]. It is also involved in the metabolism of ingested substances in the liver, and it
has been suggested that POR gene polymorphisms are involved in differences in drug metabolism
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across the population [27]. Defects in POR genes have been proven to cause a variety of symptoms,
from embryonic lethality to disordered steroidogenesis, congenital adrenal hyperplasia, ambiguous
genitalia, and Antley-Bixler syndrome [26,28,29]. The next gene, DHCR7, encodes an enzyme,
7-dehydrocholesterol reductase, that catalyzes the conversion of 7-dehydrocholesterol to cholesterol.
This fact, makes the enzyme essential in mammalian sterol biosynthesis, as it is necessary in the
final step of the synthesis pathway [30]. Defects in DHCR7 gene were proven to be the cause
of Smith-Lemli-Opitz syndrome, which may cause mental retardation, dysmorphism of the face,
syndactyly, and holoprosencephaly as a result of insufficient sterol synthesis and 7-dehydrocholesterol
accumulation [30,31]. The SEC14L2 gene encodes SEC14 like protein 2. This lipid-binding carrier
protein facilitates transport of hydrophobic molecules between different cellular sites [32]. SEC14L2
exhibits high affinity to alpha-tocopherol and weaker affinity to other tocopherols and tocotrienols.
It has been proven to stimulate squalene monooxygenase, a downstream enzyme in cholesterol
biosynthesis [33]. IL-1B encodes an interleukin 1 cytokine family member protein, which functions
as an important mediator of the inflammatory response [34]. It is usually expressed by activated
macrophages in its inactive form, which is later activated by proteolytical processing [35]. The cytokine
encoded by IL-1B is also involved in other cellular processes including proliferation, differentiation,
and apoptosis [36–38]. Proto-oncogene GFI1 (growth factor independent 1 transcriptional repressor)
encodes a nuclear zinc finger protein, functioning as a transcriptional repressor. The repression is
achieved by GFI1 working with other cofactors as a part of a complex that controls histone modifications
and silences target gene promoters [39]. It has been proven to play a role in processes such as
hematopoiesis and oncogenesis [40]. Mutations in that gene can cause neutropenia in both the
congenital and nonimmune chronic idiopathic forms, both being autosomal dominant disorders
causing predispositions to leukemia and infections [41]. The final gene described in this study is
STAT5B, signal transducer and activator of transcription 5B. This gene is only a member of the
“Regulation of steroid metabolic process” gene ontology group. It encodes a STAT family transcription
factor, expression of which is activated by cytokine activity. Transcription factors belonging to that
family function when phosphorylated by the receptor associated kinases. After phosphorylation,
hetero or homodimerization occurs, with the resulting complex functioning as a transcription activator
after translocating to the nucleus [42]. STAT5B performs various functions, mostly associated with
hematopoiesis, mammary gland development, and immune systems [43–45].
In conclusion, we identified and described the genes expressed in long term in vitro cultures,
belonging to the ontology groups “Regulation of steroid biosynthesis process” and “Regulation of
steroids metabolic process”. Analysis of the modes of their expression, together with their relation
to each other, will broaden the understanding of the ways in which the cells of human granulosa
are involved in the processes associated with steroid synthesis and metabolism, which may later
be applied in both further research and, potentially, together with other research that improves the
understanding of the molecular basis of this tissue’s functioning, to clinical applications.
4. Material and Methods
4.1. Patients and Collection of Granulosa Cells
The granulosa cells (GCs) were derived from patients undergoing in vitro fertilization (IVF)
procedures, who had given their informed consent to be included in this protocol. The study group
consisted of eight patients, aged 18–40 years, with diagnosed infertility who were referred to the
Division of Infertility and Reproductive Endocrinology, Poznan University of Medical Sciences, Poland.
Patients underwent an IVF procedure based on controlled the ovarian hyperstimulation protocol,
adjusted to the patient’s initial infertility workup and ovarian response. Stimulation was performed
with human recombinant FSH (Follicle-stimulating hormone; Gonal-F, Merck Serono, Darmstadt,
Germany) and highly purified hMG-HP (Highly purified human menopausal gonadotropin; Menopur,
Ferring, Saint-Prex, Switzerland). The injections with cetrorelix acetate (Cetrotide, Merck Serono,
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Darmstadt, Germany) were administered in an adequate dose to suppress pituitary function. Ovulation
triggering was based on subcutaneous injection of 6500 U of hCG (Human chorionic gonadotropin,
Ovitrelle; Merck-Serono, Darmstadt, Germany). Follicular fluid, containing GCs, was collected
during transvaginal ultrasound-guided oocyte pick-up, 36 h after human chorionic gonadotropin
administration. The follicular content from follicles over 16 mm in diameter was given rapidly to
the embryologist, who isolated the oocyte and pooled the fluids containing GCs together from each
ovary. Fresh follicular fluid was centrifuged for 10 min at 200× g, to separate and collect GCs. Patients
with polycystic ovary syndrome (PCOS), endometriosis, and diminished ovarian reserve (serum
antimüllerian hormone (AMH) less than 0.7 ng/mL and/or day 2–3 FSH serum level higher than
15 mU/mL and/or antral follicle count less than 9) were excluded from the study. This study was
approved with resolution 558/17 by the Bioethical Committee at the Poznan University of Medical
Sciences. All participants gave written informed consent for the research.
4.2. Primary Cell Culture
Collected cells were washed twice by centrifugation at 200× g for 10 min at room temperature
with culture medium. Medium consisted of Dulbecco’s Modified Eagle’s Medium (DMEM/F12,
Sigma-Aldrich, St. Louis, MO, USA), 2% fetal bovine serum FBS (FBS; Sigma-Aldrich Co., St. Louis,
MO, USA), 200 mM L-glutamine (Invitrogen, Carlsbad, CA, USA), 10 mg/mL gentamicin (Invitrogen,
USA), 10,000 units/mL penicillin, and 10,000 μg/mL streptomycin (Invitrogen, USA). Cells were
cultivated at 37 ◦C under aerobic conditions (5% CO2). Once adherent cells were more than 90%
confluent, they were detached with 0.05% trypsin-EDTA (Invitrogen, USA) for 1–2 min and counted
using a counting chamber “neubauer improved” (ISO LAB Laborgerate GmbH, Wertheim, Germany,
DIN EN ISO CERTIFIED 9001). GCs were cultivated for 30 days. Medium was changed twice a week.
Finally, total RNA was isolated from GCs after 24 h, 168 h, 15 days, and 30 days. The changes in cell
morphology were presented in Figure 5.
 
Figure 5. Morphology of human ovarian granulosa cells in long term in vitro culture shown using
Nomarski phase/contrast images.
4.3. Total RNA Isolation
Total RNA was isolated at four time periods, after 24 h, 168 h, 15 days, and 30 days cultivation.
For the isolation of total RNA, we used the improved Chomczyński-Sacchi method [46]. The GCs
216
Int. J. Mol. Sci. 2017, 18, 2673
were suspended in 1 mL mixture of guanidine thiocyanate and phenol in monophasic solution
(TRI Reagent®, Sigma-Aldrich, St. Luis, MO, USA). Then, chloroform was added and centrifuged
to separate the mixture into three phases. RNA was located in the upper phase—an aqueous phase.
The resulting RNA was intact with little or no contaminating DNA and protein. The last step was
to strip the RNA with 2-propanol (Sigma-Aldrich, St. Luis, MO, catalog number I9516) per 1 mL of
TRI-reagent and wash with 75% ethanol. Prepared RNA was used for further analysis.
4.4. Microarray Expression Analysis and Statistics
Total RNA (100 ng) from each pooled sample was subjected to two rounds of sense complementary
DNA (cDNA) amplification (Ambion® WT Expression Kit; Ambion, Austin, TX, USA). The obtained
cDNA was used for biotin labeling and fragmentation by Affymetrix GeneChip® WT Terminal Labeling
and Hybridization (Affymetrix, Santa Clara, CA, USA). Biotin-labeled fragments of cDNA (5.5 μg)
were hybridized to the Affymetrix® Human Genome U219 Array (48 ◦C/20 h; Affymetrix, Santa Clara,
CA, USA). Microarrays were then washed and stained according to the technical protocol using the
Affymetrix GeneAtlas Fluidics Station. The array strips were scanned employing the Imaging Station
of the GeneAtlas System. Preliminary analysis of the scanned chips was performed using Affymetrix
GeneAtlasTM Operating Software (Affymetrix, Santa Clara, CA, USA). The quality of gene expression
data was confirmed according to the quality control criteria provided by the software. The obtained
CEL files were imported into downstream data analysis software.
All of the presented analyses and graphs were performed using Bioconductor and R programming
languages. Each CEL file was merged with a description file. In order to correct background, normalize,
and summarize results, we used the Robust Multiarray Averaging (RMA) algorithm. To determine the
statistical significance of the analyzed genes, moderated t-statistics from the empirical Bayes method
were performed. The obtained p-value was corrected for multiple comparisons using Benjamini and
Hochberg’s false discovery rate. The selection of significantly altered genes was based on a p-value
beneath 0.05 and expression higher than two-fold. The differentially expressed gene list (separated for
up- and down-regulated genes) was uploaded to DAVID (Database for Annotation, Visualization and
Integrated Discovery) software (Leidos Biomedical Research, Inc., National Cancer Institute, Frederick,
MD, USA) [47].
Subsequently, sets of differentially expressed genes from selected GO BP terms were applied
to STRING software (Search Tool for the Retrieval of Interacting Genes/Proteins; STRING
Consortium) for interaction predictions. STRING is a huge database containing information of
protein/gene interactions, including experimental data, computational prediction methods, and
public text collections.
In order to further investigate the chosen gene sets, we investigated its mutual relations with the
GOplot package [48]. Moreover, the GOplot package allowed us to calculate the z-score (the number
of up- regulated genes minus the number of down- regulated genes divided by the square root of the
count). Z-score analysis allowed us to compare the enrichment of selected GO BP terms.
4.5. Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) Analysis
Total RNA was isolated from granulosa cells after 24 h, 7 days, 15 days, and 30 days of culture.
The RNA samples were re-suspended in 20 μL of RNase-free water and stored in liquid nitrogen. RNA
samples were treated with DNase I and reverse-transcribed (RT) into cDNA. RQ-PCR was conducted in
a LightCycler real-time PCR detection system (Roche Diagnostics GmbH, Mannheim, Germany) using
SYBR® Green I as a detection dye, and target cDNA was quantified using the relative quantification
method. For amplification, 2 μL of cDNA solution was added to 18 μL of QuantiTect® SYBR® Green
PCR (Master Mix Qiagen GmbH, Hilden, Germany) and primers (Table 2).
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Table 2. Oligonucleotide sequences of primers used for RT-qPCR analysis.
Gene Gene Accession Number Primer Sequence (5′-3′) Product Size (bp)
STAR NM_000349.2 GGCATCCTTAGCAACCAAGATCTCCTTGACATTGGGGTTC 199
Il1B NM_000576.2 GGGCCTCAAGGAAAAGAATCTTCTGCTTGAGAGGTGCTGA 205
POR NM_000941.2 CACAAGGTCTACGTCCAGCAGCCACGATGTCGTAGAAGGT 143
GAPDH NM_002046 TCAGCCGCATCTTCTTTTGCACGACCAAATCCGTTGACTC 90
ACTB NM_001101 AAAGACCTGTACGCCAACACCTCAGGAGGAGCAATGATCTTG 132
HPRT NM_000194 TGGCGTCGTGATTAGTGATGACATCTCGAGCAAGACGTTC 141
One RNA sample of each preparation was processed without the RT-reaction to provide a negative
control for subsequent PCR.
To quantify specific genes in the granulosa cells, expression levels of specific messenger RNAs
(mRNAs) were calculated relative to GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase), HPRT
(Hypoxanthine guanine phosphoribosyltransferase), and ACTB (Beta-actin). To ensure the integrity of
these results, the additional housekeeping gene was used as an internal standard to demonstrate that
GAPDH, HPRT, and ACTB mRNAs were not differentially regulated in the granulosa cells.
Acknowledgments: Publication of this article was made possible by grant number UMO-2012/07/N/NZ5/00069
from the Polish National Centre of Science and grant number 502-14-02227367-10694 from Poznan University of
Medical Sciences.
Author Contributions: Wiesława Kranc—investigation (conducting research and investigation processes,
specifically performing the experiments, or data/evidence collection), methodology (development of
methodology), original draft preparation; Maciej Brązert—resources (provision of study materials
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Abstract: Smoking is a preventable risk factor for stroke and smoking-derived nicotine exacerbates
post-ischemic damage via inhibition of estrogen receptor beta (ER-β) signaling in the brain of female
rats. ER-β regulates inflammasome activation in the brain. Therefore, we hypothesized that chronic
nicotine exposure activates the inflammasome in the brain, thus exacerbating ischemic brain damage
in female rats. To test this hypothesis, adult female Sprague-Dawley rats (6–7 months old) were
exposed to nicotine (4.5 mg/kg/day) or saline for 16 days. Subsequently, brain tissue was collected
for immunoblot analysis. In addition, another set of rats underwent transient middle cerebral
artery occlusion (tMCAO; 90 min) with or without nicotine exposure. One month after tMCAO,
histopathological analysis revealed a significant increase in infarct volume in the nicotine-treated
group (64.24 ± 7.3 mm3; mean ± SEM; n = 6) compared to the saline-treated group (37.12 ± 7.37 mm3;
n = 7, p < 0.05). Immunoblot analysis indicated that nicotine increased cortical protein levels of
caspase-1, apoptosis-associated speck-like protein containing a CARD (ASC) and pro-inflammatory
cytokines interleukin (IL)-1β by 88% (p < 0.05), 48% (p < 0.05) and 149% (p < 0.05), respectively, when
compared to the saline-treated group. Next, using an in vitro model of ischemia in organotypic
slice cultures, we tested the hypothesis that inhibition of nicotine-induced inflammasome activation
improves post-ischemic neuronal survival. Accordingly, slices were exposed to nicotine (100 ng/mL;
14–16 days) or saline, followed by treatment with the inflammasome inhibitor isoliquiritigenin
(ILG; 24 h) prior to oxygen-glucose deprivation (OGD; 45 min). Quantification of neuronal death
demonstrated that inflammasome inhibition significantly decreased nicotine-induced ischemic
neuronal death. Overall, this study shows that chronic nicotine exposure exacerbates ischemic
brain damage via activation of the inflammasome in the brain of female rats.
Keywords: stroke; inflammasome; nicotine; estrogen; smoking; women’s health
1. Introduction
Cigarette smoking is a preventable risk factor for stroke, and smoking-ingested nicotine
exacerbates post-stroke brain damage [1,2]. Stroke disproportionately kills more women than men
and remains one of the leading causes of death and disability in the U.S. Women have a higher risk
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of stroke, as well as a higher mortality rate associated with stroke, and a higher tendency for more
frequent recurrent strokes than men [3–5].
Although we know that women are more susceptible to stroke, we have a limited understanding
of the underlying mechanisms for increased stroke severity and possible sex-specific prevention and
treatment of stroke. Sex differences in stroke are highly complicated, and sex-specific risk factors in
part account for epidemiological findings in stroke incidence, prevalence, and mortality. As stated
in a review by Girijala et al., there are a number of modifiable risk factors such as cardiac conditions,
hypertension, diabetes mellitus type 2, metabolic syndrome, alcohol consumption, physical inactivity,
and cigarette smoke exposure, which are common for both sexes [4,6,7]. At the same time, there are
female specific risk factors, such as pregnancy, pre-eclampsia, gestational diabetes, migraine with aura
during pregnancy, oral contraceptive (OC) use, menopause, and hormone replacement therapy (HRT),
which make women more susceptible to stroke [4,8]. What is more striking is that even among women
there are studies that clearly link more damaging effects of stroke in women who combine OC/HRT
and cigarette smoking. This also points to the facts that: (1) OC/HRT and cigarette smoking/tobacco
use have synergistic deleterious effects on a woman’s brain and (2) a gender non-specific risk factor
of cigarette smoking has unique effects on the female brain that need to be identified and targeted to
reduce consequences of stroke in women. Cigarette smoking, however, is an important modifiable risk
factor that an individual does have control over. Nicotine, the main active ingredient in tobacco, has
been shown to aggravate ischemic brain damage [9], and the mechanism by which nicotine contributes
to poor outcomes after cerebral ischemia is yet to be fully elucidated.
Smoking-attributed nicotine is known to inhibit aromatase enzyme activity, which catalyzes the
conversion of androgens into estrogens [10]. Consequently, nicotine reduces circulating estrogen
levels and leads to early onset of menopause in women [11–19]. In laboratory studies on female rats,
we confirmed the aforementioned epidemiological findings that chronic nicotine exposure reduced
endogenous 17β-estradiol (E2; a potent estrogen) levels [9]. Estrogen-mediated neuroprotection
requires activation of estrogen receptor-alpha (ER-α) and beta (ER-β). Silencing of hippocampal
ER-β but not ER-α, abolishes E2-induced ischemic protection, suggesting a key role of ER-α and/or
ER-β-activation [20–22]. Our study demonstrated that ER-β activation regulates inflammasome
activation. The inflammasome is an arm of the innate immune response involved in the activation of
the pro-inflammatory cytokines interleukin (IL)-1β and IL-18 through the processing of caspase-1 [23].
The inflammasome is comprised of the signaling proteins caspase-1 and apoptosis-associated speck-like
protein containing a CARD (ASC) [23]. In a published study, we demonstrated that silencing of
ER-β attenuated E2-mediated decrease in caspase-1, ASC and IL-1β [24]. On the other hand, ER-β
agonist treatment reduces inflammasome activation and ischemic damage in reproductively senescent
female rats. ER-β agonist treatment significantly decreased inflammasome activation and increased
post-ischemic neuronal counts by 32% (p < 0.05), as compared to the vehicle-treated, reproductively
senescent rats [24]. Studies from our laboratory also showed that chronic nicotine exposure decreased
membrane-bound and mitochondrial ER-β, but not ER-α protein levels in the brain [9,25]. Therefore,
in the current study, we hypothesized that chronic nicotine exposure activates the inflammasome in
the brain, thus exacerbating ischemic brain damage in female rats.
2. Results
2.1. Nicotine Reduces ER-β Protein Levels in the Brain of Female Rats
Because our previous results demonstrated that nicotine reduced the level of membrane-bound
and mitochondrial ER-β in the hippocampus, in this study, we investigated protein expression of ER-β
in the cortex, the main brain area vulnerable after transient middle cerebral artery occlusion (tMCAO).
Our results demonstrated that nicotine significantly reduced cortical ER-β protein levels as compared
with the saline group (Figure 1). ER-β protein levels after nicotine showed a 30% (n = 8; p < 0.05)
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and 31% (n = 8; p < 0.05) reduction in cortex and hippocampus, respectively, as compared with saline
(100%; n = 8).
(A) (B) 
Figure 1. Nicotine decreases estrogen receptor beta (ER-β) protein expression in the hippocampus and
cortex of female rats. Immunoblot analyses show significant reduction in the ER-β proteins of nicotine
treated (A) hippocampus and (B) cortex when compared to the saline group. Data are presented mean
± SEM (* p < 0.05), n = 8.
2.2. Nicotine Increases Inflammasome Activation in the Brain of Female Rats
Since nicotine is an immunomodulatory agent and inflammasome activation plays a key role
in ischemic brain damage, we then tested whether nicotine alters inflammasome protein expression.
We obtained protein lysates from the cortex of female rats exposed to nicotine and resolved them by
immunoblot analysis for the expression of active caspase-1, ASC and IL-1β. Our findings indicate a
significant increase in these inflammasome proteins (Figure 2). Accordingly, nicotine increased protein
levels of caspase-1, ASC and IL-1β by 88% (p < 0.05), 48% (p < 0.05) and 149% (p < 0.05) respectively in
the cortex, as compared to the saline-treated group (Figure 2).
Figure 2. Nicotine increases inflammasome protein expression in the cortex of female rats. Immunoblot
analyses show an increase in the inflammasome proteins (A) Caspase-1 (B) apoptosis-associated
speck-like protein containing a CARD (ASC), and (C) IL-1β when compared to the saline group.
Data are presented mean ± SEM (* p < 0.05), n = 8.
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2.3. Nicotine Worsens Infarct Volume and Neurodeficit Score after tMCAO
Since inflammasome increase in the brain can exacerbate post-stroke outcomes, we tested the
hypothesis that chronic nicotine exposure exacerbates stroke outcomes. Rats exposed to nicotine or
saline for 16 days underwent tMCAO and were allowed to recover for 30 days before histological
analysis. Our data demonstrated significantly higher mean infarct volume in the nicotine-treated
group (64.24 ± 7.3 mm3; n = 6) compared to the saline-treated group (37.12 ± 7.37 mm3; Mean ± SEM;
n = 7, p < 0.05) (Figure 3A). Histological analysis of nicotine- or saline-treated rat brains that underwent
sham surgery did not show any infarct. Figure 3B shows that the neurodeficit score in each group
was more than 10 when tested at 1 h after tMCAO. Neurodeficit scores 1 h, 1, 7, 15 and 30 days
after tMCAO are shown in Figure 3B. The neurodeficit score remained unchanged in nicotine-treated
animals. These results indicate that nicotine worsens outcome after stroke.
Figure 3. Nicotine increases infarct volume after tMCAO. (A) Infarct volume was measured by
analyzing lesions after rats were subjected to 90 min of tMCAO. Volume was measured in mm3.
(B) Neurodeficit score was measured in rats post tMCAO. Higher scores represent a greater neurodeficit.
Nicotine-treated rats showed significantly higher neurodeficit scores after ischemia when compared to
control. Data presented are mean ± SEM (* p < 0.05)
2.4. Inhibition of Inflammasome Activation Decreases Neuronal Cell Death in an In Vitro Model of Stroke
Since chronic nicotine exposure increases inflammasome proteins in the brain of female rats, as a
proof-of-principle, we tested the hypothesis that the inhibition of nicotine-induced inflammasome
activation improves post-ischemic neuronal survival using our well-established in vitro model of
cerebral ischemia. We tested this hypothesis in organotypic cultures by exposing slices to saline or
nicotine for 14–19 days. We found that nicotine significantly increased ischemic neuronal death in the
Cornu Ammonis area 1 (CA1) region of the hippocampus as compared to saline. The propidium iodide
(PI) fluorescence values were 56 ± 5.5% (n = 10) and 70 ± 1.2% (n = 10) in the saline and nicotine +
vehicle-control groups respectively (p < 0.01). Nicotine and saline exposed slices were treated with the
inflammasome inhibitor isoliquiritigenin (ILG; 1, 10, and 40 μM). Inflammasome inhibition at 10 μM
ILG concentration showed a significant decrease in nicotine-induced ischemic neuronal death when
compared to the nicotine + vehicle group. The PI fluorescence values of the saline + ILG, nicotine +
ILG, and vehicle treated nicotine groups were 44 ± 6.2% (n = 8), 27 ± 1.5% (n = 8), and 70 ± 1.2%
(n = 10; p < 0.05), respectively. The PI fluorescence values of the nicotine + 1 μM ILG and nicotine +
40 μM ILG were 55 ± 5.3% (n = 8) and 61 ± 2.5% (n = 8), which were not significantly different as
compared to PI values of saline + 1 μM ILG and saline + 40 μM ILG groups (Figure 4).
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Figure 4. ILG decreases cell death in hippocampal organotypic slice cultures after oxygen-glucose
deprivation (OGD). PI fluorescence, which represents cell death, was measured in organotypic brain
slices exposed to nicotine or saline treatment, then ILG at varying concentrations 24 h before OGD. Data
shown represent cell death normalized to the respective saline groups. To normalize data, the mean
of the subgroup was divided by its respective control. PI fluorescence was significantly stronger in
the nicotine group than the saline group. PI fluorescence significantly decreased nicotine induced cell
death in the nicotine group treated with 10 μM ILG, as compared to the nicotine control. Data are
presented mean ± SEM (* p < 0.01, § p < 0.05). n = 4 to 11 per group.
3. Discussion
This study revealed for the first time that chronic nicotine exposure increases inflammasome
activation in the brain and exacerbates post-ischemic damage in the brain of female rats. Our study
also demonstrated that inhibition of inflammasome activation specifically attenuates nicotine-induced
ischemic cell death in an in vitro model of ischemia. Inhibition of inflammasome activation
was achieved with ILG, which is a chalconoid found in licorice. Studies have found that ILG
inhibits inflammasome activation via the inhibition of ASC oligomerization and the inhibition of
nucleotide-binding oligomerization domain (NOD)-like receptor 3 (NLRP3) activation [26,27]. In our
study, nicotine-exposed hippocampal slice-cultures were treated with ILG, one day prior to the
induction of OGD. Therefore, the observed neuroprotective effect of ILG in our study suggests the
suppression of nicotine-induced inflammasome activation in the brain. In vivo the half-life on ILG has
been identified to be around 4 h [28]. In this study, ILG was added before and during OGD. In vitro,
when ILG was applied to liver microsomes, the half-life was found to be 25.3 min. Since brain cells
do not have the clearance capacity of liver cells, we estimate that the half-life of ILG in the brain
slices is greater. Importantly, since OGD in our study was done in the presence of ILG for 45 min,
we anticipate that for all or most of the duration of the experiment, ILG was present. At the low dose,
the concentration of 1 μM ILG was not enough to prevent cell death. However, at the middle dose of
10 μM we found the concentration optimum at which ILG can prevent cell death in both the saline
as well as the nicotine groups. The ILG treatment showed more rigorous neuroprotection in nicotine
treated group as compared to saline group, which suggests that effects of ILG might wean off prior to
post-OGD inflammasome activation and observed effects of ILG in nicotine group could be outcome
of pre-OGD inhibition of ASC. Although the mechanism of action of how ILG inhibits inflammasome
activation remains unknown, it has been shown that this inhibition occurs between 1 and 10 μM [29],
and that at the higher dosages of even 30 μM ILG does not inhibit the inflammasome. Thus, it is
possible that at the 40 μM the effects of ILG on inflammasome inhibition are absent, resulting in greater
cell death in the 40 μM similar to the 1 μM group.
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It has been shown that inflammasome activation in the brain is regulated by sex hormones [24].
In a previous study from our laboratory, we reported that ER-β attenuates inflammasome activation
in the brain of female rats. Specifically, silencing of hippocampal ER-β increased caspase-1, ASC,
and the pro-inflammatory cytokine interleukin-1β (IL-1β) in the hippocampus of ovariectomized
rats. Conversely, periodic activation of ER-β significantly decreased inflammasome activation and
reduced post-ischemic neuronal death in the hippocampus of reproductively senescent female rats.
It has been shown that aging as well as long-term nicotine usage reduces ER-β availability in the
brain [30,31]. Therefore, nicotine-induced inflammasome activation in the brain could be due to the
direct immunomodulatory nature of nicotine or the loss of ER-β following long-term nicotine exposure
in the brain. The latter scenario is consistent with females having a higher risk from nicotine toxicity.
This notion is supported by a study showing that hippocampal neuronal damage is greater in female
rats following chronic nicotine exposure [27].
Inflammasome activation occurs after the detection of pro-inflammatory molecules by pattern
recognition receptors, such as a toll-like receptor or a NOD-like receptor (NLR) [32]. The mechanisms
of inflammasome activation include the generation of mitochondrial reactive oxygen species (ROS)
and the translocation of NLRP3 to the mitochondria [33]. Interestingly, the nicotinic acetylcholine
receptor (7α-nAChR) has been found in neuronal mitochondria [34] and its physiological significance
remains unknown. However, it is likely that it is involved in buffering cytoplasmic calcium [35,36].
It is through the mechanism of calcium buffering in which one study found that 7α-nAChRs located in
the mitochondria regulates inflammasome activation in peritoneal mouse macrophages [37]. It is well
documented that calcium overload can trigger mitochondrial dysfunction, promote the production of
reactive oxygen species (ROS), and disrupt the mitochondrial permeability transition pore, eventually
leading to neuronal death [38–40]. Therefore, nicotine-induced mitochondrial dysfunction, which has
been described in several studies [41–43], may be responsible for the increase in stroke volume in female
rats. However, studies are needed to understand the upstream mechanisms leading to mitochondrial
dysfunction that increases the susceptibility to ischemia.
Finally, relinquishing the smoking habit reduces the risk for stroke; however, impact of smoking
cessation on stroke outcome remains unknown. Because it is difficult to stop smoking, more tobacco
users have switched to the “fashionable” e-Cigarette (electronic nicotine delivery systems) as an
alternative to tobacco smoking or even as an aid for smoking cessation. However, the safety of
e-Cigarettes remains questionable and as demonstrated in the current study, negative effects of nicotine
on brain will persist, which makes current research in this area timely and of a high impact.
4. Materials and Methods
4.1. Animals
All animal procedures were carried out in accordance with the Guide for the Care and Use of
Laboratory Animals published by the U.S. Public Health and procedures involving animal subjects
and were approved by the Animal Care and Use Committee (#A-3224-01, effective 24 November 2015)
of the University of Miami.
4.2. In Vivo
Adult female Sprague–Dawley rats (290 ± 20 g; 6–7 months old) were used for this study.
The stages of estrous cycle were monitored as described [44] and only rats showing at least three
consecutive normal (4 day) estrous cycles were used for our experiments.
4.3. Nicotine or Saline Treatment
To obtain sustained nicotine delivery, osmotic pumps (type 2ML2, Alzet Corp., Palo Alto, CA,
USA) containing nicotine or saline were implanted in rats for 16–21 days as described [30]. The pump
delivered a fixed and continuous dose of nicotine hydrogen tartrate (4.5 mg/kg/day, equivalent to
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1.5 mg/kg/day free base) throughout the 16–21 days. Rats exposed to nicotine (n = 21) or saline (n = 20)
were divided into two groups. One group of eight rats treated with either nicotine or saline was used
for brain tissue collection, while the remaining rats in both treatment groups underwent transient
middle cerebral artery occlusion (tMCAO) or sham surgery. Since we have previously demonstrated
that the higher endogenous estrogen levels seen during proestrus protect CA1 neurons against cerebral
ischemia [45], tMCAO or tissue collection was performed only when nicotine/saline treated rats were
in proestrus stage. In those instances where rats were not in the proestrus stage on the last scheduled
day of treatment, we extended the treatment by 1 or 2 days.
4.4. Transient Middle Cerebral Artery Occlusion (tMCAO) and Infarct Volume
Nicotine or saline treated rats were exposed to ischemic stroke (90 min) using an occluding
intraluminal suture inserted past the internal carotid artery to occlude the middle cerebral artery
as described previously [46,47]. In parallel, we also performed sham surgery on nicotine or saline
treated rats. During this sham procedure rats were exposed to anesthesia for a period similar to that
of the tMCAO group. During the surgical procedure of tMCAO or sham, physiological parameters
including pCO2, pO2, pH, HCO3 and arterial blood pressure were maintained within normal limits
prior to and after tMCAO (data presented as Table 1). Body and head temperatures were maintained
at 37 ± 0.2 ◦C throughout the experiment with assistance of lamps placed above the animal’s body
and head. One month after tMCAO surgery, rats were perfused with saline, then with FAM (a mixture
of formaldehyde, glacial acetic acid, and methanol; 10:10:80), and brains were prepared, sectioned, and
stained to obtain infarct volumes. The sample preparations and procedures are described in more detail
in our previous publication [48]. Brains were then embedded with paraffin and 10 μm thick sections
were obtained. Infarct volume measurements were adapted from previous publications [49,50]. Briefly,
the same nine coronal sections were selected for every animal (Bregma levels 5.2, 2.7, 1.2, −0.3, −1.3,
−1.8, −3.8, −5, −7.3). Infarcted area was then measured on each section using MCID software (version,
Manufacturer, City, US State abbrev. if applicable, Country). Infarct volume was then determined
similar to previously used methods [49,50].
Table 1. Physiological variable. Physiological variables were recorded during the period when the
animal was under anesthesia. Rows with bold background denote values after tMCAO. Mean arterial
blood pressure (MABP).




(n = 4) 131.0 ± 7.4
7.39 ± 0.5 36.3 ± 2.3 135 ± 35 132.4 ± 6
0
7.39 ± 0.4 36.0 ± 4.1 133 ± 15 134 ± 11.7
Nicotine + Sham
(n = 5) 126.4 ± 2.8
7.36 ± 0.4 34 ± 7.2 133 ± 37 135 ± 3
0
7.37 ± 0.04 38.0 ± 3.4 127 ± 28 135 ± 11.4
Saline + tMCAO
(n = 8) 130.3 ± 8.7
7.36 ± 0.4 35.3 ± 2.3 134 ± 39 131 ± 7.7
1
7.37 ± 0.05 34.3 ± 5.2 140 ± 15 134 ± 9.3
Nicotine +
tMCAO (n = 8) 127.4 ± 6.8
7.4 ± 0.2 38.08±4.5 130 ± 35 129 ± 7.8
2
7.39 ± 0.04 35.8 ± 3.9 138 ± 25 132 ± 5.3
4.5. Neurodeficit Scoring
The neurological score was monitored at an hour, 1, 7, 15 and 30 days after tMCAO. A standardized
neurobehavioral test battery was conducted as described previously [51], which includes tests for
postural reflex, sensorimotor integration, and proprioception. Total neurological score ranged from a
normal score of 0 to a maximal possible score of 12.
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4.6. Western Blotting
Rats exposed to nicotine (16–21 days) or saline were anesthetized using 5% isoflurane, decapitated,
and the hippocampal and cortical tissues were collected, flash frozen, and stored at −80 ◦C. At the
time of immunoblotting, hippocampal and cortical tissues were homogenized, protein content was
analyzed, and proteins were separated by 12% SDS-PAGE as described [47]. Proteins were transferred
to Immobilon-P (Millipore, Burlington, MA, USA) membrane and incubated with primary antibodies
against rabbit polyclonal anti-ER-β (1:500; Santa Cruz Biotechnology, Dallas, TX, USA), IL-1β (1:1000;
Cell Signaling, Danvers, MA, USA), ASC (1:1000; Santa Cruz Biotechnology), Caspase-1 (1:1000; Novus
Biologicals, Littleton, CO, USA), and β-Actin (1:5000; Sigma, St. Louis, MO, USA). All data were
normalized to β-Actin (monoclonal; 1:1000; Sigma). Immunoblot images were digitized and subjected
to densitometric analysis [45].
4.7. In Vitro Organotypic Slice Cultures and Oxygen-Glucose Deprivation
Hippocampal organotypic slice cultures were prepared from female neonatal (9–11 days old)
Sprague–Dawley rats and the details of slice culture are as described previously [46,52–54]. Briefly,
hippocampal slices were cultured for 14–20 days followed by exposure to nicotine (100 ng/mL) or
saline (vehicle) for 14–16 days. At the end of the treatment period (~29–37 days), a subgroup of slices
(either treated with nicotine or saline) were exposed to the inflammasome inhibitor isoliquiritigenin
(ILG; Invivogen, San Diego, CA, USA) at different concentrations (1, 10, or 40 μM) dissolved in
dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) or vehicle control DMSO (1 μL/mL
of medium) for 24 h. After inhibitor/control treatment, each subgroup was exposed to OGD (45 min)
as described [46,52–54]. To determine the extent of neuronal damage following OGD, we used
the propidium iodide (PI) method [46,52–54]. Briefly, slices were incubated in culture medium
supplemented with 2 μg/mL PI (Sigma, St. Louis, MO, USA) for 1 h. Images were taken using
an inverted fluorescence microscope. Images of the cultured slices were taken (1) at baseline prior
to the ‘test’ ischemia procedure; (2) 24 h after the ‘test’ ischemic insult to assess ischemic damage;
and (3) 24 h after N-methyl-D-aspartate (NMDA) treatment to assess maximum damage to neuronal
cells. The hippocampal CA1 subfield was chosen as the region of interest, and quantification was
performed using Scion Image software [46,52–54]. The percentage of relative optical intensity (ROI)
served as an index of neuronal cell death [46,52–54].
4.8. Statistical Analysis
The data are presented as mean value ± SEM and results were analyzed by a two-tailed Student’s
t test and p < 0.05 was considered statistically significant.
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Abstract: Genomic actions of estrogens in vertebrates are exerted via two intracellular
estrogen receptor (ER) subtypes, ERα and ERβ, which show cell- and tissue-specific expression
profiles. Mammalian immune cells express ERs and are responsive to estrogens. More recently,
evidence became available that ERs are also present in the immune organs and cells of teleost
fish, suggesting that the immunomodulatory function of estrogens has been conserved throughout
vertebrate evolution. For a better understanding of the sensitivity and the responsiveness of the fish
immune system to estrogens, more insight is needed on the abundance of ERs in the fish immune
system, the cellular ratios of the ER subtypes, and their autoregulation by estrogens. Consequently,
the aims of the present study were (i) to determine the absolute mRNA copy numbers of the four
ER isoforms in the immune organs and cells of rainbow trout, Oncorhynchus mykiss, and to compare
them to the hepatic ER numbers; (ii) to analyse the ER mRNA isoform ratios in the immune system;
and, (iii) finally, to examine the alterations of immune ER mRNA expression levels in sexually
immature trout exposed to 17β-estradiol (E2), as well as the alterations of immune ER mRNA
expression levels in sexually mature trout during the reproductive cycle. All four ER isoforms were
present in immune organs—head kidney, spleen-and immune cells from head kidney and blood of
rainbow trout, but their mRNA levels were substantially lower than in the liver. The ER isoform
ratios were tissue- and cell-specific, both within the immune system, but also between the immune
system and the liver. Short-term administration of E2 to juvenile female trout altered the ER mRNA
levels in the liver, but the ERs of the immune organs and cells were not responsive. Changes of
ER gene transcript numbers in immune organs and cells occurred during the reproductive cycle
of mature female trout, but the changes in the immune ER profiles differed from those in the liver
and gonads. The correlation between ER gene transcript numbers and serum E2 concentrations was
only moderate to low. In conclusion, the low mRNA numbers of nuclear ER in the trout immune
system, together with their limited estrogen-responsiveness, suggest that the known estrogen actions
on trout immunity may be not primarily mediated through genomic actions, but may involve other
mechanisms, such as non-genomic pathways or indirect effects.
Keywords: estrogen receptor; isoforms; rainbow trout; immune system; reproductive cycle
1. Introduction
The main physiological function of estrogens in vertebrates is to regulate sexual development
and reproduction. However, estrogens have pleiotropic functions and beyond the “classical” function
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in the reproductive axis, estrogens target a number of other physiological systems including the
immune system [1]. In fact, for mammals it is well documented that estrogens like 17β-estradiol (E2)
modulate the development, differentiation, life span, activation, and functioning of immune cells, and
can have both immunostimulating and immunosuppressive actions [2–5]. The immunomodulatory
activity of estrogens is a key proximate mechanism contributing to the known sexual dimorphism
of mammalian immunity [6,7]. The primary effects of estrogens on the immune cells are mediated
via rapid non-genomic signaling pathways as well as via the two nuclear estrogen receptor (ER)
subtypes of mammals, ERα and ERβ [4]. Nuclear ER can either directly bind to estrogen response
elements in gene promoters or serve as cofactors with other transcription factors such as nuclear
factor-kappa beta (NFκB) [8]. ERα and ERβ are expressed in most cells of the myeloid and lymphoid
cell lineages and in many hematopoietic progenitor cells [4,9–11]. The ratios of the two ER subtypes
differ between immune tissues and cells, what has relevance for the diverse immunological effects of
estrogens [12–14].
The immunomodulatory actions of estrogens in mammals vary with respect to target cell type,
physiological condition of the organism or estrogen concentrations [2,3,15–17]. In particular, the female
reproductive status and the associated changes of estrogen and ER levels have a major influence on the
immune system response to estrogens [2]. With the evolution of internal fertilization and viviparity,
mammals had to master a delicate balance between immunological protection of the mother against
pathogens that are transmitted with fertilization, the prevention of immune responses against the
spermatozoa, and immunological tolerance against the implantation of the semi-allogeneic embryos
and the developing foetus [18–20]. In contrast to mammals, the reproductive strategy of lower
vertebrates, such as teleost fish, relies on external fertilization and ovipary. Despite this difference,
estrogens appear to have immunomodulatory actions in teleosts as well. A number of studies could
show that immune parameters and immunocompetence of fish are influenced by estrogens, both
by endogenous estrogens and by environmental (xeno) estrogens [21–23]. Moreover, recent research
provided evidence that both membrane and nuclear ERs are expressed in immune organs and cells
of teleosts [24–31]. In fact, the available evidence suggest that the immunomodulatory function of
estrogens has been conserved throughout vertebrate evolution, despite the differences of reproductive
strategies between oviparous and viviparous vertebrates [23].
The responsiveness of target cells to estrogens depends in large part on the cellular ratios of the
various ER isoforms, their numbers and stability, and the regulation of ER activity and stability by
the hormone signal, as well as by co-regulators and cross-talk with other signaling pathways [32–35].
While research during recent years has greatly advanced our understanding of the regulation of ER
activity and turnover in mammalian cells [36–38] and how this drives the responsiveness of distinct
cell types to estrogens, the current knowledge for teleost fish of the factors regulating ER activity and
cell type-specific estrogen responsiveness is rather limited. With respect to the immune system of
fish, information on absolute gene copy numbers of the ER in the immune organs and cells is lacking.
Also, it is not clear yet whether piscine immune cells express all nuclear ER isoforms. Particularly for
ERβ isoforms, there have been reports that they are not ubiquitously expressed in immune cells and
organs [25,27,31,39]. Finally, while we have a reasonably good understanding of the autoregulation
of the hepatic ERs in fish [35], no such database exists with respect to the estrogenic regulation of
the ERs in the immune system. Given these knowledge gaps, the aims of the present study were
to determine the absolute numbers of ER in immune organs and cells, and to compare them to the
hepatic ER numbers, to analyse ER subtype ratios in the immune organs and cells, and to examine
the alteration of immune ER expression levels in response to exogenous E2 and in association with
the reproductive cycle. As experimental species, the rainbow trout, Oncorhynchus mykiss, was used.
This species possesses four nuclear ER isoforms ERα1, ERα2, ERβ1, and ERβ2, which share a high
degree of similarity of their amino acid sequences, particularly in the C-domain/zinc finger motif,
in the activation function 1 (AF1) and AF2 domains [40]. In a first step, absolute gene copy numbers
of the four ER were determined in the head kidney, the spleen, as well as in leukocytes that were
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isolated from the head kidney and from the blood of juvenile trout. In a next step, we aimed to gain
insight into the regulation of the four ER subtypes in the immune system and examined the influence
of exogenous E2 exposure on immune-specific ER profiles of juvenile rainbow trout, and we evaluated
the immune ER mRNA profiles variation during the reproductive cycle and the associated fluctuations
of endogenous levels of circulating E2 in mature female trout.
2. Results
2.1. Absolute Gene Transcript Levels of Erα1, α2, β1, and β2 in Immune Organs and Cells of Juvenile Rainbow
Trout in Comparison to Liver ER Gene Transcript Levels
In juvenile rainbow trout, there exist distinct differences of the ER subtype ratios and profiles
between the various organs and cells (Figure 1). Generally, the liver has significantly higher ER gene
transcript levels than the immune tissues (except for ERα2). This applies particularly for ERβ2, where
the liver gene transcripts are about 18 times higher than in the spleen, 55 times higher than in the
head kidney and more than 1000 times higher than in the isolated leukocytes. Similar differences
are observed for ERα1, with hepatic gene transcript levels being 10 times higher than in spleen and
blood leukocytes, 160 times higher than in the head kidney, and 90 times higher than in the head
kidney leukocytes. For ERβ1 mRNA, expression levels in the liver are about 1.5 times higher than in
spleen, six times higher than in head kidney, and about 80 times higher than in the isolated leukocytes,
regardless whether they originate from the head kidney or the blood. In general, the mRNA lowest
levels were found in the isolated immune cells (with the exception of ERβ2).
Figure 1. Absolute mRNA quantification of the four estrogen receptor (ER) isoforms in liver (L),
head kidney (HK), spleen (S) and immune cells isolated from either head kidney (HKic) or blood
(BLic) of 6-month-old female rainbow trout. The gene copy number of each isoform per 1 μL cDNA
is presented by Box-Whisker plots (n = 5 individuals). Note logarithmic scale of y-axis. * p < 0.05,
** p < 0.01. a: under detection limit. b: Part of the sample was not detectable or under detection limit.
c: not detected.
When considering the mRNA profiles of ER isoforms for the various tissues and cells using
ERα1 mRNA as a reference point (Table 1), the ERα1 isoform has slightly lower expression levels than
ERβ2 in liver and head kidney, equal levels in the spleen, and 10 to 110 times higher levels in the
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leukocytes. ERβ1 mRNA levels have the greatest difference to ERα1 mRNA in the blood leukocytes
and the smallest in head kidney and spleen. ERα2 is the isoform with the lowest mRNA expression
levels, relative to ERα1 mRNA, in all of the organs and cells of control animals. Thus, each organ and
cell has a specific profile of the ER isoforms.
Table 1. The mRNA ratios of the four ER isoforms in liver, head kidney, spleen, head kidney leukocytes
and blood leukocytes.
Organ Liver Head Kidney Spleen HK Leukocytes Blood Leukocytes









ERα1 mRNA 1 1 1 1 1
ERα2 mRNA 994 10 30 10 450
ERβ1 mRNA 14 1 2 10 110
ERβ2 mRNA 0.7 0.5 1.1 10 110
The ratios are calculated by dividing the absolute gene copy number (mean value) of ERα1 in the respective organ
or cell type by the absolute gene copy numbers (mean values) of the other isoforms. For instance, a value like “ERα2
mRNA = 994” indicates that in this organ there are 994 times more gene copy numbers of ERα1 than of ERα2.
2.2. Changes of ER Gene Transcript Levels in Sexually Immature Juvenile Rainbow Trout Exposed to
Exogenous E2
Short-term (five days) exposure of sexually immature rainbow trout to E2 (via the diet) resulted in
a significant elevation of plasma E2 concentrations and hepatic VTG gene transcript levels (Figure 2A),
indicating that the treatment indeed induced an “estrogenic condition” in the animals.
The E2 treatment also affected the hepatic gene transcript levels of the two ERα isoforms: ERα1
mRNA levels were significantly upregulated (4-fold) and those of ERα2 mRNA even 17-fold (Figure 2B).
In contrast, ERβ2 was significantly downregulated, while ERβ1 gene copy numbers showed no
significant change. Interestingly, it was the ERα2 isoform that showed the strongest E2 response among
the hepatic ERs isoforms. In head kidney the E2 treatment remained without significant effects on
the ER gene transcript levels, although there was a trend for elevated values, particularly for ERα1.
Also, in the isolated immune cells, the estrogenic condition showed no significant effect on the ER
expression levels, regardless whether the cells originated from the head kidney or the blood. Thus,
the estrogenic condition had a prominent effect on the ER expression levels in the liver but did not
clearly modulate ER expression in the immune system.
By means of in situ hybridization (ISH), we tried to visualize the cellular localization of the
ERs mRNA in the immune organs of control and E2-treated fish. Liver tissue was used as control.
We obtained a weak positive staining in the liver of control rainbow trout, and a very strong staining
in the liver of E2-exposed trout (Figure 3). This finding is well in agreement with the RT-PCR
results. In the immune organs, head kidney, and spleen, we did not obtain a positive staining result.
Apparently, the sensitivity of the ISH was not sufficient to stain the low mRNA numbers of ERs in the
immune organs.
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Figure 2. Response to exogenous 17β-estradiol treatment in 6-month-old juvenile female trout.
Fish were fed with E2 containing pellets for five days and pellets prepared with only vehicle (ethanol)
were used as control diets. (A) Absolute quantification of vitellogenin (VTG) mRNA in the liver and
E2 levels in serum of the control (C) and E2-treatment (E2) groups. The absolute VTG gene copy
number per 1 μL cDNA in the liver is shown as mean ± SE (n = 5 individuals). (B) Absolute mRNA
quantification of the four ER isoforms in liver, head kidney, immune cells isolated from head kidney
and blood of 6-month-old rainbow trout treated with E2. The gene copy number of each isoform per
1 μL cDNA is presented by Box-Whisker plots (n = 5 individuals). Control and E2-treated group were
compared for statistical analysis. The asterisks denote statistically significant differences between
control and E2-treated groups. * p < 0.05, ** p < 0.01. a: under detection limit. b: Part of the sample was
not detectable or under detection limit. c: not detected.
 
Figure 3. In situ hybridization of the ERα1 mRNA in the liver of juvenile rainbow trout. Detection of the
hybridization product was done using ERα1 probes on liver sections of control (left) and E2-exposed
(right) juvenile rainbow trout and detected with NBT-BCIP (dark-purple).
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2.3. Changes of ER Gene Transcript Levels in Sexually Mature Adult Rainbow Trout Females during the
Reproductive Cycle
Changes of hepatic and immune ER gene transcript levels were studied in female rainbow
trout over a full spawning cycle. The reproductive status of the fishes was assessed by measuring
liver-somatic index (LSI), mRNA levels of hepatic vitellogenin (Figure 4), plasma E2 concentrations
(Figure 4), and gonadosomatic index (GSI). Additionally, the ovaries were examined by histology
to assess the maturation status of the oocytes. Based on these criteria, fish were categorised into
four stages: Stage A—fish at the beginning of the reproductive cycle, with low LSI, a GSI less than 1,
low hepatic vitellogenin mRNA levels, low serum E2 levels and immature and partly cortico-alveoloar
oocytes; Stage B—vitellogenic fish, with enlarged liver (LSI > 1.5), increased ovaries (GSI 12–18),
significantly elevated hepatic vitellogenin mRNA and serum E2 levels, and vitellogenic oocytes;
Stage C—spawning fish, with high LSI, high GSI, significantly reduced serum E2 and hepatic
vitellogenin mRNA levels, and mature oocytes; Stage D—post-spawning fish, with reduced LSI,
low GSI (close to stage A), low vitellogenin mRNA, and low E2 levels, similar to stage A. The ovaries
of stage D fish display spent follicles.
Figure 4. Physiological changes during the reproductive cycle of mature female rainbow trout from
September to January: Alterations of the hepatic vitellogenin (VTG) mRNA levels of the liver and
the serum 17β-estradiol (E2). Categorization of the fishes into maturation stages was done based on
the gonadosomatic index (GSI) and the histological appearance of the oocytes; Stage A: fish at the
beginning of ovarian development (GSI < 1), with primary follicles and partly cortical alveolar oocytes
(n = 4), Stage B: fish with enlarged ovaries (GSI 12 < 18) and vitellogenic oocytes; additionally they
possess an enlarged liver (liver somatic index LSI > 1.5) (n = 5), Stage C: Spawning fish with large
ovaries (GSI > 18), mature oocytes and reduced liver size (n = 3), Stage D: Post-Spawning fish, with low
(GSI < 5), spent follicles and a LSI close to 1 (n = 4). Statistically significant differences between groups
are indicated by the same letter (a–g). The absolute gene copy number of VTG per 1 μL cDNA in the
liver and E2 concentrations are shown as mean ± SE.
Figure 5 reports the mRNA changes of the four ER subtypes in the liver, gonads, and immune
organs and cells of mature rainbow trout over the reproductive cycle, i.e., from stage A to stage
D. In the liver, ERα1 mRNA showed a slight tendency for increasing values with maturation and a
decrease towards the post-spawning stage; however, the differences are not statistically significant.
In contrast, hepatic ERα2 mRNA experienced strong and significant changes during the reproductive
cycle. With ERβ1, we observed a significant downregulation in the liver with increasing maturation
of the fishes, and a partial recovery during the post-spawning stage. For the hepatic ERβ isoforms,
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alterations took place from stage A to C, with significant downregulation in the case of ERβ1 and
significant upregulation in the case of ERβ2. Thus, each of the four ER subtypes in the liver showed an
individual pattern over the reproductive cycle, and the pattern was partly different to the changes of
the hepatic ER profile of juvenile trout under E2 exposure.
In the head kidney, mRNA levels of the ERα2 isoform varied over the reproductive cycle similar
to the behaviour of the ERα2 isoform in the liver. In contrast to the liver, however, ERα1 gene
transcript levels experienced significant variations in the head kidney, whereas the ERβ2 isoform
remained unchanged.
The reproductive cycle was associated with alterations of ER expression levels in the leukocytes.
A significant mRNA upregulation of ERα2 and ERβ1 was observed in the head kidney leukocytes of
post-spawning females, and also in the blood leukocytes, ERβ2 gene copy numbers increased in the
post-spawning females. ERα1 gene transcript levels of blood leukocytes, however, decreased towards
the post-spawning stage, after they had increased from stage A to C.
In the gonads (Figure 5B), the most prominent response of the ER expression patterns during the
reproductive cycle was the strong mRNA downregulation of the two ERα isoforms in reproductive
stage C. The gene transcripts levels of the ERβ isoforms in the gonads showed limited variation during
the reproductive cycle.
A regression analysis between the changes of serum E2 concentrations and tissue ER mRNA levels
in mature rainbow trout yielded overall moderate to low correlation coefficients (Table 2). The strongest
correlations to E2 were observed for ERα2 and ERβ1. The ERα isoforms usually showed a positive
correlation, i.e., mRNA increased with increasing E2 concentrations, whereas with the ERβ isoforms,
also negative correlations were found. In general, the poorest ER-E2 correlation existed for the blood
leukocytes. This could be due to a low estrogen sensitivity of the cells or to alterations in the cellular
composition of the blood leukocyte population [41].
Figure 5. Cont.
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Figure 5. (A): The mRNA expression levels of the four ER isoforms in the liver, head kidney (HK),
immune cells isolated from head kidney or from blood during the reproductive cycle. The reproductive
cycle was subdivided into four stages: stage A = start of reproductive cycle, stage B = vitellogenic stage,
stage C = spawning stage, stage D = post-spawning stage (see Figure 4). The gene copy number of
each isoform gene per 1 μL cDNA is presented by Box-Whisker plots (group A: n = 4, B: n = 5, C: n = 3,
D: n = 4). Note logarithmic scale of y-axis. * p < 0.05, ** p < 0.01. (B): The mRNA expression levels of
the four ER isoforms in the ovaries during the reproductive cycle.
Table 2. Correlation coefficients (r2) between serum E2 concentrations and ER mRNA abundance in
liver and leukocytes of female rainbow trout over the reproductive cycle.
ER Isoforms Liver Head Kidney Leukocytes Blood Leukocytes
ERα1 0.138 ↑ 0.039 ↑ 0.044 ↑
ERα2 0.241 ↑ 0.203 ↑ 0.014 ↑
ERβ1 0.282 ↓ 0.282 ↑ 0.009 ↓
ERβ2 0.019 ↓ 0.054 ↓ 0.041 ↓
Linear regressions were calculated between serum E2 concentrations and mRNA numbers of the four ER isoforms
in liver and leukocytes of adult rainbow trout from different stages of the reproductive cycle. ↑ positive correlation
(ER gene transcript levels increase with increasing E2 concentrations); ↓ negative correlation (ER gene transcript
levels decrease with increasing E2 concentrations).
3. Discussion
To provide a baseline for understanding the physiological role of estrogens in the immune system
of teleost fish, this study (1) characterized the mRNA expression levels and ratios of the four ER
isoforms [40] in immune organs and cells of rainbow trout, (2) examined their response to exogenous
or endogenous variations of estrogen concentrations, and (3) compared the mRNA levels of the ER
isoforms in the immune system to that of the hepatic, and partly also, gonadal ERs. A first finding of
this study is that the immune organs and immune cells of rainbow trout express all four ER isoforms,
namely ERα1, α2, β1 and β2. Expression of nuclear ERs in immune cells is well documented for
mammals, where both nuclear ER subtypes, ERα, and ERβ, are present in most immune cells and
hematopoietic progenitor cells [4,9,10,42,43]. The differential expression of the ER subtypes in the
immune cells influences gene regulation and appears to be important to balance the multiple effects of
estrogens in the mammalian immune system [13,44,45]. Generally, the ERα subtype appears to have a
more prominent expression and distribution in mammalian immune cells than ERβ [5]. Also, in the
trout immune system, ERα is prominently expressed, but at least in the immune organs, head kidney
and spleen, the ERβ2 gene copy numbers are in the same range as those of ERα, pointing to an
important role of this ER isoform in teleostean immune organs.
Presence of nuclear ERs in isolated immune cells has been assessed by means of relative mRNA
quantification for a number of teleost species other than the rainbow trout: For seabream (Sparus aurata),
Liarte et al. [27] reported no presence of nuclear ER gene transcripts in the testicular and head
kidney acidophilic granulocytes, whereas macrophages and lymphocytes isolated from the head
kidney contained ERα mRNA, but not ERβ1 or ERβ2 mRNA. For channel catfish (Ictalurus punctatus),
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Iwanowicz et al. [39] described expression of ERα and ERβ mRNA in primary leukocytes from
head kidney and spleen, while only ERα was detected in peripheral blood leukocytes. For carp
(Cyprinus carpio), Szwejser et al. [31] found high mRNA levels of ERα, but no ERβ gene transcripts in
peripheral blood leukocytes. In leukocytes that were isolated from the head kidney of carp, ERβ could
be detected although at very low levels. Thus, in all three species the tissue leukocytes displayed
higher gene transcript levels of ERα than of ERβ, and the later was completely absent from peripheral
blood leukocytes. In contrast to these studies, we detected both ERβ subtypes in the peripheral blood
leukocytes of rainbow trout. Interestingly, however, while in the intact head kidney and spleen,
the ERβ2 mRNA numbers equalled those of ERα1, the isolated leukocytes displayed 10–100 times
lower mRNA numbers of ERβ2 than of ERα1. We found the two ER isoforms not only in blood
leukocytes but also in head kidney leukocytes, together with ERα1 and ERα2. Also Shelley et al. [30]
reported the presence of mRNA of all four ER subtypes in head kidney leukocytes of rainbow trout.
Thus, the overall picture arising from the various studies on nuclear ER in the immune system of
diverse teleost species point to ERα/ERα1 being the dominant nuclear ER isoform in the immune cells,
but not necessarily in the immune organs. The expression of ERβ in fish immune cells appears to vary
with the origin of the cells and across species.
Expression levels of ERα1 in the immune organs of juvenile rainbow trout were significantly lower
than in the liver. Also for ERβ1, the head kidney and the isolated leukocytes (but not spleen) displayed
significantly lower mRNA levels than the liver, while no significant tissue differences existed for ERα2.
Our findings agree with those of Nagler et al. [40] who identified the liver of rainbow trout to be the
organ with the highest gene transcript levels of ERα1 and ERβ2 and clearly lower levels in immune
organs. Similarly, Massart et al. [29] observed much higher ERα1 mRNA levels in the liver of rainbow
trout than in head kidney and spleen. However, at the protein level, Massart et al. [29] found no clear
difference of the ERα expression in liver compared to head kidney and spleen. Discrepancies between
ER levels at the protein and mRNA levels have been observed also in other studies, for instance,
Pinto et al. [46] found no measurable ERα mRNA in the scales of sea bream scale, whereas ERα
protein was well detectable. In this context it is important to keep in mind the complexity of ER
regulation as it has been highlighted from recent studies with mammals [36–38,47]. The “classical”
view of estrogen receptor activity is that, after binding of E2, ER dimerizes, and translocates into the
nucleus where it binds to Estrogen-Response Elements (ERE) on target gene promotors to activate
or repress transcription. However, there are a number of different regulation processes involved,
including the cell-specific availability of co-repressors and co-activators, ER stability or proteolysis
as well as post-translational modifications, such as ER phosphorylation. In addition, cross-talks with
other signaling pathways such as the insulin-like growth factor 1 receptor pathway modulate the
dynamics of ER-mediated gene regulation. Vice versa, both liganded and unliganded ERs are able to
influence other signaling pathways. Altogether, these diverse processes of ER regulation and activity
largely drive the target cell-specific estrogen actions. ER sequences influence isoform conformation,
turnover rates and also the regulation by co-regulators, and thus can provide a basis to understand the
E2 dependence of ER expression. Here, the information that the four ER isoforms of rainbow trout
show similarity of their amino acid sequences, particularly in the AF1 and AF2 domains [40], is an
important starting point for unravelling the mechanisms of ER functions in the trout immune cells.
A striking difference in absolute ER gene copy numbers that was observed in this study existed
between intact immune organs and the pure leukocyte preparations. ERβ1 and ERβ2 gene transcript
numbers were significantly lower in the isolated leukocytes. Only for ERα1, the blood leukocytes had
higher gene copy number levels than the head kidney and as a high levels as the spleen. Similar results
have been reported by Iwanowicz et al. [39] for channel catfish. This suggests that the ERβ isoforms
have a prominent function in the leukocytes. Blood and head kidney leukocytes differed in their ER
expression profiles in what is likely to reflect a different cellular composition [31].
Taken together, the findings from this study provide evidence that immune organs and cells of
rainbow trout express all four ER isoforms, although mostly at low levels, and that ER profiles of the
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immune organs and cells differ strongly to each other. With a relatively strong expression of ERβ2, the
immune organs are more similar to the liver than to the leukocytes, which show a dominance of ERα1.
A second aim of this study was to evaluate how ER mRNA levels in immune organs and cells
of rainbow trout respond to changing E2 concentrations under different physiological conditions.
This was investigated on one hand by exposing sexually immature juvenile trout to exogenous
E2. At this life stage, the gonads of salmonids are already differentiated into ovaries and testes
but endogenous sex steroid production is still negligible or very low [48,49]. Thus, elevating the
estrogen concentrations of these animals by exposure to exogenous E2 was considered to represent a
non-physiological situation. On the other hand, we examined mature female rainbow trout over a full
reproductive cycle. In this situation, the endogenous alterations of E2 levels are embedded in a number
of additional physiological changes, and thus, E2 is not acting in isolation, as in the juvenile fish, but in
concert with other factors. We were interested to compare these two situations since differences of the
physiological states can strongly influence the estrogenic regulation of ER expression [35,50,51].
The induction or suppression of the number of nuclear ER by E2 (autoregulation) is a way by which
a target organ or cell can modulate its sensitivity to estrogens [34,35,52]. In mammals, ER autoinduction
has been demonstrated for the liver and for reproductive tissues, as well as for immune cells.
Molero et al. [53] showed that an increases of plasma E2 concentrations during the menstrual cycle of
women are accompanied by an elevation of ERα and ERβ expression in the neutrophils. In contrast,
in isolated neutrophils of males, E2 upregulated only ERα, but not ERβ. In human macrophages,
E2 upregulated the expression of the ER splice variant, ERα46 [33]. In teleost fish, ER autoinduction
has been described to date mainly for the liver [35]. For instance, Menuet et al. [54] reported that
short-term exposure of mature zebrafish with E2 resulted in a strong upregulation of hepatic ERα,
a marked reduction of the mRNA levels of hepatic ERβ1 and virtually no change of ERβ2. Injection of
male largemouth bass (Micropterus salmoides) with E2 led to a dose-dependent upregulation of hepatic
ERα, but had no clear effect on the hepatic ERβ isoforms [55]. Comparable findings were reported from
in vivo studies with fathead minnow (Pimephales promelas) [56], and from in vitro studies with isolated
trout hepatocytes [57]. In the liver of male goldfish receiving E2 implants, ERα was highly upregulated,
ERβ1 was significantly downregulated and ERβ2 did not change [58]. As summarized by Nelson and
Habibi [35], estrogen-dependent upregulation of hepatic ERα appears to be fairly ubiquitous across
species, whereas the estrogenic regulation of the hepatic ERβ isoforms varies strongly with species
and experimental/physiological conditions. This is confirmed by the results of the present study: E2
exposure of juvenile trout led to significant mRNA upregulation of the two ERα isoforms but had no
effect on ERβ1 mRNA and significantly downregulated ERβ2 mRNA.
Tissue differences in the response of the nuclear ER to estrogens are prominent. This has been
demonstrated for mammals [59] and for fish as well [60]. Here, we focused on the regulation of the
ERs in juvenile trout immune organs and cells by short-term (five days) exogenous E2 administration.
The key finding is that exposure of sexually immature female rainbow trout to exogenous E2
concentrations that were sufficiently high to cause a significant vitellogenin mRNA induction did
not lead to significant changes in the mRNA levels of all four ER isoforms, in the head kidney
organ, in the head kidney leukocytes, or in the blood leukocytes. This behaviour is in contrast to
the prominent responses of the hepatic ER. In another study with in vivo exposure of rainbow trout
to E2, Shelley et al. [61] found an upregulation of ERα1 mRNA in leukocytes from head kidney and
blood, an upregulation of ERα2 mRNA in head kidney leukocytes, but a downregulation in blood
leukocytes, and no change of the gene transcript levels of the ERβ isoforms. Interestingly, in vitro
exposure of rainbow trout blood leukocytes had no effect on the gene transcript levels of the four
ER isoforms [61]. Developmental exposure of tilapia (Oreochromis niloticus) to ethinylestradiol was
associated with elevated ERα gene transcript levels in the spleen, but not in the head kidney [26].
Finally, Liarte et al. [27] found an upregulation of ERα and ERβ2 mRNA after in vitro treatment of
specific macrophage cultures with E2. Given the variations of experimental conditions between the
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cited studies, as well as the species differences, it appears to be too pre-mature to come up with a
general statement on whether ER autoregulation does exist in the immune system of fish or not.
In the third part of the present study we examined how immune ER mRNA levels of mature
female rainbow trout change with the reproductive cycle and the associated fluctuations of plasma
E2 concentrations. In contrast to sexually immature fish, the immune ERs of mature fish experienced
changes of their mRNA expression levels. This may indicate that the effect of E2 in the immune
system is not a simple function of estrogen concentration, but depends on the overall physiological
context [35,50,51]. One key finding from the analysis of the ER mRNA expression levels in the immune
system of mature female rainbow trout is that the reproduction-related changes of ER isoform profiles
in the immune tissues and cells are clearly different to the corresponding changes of ER profiles in liver
and gonads. Even within the immune system, there exist distinct differences between the leukocytes
from head kidney and those from blood. A second key finding that the reproduction-related changes
of nuclear ER expression in the immune system are mainly restricted to the ERα isoforms, whereas the
ERβ isoforms are less responsive. Also, while the ERα isoforms tend to increase with increasing
E2 concentrations, ERβ isoforms tend to decrease if they respond at all. Finally, a third important
observation is that the correlation between the plasma E2 concentrations and the immune ER gene
transcript levels is overall moderate to low.
The organ differences of the ER changes highlight again the importance of the specific cell and
tissue environment for shaping expression and activity of the nuclear ERs [4,59]. The differences
between the leukocyte populations of head kidney and blood are likely to reflect differences in
their cellular composition. The head kidney population, in addition to differentiated immune cells,
contains also diverse developmental stages of immune cells. Estrogens are master regulators of cell
proliferation and differentiation and in line with this, ER are well expressed in developing immune
cells of mammals. Importantly, the ER isoform profile of mammalian immune progenitor cells differs
from that of mature immune cells [4,9]. If the situation is similar in fish, this may explain our finding
of contrasting ER profiles between head kidney leukocytes and blood leukocytes of trout.
The functional interpretation of the reproduction-related changing the ER mRNA profiles of the
trout immune cells is difficult if not impossible at the current state of knowledge on the immune
functional roles of the four isoforms. In mammals there exists evidence that the ERα subtype mediates
anti-inflammatory actions in the immune system, [13,62], and the upregulation of this subtype by the
elevated E2 levels during pregnancy is considered as one mechanism of the pregnancy-associated
lowering of the immune activity in women. Likewise, the increase of immune ERα isoforms in
trout with progressing ovarian maturation may represent an immunosuppressive mechanism as well.
However, different to mammals, the purpose of this mechanism in oviparous fish could not be the
protection of the embryos, but should have an alternative function, for instance, it may be speculated
that it is mediating resource trade-offs between the immune and reproductive systems [63].
When initiating this study, we expected a rather close correlation between nuclear ERs in the
immune system of rainbow trout and E2 levels, and we expected relatively high gene copy numbers of
the ERs in the immune cells since E2 has prominent immunomodulatory actions in fish [21]. Our results
prove the opposite to our expectations—the correlation between E2 levels and nuclear ER mRNA
levels is moderate at its best, and the ER mRNA numbers in immune organs and cells are very
low. The discrepancy between the pronounced immunomodulatory activity of estrogens in trout
and low nuclear ER numbers and the limited estrogen-responsiveness suggests that the estrogen
actions on the trout immune system involve, in addition to genomic signaling, alternative mechanisms.
These could include membrane estrogen receptors [28,31], or indirect effects via interaction with other
endocrine systems. Such indirect effects are well documented for the immune effects of estrogens in
mammals [64–67], and may be of particular importance to mediate the resource trade-offs between the
immune system and other fitness-relevant traits.
In conclusion, the results from this study provide insight into the tissue-specific and physiological
status-related expression and estrogenic regulation of the four nuclear ER isoforms in rainbow trout.
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While all four nuclear ER isoforms are present in the immune organs and immune cells of rainbow
trout, their expression levels, ratios, as well as their autoregulation by E2, show distinct differences to
liver or gonads. This data provides important baseline information for the immunomodulatory role of
estrogens in fish, but to advance our understanding we need more insight into the functional role of
the ER isoforms in the immune system, as well as an on the relative importance of genomic estrogenic
signaling versus non-genomic and/or indirect pathways of estrogen action.
4. Materials and Methods
4.1. Animal Experiments
4.1.1. Juvenile Rainbow Trout
Juvenile all-female rainbow trout (Oncorhynchus mykiss) of an average weight of three grams were
bought at DSM SA (Village Neuf, France) and were reared at the Centre for Fish and Wildlife Health,
University of Berne, Switzerland. Fish were kept at 11.3–11.8 ◦C, in 130 L flow-through glass tanks
supplied with tap-water (approx. 1 L/m), constant aeration, and artificial light (12 h light to 12 h
dark). On arrival, ten fish were randomly sampled and were screened for the presence of pathogens.
No infectious agents were found. Any mortalities were recorded, and necropsied and investigated for
the presence of parasites and other infectious agents. The fish were fed with a commercial dry pellet
(Hokovit, Bützberg, Switzerland) with 1.5% body weight per day.
When the fish were six months old and had achieved an average weight of 50 g samples,
the fishes were split into two groups: a control group that received the commercial diet and a
17β-estradiol (E2)-exposed group that received the commercial diet enriched with 20 mg E2/kg
diet: this concentration was found to be sufficient to induce an estrogenic condition of juvenile trout in
previous studies [11]. The feeding with the E2-enriched diet lasted for five days; the feeding level was
1% body weight per day both in the control and in the E2-exposed groups.
4.1.2. Adult rainbow trout
Two-year-old rainbow trout of the breeding stock of the Centre for Fish and Wildlife Health were
maintained in 1500 L tanks under flow-through conditions and light/dark cycles of Berne, Switzerland
from September 2012 to January 2013. Water temperatures varied between 11 ◦C and 15 ◦C. The period
from September to January covered the reproductive cycle of the fish, form the onset of ovarian
maturation through the vitellogenic and spawning stage to the post-spawning stage (see Results).
The fish were fed with the commercial diet at 0.5% body weight/day.
4.2. Preparation of Samples and Immune Cell Isolation
Trout were euthanized in neutralized MS222, and liver, head kidney, spleen, ovary, and blood were
sampled. All procedures were carried out according to the Swiss legislation for animal experimentation
guidelines (Ethics Comitee Bern, approval date 31 August 2017, approval No. BE84/11). The blood
was taken from the caudal vein. In addition to the tissue sampling, leukocytes were prepared from
blood and head kidney. A thousand-fold dilution from blood or head kidney cell preparations was
used to count the number of leukocytes using a Neubauer chamber. Moreover, serum was collected
to determine plasma E2 concentrations by means of competitive enzyme-linked immunosorbent
assay (ELISA).
For the immune cell isolation from the head kidney, the tissue was mechanically disrupted
and passed through nylon nets with 250 μm and 125 μm nylon mesh, and the cells were collected
in L-15 medium (Gibco) containing 10 IU/mL heparin. For the immune cell preparation that was
isolated from the blood, the blood was diluted 10 times with L-15 medium containing 10 IU/mL
heparin. The resulting cell suspensions from blood or head kidney were layered onto a Ficoll solution
(Biochrom AG, Berlin, Germany) and were centrifuged at 400× g, 4 ◦C for 40 min. The immune cell
244
Int. J. Mol. Sci. 2018, 19, 932
fractions were collected in L-15 medium, washed repeatedly, and then adjusted to the appropriate
different concentrations.
4.3. RNA Extraction and Gene Expression Analysis
Isolated immune cells adjusted to 107 cells were stored in 1 mL of TRIzol reagent (Sigma-Aldrich,
St. Louis, MO, USA), homogenized. After adding 200 μL of bromochloropropane (Sigma-Aldrich, Buch,
Switzerland), cell sample was mixed and centrifuged at 10,000× g for 15 min at room temperature.
An aqueous phase of each cell sample was replaced by 500 μL of isopropanol and samples were
stored at −80 ◦C until use. Tissue samples (approximately 5 × 5 × 5 mm) were kept in RNAlater
(Sigma-Aldrich) at 4 ◦C overnight and were then stored −20 ◦C before use. Tissues were replaced
in TRIzol reagent and homogenized, followed by the phase separation with bromochloropropane.
The RNA precipitation with isopropanol and ethanol wash for both cell and tissue samples were
performed and the resulting RNA was dissolved in nuclease-free water. After the digestion of resting
DNA with RQ1 RNase-Free DNase (Promega AG, Dübendorf, Switzerland), 500 ng of RNA were
reverse-transcribed to cDNA using GoScriptTM reverse transcriptase containing random primers,
and dNTP as described in the manufacturer’s protocol (Promega AG) and total volume of cDNA
was adjust to 25 μL. The TaqMan®-based real-time RT-PCR was carried out in triplicate for each
sample mixture of total volume (12.5 μL) with 1 μL of cDNA template, 0.5 μM of each forward and
reverse primer, 0.2 μM of the probe and TaqMan® Gene Expression Master Mix (Applied Biosystems,
Foster City, CA, USA) using a 7500 Fast Real-time PCR System (Applied Biosystems). The used
primer and probe sequences were listed in Table 3. Expression of each ER isoform was calculated by
absolute quantification using each plasmid DNA that prepared with a pGEM-T Easy Vector System I
(for ERα1 with fwd: 5′-CGGCCCCTCTCTATTACTCC-3′, rev: 5′-TGTACGACTGCTGCCTATCG-3′,
for ERα2 with fwd: 5′-TGCTGGTGACAACAGTGTCC-3′, rev: 5′-GGCCCAACTGCTGACTAGAA-3′,
for ERβ1 with fwd: 5′-CAGCTACCGGGGTCATAAAC-3′, rev: 5′-ACAGGCACAGGTCCACAAAT-3′,
for ERβ2 with fwd: 5′-TCATTCCAGCAGCAGTCATC-3′, rev: 5′-CTGAGGTACACATCTCCCCTCT-3′),
and expressed mean of copy number per 1 μL cDNA ± standard error. In accordance with our
PCR-system, the detection limit of ERα1, α2, β1, and β2 was 1, 5, 10, and 1 copy/μL cDNA, respectively.
As an endogenous reference, 18S rRNA (Applied Biosystems, Foster City, CA, USA) was measured for
the quality check of reverse-transcription of each cDNA. The gene expression level of liver-vitellogenin
(VTG, Hamburg, Germany) [68] was utilized as an indicator for E2 response.
Table 3. Primer sequences used for the gene expression analysis and related accession numbers.

















4.4. In Situ Hybridization
Plasmid DNA of ERs (ERα1 with fwd: 5′-CTCTCCCCAGCCAGTCATAC-3′ and rev:
5′-CCTCCACCACCATTGAGACT-3′, ERβ1, and β2, as described above) was cloned in pGEM-T
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Easy Vector System I. Following digestion with NdeI and NcoI (Promega, Medison, MI, USA),
linearized plasmid DNA was transcribed with T7 and SP6 polymerases (Roche Diagnostics AG,
Rotkreuz, Switzerland), respectively, and labelled with digoxigenin (DIG) (Roche Diagnostics AG),
as described in the manufacturer’s protocol. Synthesized labelled probes were stored at −20 ◦C in
50/50 (v/v) nuclease-free water/formamide buffer before use.
Dissected organs, liver, and head kidney were placed immediately into cold Histochoice MB
(Electron Microscopy Sciences, Hatfield, PA, USA) and were fixed at 4 ◦C for 3 h. Fixed organs were
dehydrated in a graded ethanol series at 4 ◦C. For paraffin-embedding, the tissue were infiltrated
with Histoclear (National Diagnostic, Chemie Brunschwig, Lausanne, Switzerland) for 60 min at room
temperature, followed by Histoclear/Paraplast (50/50, v/v) for 60 min at 65 ◦C twice. After repeated
cleaning in 100% of Paraplast for 60 min at 65 ◦C, tissues were incubated in 100% of Paraplast for
overnight at 65 ◦C. The tissues were embedded in the fresh prepared Paraplast and stored at 4 ◦C
before sectioning.
Tissues were deparaffinised and washed in diethyl pyrocarbonate (DEPC)-treated water.
The acetylation of sections was performed in a buffer containing 100 mM of triethanolamine (pH 8.0)
and 0.25% of acetic anhydride by shaking for 10 min. After repeated washing, hybridization was
done using an antisense RNA- digoxigenin (DIG) probe in a hybridization buffer that was mixed
with 50% deionized formamide, 4 × saline-sodium citrate (SSC), 10% dextran sulfate, 1 × Denhardt’s
and 1 mg/mL ribonucleic acid from torula yeast for 16 h at 50 ◦C in a humid box. Sense RNA-DIG
probe was applied in the same hybridization buffer as negative control. For post-hybridization,
the slides were washed in tris-buffered saline with Tween20 (TTBS) (0.5 M NaCl, 0.1 M Tris-HCl
(pH 8.0), 0.1% Tween-20). Following blocking with 6% milk powder that was diluted in TTBS for
1 h and bovine serum albumin (BSA)-Triton X-100 buffer containing 0.1 M Tris-HCl (pH 7.5), 0.15 M
NaCl, 1% BSA and 0.3% Triton X-100 for 1 h, the specimens were incubated with a sheep anti-DIG
antibody-alkaline phosphatase (AP) (Roche Diagnostics AG, Basel, Switzerland) diluted to 1:500
in the BSA-Triton X-100 buffer for 2 h at room temperature. The slides were then washed in the
BSA-Triton X-100 buffer three times for 20 min. To equilibrate the slide, a buffer containing 0.1 M
Tris-HCl (pH 9.5), 0.05 M MgCl2 and 0.1 M NaCl was used for 15 min, then the nitro blue tetrazolium
(NBT)/5-bromo-4-chloro-3-indolyl-phosphate (BCIP) was applied on the slide for the development.
The reaction was stopped by Tris-EDTA (TE)-buffer containing 0.01 M Tris-HCl (pH 7.5) and 1 mM
EDTA (pH 8.0). For the head kidney, the same procedure as described for liver until post-hybridization
was done; then, an additional endogenous peroxidase-blocking step with 1% of hydrogen peroxide was
performed to account for the high endogenous alkaline phosphatase in the head kidney, Afterwards,
the visualization was done as follows: The sections were blocked using 5% normal donkey serum
(Jackson ImmunoResearch, West Grove, PA, USA) diluted in TTBS; this was followed by 30 min
incubation with a sheep anti-DIG antibody diluted to 1:1000 in TTBS. Then, the sections were incubated
with a donkey anti-sheep antibody (Jackson ImmunoResearch) diluted to 1:100 in TTBS, and after
repeated washing a sheep peroxidase anti-peroxidase (PAP) soluble complex diluted to 1:100 with
TTBS was applied. NBT-BCIP was used for visualization.
4.5. Competitive Enzyme-Linked Immunosorbent Assay (Celisa) to Determine 17β-Estradiol Concentrations
in Serum
The blood samples were centrifuged at 3000× g for 15 min at 4 ◦C. 200 μL of serum were diluted
in 300 μL of PBS (pH 7.4) and then extracted by adding 3 mL of diethyl ether, vortexing for 10 s 6 times,
and centrifuging at 1800× g for 10 min at 20 ◦C. After the samples were frozen at −80 ◦C for 20 min,
the organic phase was transferred into a new glass tube and were completely dried in a heat block at
30 ◦C for overnight prior to be resuspended in 200 μL of PBS.
A high binding ELISA-plate (Greiner bio-one, Frickenhausen, Germany) was coated with a mouse
anti-rabbit antibody (Sigma-Aldrich, 1:2000 diluted in PBS) for 24 h at 4 ◦C. After repeated washes with
PBST (0.05% Tween-20), the plate was blocked with 1% of BSA-PBST for 12 h at 4 ◦C. Fifty μl of the
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sample, 50 μL of the estradiol- horseradish peroxidase (HRP) (Cal Bioreagents, San Mateo, CA, USA,
1:10,000 diluted in PBS) and 50 μL of a rabbit anti-estradiol antibody (Cal Bioreagents, 1:2500 diluted
in PBS) were mixed and incubated for 2 h at room temperature. For the standard, first 17β-Estradiol
(Sigma-Aldrich) was dissolved in ethanol, and then the same volume of 17β-Estradiol instead of the
sample ranging from 0.36 to 40 ng/mL diluted in PBS was used. Following five washes with PBST for
5 min each, the ABTS® Peroxidase Substrate (Kirkegaard & Perry Laboratories, Maryland, USA) was
applied for the color development. The plate was measured at 405 nm by an EnSpire 2300 Multimode
Plate Reader (Perkin Elmer, Waltham, MA, USA).
4.6. Statistical Analysis
Normal distribution and homogeneity of variances of qRT-PCR data from control and
E2-treatment group (Figure 2A,B) were first individually estimated. For statistical analysis between
control and E2-treatment group within the same gene expression analysis, Student’s t-test or
Mann-Whitney’s U test were applied. Multiple comparisons between different maturation stages
were performed by Kruskal-Wallis test, followed by Sheffè multiple comparison test. Results were
considered statistically significant when p < 0.05.
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Abstract: Post-parturient behavior of mammalian females is essential for early parent–offspring
contact. After delivery, lambs need to ingest colostrum for obtaining the related immunological
protection, and early interactions between the mother and the lamb are crucial. Despite visual and
auditory cues, olfactory cues are decisive in lamb orientation to the mammary gland. In sheep,
the inguinal sinus is located bilaterally near the mammary gland as a skin pouch (IGS) that
presents a gland that secretes a strong-smelling wax. Sheep IGS gland functions have many aspects
under evaluation. The objective of the present study was to evaluate sheep IGS gland functional
aspects and mRNA transcription and the protein expression of several hormone receptors, such as
progesterone receptor (PGR), estrogen receptor 1 (ESR1), and 2 (ESR2) and prolactin receptor (PRLR)
present. In addition, another aim was to achieve information about IGS ultrastructure and chemical
compounds produced in this gland. All hormone receptors evaluated show expression in IGS during
the estrous cycle (follicular/luteal phases), pregnancy, and the post-partum period. IGS secretion is
rich in triterpenoids that totally differ from the surrounding skin. They might be essential substances
for the development of an olfactory preference of newborns to their mothers.
Keywords: inguinal sinus; morphology; transcription; ESR1; ESR2; PGR; PRLR; chemical
compounds; triterpenoids
1. Introduction
Shortly after birth, the mammalian neonate and its mother interact in order to favor
parent–offspring contact. Under evolutionary pressure to meet the needs of their neonates, selected
Int. J. Mol. Sci. 2017, 18, 1516; doi:10.3390/ijms18071516 www.mdpi.com/journal/ijms251
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behaviors of post-parturient females occur, with nursing patterns being very broad across species
concerning duration or frequency [1]. In fact, nursing patterns are different depending on the species.
The amount of parental nursing and milk investment determines not only the number of young
the parent can produce, but also affects the offspring’s fitness. As a an example, while penguins
are known to sacrifice their own health and wellbeing in exchange for the survival of their young,
Sprague–Dawley rats eject milk to feed their pups only when the mother is asleep and therefore
without any nursing care burden [2,3].
In eutherian mammals, the mammary gland suffers modifications due to the presence of a
prehensile nipple that facilitates the milk intake. The neonate, especially in a precocious mammal,
is highly aroused by the stimulatory process caused by birth and is tuned towards the sensory cues
that facilitate localization of the mother’s nipples. Since lambs are born with fully functional sensory
systems, they can use multisensory cues to find the teat. In addition, ewes lick their lambs after birth
and make a low-pitched moaning, which is an important behavior for the development of ewe–lamb
binding and directs the lamb towards the inguinal region. That area is wool-free and has a higher
temperature, eliciting lambs’ nosing and directing them towards IGS. When considering lambing,
the desired outcome is to have more lambs born alive and allowing them to get adequate colostrum so
they stay alive [4,5].
Newly born mammals have to reach the source of milk as promptly as possible to ensure
uninterrupted mother-to-offspring transfer of hydration and nutrients. Colostrum intake guards
against immediate exposure to micronutrients and antioxidants, passive immunization, innocuous
bacterial strains, growth factors, and a range of bioactive peptides that control conservative behavioral
function [4,5].
While some species give birth to altricial neonates, other species bear precocial or semiprecocial
newborns whose behavior is under the control of all their senses (e.g., ungulates, some rodents). We do
not fully understand how mammalian neonates perceive and analyze chemosignals and the olfactory
scene that is associated with the mammary structure. The fact is that, by staying alive, the majority
of them prove their competence to position themselves adequately from the very first exposure to
a nipple. Suckling is the most intimate form of contact with the maternal body, which strengthens
the relationship with the mother [6]. Besides maintaining the newborn’s warmth, nursing/suckling
interactions also facilitate olfactory learning in newborns, as long as suckling and the olfactory stimulus
temporally overlap [7].
Chemical communication plays a major role in mammalian behavior and starts by understanding
olfactory communication and acquiring knowledge on body sources of odors and the behaviors
associated with their deposition. This is the starting point for knowledge concerning putative
chemosignals. Some insights concerning the mechanisms used by the newborn for detection and
transduction of chemical stimuli are also needed. Odors refer to any chemical released by an individual,
that is potentially detectable by another individual, and a pheromone is an odor that elicits a predictable
and stereotypical behavior or physiological response, provides specific information, or modulates
responses in the receiving individual [8]. Some of those chemosignals are of skin and gland origin
(examples: the tarsal gland of the black-tailed deer, the inguinal and chin glands of rabbits for
individual identification, the preputial glands in mature male pigs, and submaxillary glands for
mating stance in estrus gilts) [9–11].
Across very different phylogenies, the mechanisms for pheromones and odor learning have much
in common. The medial amygdala appears to be involved in both the recognition of social odors
and their association with chemosensory information sensed by the vomeronasal system and sensory
neurons and GABAergic interneurons in the olfactory bulb, which are continuously replaced. In fact,
this contradicts the idea that neurogenesis is purely restorative in the adult stage since it develops the
necessary plasticity for induction and maintenance of learned chemosensory responses [12,13].
In the ungulate family (Caprinae, Cephalophinae, Antilopinae), circumscribed scent glands are
located bilaterally as pouches or pockets near the exterior base of the udder. Several morphological
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features that present a gland, such as the infraorbital sinus, the interdigital sinus, and the inguinal
sinus, characterize the genus Ovis aries. Therefore, we can find the inguinal sinus in the ram as well
as in the ewe. Different research groups have pointed out different responsibilities in the secretion of
these three different glands. In some cases, they function as trail glands, while in others they have a
role in the known “male effect”. By producing pheromones in the male, they elicit female reproductive
physiologic responses [14,15].
After giving birth, mothers position their bodies so that the neonate finds the mammary zone.
The suckling/nursing relationship becomes the core of their physiological and behavioral relationship
and involves the blocking of the estrous cycle, the stimulation of lactation, and the development
of a bond with repercussions for the future of the neonate, as this contact stimulates the mother’s
care and the infant’s willing to find the nipple and ingest milk. Since lambs are born with fully
functional sensory modalities, they can use multisensory cues to find the teat. In return, ewes lick
their lambs after birth and present low-pitched bleating, an important behavior for the development of
ewe–lamb attachment and direct the lamb towards the inguinal region, where areas free of wool have
a higher temperature, eliciting the lambs’ nosing and directing them towards IGS. When considering
lambing, the pressure is to have as many lambs born alive as possible and allow them to get adequate
colostrum so that they stay alive. The parental investment in producing a new young life (or two) per
reproductive cycle is very high and the behavior of the young and its likelihood to survive is under the
responsibility of its mother at the beginning of its life throughout lactation. This mother–young unit
is a major part of the welfare of the neonate and inadequate maternal care invariably leads to early
death [6,16].
In the literature, references to inguinal gland wax production describe a strong-smelling substance
that seems to activate udder-seeking behavior, in combination with vocal and tactile stimuli [17,18].
Records of respiration and heart rates demonstrated that non-suckling lambs respond to the smell of
mother’s inguinal sinus production in a more reactive way than the response found when odors of
wool or milk from an unfamiliar ewe are available. In addition, newborns can discriminate between the
smell of their mothers and that of an alien ewe and it was shown that when lambs are made anosmic by
applying lidocaine to their nostrils, localization of the teat was delayed [19–21]. Initiation of suckling
is dependent on variable blends of maternal “signature odors” that are learned and recognized prior to
first suckling. In rabbits, the pheromone responsible for initiating suckling has already been identified
and newborn mice require maternal olfactory or “signature odors” cues to start suckling since this
blend of volatile odors (not necessarily a classical pheromone) produced from the mother elicits the
behavior [22]. In sheep, maternal behavior (low-pitched bleats, licking, and nursing) is triggered by
changes of plasma progesterone and estradiol around parturition, and the release of oxytocin in the
brain [17]. Thus, the hypothesis we presented was that sheep IGS might play a role as a chemosensory
clue to the newborn lamb.
As IGS gland functions are in many aspects under evaluation, the objective of the present study
was to evaluate: (i) IGS morphology, histology and ultrastructure; (ii) mRNA transcription and protein
expression of progesterone (PGR), estrogen receptors 1 (ESR1) and 2 (ESR2) and prolactin receptor
(PRLR). Also, as these hormones show associations with sexual and nursing behavior in many aspects,
achieving information about putative changes in the chemical compounds produced in this body sinus
along the estrous cycle was also one of the goals.
2. Results
Near the mammary gland, one can observe by abduction of the hind limb the inguinal sinus
located bilaterally as pockets at the external base of this gland. When exposed, a yellowish substance
with a wax appearance seems to spread downward to the teats (Figure 1). The histology of the inguinal
sinus demonstrates invaginated skin presenting sebaceous and acinar glandular fields, with collagen
sheath fibers sustaining the secretory epithelium (Figure 2A–C). The acinar glands appear with different
patterns of secretion, from a resting phase to the development of huge cellular protrusions of apocrine
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secretions towards the glandular lumen (for example comparing Figure 2C,F,G,H). According to dye
affinities, the parenchyma is shown to be rich in glycogen (PAS; Figure 2E,F) and lipid granules
(Sudan Black stain, 2 G), and mucin content as well (Alcian blue-2H-I). Myoepithelial cells can be
depicted (Figure 2E). Secretion production appears with an uneven distribution in different areas of
the inguinal pouch and in different acinar units, as shown in different plates of Figure 2.
 
Figure 1. By abduction of the hind-left leg one can observe the skin pouch (IGS) over the mammary
gland. On the right, the arrow points out the IGS and its yellowish secretion.
 
Figure 2. Histology-Bar = 100 μm. Van Gieson’s Stain. (A) Organization of the inguinal sinus
presenting sebaceous (black arrows) and acinar glandular fields (white arrow); (B) collagen fibers
sustain the secretory epithelium of the acinar glands that presents; (C) cellular protrusions towards
the glandular lumen (apocrine secretion). Parenchyma rich in glycogen can be observed and its
amount varies in different areas of the gland being the secretory cells in different stages of secretion
production in different areas of the gland–PAS; (D–F); In (E) the arrow points out a myoepithelial
cell. (D) = 40× magnification; (E) = 1000×. Visualizations of lipid granules with Sudan black stain;
(G) Alcian blue stain depicts mucin content; (H,I) Magnification = 1000×.
Ultrastructural observations of scanning electronic microscopy (SEM) (Figure 3) showed that the
apocrine glandular units are of alveolar type but not tubuloalveolar and that these secretion units
appear in clusters (Figure 3A,B). Luminal surface secretion presents a paved appearance, with secretory
cells in diverse stages of differentiation (Figure 3C). In fact, some acini at different stages depict
fragments of secretion being “pinched off”, exhibiting secretory vesicles or secretion blebs (Figure 3D,E),
although cells preserve a clear demarcation with neighboring cells by means of rows of microvilli.
Apical end-pieces show a progressive filling process that upsurges as bulge-like structures. In other
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acini, cells appear to be in a transitional process where the clear demarcation with surrounding cells is
no longer as visible, resulting from the development of apical protrusions that in a final stage denote a
smooth plasma membrane devoid of microvilli and covering the protrusions (Figure 3F,H).
 
Figure 3. Scanning electronic images of IGS. In (A) (bar = 500 μm); (B) (bar = 50 μm) and
(C) (bar = 10 μm) it is clear that apocrine glandular structures appear in clusters inside the IGS. Luminal
surface can show a paved appearance; (D) bar = 10 μm or an irregular one resulting from the secretory
process. Secretory cells appear in different stages of differentiation, where fragments of secretion
are being “pinched off” exhibiting secretory vesicles (secretion blebs), while cells maintain a clear
demarcation with neighboring cells by means of rows of microvilli; (D) (bar = 10 μm); (E) (bar = 5 μm)
and (F) (bar = 5 μm). A progressive gland filling process results on the upsurge of bulge-like structure;
(G) (bar = 5 μm) and (H) (bar = 5 μm). Some cells appear to be in a transitional process where
demarcation with surrounding cells is no longer as visible resulting from the development of apical
protrusions that in a final stage denote a smooth plasma membrane devoid of microvilli and covering
the protrusions; (I) bar = 10 μm.
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According to specific primer sequences used for quantitative real-time PCR (reported in Section 4),
it was possible to show transcription of mRNA for ESR1, ESR2, PGR and PRLR during the follicular
and mid-luteal phase of the estrous cycle (Figure 4).
Figure 4. Qualitative PCR electrophoresis gel and dissociation curves of real-time PCR confirming
estrogen receptor 1 (ESR1), and 2 ESR2, progesterone receptor (PGR) and prolactin receptor (PRLR)
gene transcription in the IGS in different phase of the estrous cycle. Green arrow indicates the specific
gene band. (F) follicular phase; (ML) mid luteal phase; (M) DNA marker; bp (base pairs). All primers
validated for 80 nM in the real time PCR run. Single product confirmation with the single peak in the
dissociation curve.
Confocal scanning microscopy demonstrated immunoreactivity towards ESR1, ESR2, PGR and
PLRL receptors regardless of the estrous phase or the differentiation of acini cells concerning secretion
process. Evidence was found of non-nuclear estrogen receptor and PGR in a clear border basilar
position (Figure 5).
Flow cytometry analysis of cell suspensions showed cells with distinct auto fluorescence levels
and different behavior towards ESR1, ESR2, PRLR and PGR); (Figure 6). Along with the different
estrous cycle phases studied, PRLR and ESR2 positive cell populations showed always a higher
fluorescence intensity compared to PGR and ESR1 positive cells (p < 0.05). At pregnancy, PRLR also
showed a higher expression (p < 0.01) in comparison with other fluorescence intensities.
Thin-layer chromatography was performed on the available set of samples (n = 28), applied
semi-quantitatively. The conditions allowed for the identification of a chromatographic profile
(retention factor, fluorescence) characteristic of the presence of triterpenoids, with three major bands
(Figure 7, compounds 1–3) in post-partum ewes (PP), non-pregnant (NP), and pregnant ewes IGS
(P). The relative intensities of these three bands in these groups of samples made it possible to infer
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the existence of a higher relative content of these triterpenoids in P samples, as also demonstrated in
Supplementary Data.
 
Figure 5. Examples of laser-scanning confocal fluorescence (LSC—lens 63.03 oil) images of IGS. One can
observe immunoreactivity towards ESR1, ESR2, PGR and PRLR in cells of the apocrine glands labeled
with PE and stained for the different receptors (fluorescence in green). Use of To-Pro-3 iodide for
nuclear counterstaining (fluorescence in red).
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Figure 6. Flow cytometry analysis of gated cells of IGS. Examples of gated and dot plots and histograms
showing the expression of ESR1, ESR2, PLRL and PGR. Shown flow cytometry data depict a positive
cell expression towards the receptors under evaluation.
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Figure 7. Chromatogram analysis revealed the presence of triterpenoids as marker chemical classes of
post-partum ewes (PP), pregnant ewes (P) and non-pregnant (NP) samples, and a chemical profile that
clearly portrait three major bands: 1, 2 and 3. These compounds were absent on S, the surrounding
skin sample used as a negative control. The background color of the chromatogram is not uniform,
which is a normal and recognized situation and does not interfere with the interpretation of the results.
3. Discussion
Several studies suggest that mammalian species have evolved multiple strategies to release
olfactory signals to their offspring and ensure the onset of suckling as a critical behavior [23].
These tactics can be a pheromone-mediated behavior, or a reply to signature odors. Both appear
to elicit innate behavior [22]. In the domestic pig, for example, after washing the sow’s abdomen with
organic solvents, the piglets lost teat localization [24]. As reported, mammalian females are known to
use odor cues to control infant state, attention and directional responses, to delay distress responses,
to stimulate breathing and positive oral actions, and finally they can boost learning. Female–offspring
odor communication in European rabbits and humans is representatives of evolutionary extremes in
terms of the structure and dynamics of mother–infant relationships, and levels of neonatal autonomy.
In fact, both species have evolved mammary structures and chemosignal sources under greasy
fixatives [24]. These features confer on them a chemo-communicative function and promote the
success of the offspring’s approach and exploration of the maternal body surface, resulting in effective
initial feeds and rapid learning of maternal identity [25]. In women, for example, the literature
reports several volatile compounds in the nipple/areola region during pregnancy and after childbirth
that are not present in other phases [26]. Human neonatal reactivity to these areolar odors tested
against several reference stimuli (e.g., human milk or sebum, solvent, vanilla, fresh cow’s milk,
cow’s-milk-based formula) showed that pure Montgomery gland secretion elicits more orofacial
activity. Nevertheless, further investigation is necessary to pin down the volatile compounds that can
then be evaluated under the nose of human newborns in repeatable bioassays. So far, no evidence
for any chemo-stimulus that would qualify as a pheromone is at hand in primates, including human
mother-to-infant communication [23,27].
Lactating rabbits emit in their milk a volatile aldehyde, 2-methylbut-2-enal, that provokes
searching and grasping behaviors in neonates [28,29]; newborn rabbits’ survival depends on the
perception of this odor signal emitted from the mother’s ventrum area that allows them to locate the
mother’s nipples and suckle. Emission of nipple pheromones in the rabbit is induced during pregnancy
by the combined action of estrogen and progesterone [11,30].
It was recently demonstrated that peripheral olfactory neurogenesis driven by estrogen occurs
in the vomeronasal organ. A fraction of those cells are able to extend their dendrites to contact the
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vomeronasal lumen and detect proteins that show pheromone activity, while concomitant differences
in gene expression in the vomeronasal transcriptomes of pregnant female mice also occur [11].
In sheep, endocrine changes at parturition, together with interactions with the newborn, modulate cell
proliferation and neurogenesis in the sub-ventricular zone, the main olfactory bulb, and the dentate
gyrus. Also at parturition, with or without interactions with the lamb for two days, a downregulation of
the number of newly born cells in those neurological areas occurs in comparison to non-pregnant sheep.
Therefore, in sheep it was postulated that the downregulation of cell proliferation observed in the early
post-partum period could facilitate the olfactory perceptual and memory demands associated with
maternal behavior, by favoring the survival and integration of neurons born earlier [31]. This situation
contrasts with the occurrence of peripheral olfactory neurogenesis driven by estrogen and prolactin,
which induce an increase in neural progenitors in the sub-ventricular zone of the lateral ventricle of
the brain in other species [13]. A huge field of possibilities must be tested since these facts suggest the
likelihood that lamb post-partum survival might depend on an olfactory perception fulfilled by the
production of substances present in the IGS of the mother.
A common factor that characterizes most post-partum lamb deaths is the disturbance of bond
formation between ewes and their offspring [32]. The glandular area near the mammary gland
produces a substance with a yellowish aspect that spreads down the teats. This glandular substrate
can dislodge itself while the animal walks or licks the area, making lambs reactive when exposed to
it by means of directional movements of the head resulting in an increase in respiratory and cardiac
rates [33]. Moreover, the odor of the IGS secretion elicits a more major response than the odor of wool
or milk. It should be underlined that the maternal “wax production” by the IGS is more reactogenic
than a similar product from an alien ewe. Moreover, newly born lambs showed a reaction to ovine milk
odor even if impregnated in a cloth, a situation that did not occur when a scentless and humid cloth
was used instead, and it was shown that when lambs are made anosmic by having lidocaine applied
to their nostrils, localization of the teat was delayed [1]. Altogether, data from different researchers
call attention to IGS production as a potential candidate for a strong scent effect. Although no studies
have pointed out the exact constitutive compounds of IGS, our data have shown that when comparing
IGS secretions it is clear that they show differences compared to the surrounding skin secretions and
change from early motherhood. Although it was outside the scope of this work, by looking at the
possible neurogenesis associated with olfactory neurogenic repercussion of this IGS secreted substance
or how this complex material will behave under down/upregulation of steroid hormones or prolactin,
we gained an overall picture of the complexity of the mechanisms involved, considering the putative
hormonal influence in olfactory signaling . As a unique feature, not present in the majority of other
animals, evaluation of IGS and its production in our work aimed to find out their particularities with
respect to normal skin and the nature of this substance in different reproductive phases of the ewe
life cycle (estrous cycle, pregnancy and post-partum). The differences we have found might have an
impact on sheep herd management.
Thin-layer chromatography (TLC) is a method for the chemical screening of compounds,
considered one of the first steps to establishment of the chemical profile of a sample. The thin-layer
chromatography conditions used allowed us to identify a chromatographic profile characteristic of
triterpenoids [34] present on PP, NP and P. The relative intensities of these three bands on these
groups of samples made it possible to infer the existence of a higher relative content of these
triterpenoids in P samples. This technique was applied semi-quantitatively to the available samples.
It is expected that after structural identification of the three detectable marker compounds, they will be
quantified by means of a suitable method specifically validated for that purpose. Nevertheless, the NP
group’s lowest relative content on these compounds calls attention to their putative involvement in
chemo-communication and, as mentioned, further studies will be carried out in order to confirm the
involvement of those triterpenoids in the development of an olfactory preference of the newborn lambs
towards the mother’s mammary gland.
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In sheep and goats the beginning of maternal behavior at parturition is under the control
of hormonal changes and fetus expulsion [35,36]. Thus, our interest concerning the presence of
progesterone, estrogens, and prolactin receptors in IGS in the ewe is justified beyond a down- or
upregulation involved in peripheral olfactory neurogenesis, previously discussed. Prolactin (PRL)
is a versatile hormone in mammals with effects in reproductive, sexual, metabolic, and immune
functions, among others [37]. The distribution of PRLR and the awareness of several extra-pituitary
PRL-expressing tissues, has called attention to the range of PRL actions beyond mammary gland
function [38–40]. Rabbit maternal behavior consists of building an underlayer of fur during late
pregnancy and displaying, with circadian periodicity, a single 3-min nursing bout/day across lactation.
It is synthesized in multiple tissues and its biological actions are not limited solely to reproduction,
as it has been shown to control a variety of behaviors [41]. Synthesis of female-attracting pheromones
in amphibians is regulated by prolactin (PRL) and the responsiveness of the female vomeronasal
epithelium is enhanced by PRL and estrogen [42]. Estrogen, androgen, progesterone, and prolactin
regulate specific aspects of nest-building and promote the onset of maternal responsiveness. However,
the maintenance of this behavior relies on stimuli from the litter. By preventing mother/young contact
at parturition or during early lactation, maternal responsiveness changes or became abolished. In the
rabbit, brain areas controlling the expression of nest- building and nursing were under investigation
by implanting estradiol and locating the distribution of estrogen and prolactin receptors in the
forebrain [43]. That work showed that ESR1 present in the preoptic region may mediate the stimulation
of nest-building by estradiol and that prolactin-binding sites, located mainly in periventricular
structures, are more abundant in late pregnancy and early lactation [34]. Moreover, in the rabbit,
scent emission is responsible for nipple search and is depressed following ovariectomy but further
stimulated by estradiol administration [43].
These aspects legitimate our findings of ESR1 and ESR2 receptors in the IGS, as these estrogen
receptors might be involved in the process of signaling pathways that may regulate conspecific
chemical messages attributed to IGS as binding steroid hormones to specific receptors. Therefore,
generating changes in the rates of nucleic acids and proteins synthesis might result in chemosensation.
We should underline that there are subtypes of cytoplasmic estrogen receptors, as they perform their
biological actions in the cytosol at a fast rate to be compatible with transcriptional mechanisms [44–52].
The canonical model for ER-mediated regulation of gene expression involves the direct binding of
dimeric ER to DNA sequences known as estrogen response elements, which are specific and inverted
palindromic sequences [53]. ER can associate indirectly with promoters through protein–protein
interactions with other DNA-binding transcription factors and interaction of ERs with E2 leads to
transcriptional activation of the associated genes via the recruitment of coactivators and components
of the basal transcriptional machinery [54,55]. The “genomic action” of steroid hormones occurs after a
time lag of at least 2 h after E2 stimulation and explains some of the hormone functions in physiological
and pathological situations. However, some effects are too rapid to account for genomic action [56].
In fact, cytosol receptors can be turned on and off, suggesting different roles in physiological functions
and pathogenesis [51,52]. These findings point out the evidence for an important role of the non-nuclear
estrogen receptor in a fast non-transcriptional response of cells to estrogen. The way they contribute to
the signaling of the mammary gland has been ascertained and already demonstrated in the interdigital
sinus of the ewe as well [57].
In the present study, we demonstrated that the IGS appears as an invaginated skin fold presenting
sebaceous and acinar glandular areas sustained by collagen sheath fibers. Since the apocrine unit is
alveolar, but not tubuloalveolar, the spread of the wax is probably a result of the compression of the
medial face of the hind limb against the upper area of the mammary gland where the IGS is located.
In addition, myoepithelial cells contribute to the expelling of the apocrine secretion toward the lumen
of the acinar units. Acinar cells present lipid granules, which we should link with the greasy aspect of
the IGS production. Mucin content is present and seen in the matrix. It might eventually contribute to
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the capacity to resist proteolysis to maintain the “scent” production characteristics of this gland for a
longer period.
According to our data, we can pinpoint the same acini cells where exocytosis of the glandular
content release occurs via a mechanism of non-protrusion [58–60]. In addition, a process of gradual
accumulation of secretory products that form balloon-like swellings protruding into the lumen was
also depicted [61]. In accordance with the presence of a mixed population of epithelial cells in the acini,
a dual pattern secretion can result in the same alveolar unit, as demonstrated in the sweat glands of
Karagouniko sheep [62], although the signaling pathway that triggers vesicular sorting in still under
discussion [60–63]. The parenchyma is rich in glycogen, whose amount varies in different areas of
the gland.
PRL simultaneously embraces a high diversity of physiological actions beyond mammary gland
development or milk production. It is synthesized in multiple tissues and its biological actions are
not limited solely to reproduction, as it has been shown to control a variety of behaviors [41,42].
This hormone appears in the background of pathological skin conditions and skin derivatives such as
disruption of time regulation of hair growth cycles in mice [64,65], alopecia, and psoriasis [40].
Indeed, this fact raises questions about the primitive function of PRL. This would explain
its maintenance during pre-mammalian evolution, as some of those functions attributed to
PRL are associated with the post-mating phase of reproductive cycles in different reproductive
strategies. These fit with seasonal gonadal suppression or behavioral changes, such as inhibition
of aggression [66,67]. Seeing as the integument and its appendages (feathers, hair, glands, and the
mammary gland itself) are the focal point of numerous PRL actions, even in non-mammalian
vertebrates [40,68–71], and as it has already been revealed that PRL controls lobule-alveolar
proliferation and differentiation of secretory epithelium [72,73], it is important to find its receptor’s
presence in the IGS. Moreover, since PRL shares the signal transduction pathway used by a variety
of cytokines and growth factors [74,75], this hormone might therefore be important in signaling the
onset of lactation for lambs. Epithelial growth is known to result from combined effects of P4 and PRL,
both triggering a juxtacrine RANKL signal, which induces alveolar growth [76–80]. The simultaneous
presence of PGR and PRLR in the inguinal sinus gland can also suggest the role of PG and PRL in IGS
function in sheep. Synthesis of female-attracting pheromones in some species is regulated by prolactin
(PRL) and responsiveness of the female vomeronasal epithelium is enhanced by PRL and estrogen [42].
Overall, the evaluation of the chosen receptors under research in our study seems to be of interest since
these receptors are needed for the related hormone action, which may work together in the putative
mechanisms involved in IGS function.
Data found in the present work agree with previous reports and contribute to the body of
knowledge. At this point, it is not possible to state that there is a direct cause/effect action between
plasma E2, P4 and prolactin on IGS function. Nevertheless, the receptors of these hormones found in
IGS present variations in the different phases of the estrous cycle and pregnancy. Thus, we do suggest
the involvement of those hormones in IGS function in ewes. Their presence constitutes a hallmark and
an important point to start to manipulate responses [81]. Further studies investigating these hormones’
regulation will be mandatory since estrogen and prolactin up- or downregulation behave differently
among species when considering the generation of neural progenitors in the brain, as mentioned
earlier. By widening this field of research, which will contribute to an understanding and further
development of odor-specific products, we may be able to promote newborn lambs’ survival.
4. Materials and Methods
For the present work, IGS (n = 92) were collected post mortem from adult merino ewes for different
evaluations, as described below. As the reproductive history of the ewes was unknown, their estrous
cycle phases were determined based on ovarian structures and plasma progesterone (P4) concentrations.
Therefore, when a pre-ovulatory follicle was present in the ovary, in the absence of a corpus luteum
(CL), and plasma P4 concentration was below 1 ng/mL, the ewes were considered as being in the
262
Int. J. Mol. Sci. 2017, 18, 1516
follicular phase. Nevertheless, the presence of a CL in the ovary, and plasma P4 concentration above
1 ng/mL, indicated the ewe was in the luteal phase. Right after collection, IGS samples were immersed
in (i) RNAlater (AM7020, Ambion, Applied Biosystems, Carlsbad, CA, USA) for mRNA transcription
quantification; (ii) 4% buffered formaldehyde, for histology, immunohistochemistry, and confocal
microscopy; (iii) Karnovsky’s solution for ultrastructure studies; or (iv) a sterile tube with RPMI
1640 (Gibco-Brl, Gaithersburg, MD, USA) for flow cytometry studies. In addition, the contents of
IGS were collected into sterile tubes for biochemical quantifications. Blood samples were drawn into
heparinized tubes at the time of exsanguination (MonovettesVR-Sarstedt, Numbrecht, Germany) for
further estrous cycle confirmation. Furthermore, from 28 sheep (n = 8 from follicular phase, n = 10
pregnant, and n = 10 post-partum period (1–3 days after delivery)), the content of IGS obtained post
mortem as a byproduct from animals used for other research purposes was collected to evaluate
putative variations in secretions.
Competent veterinary authorities monitored the experiments. The ethical committee of the Faculty
of Veterinary Medicine (Lisbon, Portugal) approved these. Several authors are holders of Federation
of European Laboratory Animal Science Associations (FELASA) grade C certificate, which permits
designing and conducting laboratory animal experimentation in the European Union.
4.1. Histology Evaluation
Ovine IGS samples (follicular phase, n = 5; luteal phase, n = 5) were cut into small pieces, fixed in
buffered formaldehyde for 24 h, and processed for light microscopic study. Tissue serial sections were
cut (5 mM thick—Microtome Leica SM2000R, Berlin, Germany) and stained with Weigert Van Gieson
for collagen detection, Periodic Acid Schiff to assess glycogen content, Alcian Blue for mucin detection,
and Black Sudan for detection of lipid production [82].
4.2. Scanning Electron Microscopy
Scanning electron microscopy (SEM) evaluation of intact IGS tissue (follicular phase, n = 5;
luteal phase, n = 5) was performed. Immersion of the intact IGS tissue in Karnovsky’s solution
(Sigma-Aldrich, Lisboa, Portugal), rinsed in cacodylate buffer, and post-fixed in a 2% osmium tetroxide
solution for 1h. Rinsed once again with cacodylate buffer and subsequently dehydrated in a graded
ethanol series. Samples dried using the critical point drying method and coated with gold palladium.
IS were mounted on stubs, observed in a scanning electronic microscope (JEOL 5200-LV, Tokyo, Japan),
and photographed.
4.3. Flow Cytometry Analysis
Flow cytometry analysis of IGS was carried out to quantify the expression of ESR1, ESR2, PGR
and PRLR proteins. Ewe IGS (estrus n = 14; diestrus n = 14) were removed with a surgical blade
and collected in a sterile tube with 1 mL of RPMI 1640 (Gibco-Brl). After disaggregation of the tissue
with a surgical blade, samples of whole IGS were centrifuged at 190 g for 10 min. Then, they were
resuspended in phosphate-buffered saline solution (PBS-P3813 Sigma). Fixation and permeabilization
of cell suspensions with FIX & PERM VR-Fixation and Permeabilization Kit (Invitrogen Laboratories,
Life Technologies, Waltham, MA, USA) were performed for 15 min longer in the dark at room
temperature. After a final washing step, the pellet was suspended once again in 500 mL of BD
FACS Flow for no longer than 15 min in the dark, at room temperature. After a new washing and
centrifugation step, RPE-conjugated secondary antibody (10 mL) was added and cells were incubated
15 min longer in the dark at room temperature. A final washing step was necessary, and the resulting
pellet was suspended once again in 500 μL of BD FACS Flow (BD Biosciences, San Jose, CA, USA).
Cell acquisition was performed on a BD FACS Calibur flow cytometer (BD Biosciences) and data were
analyzed using Paint-A-Gate Pro and Cell-Quest Pro software (BD Biosciences). In each experiment,
incubation of cells was done according to the above protocol but with the secondary antibody only.
This control tube was performed in order to assess the level of unspecific fluorescence signal of the
263
Int. J. Mol. Sci. 2017, 18, 1516
secondary antibody. Selection of primary antibodies’ dilutions was as follows: 1. Mouse monoclonal
anti progesterone receptor (77201704 AbD Serotec, Kidlington, UK), diluted at 1:10 in PBS; 2. Mouse
anti-human monoclonal antibody ESR1 (ref. 41700, Invitrogen, Dorset, UK), diluted at 1:10 in PBS;
3. Mouse anti-human polyclonal ESR2 (MCA2279S, AbD Serotec), diluted at 1:10 in PBS, 4. Mouse
monoclonal (U5) to prolactin receptor (abcam 2772, Cambridge, UK), diluted at 1:10 in PBS. The
secondary antibody used was R-phycoerythrin F(ab’)2 frag. of goat anti-mouse (F2653 Sigma).
4.4. Laser-Scanning Confocal Microscopy
The locations of ESR1, ESR2, PGR and PRLR protein in IGS were assessed using laser-scanning
confocal microscopy (Leica TCS SP2, Leica Microsystems; Berlin, Germany). The same antibodies
used in flow cytometry evaluation were employed in this study (n = 6). Incubation of antibodies was
performed overnight with the following dilutions: (1) Mouse monoclonal anti-progesterone receptor
diluted at 1:50; (2) estrogen receptor (ESR1) diluted at 1:50 and rabbit anti-human estrogen receptor
(ESR2) diluted at 1:50. Again, the FIX & PERM VR Fixation and Permeabilization Kit (Invitrogen
Laboratories, Life Technologies, Waltham, MA, USA) was used. Briefly, reagent A was added for
no longer than 15 min in the dark at room temperature before the addition of the primary antibody,
which was incubated for an hour. For another 15 min, solution B was added followed by the addition
of the second antibody.
To-Pro-3 iodide 1 mM solution (Invitrogen Molecular Probes, Eugene, OR, USA) was used for
nuclear counterstaining. Negative controls were performed by replacing the primary antibody with
either rabbit polyclonal IgG (ab27478, Abcam), for antibodies developed in a rabbit, or mouse IgG
(550878, BD Biosciences, San Jose, CA, USA) for antibodies developed in a mouse, with the same
dilution and incubation times as the primary antibody, followed by To-Pro-3 iodide for nuclear
counterstaining. Selected sections were photographed with confocal laser microscopy, Leica TCS SP2.
4.5. Genomic Analysis
Conventional polymerase chain reaction (PCR) was used to assess mRNA gene expression of
PGR, ESR1, ESR1 and PRLR in sheep’s inguinal glands (follicular phase, n = 5; luteal phase, n = 5)
Specific primers for PGR, ESR1, ESR2 and PRLR were designed (Table 1), as follows:
Table 1. Specific primers were designed—sequences used for quantitative real-time PCR (bp = base
pair).
Gene (Acession Number) Sequence 5′–3′ Amplicon (Base Pairs)
ESR1
(XM_015097472.1)












Forward: GTCTCCACCCACCCTGACTG (320 bp)
Reverse: AAGCCACTGCCCAGACCATA
RNA was extracted from IGS tissue (Qiagen’s Kit for Total RNA Extraction and Purification;
ref. 28704, Qiagen, Hilden, Germany) and DNA digested (RNase-free DNase Set; ref. 50979254,
Qiagen), according to the manufacturer’s instructions. By the use of a spectrophotometer, RNA
concentration was determined (260 and 280 nm) and RNA quality assessed by visualization of 28S
and 18S rRNA bands, after electrophoresis through a 1.5% gel agarose and ethidium bromide staining.
Reverse transcription was carried out using Reverse Transcriptase Superscript III enzyme (ref. 18080093,
Invitrogene, Gibco, Carlsbad, CA, USA), from 1 mg total RNA in a 20 mL reaction volume, using oligo
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(dT) primer (27–7858-01, GE Healthcare, Buckinghamshire, UK). Different Internet-based interfaces,
such as Primer-3 (Untergasser et al. 2012) and Primer Premier Software (Premier Biosoft Int., Palo Alto,
CA, USA) were used for specific primers for target genes. Several conventional PCR reactions were
carried out using a default thermocycler (Applied Biosystems, Foster City, CA, USA) as follows:
2 min at 94 ◦C for denaturation; 35 cycles of 15 s at 94 ◦C for enzyme activation, 45 s at 57–60 ◦C
for annealing (depending on the gene-PGR-57.8 ◦C; ESR2-58.5 ◦C and ESR1-60 ◦C) and 45 s at 68 ◦C for
extension; and 5 min at 68 ◦C for finalization. The design of all primers for two different exons followed
specific guidelines in order to avoid genomic DNA amplification (www.qiagen.com). All reactions
were carried out in duplicate in 0.2-mL PCR tubes (PCR-0.2-C, Axygen 321-02-051, Corning, CA, USA)
in a 25 μL reaction volume: 8.5 μL water; 1 μL forward primer (10 pmol/μL); 1 μL reverse primer
(10 pmol/μL); 12.5 μL using FideliTaq DNA polymerase master mix (71180, USB, Cleveland, OH, USA),
and 2 μL of cDNA. All Agarose (2%) (BIO-41025, Bioline, Luckenwalde, Germany) electrophoresis gel
and ethidium bromide (17896, Thermo, Waltham, MA, USA) staining showed a specific and single
product. For dissociation curve analysis, cDNA was amplified with real-time PCR, as describe before.
All primers were validated and used at 80 nM.
4.6. Progesterone Analysis
Evaluation of progesterone concentration was in plasma using a solid-phase radioimmunoassay
(Coat-a-Count Progesterone, Diagnostic Product Corp., Los Angeles, CA, USA). Intra-assay coefficient
was 6.4% for the level of 3.2 nmol/L (1 ng/mL) and 4.2% for the level of 15.9 nmol/L (5 ng/mL).
4.7. Chemical Studies
The total content of the inguinal sinus was collected from non-pregnant (NP), pregnant (P),
and post-parturient (PP) ewes (n = 28) and extracted with ethyl acetate using an ultrasonic bath
(1 mg/mL; 5 min). The total content of the inguinal sinus was collected from non-pregnant (NP),
pregnant (P) and post parturient (PP) ewes (n = 28) and extracted with ethyl acetate using an
ultrasonic bath (1 mg/mL; 5min). After, centrifugation (2000 rpm/15min), the supernatant was
evaporated to dryness under vacuum at a temperature below 40 ◦C. The obtained residue was
dissolved in ethyl acetate (1 mL) and then analyzed by thin layer chromatography (TLC) using
different chromatographic and derivatization systems, including silica gel F254 Merck as stationary
phase, and toluene: ethyl acetate (9:1 v/v) as mobile phase and Liebermann and Dragendorff as
spraying reagents [83]. After derivatization, visible and UV light at 365 nm used for data acquisition.
Samples of the surrounding skin prepared in the same way used as negative control.
4.8. Statistical Analysis
Flow cytometry data of ERSR1, ESR2, PRLR, and PGR proteins in IGS from ewes in the follicular,
luteal, pregnancy, and post-partum phases, were subjected to a one-way analysis of variance (ANOVA).
Significance was defined as values of p < 0.05. For statistically different results, the means were further
analyzed by post hoc comparison test, such as LSD (least significant differences) and Scheffé tests
(probabilities for post hoc tests).
5. Conclusions
Our data, to the best of our knowledge, have not been reported elsewhere. These findings concern
the expression of steroid hormones and prolactin receptors in sheep IGS and point out that a particular
triterpenoid-rich secretion and organic nitrogen compounds that totally differ from the surrounding
skin are present in IGS. These secretions show modifications, particularly during pregnancy and
post-partum. Altogether, IGS secretion in the ewe might contribute to the putative involvement of this
gland in the signaling cues that direct the lamb to the mammary gland.
Since impairment of bond formation between ewes and their offspring is a common cause of
offspring death, this research will potentially benefit farmers by contributing to the increased survival
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of lambs due to understanding and using these odor products. As stated, IGS fluctuations in the
expression of ERS1, ERS2, PGR, and PRLR are present and might be linked to putative chemosignals.
Further research by our team will give rise to new data regarding a direct hormonal cause/effect
on IGS, in agreement with other researchers who claim to have achieved methods of manipulating
reproduction in domestic ungulates by using specific odors.
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Abstract: Comprehension of compound interactions in mixtures is of increasing interest to scientists,
especially from a perspective of mixture risk assessment. However, most of conducted studies have
been dedicated to the effects on gonads, while only few of them were. interested in the effects on
the central nervous system which is a known target for estrogenic compounds. In the present study,
the effects of estradiol (E2), a natural estrogen, and genistein (GEN), a phyto-estrogen, on the brain
ER-regulated cyp19a1b gene in radial glial cells were investigated alone and in mixtures. For that,
zebrafish-specific in vitro and in vivo bioassays were used. In U251-MG transactivation assays,
E2 and GEN produced antagonistic effects at low mixture concentrations. In the cyp19a1b-GFP
transgenic zebrafish, this antagonism was observed at all ratios and all concentrations of mixtures,
confirming the in vitro effects. In the present study, we confirm (i) that our in vitro and in vivo
biological models are valuable complementary tools to assess the estrogenic potency of chemicals
both alone and in mixtures; (ii) the usefulness of the ray design approach combined with the
concentration-addition modeling to highlight interactions between mixture components.
Keywords: estradiol; genistein; mixture; aromatase B; transgenic zebrafish; U251-MG
1. Introduction
Compounds able to interact with the estrogen receptors (ER) have been extensively studied over
the years due to the threat they represent to aquatic species and particularly to fish reproduction and
development [1,2]. However, in the aquatic environment, fish are often exposed not only to estrogenic
chemicals alone but rather to mixtures, highlighting the constant need to understand compound
interactions in mixtures and to develop new assays and approaches to this end.
Several studies have evaluated the combined effects of estrogenic compounds on aquatic
organisms [3–12], generally concluding on an additive effect in mixtures both in vivo and in vitro.
However, most in vivo studies addressed the effects of mixtures of estrogenic compounds on gonads
and other peripheral organs, while only few of them studied effects on the central nervous system
despite increasing evidences that estrogenic compounds interfere in neuroendocrine regulations.
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In fish, the cyp19a1b gene encodes the brain aromatase. In zebrafish, cyp19a1b is expressed in
radial glial cells of the brain which are crucial neuronal progenitors [13,14]. Estrogenic compounds
are known to highly up-regulate cyp19a1b gene expression by an ER-dependent mechanism [3,15].
By using zebrafish-specific in vitro and in vivo bioassays based on the cyp19a1b gene coupled to
a complete modeling approach, we recently demonstrated additive effects of ethynilestradiol and
levonorgestrel, a pro-estrogenic compound, on cyp19a1b gene in glial cells [12].
In this context, the present study aimed to investigate the effects of single and combined exposure
to two estrogens with different estrogenic potencies, on the expression of the zebrafish cyp19a1b gene.
For this purpose, two in vitro and in vivo bioassays based on the zebrafish cyp19a1b gene were used:
(i) an ER-negative human glial cell culture (U251-MG) co-transfected with two different zebrafish
ER subtypes (zfERα and zfERβ2) and a luciferase gene under the control of the zebrafish cyp19a1b
promoter [16] and (ii) a transgenic zebrafish (cyp19a1b-GFP) line expressing GFP under the control of the
zebrafish cyp19a1b promoter which is used to evaluate estrogenicity of chemicals at the embryo-larval
stage [3,6]. Mixtures assessed were composed of a natural potent estrogen, i.e., 17β-estradiol (E2), and a
weaker estrogen, i.e., genistein (GEN), a major phytoestrogen of the isoflavone class. GEN, a human
ERβ selective activator, was shown to be estrogenic in diverse in vitro and in vivo assays (for review
see [17]), including in the U251-MG and in transgenic cyp19a1b-GFP zebrafish bioassays [3,16]. In the
end, this comparative in vitro and in vivo approach was used to (i) determine the potential interactions
between E2 and GEN in mixtures and (ii) evaluate the complementarity of the in vitro and in vivo
models used in these experiments. The concentration-addition (CA) model for mixtures was used
as the reference no-interaction model. Deviations from the CA model were quantified in terms of
antagonism or synergism by using Jonker et al. interaction models [18] and their statistical significance
was tested. Thereby, the present study reports antagonistic effects of E2 and GEN in mixtures on the
expression of the ER-regulated gene cyp19a1b in a glial cell context.
2. Results
2.1. In Vitro Effects of Single Test Compounds
The effects of E2 and GEN alone were assessed in U251-MG glial cells co-transfected with zfERs
and the zf-cyp19a1b promoter-luciferase reporter. One concentration-response experiment was carried out
for each compound and each ER with three replicate wells for each condition. Luciferase activity was
induced by E2 treatment in a concentration-dependent manner (Supplementary Figure S1). The EC50s
(median effective concentration) were estimated at 1.86 × 10−10 M for ERα and 1.18 × 10−10 M for ERβ2.
EC50s for GEN were estimated at 5.05 × 10−8 M for ERα and 2.96 × 10−9 M for ERβ2.
2.2. In Vitro Effects of Binary Mixtures of E2 and GEN
To confirm EC50s previously obtained in single test compound experiments, EC50s for E2 and
GEN were also estimated from mixture experiments. EC50s for E2 were 4.29 × 10−11 and
1.38 × 10−11 M for U251-MG glial cells transfected with ERα and ERβ2 respectively. For GEN,
EC50s were 1.68 × 10−8 and 4.78 × 10−9 M for U251-MG glial cells transfected with ERα and
ERβ2 respectively. The U251-MG cells were slightly more sensitive to estradiol in the mixture
experiments (EC50s were 2 to ten-fold lower than in the single compound experiments), but the relative
potency on ERα was relatively unchanged (1.5 factor) and the relative potency on ERβ2 changed over
ten-fold, so that in the mixture experiment the relative potencies were the same on ERα and ERβ2.
In vitro, a concentration-dependent induction of luciferase activity was measured with the three
different mixture ratios of E2 and GEN in U251-MG cells transfected both with ERα and ERβ2
(Figure 1). The mixture model that displayed the best fit to the in vitro data was the dose-level
dependent interaction model (DL) with identical slopes for the single compounds [18]. This model
showed a significant improvement of the goodness of fit as compared to the CA model (approximate
F-tests: p = 7.9 × 10−4 for ERα and p = 8.4 × 10−3 for ERβ2). Interaction parameters of the DL model
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(α = 19.3 and β = 0.0248 for ERα, α = 12.9 and β = 0.0158 for ERβ2) indicated strong antagonism at low
concentrations between E2 and GEN in mixtures for both estrogen receptors. This antagonism was
also highlighted by the deviation of the EC50s isoboles observed in the two experiments (Figure 2).
Figure 1. Concentration-response curves of luciferase activity in U251-MG cells transfected with ERα
or ERβ2 after exposure to estradiol (E2) and genistein (GEN) alone or in combinations (three different
ratios of substances). These data originated from 2 (ERα) or 3 (ERβ2) independent experiments. All the
data were modeled by the dose-level dependent interaction model (DL). Each point represents the
mean of triplicated wells. E2 and GEN concentration-response curves are superimposed because
the concentration is expressed in E2-equivalents which have been calculated with the EC50s from
these curves.
Figure 2. Illustration of the EC50 for each ray of the estradiol (E2) + genistein mixtures (EC50s isobologram).
The points represent the EC50 and the bars represent the 95% confidence interval. These data originated
from the in vitro assays with U251-MG cells transfected with the promoter of the zebrafish cyp19a1b
gene coupled to the luciferase reporter gene and the zebrafish ERs (ERα or ERβ2). The isobole is the line
formed when EC50s of each ray are joined. A straight isobole would indicate additivity. The deviation
of the isobole to the right indicates an antagonism.
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2.3. In Vivo Effects of Single Test Compounds
No effect due to chemical exposure was observed on lethality or time to hatch during any of the
in vivo studies at the concentrations used in the experiments reported here.
A 96-h exposure to E2 led to a concentration-dependent induction of GFP expression in transgenic
cyp19a1b-GFP zebrafish (Supplementary Figure S2), with an EC50 of 2.25 × 10−10 M (4 independent
experiments with 8–19 transgenic zebrafish per condition). GFP expression is detected in radial
glial cells of the brain (Figure 3). A concentration-dependent induction of GFP expression in radial
glial cells of the brain after exposure to GEN was measured with an EC50 of 1.45 × 10−6 M
(Supplementary Figure S2) (2 experiments with 8–19 transgenic zebrafish per condition).
Figure 3. In vivo imaging of transgenic cyp19a1b-GFP zebrafish embryos (4-dpf old) exposed to solvent
(DMSO), estradiol (E2) or genistein (GEN) for 96 h. Dorsal view of the brain showing GFP induction
in the radial glial cells. For each chemical, the concentration used is indicated. Dotted lines delimit
the eyes.
2.4. In Vivo Effects of Binary Mixtures of E2 and GEN
In the two independent mixture experiments with transgenic cyp19a1b-GFP zebrafish, estimated
EC50s for single compounds were 2.69 × 10−10 M for E2 and 7.48 × 10−7 M for GEN. The relative
potency based on these EC50s is of the same order of magnitude as in the single compound experiments.
In transgenic cyp19a1b-GFP zebrafish, the mixtures of E2 and GEN induced GFP expression
in radial glial cells in a concentration-dependent manner (Figure 4). Observed responses were
compared to the concentration-response surfaces modeled with the CA model with different slopes
for each compound to improve the model goodness of fit [19] and were in good agreement in
the two independent experiments (lack-of-fit F-test compared to the analysis of variance model:
p = 0.755 (experiment 1) and p = 0.195 (experiment 2)) indicating that the CA model was not rejected.
Interactions were then added to the CA model [18]. The simple interaction model (SA) showed a
significant improvement of the adjustment quality of the model (approximate F-tests: p = 0.00325 for
experiment 1 and p = 0.0276 for experiment 2) with interaction parameters of 2.19 (experiment 1)
and 1.54 (experiment 2), indicating antagonism between E2 and GEN. This antagonism was also
highlighted by the deviation of the isoboles observed in the two experiments (Figure 5). The simple
antagonism model was the one finally accepted as none of the two-parameters models (dose-ratio (DR)
and DL) improved goodness of fit compared to the SA model.
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Figure 4. Concentration-response curves of GFP in cyp19a1b-GFP transgenic zebrafish after exposure
to estradiol (E2) and genistein (GEN) alone or in combinations (3 different mixture ratios). These data
originated from two independent experiments (Exp. 1 and Exp. 2). All the data were modeled by the
simple interaction (SA) model. In the first five graphics, each point represents one measure of GFP
in one transgenic fish brain (n = 8–19 fish per condition). In the last two graphics (bottom) which
gather all the concentration-response curves, the points represent the means of the GFP experimentally
measured for each experiment.
Figure 5. Illustration of the EC50 for each ray of the estradiol (E2) + genistein mixtures. The points
represent the EC50 and the bars represent the standard error. These data originated from two
independent exposure experiments with the cyp19a1b-GFP transgenic zebrafish line (described in
Figure 4). The isobole is the line formed when EC50s of each ray are joined. A straight isobole would
indicate additivity. The deviation of the isobole to the right indicates an antagonism.
275
Int. J. Mol. Sci. 2018, 19, 1047
3. Discussion
In the present study, natural estrogen (E2) and phytoestrogen (GEN) were shown to be potent
inducers of the ER-regulated cyp19a1b gene both in vitro and in vivo. In the cyp19a1b-GFP transgenic
zebrafish line, E2 up-regulated GFP expression in radial glial cells of the brain. In a previous study,
a similar EC50 was reported for the same in vivo biological model [3]. As previously reported for
EE2, EC50 reported for E2 in an ERE-GFP transgenic zebrafish line [20] is over ten times higher
than that calculated in the cyp19a1b-GFP transgenic zebrafish line, confirming the high sensitivity of
this biological in vivo model to (xeno-)estrogens. In U251-MG cells transfected with ERα or ERβ2,
calculated EC50s are equivalent to those reported for the cyp19a1b-GFP transgenic zebrafish line and
for transactivation assays using human embryonic kidney (293HEK) cells [20] and zebrafish liver
cells (ZELH) [21] transfected with zfERs. However, 293HEK cells displayed a greater sensitivity to
E2 when transfected with human ERs than with zfERs, supporting the relevance of using fish models
to evaluate potential effects of compounds on fish. Nevertheless, our results confirm that the two
biological models used in the present study are sensitive and reliable tools for the study of estrogenic
potency of chemicals.
GEN is a phytoestrogen with several effects on fish reproduction and development (for a review
see [22]), and is known to have a lower estrogenic potency than E2. In U251-MG cells, EC50s calculated
for GEN were 270 (ERα) and 25 (ERβ2) times higher than those calculated for E2 (based on single
compound experiments), confirming the higher estrogenic potency of E2. In other human cell lines
(MELN with endogenous human ERs, HELN transfected with human ERs), EC50 reported for GEN
were in the same range as in our U251-MG assays [23,24], while in fish cell lines transfected with fish
ERs (PELN, PRTH, ZELH), EC50s were 10–100 times higher suggesting a lower sensitivity of these
biological models to estrogens [21,25]. Interestingly, in our U251-MG cell model, GEN is a selective
ERβ modulator as previously reported in humans [23]. Furthermore, while for E2, the sensitivity of
cyp19a1b gene expression was the same in both cyp19a1b-GFP transgenic zebrafish and U251-MG cells;
for GEN, the transgenic zebrafish line was less sensitive than the U251-MG cells. These differences
might be related to the presence in the entire organism (transgenic zebrafish) of metabolic capacities,
including phase I and II biotransformation and efflux transporter proteins. Such metabolic processes
might help reducing GEN availability for the ERs in radial glial cells, leading to higher EC50s in vivo.
Although high GEN concentrations are necessary to induce cyp19a1b expression in the cyp19a1b-GFP
transgenic zebrafish assay, response to GEN seems to be more sensitive compared to another in vivo
short-term (48 h) zebrafish embryo assay using morphological defects as endpoints (edema, head
and tail malformation, reduced spontaneous movement and blood circulation) (EC50 for GEN of
427 μg/L in cyp19a1b-GFP transgenic zebrafish vs. 2.8 mg/L) [26]. Moreover, it is of interest to note
that, in the cyp19a1b-GFP transgenic zebrafish assay, the effects were observed in the central nervous
system, i.e., radial glial cells that are progenitor cells of the brain, in early-life stage fish exposed for
very short periods.
In the present study, the effects of mixtures of E2 and GEN on the expression of zebrafish cyp19a1b
gene were also addressed both in vitro and in vivo. By this approach, antagonistic effects of E2 and
GEN in mixtures on cyp19a1b gene expression in a glial cell context were highlighted. In vivo in
transgenic cyp19a1b-GFP zebrafish, these antagonistic effects were observed at all concentrations
and ratios of mixtures while in vitro in U251-MG cells, the antagonism was underlined at low
concentrations for both estrogen receptors. Even if mixtures of estrogenic compounds usually lead
to additive effects, some deviations from the CA model (antagonisms/synergisms) have already
been reported both in vitro [8,27,28] and in vivo [5,29]. As regards E2 and GEN mixtures, only
additive effects were observed in MCF-7 human breast cancer cells on the ER-dependent proliferation
process [30,31]. However, in MCF-7 cells transfected with an ER-reporter gene transactivation system,
E2 and GEN exerted an antagonistic interaction at low concentrations of mixtures [32] just like the
effects measured in our U251-MG cells model. To our knowledge, in the literature, no antagonism
of E2 and GEN in mixtures was reported for in vivo experiments, however, the results obtained in
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the present study in the cyp19a1b-GFP transgenic zebrafish usefully confirmed the antagonistic effects
of these compounds in a glial cell context. The origin of the antagonistic interaction observed both
in vitro and in vivo is not known but it may rely on the differing abilities of E2 and GEN to recruit ERs
and/or coregulators as previously showed in human cell lines [33,34]. Overall, these results clearly
demonstrate the importance of our two biological models for the study of mixtures since they both
highlighted the antagonistic effects of E2 and GEN in mixtures on the cyp19a1b gene expression.
4. Materials and Methods
4.1. Compounds
E2 (purity ≥ 98%, CAS number: 50-28-2; ref E8875) and GEN (purity ≥ 98%; CAS number:
446-72-0; ref G6649) were purchased from Sigma-Aldrich (Saint Quentin Fallavier, France).
4.2. Zebrafish Maintenance and Breeding
The cyp19a1b-GFP transgenic zebrafish [35] were raised in our laboratory facility at INERIS
(Institut National de l’Environnement Industriel et des Risques, Verneuil-en-Halatte, France).
They were maintained in a recirculation system (Zebtec, Tecniplast, Buguggiate, Italy) filled with
3.5 L aquaria. They were kept on a 14 h light:10 h dark cycle at a temperature of 27.0 ± 2.0 ◦C.
For reproductions, 2 males and 1 female adult fish were gathered in each aquarium. Fertilized eggs
were harvested and disinfected for 5 min in water supplemented with 0.1% of commercial bleach (2.6%
of sodium hypochlorite).
4.3. Zebrafish Exposure to Estrogenic Compounds
Fertilized cyp19a1b-GFP transgenic zebrafish eggs were exposed to chemicals (alone or in mixtures)
or to solvent control (DMSO, 0.02% v/v) according to [12]. Each experimental condition contained
20 embryos in 100 mL of water. Embryos were exposed for 96 h between 0 and 4 days post fertilization
(dpf) without water renewal. At the end of the exposure period, 4-dpf old zebrafish were processed
for fluorescence measurement by image analysis. Only cyp19a1b-GFP transgenic zebrafish larvae were
photographed at the end of the experiment. Each experiment was conducted twice independently.
All experimentations were performed in accordance with the European directive 2010/63/EU for
animal experimentation.
4.4. In Vivo Imaging
In vivo fluorescence imaging was performed according to [3]. Each live cyp19a1b-GFP transgenic
embryo was photographed once in dorsal view using a Zeiss AxioImager Z1 fluorescence microscope
equipped with an AxioCam Mrm camera (Zeiss GmbH, Göttingen, Germany). The same exposure
conditions were used to acquire each photograph (X10 objective, 134 ms of fluorescent light exposure,
maximal light intensity). Fluorescence quantification was performed using Image J software
(available online: http://rsb.info.nih.gov/ij/). For each picture, the integrated density (IntDen) was
measured, i.e., the sum of the gray-values of all the pixels within the region of interest. All gray-values
of 300 or less were considered as background values.
4.5. U251-MG Cell Bioassay
The U251-MG (ECACC, human astrocyte) are ER-negative glial cell line and were maintained at
37 ◦C in 5% CO2 atmosphere in phenol red–free Dulbecco’s Modified Eagle’s Medium (DMEM-F12,
Sigma-Aldrich, St. Louis, MO, USA) supplemented with 8% fetal calf serum (FCS), 2 mM L-glutamine,
20 U/mL penicillin, 20 μg/mL streptomycin and 50 ng/mL amphotericin B.
One day before the transfection, cells were scraped, washed and seeded at 2 × 104 cells/mL in
24-well plates in fresh medium containing 8% FCS. Transfection and luciferase assays were performed
as previously described [16]. Briefly, after 24 h, the medium was replaced with fresh phenol red-free
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DMEM containing 2% charcoal/dextran FCS. Cells were transfected with plasmid-DNA using JetPEITM
reagent, as indicated by the manufacturer (Polyplus-transfection, Illkirch, France). The DNA templates
for each well correspond to 25 ng of zfER expression plasmid [36], 150 ng of the zebrafish cyp19a1b
promoter linked to the luciferase reporter plasmid [37] and 25 ng of the internal β-galactosidase control
vector (CMV-βgal). After one night, medium was replaced with fresh DMEM-F12 containing 2%
charcoal/dextran FCS and cells were exposed to vehicle (DMSO, 0.1% v/v) and various concentrations
of the test compounds. After 36 h, the luciferase activities were determined using the luciferase
assay system (Promega, Charbonnières-les-Bains, France) and the β-galactosidase activity was used
to normalize transfection efficiency in all experiments. Each experiment was performed at least in
triplicate and the results were expressed as fold induction relative to the vehicle.
4.6. Data Normalization
In the in vivo assay with cyp19a1b-GFP transgenic zebrafish, induction of GFP fluorescence was
measured as IntDen and, since the data were obtained from several independent experiments, they
were normalized by dividing by the geometric mean of the IntDen in the DMSO control group, thus
expressing results as Log Fold inductions.
In the in vitro assays with U251-MG cell cultures, data normalization was performed by dividing
by the geometric mean of the corresponding solvent control group. The mixture dose-response
experiments were reproduced twice in vivo and in the ERα assay, and three times in the ERβ2 assay.
However, due to high variability in replicate measures within each experiment, the three replicate
datapoints at each concentration within each experiment were averaged, and the mixture dose-response
model was based on two (ERα) or three (ERβ2) average values at each concentration. Moreover,
in the ERβ2 assay, the maximum responses varied between experiments, and the data were therefore
expressed as a percent of log-fold induction produced by E2 in each experiment.
4.7. Concentration-Response Modeling
The relationship between concentration and log-fold induction was modeled with a 4-parameter
Hill model:






where Min is the minimum level of induction, Max is the maximum level of induction, c is the
concentration, EC50 is the concentration producing 50% of the maximum induction, and β is the Hill
slope. The first step of the dose-response analysis in both in vivo and in vitro experiments was to
estimate common values of Min and Max for both single compounds within each biological model.
The models with a common Min and Max on the one hand and with freely varying Min and Max on the
other hand were compared with lack-of-fit F-tests. Appropriateness of the dose-response models were
also tested with a test for lack-of-fit compared to ANOVA models. As a second step, common values
of Min, Max and Slope were estimated for E2 and GEN. Lack-of-fit F-tests were performed to check
that the model did not fit less well than when the slope varied freely. The parameters were estimated
by least squares, using R 3.1.1 [38] and package drc [39]. All the data and R codes used in this study
are available in Supplementary materials (Supplementary Figure S3).
4.8. Mixture Experimental Designs
The mixture experimental design was developed based on relative potency of single compounds
according to [12].
In the in vivo assay, relative potency of E2 and GEN were estimated with the EC50 obtained
by modelling dose-response data from respectively four and two experiments with the 4-parameter
Hill model. Mixture experiments were performed according to a ray design with one ray for each
single chemical and three mixture ratios (3:1, 1:1, and 1:3 expressed as relative potencies). Each ray
was tested with five concentrations with 4-fold serial dilutions, centered around the EC50, except for
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GEN for which the highest concentrations were reduced because of their toxicity to fish (range of
E2 concentrations from 4.8 × 10−12 to 5 × 10−9 M and range of GEN concentrations from 2.4 × 10−8
to 6.25 × 10−6 M) (Table 1). In theory, interactions are likely to be most visible at the equimolar
mixture ratios.
The same approach was used to design the experiments for the in vitro assay with U251-MG
cells. To calibrate the design, we used one experiment with E2 and GEN performed on the same plate.
The ray designs built for the in vitro assays are presented in Table 2 for both ERα and ERβ2.
Table 1. Experimental ray design for the assessment of the effects of estradiol (E2) and genistein (GEN)
alone and in mixtures on the expression of GFP in the brain of cyp19a1b-GFP transgenic zebrafish line.
Condition [E2] (M) [GEN] (M) Ray
1 0 0 -
2 5.00 × 10−9 0 1:0
3 1.25 × 10−9 0 1:0
4 3.12 × 10−10 0 1:0
5 7.81 × 10−11 0 1:0
6 1.95 × 10−11 0 1:0
7 3.75 × 10−9 6.25 × 10−6 3:1
8 9.37 × 10−10 1.56 × 10−6 3:1
9 2.34 × 10−10 3.91 × 10−7 3:1
10 5.86 × 10−11 9.77 × 10−8 3:1
11 1.46 × 10−11 2.44 × 10−8 3:1
12 1.25 × 10−9 6.25 × 10−6 1:1
13 6.25 × 10−10 3.12 × 10−6 1:1
14 1.56 × 10−10 7.81 × 10−7 1:1
15 3.91 × 10−11 1.95 × 10−7 1:1
16 9.77 × 10−12 4.88 × 10−8 1:1
17 3.12 × 10−10 4.69 × 10−6 1:3
18 1.56 × 10−10 2.34 × 10−6 1:3
19 7.81 × 10−11 1.17 × 10−6 1:3
20 1.95 × 10−11 2.93 × 10−7 1:3
21 4.88 × 10−12 7.32 × 10−8 1:3
22 0 6.25 × 10−6 0:1
23 0 3.12 × 10−6 0:1
24 0 1.56 × 10−6 0:1
25 0 3.91 × 10−7 0:1
26 0 9.77 × 10−8 0:1
Table 2. Experimental ray design for the assessment of the effects of estradiol (E2) and genistein (GEN)
alone and in mixtures on the luciferase activity in U251-MG cells transfected with zebrafish ERs.
ERα ERβ2
Condition [E2] (M) [GEN] (M) [E2] (M) [GEN] (M) Ray
1 0 0 0 0 -
2 2.00 × 10−8 0 2.00 × 10−8 0 1:0
3 2.00 × 10−9 0 2.00 × 10−9 0 1:0
4 2.00 × 10−10 0 2.00 × 10−10 0 1:0
5 2.00 × 10−11 0 2.00 × 10−11 0 1:0
6 2.00 × 10−12 0 2.00 × 10−12 0 1:0
7 1.50 × 10−8 1.00 × 10−6 1.50 × 10−8 2.00 × 10−7 3:1
8 1.50 × 10−9 1.00 × 10−7 1.50 × 10−9 2.00 × 10−8 3:1
9 1.50 × 10−10 1.00 × 10−8 1.50 × 10−10 2.00 × 10−9 3:1
10 1.50 × 10−11 1.00 × 10−9 1.50 × 10−11 2.00 × 10−10 3:1
11 1.50 × 10−12 1.00 × 10−10 1.50 × 10−12 2.00 × 10−11 3:1
12 1.00 × 10−8 2.00 × 10−6 1.00 × 10−8 4.00 × 10−7 1:1
13 1.00 × 10−9 2.00 × 10−7 1.00 × 10−9 4.00 × 10−8 1:1
14 1.00 × 10−10 2.00 × 10−8 1.00 × 10−10 4.00 × 10−9 1:1
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Table 2. Cont.
ERα ERβ2
Condition [E2] (M) [GEN] (M) [E2] (M) [GEN] (M) Ray
15 1.00 × 10−11 2.00 × 10−9 1.00 × 10−11 4.00 × 10−10 1:1
16 1.00 × 10−12 2.00 × 10−10 1.00 × 10−12 4.00 × 10−11 1:1
17 5.00 × 10−9 3.00 × 10−6 5.00 × 10−9 6.00 × 10−7 1:3
18 5.00 × 10−10 3.00 × 10−7 5.00 × 10−10 6.00 × 10−8 1:3
19 5.00 × 10−11 3.00 × 10−8 5.00 × 10−11 6.00 × 10−9 1:3
20 5.00 × 10−12 3.00 × 10−9 5.00 × 10−12 6.00 × 10−10 1:3
21 5.00 × 10−13 3.00 × 10−10 5.00 × 10−13 6.00 × 10−11 1:3
22 0 4.00 × 10−6 0 8.00 × 10−7 0:1
23 0 4.00 × 10−7 0 8.00 × 10−8 0:1
24 0 4.00 × 10−8 0 8.00 × 10−9 0:1
25 0 4.00 × 10−9 0 8.00 × 10−10 0:1
26 0 4.00 × 10−10 0 8.00 × 10−11 0:1
4.9. Mixture Concentration-Response Modeling
The mixture concentration-response modeling was performed as described in [12] with
some adjustments when necessary. Concentration-response surfaces were modeled with the CA
model [19] under the assumption of absence of interactions, using Berenbaum’s general solution [40].
This application of the CA model can be used in cases where the dose-responses of the mixture
components produce same minimal and maximal effect: it does not require equal slopes in the
dose-response models for single compounds. The use of the CA model when slopes differ remains a
subject of controversy, because this would suggest that the single compound’s modes of action are
different [41,42]. In agreement with Berenbaum’s general solution, the concept of Toxic Equivalent
Factors, where slopes are required to be equal, is viewed as a more restrictive version of CA [43].
Prior to modelling the dose-response surface, individual rays were modelled with a Hill model with
either freely varying slopes and EC50s or simply freely varying EC50s when this was not detrimental
to the goodness-of-fit. On the other hand, Faust et al. [44] underline that their results do not support
the idea that CA can only be applied with similar DR curves. Other authors believe that differences in
Hill parameters or even differences in dose-response functions do not necessarily imply different sites
of action and consider that the heterogeneity of binding sites can imply more complex dose-response
functions [45]. CA has however provided adequate predictions even for mixtures where the mode of
action was not identical [46].
A variety of methods have been developed for quantifying interactions based on analysis
of specifically designed mixture dose-response data [47]. These include graphical methods that
quantify deviations from isoboles [48,49], the widely-used Combination Index designed by Chou
and Talalay [50,51], statistical methods for testing local departure from additivity [52], and modelling
of the entire dose-response surface [47]. The method developed by [52] and dose-response surface
modeling both allow appropriate error structure modelling [53,54] statistical tests of the significance
of departures from the no-interaction model. Nonlinear response-surface analysis has the additional
advantage of allowing for more complex interactions that depend on the response level or the mixture
ratio [18] which could be relevant especially for endocrine disrupting compounds.
Interaction terms for simple antagonism/synergy (SA), dose-ratio dependent interactions
(DR), and dose-level dependent interactions (DL) were subsequently added to the CA model [18].
These interaction models developed by Jonker et al. (2005) [18] allow for different slopes for the single
compounds, but the interactions can be either calculated on toxic units based on the EC50 or on the EC
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For example, for simple synergism or antagonism, these
toxic units are used in the following deviation function used by Jonker et al. (2005) [18].





We therefore tested both implementations of the interaction definitions. Significance of the
interactions was assessed using approximate F-tests on the residual sums of squares by considering
that the models were nested. Acceptability of the concentration-response surface models was assessed
with a lack-of-fit F-test compared to the analysis of variance model. Optimisation of parameter values
for the dose-response surfaces was performed with R 3.1.1 [38], package dfoptim [55].
5. Conclusions
In the present study, we confirm (i) that our in vitro (U251-MG cells) and in vivo (cyp19a1b-GFP
transgenic zebrafish) biological models are valuable tools to assess the estrogenic potency of chemicals
both alone and in mixtures as previously stated [12]; (ii) the usefulness of the ray design approach
to highlight interactions between mixture components in providing surface dose-response data and
simple graphical representations. Our results show that mixture of two ER agonists, a phytoestrogen
(GEN) and a natural estrogen (E2), could produce effects that deviate from the assumption of
simple additivity, i.e., antagonistic effects, demonstrating the importance of considering chemical
mixtures for a better understanding of the effects of ER agonists on organisms. From that point of
view, both the U251-MG transactivation assay and the cyp19a1b-GFP transgenic zebrafish assay are
reliable, flexible and simple assays, useful for the complex experimental design needed for mixture
testing. Although extrapolation from the present assays to environmental situations appears difficult,
as reported in our previous study [12], this assay could possibly help in determining the interactions
of compounds in multi-component mixtures and/or identify compounds/mixtures that need further
investigations in in vivo studies with more integrative endpoints.
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Abstract: Triclosan (TCS), an antimicrobial agent widely found in the aquatic environment, is
suspected to act as an endocrine disrupting compound, however mechanistic information is lacking
in regards to aquatic species. This study assessed the ability of TCS to interfere with estrogen
receptor (ER) transcriptional activity, in zebrafish-specific in vitro and in vivo reporter gene assays.
We report that TCS exhibits a lack of either agonistic or antagonistic effects on a panel of ER-expressing
zebrafish (ZELH-zfERα and -zfERβ) and human (MELN) cell lines. At the organism level, TCS at
concentrations of up to 0.3 μM had no effect on ER-regulated brain aromatase gene expression in
transgenic cyp19a1b-GFP zebrafish embryos. At a concentration of 1 μM, TCS interfered with the E2
response in an ambivalent manner by potentializing a low E2 response (0.625 nM), but decreasing
a high E2 response (10 nM). Altogether, our study suggests that while modulation of ER-regulated
genes by TCS may occur in zebrafish, it does so irrespective of a direct binding and activation of zfERs.
Keywords: in vitro; in vivo; estrogen receptor; zebrafish; triclosan; brain aromatase
1. Introduction
Triclosan (TCS) is a chlorinated phenolic chemical used as a wide spectrum antimicrobial agent
in many personal care products, such as cosmetics. Around 400 tons of TCS was used in Europe in
2007, reflecting its extensive application over the last few decades [1]. As a household chemical, TCS
enters the aquatic environment mainly through wastewater treatment plant (WWTP) effluent releases,
after incomplete removal by adsorption from sewage sludge [2]. TCS is commonly detected in WWTP
effluents [3] and in river water, where it was reported to occur at concentrations ranging from the ng/L
range up to 2.3 μg/L [4–6].
TCS toxicity for mammalian and several aquatic species has been well documented, as thoroughly
reviewed by Dann and Hontela [2]. Among its different potential effects, concern has been
raised regarding its endocrine-disrupting activity in aquatic species. TCS was reported to alter
endocrine-regulated processes, such as thyroid hormone homeostasis and reproduction. In fish,
different outcomes were reported. Foran et al. (2000) reported a sex ratio weakly biased toward
males after exposure of medaka fry to 100 μg/L, however not at lower or higher concentrations,
suggesting that TCS has a slight androgenic effect [7]. The induction of vitellogenin (VTG) expression
in male mosquitofish [8] and medaka [9] was observed after exposure to 100 μg/L TCS, while it did
not alter VTG in male fathead minnow [6]. A recent study using medaka reported dual effects, as
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TCS was shown to decrease VTG expression in males and increase it in females after exposure to
concentrations of 174 μg/L and above of TCS [10]. Overall, studies on aquatic vertebrates suggest that
TCS has an endocrine-disrupting capacity, however the mechanisms by which it interferes with sex
steroid-regulated pathways remain unclear [2].
Several in vitro studies using mammalian cell systems have addressed the ability of TCS to
interfere with the human estrogen receptor (hER), with contrasting outcomes. For instance, in one
study, TCS was found to weakly transactivate hERα in transiently transfected CV-1 cells [11], and to
promote MCF-7 cell growth up to 80% of positive control at 75 μM [12]. In other studies, TCS was
reported to lack agonistic effects in similar human ER- and androgen receptor (AR)-dependent reporter
gene assays [13–15], but to have ER and AR antagonistic activity [13]. To date, most in vitro studies on
the anti-estrogenic effects of TCS originate from mammalian test systems, and only a few mechanistic studies
have focused on ER signaling pathways in fish. A recent study examined the ability of TCS to activate
the ERα ligand-binding domain of different fish species using a transient reporter gene assay in human
cells, and showed only weak activation at high μM concentrations of TCS on some fish ERα, but not on
others [16]. Despite information obtained so far suggesting the involvement of ER signaling in TCS response,
the underlying mechanism of its estrogen-related effects remains unclear, notably in aquatic species.
In this context, the aim of the present study was to assess TCS interaction with ER signaling
pathways in a model fish species, the zebrafish (zf), by using recently established in vitro and in vivo
zf-specific reporter gene assays. Integrative strategy based on complementary screening bioassays has
been shown to be relevant for characterizing the estrogenic potency of chemicals [17], and quantifying
estrogenic activity in the environmental matrices [18] in fish. In the present study, we used a panel of
in vitro assays based on (1) zf liver cell lines stably transfected to express zfERα (ZELHα), zfERβ1 (ZELHβ1)
or zfERβ2 (ZELHβ2) [19]; (2) human breast cancer MCF-7 cells expressing endogenous hERα (MELN) [20];
and an in vivo assay based on (3) transgenic cyp19a1b-GFP zebrafish embryos, which express cyp19a1b
gene under the strict regulation of ER in radial glial cells (RGCs) [21]. The in vitro and in vivo effect of
serial concentrations of TCS was assessed in the presence or absence of the endogenous steroidal estrogen
17β-estradiol (E2), in order to investigate agonistic and antagonistic activity.
2. Results
2.1. Triclosan Does Not Alter ZfER Transactivation In Vitro
The different reporter cell lines responded to E2, the reference compound, in the expected range
of sensitivity (Figure 1), with EC50s ranging from 0.01–0.02 nM in MELN, ZELHβ1, and ZELHβ2 cells,
to 2 nM in ZELHα cells. This sensitivity and different affinity of ERs for E2 is in perfect line with our
previous studies using the same cell lines [18,19], which confirms the reproducibility and robustness
of established cell models.
Figure 1. Luciferase induction by E2 in human (MELN) and zebrafish (ZELHα, ZELHβ1, and ZELHβ2)
cell lines. Data were normalized to solvent control and to E2 maximal effect. Data are mean values
±SD (technical triplicates) and Hill fitting curve with 95% confidence interval belt.
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Across all ER-expressing reporter cell lines, exposure to between 0.01 and 10 μM TCS did not
induce any ER transactivation (Figure 2A–D, light bars). A slight decrease in luciferase activity was
noted at 30 μM, where a cytotoxic event was also evidenced, as measured by the MTT test (Figure 2A–D,
light circles). When cells were co-exposed to E2, E2-induced luciferase remained unaffected by the
addition of up to 10 μM of TCS in the MELN and ZELHα cells (Figure 2A,B, dark bars), while a slight
but significant decrease in E2-induced luciferase activity was observed in ZELHβ1 and ZELHβ2 cells
at 10 μM (Figure 2C,D, dark bars). Above 10 μM TCS, luciferase activity significantly decreased in
all the reporter cell lines, in both the presence and absence of E2. The ER-independent decrease of
luciferase activity and cell viability at 30 μM TCS was confirmed in the parental ZFL and ZELH cell
lines that do not express any functional zfER (Figure 2E,F). Altogether, our results suggest that TCS
did not interact with ER in zebrafish liver cells, either as an ER agonist or an ER antagonist.
Figure 2. Luciferase response (LUC, bars) and cell viability (circles) of MELN (A), ZELHα (B), ZELHβ1
(C), ZELHβ2 (D), ZELH (E) and ZFL (F) cells after exposure to TCS (0.03 to 30 μM) for 24 h (MELN) or
72 h (ZELH-zfERs), in presence (dark symbols) or absence (light symbols) of E2. MELN, ZELHβ1 and
ZELHβ2 cells were co-exposed to TCS + E2 0.1 nM, and ZELHα, ZELH and ZFL cells to TCS + E2 1
nM. Data represent the mean (+/− SD) of a minimum of 3 independent experiments using technical
triplicates. Data were normalized to E2 positive control for luciferase activity. SC: solvent control ¤:
response significantly different from control cell viability *: response significantly different from control
luciferase activity (Mann-Whitney, p < 0.05).
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2.2. Effect of Triclosan on Brain Aromatase Expression Using the Cyp19a1b-GFP Transgenic Zebrafish Embryo
Assay (EASZY Assay)
Representative patterns of GFP expression in the developing brain of transgenic cyp19a1b-GFP
zebrafish embryos are shown in Figure 3. Typically, a low GFP signal is observed in the control
fish (Figure 3A) while in the E2-treated fish, a strong GFP signal is observed in the radial glial cells
(Figure 3C,E). To investigate the potential effects of TCS on the expression of ER-regulated genes,
transgenic cyp19a1b-GFP zebrafish embryos were exposed to graded concentrations of TCS, either
alone or in combination with E2, from 3 h post fertilization (hpf) to 96 hpf. The quantification of the
GFP signal after chemical treatment is presented in Figure 4.
Figure 3. Dorsal view of the developing brain showing in vivo GFP expression (green signal) in the
radial glial cells (RGCs) of transgenic cyp19a1b-GFP zebrafish (zf) embryos (4-dpf old) exposed to (A)
solvent (DMSO); (B) TCS (1 μM); (C) and (E) E2 (10 nM and 0.625 nM); and (D,F) E2 + TCS for 96 h.
Figure 4. Effect of TCS on cyp19a1b expression in transgenic zebrafish larvae. Zebrafish embryos were
exposed to TCS from 0.03 to 1 μM alone (A) or in co-exposure to E2 10 nM (B); from 3 h post fertilization
(hpf) for 96 h with daily renewal of medium. GFP intensity was measured on day 4 on living organisms
by fluorescence microscopy. Data are mean values ± SEM of a minimum of 2 experiments. N = 2
independent experiments with n = 20 embryos per condition per experiment. * and ***: significantly
different from (A) control or (B) E2 groups (p < 0.05 and p < 0.001, respectively, Mann–Whitney test).
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TCS alone did not induce any GFP expression in the EASZY assay (Figure 3A). In contrast, TCS
1 μM consistently and significantly reduced GFP intensity by 60% of the control group (p = 0.0002)
(Figures 3B and 4A). To further assess the interference of TCS with the ER-regulated expression of
the cyp19a1b gene, zf embryos were exposed to different concentrations of TCS in the presence of E2
10 nM. At this concentration, E2 alone strongly induced GFP intensity by a factor of 15 as compared to
controls (Figures 3C and 4B). Co-exposure to graded concentrations of TCS had no significant effects
on E2-induced cyp19a1b expression from 0.03 to 0.3 μM, but significantly decreased the E2-induced
GFP intensity by 30% at 1 μM TCS (Figures 3D and 4B, p = 0.034).
We then further investigated the ability of TCS 1 μM to modulate the E2 concentration-dependent
induction of GFP (Figure 5). E2 alone induced GFP in a concentration-dependent manner with an
EC50 = 0.98 nM. In the presence of TCS 1 μM, modulation of the E2-induced response was observed,
resulting in a reduction of the EC50 of E2 to 0.52 nM. This was the consequence of a significant 2.8-fold
increase in GFP intensity at 0.625 nM E2 in the presence of TCS 1 μM, as compared to E2 alone
(p = 0.0095) (Figure 3E,F). Furthermore, TCS reduced the response induced by E2 at 10 nM (p = 0.061)
by 20%, a trend which confirmed the inhibitory effect of 1 μM TCS, as noted in Figure 4.
Figure 5. Effect of E2 from 0.16 to 10 nM alone (solid line) or in the presence of TCS 1 μM (dashed line)
on cyp19a1b expression in transgenic zebrafish embryos. Data represent mean of log-10 transformed
fold induction values ± SEM (**: significant difference at p < 0.01, Mann–Whitney test). N = 2
independent experiments with n = 20 embryos per condition per experiment.
3. Discussion
The in vitro assay data in ZELHs and MELN reporter cell lines demonstrate the lack of agonistic
and antagonistic activity of TCS toward zfERs and hERα, in the range of tested concentrations
(0.03–30 μM as nominal concentrations). A small but significant decrease in E2-induced luciferase
activity was observed at TCS 10 μM in ZELHβ1 and ZELHβ2 cells. However, the decrease was
minimal, and occurred close to cytotoxic concentrations, suggesting an unspecific effect on luciferase
activity rather than a direct effect mediated by zfERβs. There is a lot of information regarding the
estrogenic and anti-estrogenic effects of TCS in vitro. The absence of ER transactivation by TCS
alone in the zebrafish reporter cell lines is in accordance with previous studies based on human cells
transfected with recombinant fish [16] or human ERα [13,14]. To our knowledge, no information
on the implication of zfERβ1 and zfERβ2 subtypes in TCS responses is available so far, impeding
any comparison. In contrast to the lack of estrogenic effects, the absence of anti-estrogenic activity
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observed in the zf and human reporter cell lines differs from the findings of previous reports. With
the exception of one study, which showed no effect of TCS on 17α-ethynylestradiol (EE2)-induced
hERα activation in T47D-kbLuc breast cancer cell line [22], several in vitro studies have described TCS
as anti-estrogenic in transactivation and proliferative assays using human cells [12–14]. Differences
between test systems, e.g., organism (fish vs. human), tissue (breast cancer cells vs. hepatocytes),
and ER subtype (ERα vs. ERβ1/β2), may have contributed to the differences in observations.
In the present study, we noticed a decrease in reporter gene activity at 30 μM TCS irrespective of
E2 in all the cell lines, which paralleled a marked decrease in cell viability. TCS was shown to induce
a caspase-dependent apoptosis in neuronal cells [23,24], and to reduce cell viability by targeting cell
proliferation in mouse embryonic stem cells [25] and MCF-7 cells [26]. Thus, the decreased cell viability
observed in ZFL-derived cells and in MELN cells at 30 μM is in line with the broad cellular toxicity of
TCS reported in the high μM range.
The (anti-)estrogenic effects of TCS were further investigated in vivo using transgenic zf embryos,
which express GFP under the control of cyp19a1b promoter in RGCs [21]. Cyp19a1b codes for the brain
aromatase (aromatase B)—it is responsible for the conversion of androgens into estrogens, and its
expression is highly inducible by ER agonists at the embryonic stage, by way of an autoregulatory
loop [27,28]. In the present study, we showed that TCS alone did not induce the expression of cyp19a1b.
These results are in line with the in vitro data obtained in this study in the same model species.
At 1 μM, TCS alone significantly decreased GFP intensity in comparison to controls.
The significantly decreased GFP observed in the presence of TCS alone is unlikely due to its acute
toxic effect on embryos, as no significant mortality was observed under this exposure condition.
Furthermore, among the more than 100 substances tested in the EASZY assay so far [17,21,29,30], none
has been reported to decrease basal cyp19a1b expression in zf embryos, even those that are known to
act as anti-estrogens, such as ICI 182,780. It is therefore unlikely that the observed decrease reflects
TCS anti-estrogenic activity through direct interaction with ER, as also supported by our in vitro data.
TCS is known to target the thyroid axis in many organisms, including, in fish, at the larval and
adult stages [31,32]. Thyroid hormones are essential to central nervous system development and
function [33]. For instance, triiodothyronine (T3) is necessary for the differentiation of glial cells
onto oligodendrocytes and astrocytes [34]. TCS was shown to alter the thyroid system of Cyprinodon
variegatus larvae, including T3 levels [32]. Thus, we may hypothesize that the observed decrease in
GFP intensity observed at 1 μM TCS in zf embryos may result from neuro-developmental toxicity,
including effects on RGCs expressing cyp19a1b. Further investigation at the embryonic stage in fish
would be warranted, in order to study the potential direct or indirect effects of TCS on RGCs, and its
consequences for brain development.
Our study suggests that TCS acts in a complex manner in the presence of E2. On the one
hand, TCS at 1 μM significantly potentiates the GFP expression induced by E2, but only at a low
concentration (i.e., 0.625 nM), resulting in a shift of E2 EC50. On the other hand, TCS tends to
decrease the effect of E2, but only at the highest E2 concentrations (i.e., 10 nM). The potentiation of
EE2 effects by TCS has been observed in the uterotrophic assay following a 21-day exposure period,
while TCS alone lacked estrogenic effect [35]. Overall, our results show that TCS can act on the
ER-regulated brain aromatase as an ambivalent substance, since its effects appear to be dependent
on exposure conditions and concentration ratios between E2 and TCS. Interestingly, our observations
support recent data regarding adult medaka, where TCS exposure led to either the inhibition of VTG
synthesis in males, or an increased VTG synthesis in reproductive active females [10]. Other studies of
adult carp (Cyprinus carpio) reported the ability of a 42-day exposure to TCS to increase VTG levels
through non-ER pathways [36,37]. This induction resulted from increased E2 synthesis in gonads, i.e.,
gonadal aromatase (Cyp19a1a) induction. The authors also noticed aromatase (Cyp19a1b) induction
in the hypothalamus, likely due to an increase in plasmatic E2-levels following induction of gonadal
aromatase. The hypothalamus-pituitary gonadal (HPG) axis is not functional at the investigated
embryonic stage, impeding the assessment of such effects of TCS in the EASZY assay. Altogether, our
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data provide complementary information supporting the hypothesis that steroid levels may influence
the endocrine-disrupting effects of TCS in mammalian and non-mammalian models, through non-ER
mediated but still undefined mechanisms.
In summary, among the possible TCS toxicity pathways, our study addressed the very specific
effect of TCS on zfER transactivation and the ER-regulated expression of brain aromatase in zebrafish
reporter gene assays. Our results demonstrated that TCS lacks agonistic and antagonistic activities
towards zfER α, β1 and β2 subtypes, and hERα in vitro. At the organism level, TCS interfered with
the expression of the ER-regulated brain aromatase in an ambivalent manner in zebrafish, irrespective
of direct binding to and transactivation of zfERs.
4. Materials and Methods
4.1. Chemicals and Reagents
17β-estradiol (E2, CAS No. 50-28-2) and triclosan (TCS, CAS No. 3380-34-5) were purchased from
Sigma-Aldrich (Saint-Quentin Fallavier, France). Dimethylsulfoxide (DMSO), Leibovitz 15 culture
medium (L-15), fetal calf serum (FCS), 4-(2-hydroxy-ethyl)-1-piperazineethanesulfonic acid (HEPES),
epidermal growth factor (EGF), G418, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium-bromide
(MTT), and D-luciferin were purchased from Sigma Aldrich. Dulbecco’s Modified Eagle Medium High
Glucose (DMEM HG) powder, F-12 nutrient mixture (Ham’s F12) powder, penicillin, and streptomycin
were purchased from Gibco. Insulin, hygromycin B, and sodium bicarbonate were purchased from
Dominique Dutscher (Issy-les-Moulineaux, France).
4.2. In Vitro Assays: Cell Culture, Luciferase and Cell Viability Assays
The zf in vitro assays were derived from the zf liver (ZFL) cell line, which was stably transfected,
firstly by an ERE-driven luciferase gene, yielding the ZELH cell line, secondly by zfERα subtype,
yielding the ZELH-zfERα, or by zfERβ1 subtype yielding the ZELH-zfERβ1 cell lines, or by zfERβ2
subtype yielding the ZELHβ2 cell lines. The establishment of these cell models, and their response
to different classes of well-known xeno-estrogens has been previously described [18,19]. In addition,
the ZFL and ZELH cell lines were used as ER-negative controls. In addition to the zebrafish cell models,
we used the human-derived MELN cell line [20], kindly provided by Dr. Patrick Balaguer (INSERM,
Montpellier, France). The MELN cells are derived from the MCF-7 cells, which endogenously express
the hERα, but no functional hERβ (P. Balaguer, personal communication).
Conditions for routine cell culture and exposure to chemicals have been detailed previously [19,20].
Briefly, ZELH-zfERs cells were seeded in 96-well white opaque culture plates (Greiner CellStar™,
Dominique Dutscher, Brumath, France) at 25,000 cells per well in phenol red free LDF-DCC medium
(containing 50% of L-15, 35% of DMEM HG, 15% of Ham’s F12, 15 mM of HEPES, 0.15 g/L of
sodium bicarbonate, 0.01 mg/mL of insulin, 50 ng/mL of EGF, 50 U/mL of penicillin and streptomycin
antibiotics, and 5% v/v stripped FCS). MELN were seeded at 80,000 cells per well cell line in steroid-free
DMEM medium. Cells were left to adhere for 24 h. Following this, they were exposed in triplicates
to serial dilutions of test compound for either 72 h at 28 ◦C for zebrafish cells, or 16 h at 37 ◦C
for MELN cells. After exposure, luciferase activity was measured. The medium was removed and
replaced by 50 μL per well of medium containing 0.3 mM luciferin. The luminescence signal was
measured in living cells using a microtiter plate luminometer (Synergy H4, BioTek Instruments,
Luzern, Switzerland). The effect of test chemicals on cell viability was assessed by using the
3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [38]. After cell exposure,
culture medium was removed and replaced by 100 μL of medium containing 0.5 mg/mL MTT.
Cells were incubated for 3 h. In metabolically active cells, MTT was reduced onto a blue formazan
precipitate, which was dissolved by adding 100 μL of DMSO after removal of MTT containing medium.
Plates were then read at 570 nm against a 640 nm reference wavelength on a microplate reader (KC-4,
BioTek Instruments, Colmar, France), and results were expressed as absorbance relative to control cells.
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4.3. In Vivo Zebrafish Bioassays
In vivo anti-estrogenicity of TCS was assessed using the transgenic cyp19a1b-GFP zebrafish line,
previously developed [39] and well characterized with different classes of estrogens and xeno-estrogen
compounds [21]. The assay procedure for individual chemical testing has been described in detail by
Brion et al. [21]. To briefly summarize, 20 fertilized transgenic eggs were selected for each experimental
group and exposed for 96 h in 25 mL of acclimated water in glass crystallizers. Serial dilutions were
tested with a final volume of solvent (DMSO) of 0.01% v/v, a concentration without any effects on
embryo development or GFP expression. In each experimental series, positive (EE2 0.05 nM) and
DMSO controls were included as separate experimental groups. Exposed embryos were incubated at
28 ◦C, under semi-static conditions with complete renewal of the medium daily. After the exposure
period, each zebrafish larva was photographed using a Zeiss Axio Imager.Z1 microscope equipped
with an AxioCam Mrm camera (Zeiss GmbH, Gottingen, Germany) to measure GFP expression in the
brain. Image analysis was performed using the ImageJ software, and fluorescence data was treated
exactly as previously described [21].
Animal maintenance was performed under strict respect of animal welfare. The assays based on
zebrafish embryos used in this study are not subjected to animal experiments according to the European
Directive 2010/63/EU, and are to be considered as alternative methods for animal experiments.
4.4. Data Analysis
Dose-response curves were fitted to the experimental data using the Hill equation as provided in
the RegTox 7.5 Microsoft Excel™ macro [40]. Significant effects on luciferase induction, GFP intensity,
and cell viability in exposed conditions were determined by comparing each condition to solvent
control (estrogenic effects), or to E2 control (antiestrogenic effects), applying a non-parametric bilateral
Mann–Whitney statistical test with α set at 5%. Furthermore, DMSO and water controls of zebrafish
cyp19ab-GFP larvae were pooled together when no significant differences were observed, applying a
non-parametric bilateral Mann–Whitney statistical test with α set at 5%.
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